index	sentence	label
DDI-DrugBank.d0.s1.p0	Pharmacokinetic studies indicate that administration of @DRUG$ or @DRUG$ does not affect the pharmacokinetics of acamprosate.	DDI-false
DDI-DrugBank.d0.s1.p1	Pharmacokinetic studies indicate that administration of @DRUG$ or diazepam does not affect the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d0.s1.p2	Pharmacokinetic studies indicate that administration of disulfiram or @DRUG$ does not affect the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d100.s0.p0	Increased nephrotoxicity has been reported following concomitant administration of @DRUG$ and @DRUG$.	DDI-effect
DDI-DrugBank.d103.s0.p0	@DRUG$: Aerosol @DRUG$ of the short-acting adrenergic stimulant type may be used for relief of breakthrough symptoms while using formoterol.	DDI-false
DDI-DrugBank.d103.s0.p1	@DRUG$: Aerosol bronchodilators of the short-acting adrenergic stimulant type may be used for relief of breakthrough symptoms while using @DRUG$.	DDI-false
DDI-DrugBank.d103.s0.p2	Short-Acting beta2-agonists: Aerosol @DRUG$ of the short-acting adrenergic stimulant type may be used for relief of breakthrough symptoms while using @DRUG$.	DDI-false
DDI-DrugBank.d104.s1.p0	Other @DRUG$ should be used with caution in patients taking @DRUG$, since the effects may be additive.	DDI-advise
DDI-DrugBank.d106.s0.p0	A 30 to 45% increase in AUC and Cmax of @DRUG$ was observed with concomitant administration of @DRUG$ twice daily.	DDI-mechanism
DDI-DrugBank.d106.s4.p0	Coadministration of @DRUG$ with @DRUG$ or any known CYP3A4 inducer should be avoided and alternative antihypertensive therapy should be considered.	DDI-advise
DDI-DrugBank.d106.s4.p1	Coadministration of @DRUG$ with phenytoin or any known CYP3A4 inducer should be avoided and alternative @DRUG$ therapy should be considered.	DDI-false
DDI-DrugBank.d106.s4.p2	Coadministration of SULAR with @DRUG$ or any known CYP3A4 inducer should be avoided and alternative @DRUG$ therapy should be considered.	DDI-false
DDI-DrugBank.d106.s5.p0	Pharmacokinetic interactions between @DRUG$ and @DRUG$ (atenolol, propranolol) were variable and not significant.	DDI-false
DDI-DrugBank.d106.s5.p1	Pharmacokinetic interactions between @DRUG$ and beta-blockers (@DRUG$, propranolol) were variable and not significant.	DDI-false
DDI-DrugBank.d106.s5.p2	Pharmacokinetic interactions between @DRUG$ and beta-blockers (atenolol, @DRUG$) were variable and not significant.	DDI-false
DDI-DrugBank.d106.s5.p3	Pharmacokinetic interactions between nisoldipine and @DRUG$ (@DRUG$, propranolol) were variable and not significant.	DDI-false
DDI-DrugBank.d106.s5.p4	Pharmacokinetic interactions between nisoldipine and @DRUG$ (atenolol, @DRUG$) were variable and not significant.	DDI-false
DDI-DrugBank.d106.s5.p5	Pharmacokinetic interactions between nisoldipine and beta-blockers (@DRUG$, @DRUG$) were variable and not significant.	DDI-false
DDI-DrugBank.d106.s6.p0	@DRUG$ attenuated the heart rate increase following administration of immediate release @DRUG$.	DDI-effect
DDI-DrugBank.d106.s8.p0	@DRUG$ at 648 mg bid decreased the bioavailability (AUC) of @DRUG$ by 26%, but not the peak concentration.	DDI-mechanism
DDI-DrugBank.d107.s12.p0	Agents Increasing Serum Potassium: @DRUG$ and @DRUG$ IV attenuate potassium loss caused by thiazide-type diuretics.	DDI-false
DDI-DrugBank.d107.s12.p1	Agents Increasing Serum Potassium: @DRUG$ and enalapril IV attenuate potassium loss caused by @DRUG$.	DDI-effect
DDI-DrugBank.d107.s12.p2	Agents Increasing Serum Potassium: Enalapril and @DRUG$ IV attenuate potassium loss caused by @DRUG$.	DDI-effect
DDI-DrugBank.d107.s17.p0	It is recommended that serum @DRUG$ levels be monitored frequently if @DRUG$ is administered concomitantly with lithium.	DDI-false
DDI-DrugBank.d107.s17.p1	It is recommended that serum @DRUG$ levels be monitored frequently if enalapril is administered concomitantly with @DRUG$.	DDI-false
DDI-DrugBank.d107.s17.p2	It is recommended that serum lithium levels be monitored frequently if @DRUG$ is administered concomitantly with @DRUG$.	DDI-advise
DDI-DrugBank.d108.s1.p0	In a single study, rats given high intraperitoneal doses of an @DRUG$ plus @DRUG$ experienced severe toxicity, including convulsions and death.	DDI-effect
DDI-DrugBank.d108.s2.p0	Concomitant use of @DRUG$ and other @DRUG$ is generally not recommended because of possible potentiating effects.	DDI-advise
DDI-DrugBank.d109.s0.p0	@DRUG$/@DRUG$, Macrolides, Including Erythromycin	DDI-false
DDI-DrugBank.d109.s0.p1	@DRUG$/Itraconazole, @DRUG$, Including Erythromycin	DDI-false
DDI-DrugBank.d109.s0.p2	@DRUG$/Itraconazole, Macrolides, Including @DRUG$	DDI-false
DDI-DrugBank.d109.s0.p3	Ketoconazole/@DRUG$, @DRUG$, Including Erythromycin	DDI-false
DDI-DrugBank.d109.s0.p4	Ketoconazole/@DRUG$, Macrolides, Including @DRUG$	DDI-false
DDI-DrugBank.d109.s0.p5	Ketoconazole/Itraconazole, @DRUG$, Including @DRUG$	DDI-false
DDI-DrugBank.d11.s0.p0	Drug-Drug Interactions @DRUG$ - @DRUG$ should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.	DDI-false
DDI-DrugBank.d11.s0.p1	Drug-Drug Interactions @DRUG$ - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) @DRUG$ (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.	DDI-false
DDI-DrugBank.d11.s0.p2	Drug-Drug Interactions @DRUG$ - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other @DRUG$) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.	DDI-false
DDI-DrugBank.d11.s0.p3	Drug-Drug Interactions @DRUG$ - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of @DRUG$ on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.	DDI-false
DDI-DrugBank.d11.s0.p4	Drug-Drug Interactions Albuterol - @DRUG$ should be administered with caution to patients being treated with systemically-administered (oral or intravenous) @DRUG$ (or other beta2 agonists) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.	DDI-advise
DDI-DrugBank.d11.s0.p5	Drug-Drug Interactions Albuterol - @DRUG$ should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other @DRUG$) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.	DDI-false
DDI-DrugBank.d11.s0.p6	Drug-Drug Interactions Albuterol - @DRUG$ should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other beta2 agonists) because the action of @DRUG$ on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.	DDI-false
DDI-DrugBank.d11.s0.p7	Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) @DRUG$ (or other @DRUG$) because the action of albuterol on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.	DDI-false
DDI-DrugBank.d11.s0.p8	Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) @DRUG$ (or other beta2 agonists) because the action of @DRUG$ on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.	DDI-false
DDI-DrugBank.d11.s0.p9	Drug-Drug Interactions Albuterol - STRATTERA should be administered with caution to patients being treated with systemically-administered (oral or intravenous) albuterol (or other @DRUG$) because the action of @DRUG$ on the cardiovascular system can be potentiated resulting in increases in heart rate and blood pressure.	DDI-false
DDI-DrugBank.d110.s5.p0	Therefore, @DRUG$ should not be used in any condition in which a @DRUG$ is being employed.	DDI-advise
DDI-DrugBank.d113.s3.p0	The urinary excretion of @DRUG$ is unaffected by @DRUG$, indicating no change in meclofenamate sodium absorption.	DDI-false
DDI-DrugBank.d113.s3.p1	The urinary excretion of @DRUG$ is unaffected by aspirin, indicating no change in @DRUG$ absorption.	DDI-false
DDI-DrugBank.d113.s3.p2	The urinary excretion of meclofenamate sodium is unaffected by @DRUG$, indicating no change in @DRUG$ absorption.	DDI-false
DDI-DrugBank.d113.s6.p0	@DRUG$: The concurrent administration of @DRUG$ does not affect the bioavailability of meclofenamate sodium.	DDI-false
DDI-DrugBank.d113.s6.p1	@DRUG$: The concurrent administration of propoxyphene hydrochloride does not affect the bioavailability of @DRUG$.	DDI-false
DDI-DrugBank.d113.s6.p2	Propoxyphene: The concurrent administration of @DRUG$ does not affect the bioavailability of @DRUG$.	DDI-false
DDI-DrugBank.d113.s7.p0	@DRUG$: Concomitant administration of @DRUG$s does not interfere with absorption of meclofenamate sodium.	DDI-false
DDI-DrugBank.d113.s7.p1	@DRUG$: Concomitant administration of aluminum and @DRUG$s does not interfere with absorption of meclofenamate sodium.	DDI-false
DDI-DrugBank.d113.s7.p2	@DRUG$: Concomitant administration of aluminum and magnesium hydroxides does not interfere with absorption of @DRUG$.	DDI-false
DDI-DrugBank.d113.s7.p3	Antacids: Concomitant administration of @DRUG-DRUG$s does not interfere with absorption of meclofenamate sodium.	DDI-false
DDI-DrugBank.d113.s7.p4	Antacids: Concomitant administration of @DRUG$s does not interfere with absorption of @DRUG$.	DDI-false
DDI-DrugBank.d113.s7.p5	Antacids: Concomitant administration of aluminum and @DRUG$s does not interfere with absorption of @DRUG$.	DDI-false
DDI-DrugBank.d115.s16.p0	Systemic exposure to @DRUG$ is expected to be increased when coadministered with @DRUG$.	DDI-mechanism
DDI-DrugBank.d115.s3.p0	Drugs that may decrease @DRUG$ plasma concentrations: Substances that are inducers of CYP3A4 activity may increase metabolism and decrease @DRUG$ plasma concentrations.	DDI-false
DDI-DrugBank.d115.s8.p0	Drugs that may have their plasma concentration altered by @DRUG$ @DRUG$ increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.	DDI-false
DDI-DrugBank.d115.s8.p1	Drugs that may have their plasma concentration altered by @DRUG$ Gleevec increases the mean cmax and AUC of @DRUG$ (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.	DDI-false
DDI-DrugBank.d115.s8.p2	Drugs that may have their plasma concentration altered by @DRUG$ Gleevec increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by @DRUG$.	DDI-false
DDI-DrugBank.d115.s8.p3	Drugs that may have their plasma concentration altered by Gleevec @DRUG$ increases the mean cmax and AUC of @DRUG$ (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by Gleevec.	DDI-mechanism
DDI-DrugBank.d115.s8.p4	Drugs that may have their plasma concentration altered by Gleevec @DRUG$ increases the mean cmax and AUC of simvastatin (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by @DRUG$.	DDI-false
DDI-DrugBank.d115.s8.p5	Drugs that may have their plasma concentration altered by Gleevec Gleevec increases the mean cmax and AUC of @DRUG$ (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by @DRUG$.	DDI-false
DDI-DrugBank.d119.s2.p0	@DRUG$    Prolonged action of @DRUG$	DDI-false
DDI-DrugBank.d12.s8.p0	While it is not known whether this interaction occurs with @DRUG$ other than @DRUG$, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including clofibrate.	DDI-false
DDI-DrugBank.d12.s8.p1	While it is not known whether this interaction occurs with @DRUG$ other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of @DRUG$ alone, including clofibrate.	DDI-false
DDI-DrugBank.d12.s8.p2	While it is not known whether this interaction occurs with @DRUG$ other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including @DRUG$.	DDI-false
DDI-DrugBank.d12.s8.p3	While it is not known whether this interaction occurs with fibrates other than @DRUG$, myopathy and rhabdomyolysis have occasionally been associated with the use of @DRUG$ alone, including clofibrate.	DDI-false
DDI-DrugBank.d12.s8.p4	While it is not known whether this interaction occurs with fibrates other than @DRUG$, myopathy and rhabdomyolysis have occasionally been associated with the use of fibrates alone, including @DRUG$.	DDI-false
DDI-DrugBank.d12.s8.p5	While it is not known whether this interaction occurs with fibrates other than gemfibrozil, myopathy and rhabdomyolysis have occasionally been associated with the use of @DRUG$ alone, including @DRUG$.	DDI-false
DDI-DrugBank.d122.s1.p0	Renal function should be carefully monitored, especially if higher dosages of the @DRUG$ are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of @DRUG$.	DDI-false
DDI-DrugBank.d123.s0.p0	Some @DRUG$, including @DRUG$, have also been shown to interfere with the metabolism of caffeine.	DDI-false
DDI-DrugBank.d123.s0.p1	Some @DRUG$, including ciprofloxacin, have also been shown to interfere with the metabolism of @DRUG$.	DDI-mechanism
DDI-DrugBank.d123.s0.p2	Some quinolones, including @DRUG$, have also been shown to interfere with the metabolism of @DRUG$.	DDI-mechanism
DDI-DrugBank.d123.s2.p0	Some @DRUG$, including @DRUG$, have been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.	DDI-false
DDI-DrugBank.d123.s2.p1	Some @DRUG$, including ciprofloxacin, have been associated with transient elevations in serum creatinine in patients receiving @DRUG$ concomitantly.	DDI-effect
DDI-DrugBank.d123.s2.p2	Some quinolones, including @DRUG$, have been associated with transient elevations in serum creatinine in patients receiving @DRUG$ concomitantly.	DDI-effect
DDI-DrugBank.d124.s12.p0	Drugs That Should Not Be Coadministered With @DRUG$/@DRUG$	DDI-false
DDI-DrugBank.d124.s22.p0	@DRUG$: @DRUG$, simvastatin WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis.	DDI-false
DDI-DrugBank.d124.s22.p1	@DRUG$: lovastatin, @DRUG$ WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis.	DDI-false
DDI-DrugBank.d124.s22.p2	HMG-CoA Reductase Inhibitors: @DRUG$, @DRUG$ WARNING potential for serious reactions such as risk of myopathy including rhabdomyolysis.	DDI-false
DDI-DrugBank.d124.s28.p0	Since @DRUG$ is coadministered with @DRUG$, the ritonavir label should be reviewed for additional drugs that should not be coadministered.	DDI-advise
DDI-DrugBank.d124.s28.p1	Since @DRUG$ is coadministered with ritonavir, the @DRUG$ label should be reviewed for additional drugs that should not be coadministered.	DDI-false
DDI-DrugBank.d124.s28.p2	Since INVIRASE is coadministered with @DRUG$, the @DRUG$ label should be reviewed for additional drugs that should not be coadministered.	DDI-false
DDI-DrugBank.d124.s3.p0	Because @DRUG$ is coadministered, prescribers should also refer to the prescribing information for @DRUG$ regarding drug interactions associated with this agent.	DDI-false
DDI-DrugBank.d128.s0.p0	May interact with wthionamide (@DRUG$) and @DRUG$ (Nydrazid).	DDI-false
DDI-DrugBank.d128.s0.p1	May interact with wthionamide (@DRUG$) and isoniazid (@DRUG$).	DDI-false
DDI-DrugBank.d128.s0.p2	May interact with wthionamide (Trecator-SC) and @DRUG$ (@DRUG$).	DDI-false
DDI-DrugBank.d129.s3.p0	In diabetic patients, the metabolic effects of @DRUG$ may decrease blood glucose and therefore, @DRUG$ requirements.	DDI-effect
DDI-DrugBank.d131.s0.p0	The @DRUG$, including @DRUG$, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.	DDI-false
DDI-DrugBank.d131.s0.p1	The @DRUG$, including alprazolam, produce additive CNS depressant effects when co-administered with other @DRUG$, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.	DDI-effect
DDI-DrugBank.d131.s0.p2	The @DRUG$, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, @DRUG$, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.	DDI-effect
DDI-DrugBank.d131.s0.p3	The @DRUG$, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, @DRUG$, ethanol, and other drugs which themselves produce CNS depression.	DDI-effect
DDI-DrugBank.d131.s0.p4	The @DRUG$, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, @DRUG$, and other drugs which themselves produce CNS depression.	DDI-effect
DDI-DrugBank.d131.s0.p5	The benzodiazepines, including @DRUG$, produce additive CNS depressant effects when co-administered with other @DRUG$, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.	DDI-effect
DDI-DrugBank.d131.s0.p6	The benzodiazepines, including @DRUG$, produce additive CNS depressant effects when co-administered with other psychotropic medications, @DRUG$, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.	DDI-effect
DDI-DrugBank.d131.s0.p7	The benzodiazepines, including @DRUG$, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, @DRUG$, ethanol, and other drugs which themselves produce CNS depression.	DDI-effect
DDI-DrugBank.d131.s0.p8	The benzodiazepines, including @DRUG$, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, @DRUG$, and other drugs which themselves produce CNS depression.	DDI-effect
DDI-DrugBank.d131.s0.p9	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other @DRUG$, @DRUG$, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.	DDI-false
DDI-DrugBank.d131.s0.p10	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other @DRUG$, anticonvulsants, @DRUG$, ethanol, and other drugs which themselves produce CNS depression.	DDI-false
DDI-DrugBank.d131.s0.p11	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other @DRUG$, anticonvulsants, antihistaminics, @DRUG$, and other drugs which themselves produce CNS depression.	DDI-false
DDI-DrugBank.d131.s0.p12	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, @DRUG$, @DRUG$, ethanol, and other drugs which themselves produce CNS depression.	DDI-false
DDI-DrugBank.d131.s0.p13	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, @DRUG$, antihistaminics, @DRUG$, and other drugs which themselves produce CNS depression.	DDI-false
DDI-DrugBank.d131.s0.p14	The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, @DRUG$, @DRUG$, and other drugs which themselves produce CNS depression.	DDI-false
DDI-DrugBank.d131.s7.p0	Coadministration of oral @DRUG$ increased the maximum plasma concentration of @DRUG$ by 18%, decreased clearance by 22%, and increased half-life by 29%.	DDI-mechanism
DDI-DrugBank.d131.s8.p0	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p1	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p2	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p3	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p4	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p5	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p6	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p7	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p8	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p9	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p10	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p11	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving @DRUG$ metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p12	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p13	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p14	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p15	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p16	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p17	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p18	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p19	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p20	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p21	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p22	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to @DRUG$ or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p23	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p24	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p25	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p26	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p27	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p28	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p29	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p30	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p31	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p32	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with @DRUG$ or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p33	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p34	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p35	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p36	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p37	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p38	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p39	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p40	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p41	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other @DRUG$ (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p42	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p43	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p44	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p45	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p46	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p47	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p48	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p49	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with @DRUG$): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p50	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p51	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p52	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p53	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p54	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p55	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p56	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of @DRUG$ other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p57	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p58	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p59	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p60	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p61	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p62	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p63	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-int
DDI-DrugBank.d131.s8.p64	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-int
DDI-DrugBank.d131.s8.p65	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.	DDI-int
DDI-DrugBank.d131.s8.p66	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.	DDI-int
DDI-DrugBank.d131.s8.p67	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with @DRUG$ for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.	DDI-int
DDI-DrugBank.d131.s8.p68	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, @DRUG$, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p69	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p70	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p71	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$, isoniazid, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p72	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, @DRUG$ such as erythromycin and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p73	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as @DRUG$ and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p74	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, @DRUG$, macrolide antibiotics such as erythromycin and @DRUG$, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p75	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as @DRUG$ and clarithromycin, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p76	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, @DRUG$ such as erythromycin and @DRUG$, and grapefruit juice.	DDI-false
DDI-DrugBank.d131.s8.p77	Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as @DRUG$ and @DRUG$, and grapefruit juice.	DDI-false
DDI-DrugBank.d132.s0.p0	Oral @DRUG$: In some normal volunteers, the concomitant administration of @DRUG$ and warfarin, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.	DDI-false
DDI-DrugBank.d132.s0.p1	Oral @DRUG$: In some normal volunteers, the concomitant administration of diflunisal and @DRUG$, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.	DDI-false
DDI-DrugBank.d132.s0.p2	Oral @DRUG$: In some normal volunteers, the concomitant administration of diflunisal and warfarin, @DRUG$, or phenprocoumon resulted in prolongation of prothrombin time.	DDI-false
DDI-DrugBank.d132.s0.p3	Oral @DRUG$: In some normal volunteers, the concomitant administration of diflunisal and warfarin, acenocoumarol, or @DRUG$ resulted in prolongation of prothrombin time.	DDI-false
DDI-DrugBank.d132.s0.p4	Oral Anticoagulants: In some normal volunteers, the concomitant administration of @DRUG$ and @DRUG$, acenocoumarol, or phenprocoumon resulted in prolongation of prothrombin time.	DDI-effect
DDI-DrugBank.d132.s0.p5	Oral Anticoagulants: In some normal volunteers, the concomitant administration of @DRUG$ and warfarin, @DRUG$, or phenprocoumon resulted in prolongation of prothrombin time.	DDI-effect
DDI-DrugBank.d132.s0.p6	Oral Anticoagulants: In some normal volunteers, the concomitant administration of @DRUG$ and warfarin, acenocoumarol, or @DRUG$ resulted in prolongation of prothrombin time.	DDI-effect
DDI-DrugBank.d132.s0.p7	Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and @DRUG$, @DRUG$, or phenprocoumon resulted in prolongation of prothrombin time.	DDI-false
DDI-DrugBank.d132.s0.p8	Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and @DRUG$, acenocoumarol, or @DRUG$ resulted in prolongation of prothrombin time.	DDI-false
DDI-DrugBank.d132.s0.p9	Oral Anticoagulants: In some normal volunteers, the concomitant administration of diflunisal and warfarin, @DRUG$, or @DRUG$ resulted in prolongation of prothrombin time.	DDI-false
DDI-DrugBank.d132.s12.p0	@DRUG$ had no effect on plasma levels of @DRUG$.	DDI-false
DDI-DrugBank.d132.s13.p0	Since @DRUG$ in high doses has been associated with hepatotoxicity, concomitant administration of @DRUG$ and acetaminophen should be used cautiously, with careful monitoring of patients.	DDI-false
DDI-DrugBank.d132.s13.p1	Since @DRUG$ in high doses has been associated with hepatotoxicity, concomitant administration of diflunisal and @DRUG$ should be used cautiously, with careful monitoring of patients.	DDI-false
DDI-DrugBank.d132.s13.p2	Since acetaminophen in high doses has been associated with hepatotoxicity, concomitant administration of @DRUG$ and @DRUG$ should be used cautiously, with careful monitoring of patients.	DDI-advise
DDI-DrugBank.d132.s14.p0	Concomitant administration of @DRUG$ and @DRUG$ in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.	DDI-effect
DDI-DrugBank.d132.s14.p1	Concomitant administration of @DRUG$ and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of @DRUG$/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.	DDI-false
DDI-DrugBank.d132.s14.p2	Concomitant administration of @DRUG$ and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/@DRUG$) resulted in greater gastrointestinal toxicity than when either drug was administered alone.	DDI-false
DDI-DrugBank.d132.s14.p3	Concomitant administration of diflunisal and @DRUG$ in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of @DRUG$/acetaminophen) resulted in greater gastrointestinal toxicity than when either drug was administered alone.	DDI-false
DDI-DrugBank.d132.s14.p4	Concomitant administration of diflunisal and @DRUG$ in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of diflunisal/@DRUG$) resulted in greater gastrointestinal toxicity than when either drug was administered alone.	DDI-false
DDI-DrugBank.d132.s14.p5	Concomitant administration of diflunisal and acetaminophen in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of @DRUG$/@DRUG$) resulted in greater gastrointestinal toxicity than when either drug was administered alone.	DDI-false
DDI-DrugBank.d132.s7.p0	@DRUG$: In normal volunteers, the concomitant administration of @DRUG$ and furosemide had no effect on the diuretic activity of furosemide.	DDI-false
DDI-DrugBank.d132.s7.p1	@DRUG$: In normal volunteers, the concomitant administration of diflunisal and @DRUG$ had no effect on the diuretic activity of furosemide.	DDI-false
DDI-DrugBank.d132.s7.p2	@DRUG$: In normal volunteers, the concomitant administration of diflunisal and furosemide had no effect on the diuretic activity of @DRUG$.	DDI-false
DDI-DrugBank.d132.s7.p3	Furosemide: In normal volunteers, the concomitant administration of @DRUG$ and @DRUG$ had no effect on the diuretic activity of furosemide.	DDI-false
DDI-DrugBank.d132.s7.p4	Furosemide: In normal volunteers, the concomitant administration of @DRUG$ and furosemide had no effect on the diuretic activity of @DRUG$.	DDI-false
DDI-DrugBank.d132.s7.p5	Furosemide: In normal volunteers, the concomitant administration of diflunisal and @DRUG$ had no effect on the diuretic activity of @DRUG$.	DDI-false
DDI-DrugBank.d133.s2.p0	Excessive neuromuscular weakness may be exacerbated by administration of another @DRUG$ prior to the resolution of the effects of a previously administered @DRUG$.	DDI-effect
DDI-DrugBank.d137.s1.p0	Sublingual @DRUG$ may be taken if necessary for the control of acute angina attacks during @DRUG$ therapy.	DDI-false
DDI-DrugBank.d137.s7.p0	Oral @DRUG$: @DRUG$ has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral hypoglycemic agents.	DDI-false
DDI-DrugBank.d137.s7.p1	Oral @DRUG$: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for @DRUG$ or oral hypoglycemic agents.	DDI-false
DDI-DrugBank.d137.s7.p2	Oral @DRUG$: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral @DRUG$.	DDI-false
DDI-DrugBank.d137.s7.p3	Oral Hypoglycemics: @DRUG$ has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for @DRUG$ or oral hypoglycemic agents.	DDI-false
DDI-DrugBank.d137.s7.p4	Oral Hypoglycemics: @DRUG$ has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for insulin or oral @DRUG$.	DDI-false
DDI-DrugBank.d137.s7.p5	Oral Hypoglycemics: Bepridil has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for @DRUG$ or oral @DRUG$.	DDI-false
DDI-DrugBank.d138.s0.p0	Although specific drug interaction studies have not been conducted with @DRUG$, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.	DDI-advise
DDI-DrugBank.d138.s0.p1	Although specific drug interaction studies have not been conducted with @DRUG$, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, sedatives, or anesthetics) should be considered.	DDI-advise
DDI-DrugBank.d138.s0.p2	Although specific drug interaction studies have not been conducted with @DRUG$, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, opiates, sedatives, or anesthetics) should be considered.	DDI-advise
DDI-DrugBank.d138.s0.p3	Although specific drug interaction studies have not been conducted with @DRUG$, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, @DRUG$, sedatives, or anesthetics) should be considered.	DDI-advise
DDI-DrugBank.d138.s0.p4	Although specific drug interaction studies have not been conducted with @DRUG$, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, @DRUG$, or anesthetics) should be considered.	DDI-advise
DDI-DrugBank.d138.s0.p5	Although specific drug interaction studies have not been conducted with @DRUG$, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or @DRUG$) should be considered.	DDI-advise
DDI-DrugBank.d138.s0.p6	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with @DRUG$ (@DRUG$, barbiturates, opiates, sedatives, or anesthetics) should be considered.	DDI-false
DDI-DrugBank.d138.s0.p7	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, @DRUG$, opiates, sedatives, or anesthetics) should be considered.	DDI-false
DDI-DrugBank.d138.s0.p8	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, @DRUG$, sedatives, or anesthetics) should be considered.	DDI-false
DDI-DrugBank.d138.s0.p9	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, @DRUG$, or anesthetics) should be considered.	DDI-false
DDI-DrugBank.d138.s0.p10	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, sedatives, or @DRUG$) should be considered.	DDI-false
DDI-DrugBank.d138.s0.p11	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, @DRUG$, opiates, sedatives, or anesthetics) should be considered.	DDI-false
DDI-DrugBank.d138.s0.p12	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, @DRUG$, sedatives, or anesthetics) should be considered.	DDI-false
DDI-DrugBank.d138.s0.p13	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, @DRUG$, or anesthetics) should be considered.	DDI-false
DDI-DrugBank.d138.s0.p14	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, sedatives, or @DRUG$) should be considered.	DDI-false
DDI-DrugBank.d138.s0.p15	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, @DRUG$, sedatives, or anesthetics) should be considered.	DDI-false
DDI-DrugBank.d138.s0.p16	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, opiates, @DRUG$, or anesthetics) should be considered.	DDI-false
DDI-DrugBank.d138.s0.p17	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, opiates, sedatives, or @DRUG$) should be considered.	DDI-false
DDI-DrugBank.d138.s0.p18	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, @DRUG$, @DRUG$, or anesthetics) should be considered.	DDI-false
DDI-DrugBank.d138.s0.p19	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, @DRUG$, sedatives, or @DRUG$) should be considered.	DDI-false
DDI-DrugBank.d138.s0.p20	Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, @DRUG$, or @DRUG$) should be considered.	DDI-false
DDI-DrugBank.d138.s2.p0	Caution in using concomitant drugs such as @DRUG$ (ophthalmic and systemic), @DRUG$ and/or cardiac glycosides is advised.	DDI-false
DDI-DrugBank.d138.s2.p1	Caution in using concomitant drugs such as @DRUG$ (ophthalmic and systemic), anti-hypertensives and/or @DRUG$ is advised.	DDI-false
DDI-DrugBank.d138.s2.p2	Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), @DRUG$ and/or @DRUG$ is advised.	DDI-false
DDI-DrugBank.d14.s0.p0	The vasodilating effects of @DRUG$ may be additive with those of other @DRUG$.	DDI-effect
DDI-DrugBank.d14.s2.p0	Marked symptomatic orthostatic hypotension has been reported when @DRUG$ and organic @DRUG$ were used in combination.	DDI-effect
DDI-DrugBank.d140.s1.p0	@DRUG$: When @DRUG$ and Maalox TC suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.	DDI-false
DDI-DrugBank.d140.s1.p1	@DRUG$: When atorvastatin and @DRUG$ suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.	DDI-false
DDI-DrugBank.d140.s1.p2	@DRUG$: When atorvastatin and Maalox TC suspension were coadministered, plasma concentrations of @DRUG$ decreased approximately 35%.	DDI-false
DDI-DrugBank.d140.s1.p3	Antacid: When @DRUG$ and @DRUG$ suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%.	DDI-mechanism
DDI-DrugBank.d140.s1.p4	Antacid: When @DRUG$ and Maalox TC suspension were coadministered, plasma concentrations of @DRUG$ decreased approximately 35%.	DDI-false
DDI-DrugBank.d140.s1.p5	Antacid: When atorvastatin and @DRUG$ suspension were coadministered, plasma concentrations of @DRUG$ decreased approximately 35%.	DDI-false
DDI-DrugBank.d141.s0.p0	@DRUG$, @DRUG$, Niacin (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle.	DDI-false
DDI-DrugBank.d141.s0.p1	@DRUG$, Fibric Acid Derivatives, @DRUG$ (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle.	DDI-false
DDI-DrugBank.d141.s0.p2	@DRUG$, Fibric Acid Derivatives, Niacin (@DRUG$, Erythromycin, Azole Antifungals: Skeletal Muscle.	DDI-false
DDI-DrugBank.d141.s0.p3	@DRUG$, Fibric Acid Derivatives, Niacin (Nicotinic Acid, @DRUG$, Azole Antifungals: Skeletal Muscle.	DDI-false
DDI-DrugBank.d141.s0.p4	@DRUG$, Fibric Acid Derivatives, Niacin (Nicotinic Acid, Erythromycin, @DRUG$: Skeletal Muscle.	DDI-false
DDI-DrugBank.d141.s0.p5	Immunosuppressive Drugs, @DRUG$, @DRUG$ (Nicotinic Acid, Erythromycin, Azole Antifungals: Skeletal Muscle.	DDI-false
DDI-DrugBank.d141.s0.p6	Immunosuppressive Drugs, @DRUG$, Niacin (@DRUG$, Erythromycin, Azole Antifungals: Skeletal Muscle.	DDI-false
DDI-DrugBank.d141.s0.p7	Immunosuppressive Drugs, @DRUG$, Niacin (Nicotinic Acid, @DRUG$, Azole Antifungals: Skeletal Muscle.	DDI-false
DDI-DrugBank.d141.s0.p8	Immunosuppressive Drugs, @DRUG$, Niacin (Nicotinic Acid, Erythromycin, @DRUG$: Skeletal Muscle.	DDI-false
DDI-DrugBank.d141.s0.p9	Immunosuppressive Drugs, Fibric Acid Derivatives, @DRUG$ (@DRUG$, Erythromycin, Azole Antifungals: Skeletal Muscle.	DDI-false
DDI-DrugBank.d141.s0.p10	Immunosuppressive Drugs, Fibric Acid Derivatives, @DRUG$ (Nicotinic Acid, @DRUG$, Azole Antifungals: Skeletal Muscle.	DDI-false
DDI-DrugBank.d141.s0.p11	Immunosuppressive Drugs, Fibric Acid Derivatives, @DRUG$ (Nicotinic Acid, Erythromycin, @DRUG$: Skeletal Muscle.	DDI-false
DDI-DrugBank.d141.s0.p12	Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (@DRUG$, @DRUG$, Azole Antifungals: Skeletal Muscle.	DDI-false
DDI-DrugBank.d141.s0.p13	Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (@DRUG$, Erythromycin, @DRUG$: Skeletal Muscle.	DDI-false
DDI-DrugBank.d141.s0.p14	Immunosuppressive Drugs, Fibric Acid Derivatives, Niacin (Nicotinic Acid, @DRUG$, @DRUG$: Skeletal Muscle.	DDI-false
DDI-DrugBank.d141.s2.p0	@DRUG$: @DRUG$ plasma concentrations were not affected by co-administration of cimetidine.	DDI-false
DDI-DrugBank.d141.s2.p1	@DRUG$: Cerivastatin plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
DDI-DrugBank.d141.s2.p2	CIMETlDINE: @DRUG$ plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
DDI-DrugBank.d141.s3.p0	@DRUG$: The influence of the bile-acidsequestering agent @DRUG$ on the pharmacokinetits of cerivastatin sodium was evaluated in 12 healthy males in 2 separate randomized crossover studies.	DDI-false
DDI-DrugBank.d141.s3.p1	@DRUG$: The influence of the bile-acidsequestering agent cholestyramine on the pharmacokinetits of @DRUG$ was evaluated in 12 healthy males in 2 separate randomized crossover studies.	DDI-false
DDI-DrugBank.d141.s3.p2	CHOLESTYRAMINE: The influence of the bile-acidsequestering agent @DRUG$ on the pharmacokinetits of @DRUG$ was evaluated in 12 healthy males in 2 separate randomized crossover studies.	DDI-false
DDI-DrugBank.d141.s8.p0	@DRUG$ plasma concentrations were also not affected by co-administration of @DRUG$.	DDI-false
DDI-DrugBank.d143.s10.p0	A case report of one patient taking @DRUG$ 200 mg and @DRUG$ 800 mg three times a day resulted in increases in amiodarone concentrations from 0.9 mg/L to 1.3 mg/L.	DDI-mechanism
DDI-DrugBank.d143.s10.p1	A case report of one patient taking @DRUG$ 200 mg and indinavir 800 mg three times a day resulted in increases in @DRUG$ concentrations from 0.9 mg/L to 1.3 mg/L.	DDI-false
DDI-DrugBank.d143.s10.p2	A case report of one patient taking amiodarone 200 mg and @DRUG$ 800 mg three times a day resulted in increases in @DRUG$ concentrations from 0.9 mg/L to 1.3 mg/L.	DDI-false
DDI-DrugBank.d143.s14.p0	@DRUG$: @DRUG$ inhibits CYP3A4 and can increase serum amiodarone levels.	DDI-mechanism
DDI-DrugBank.d143.s14.p1	@DRUG$: Cimetidine inhibits CYP3A4 and can increase serum @DRUG$ levels.	DDI-false
DDI-DrugBank.d143.s14.p2	Histamine H2 antagonists: @DRUG$ inhibits CYP3A4 and can increase serum @DRUG$ levels.	DDI-false
DDI-DrugBank.d143.s17.p0	This information should be considered when changing from intravenous @DRUG$ to oral @DRUG$ .	DDI-false
DDI-DrugBank.d143.s20.p0	Reported examples of this interaction include the following: @DRUG$s: @DRUG$ (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.	DDI-false
DDI-DrugBank.d143.s20.p1	Reported examples of this interaction include the following: @DRUG$s: Cyclosporine (@DRUG$ substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.	DDI-false
DDI-DrugBank.d143.s20.p2	Reported examples of this interaction include the following: @DRUG$s: Cyclosporine (CYP3A4 substrate) administered in combination with oral @DRUG$ has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.	DDI-false
DDI-DrugBank.d143.s20.p3	Reported examples of this interaction include the following: @DRUG$s: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of @DRUG$ resulting in elevated creatinine, despite reduction in dose of cyclosporine.	DDI-false
DDI-DrugBank.d143.s20.p4	Reported examples of this interaction include the following: @DRUG$s: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of @DRUG$.	DDI-false
DDI-DrugBank.d143.s20.p5	Reported examples of this interaction include the following: Immunosuppressives: @DRUG$ (@DRUG$ substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.	DDI-false
DDI-DrugBank.d143.s20.p6	Reported examples of this interaction include the following: Immunosuppressives: @DRUG$ (CYP3A4 substrate) administered in combination with oral @DRUG$ has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.	DDI-false
DDI-DrugBank.d143.s20.p7	Reported examples of this interaction include the following: Immunosuppressives: @DRUG$ (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of @DRUG$ resulting in elevated creatinine, despite reduction in dose of cyclosporine.	DDI-false
DDI-DrugBank.d143.s20.p8	Reported examples of this interaction include the following: Immunosuppressives: @DRUG$ (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of @DRUG$.	DDI-false
DDI-DrugBank.d143.s20.p9	Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (@DRUG$ substrate) administered in combination with oral @DRUG$ has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of cyclosporine.	DDI-false
DDI-DrugBank.d143.s20.p10	Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (@DRUG$ substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of @DRUG$ resulting in elevated creatinine, despite reduction in dose of cyclosporine.	DDI-false
DDI-DrugBank.d143.s20.p11	Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (@DRUG$ substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of @DRUG$.	DDI-false
DDI-DrugBank.d143.s20.p12	Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral @DRUG$ has been reported to produce persistently elevated plasma concentrations of @DRUG$ resulting in elevated creatinine, despite reduction in dose of cyclosporine.	DDI-false
DDI-DrugBank.d143.s20.p13	Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral @DRUG$ has been reported to produce persistently elevated plasma concentrations of cyclosporine resulting in elevated creatinine, despite reduction in dose of @DRUG$.	DDI-false
DDI-DrugBank.d143.s20.p14	Reported examples of this interaction include the following: Immunosuppressives: Cyclosporine (CYP3A4 substrate) administered in combination with oral amiodarone has been reported to produce persistently elevated plasma concentrations of @DRUG$ resulting in elevated creatinine, despite reduction in dose of @DRUG$.	DDI-false
DDI-DrugBank.d143.s23.p0	@DRUG$ taken concomitantly with @DRUG$ increases the serum digoxin concentration by 70% after one day.	DDI-false
DDI-DrugBank.d143.s23.p1	@DRUG$ taken concomitantly with digoxin increases the serum @DRUG$ concentration by 70% after one day.	DDI-false
DDI-DrugBank.d143.s23.p2	Amiodarone taken concomitantly with @DRUG$ increases the serum @DRUG$ concentration by 70% after one day.	DDI-false
DDI-DrugBank.d143.s40.p0	In @DRUG$-treated patients who require additional @DRUG$ therapy, the initial dose of such agents should be approximately half of the usual recommended dose.	DDI-false
DDI-DrugBank.d143.s47.p0	Reported examples of this interaction include the following: @DRUG$: @DRUG$ is a potent inducer of CYP3A4.	DDI-false
DDI-DrugBank.d143.s47.p1	Reported examples of this interaction include the following: @DRUG$: Rifampin is a potent inducer of @DRUG$.	DDI-false
DDI-DrugBank.d143.s47.p2	Reported examples of this interaction include the following: Antibiotics: @DRUG$ is a potent inducer of @DRUG$.	DDI-false
DDI-DrugBank.d146.s1.p0	The action of @DRUG$ is potentiated by @DRUG$.	DDI-mechanism
DDI-DrugBank.d148.s0.p0	@DRUG$: Since @DRUG$ is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p1	@DRUG$: Since heparin is contraindicated in patients with @DRUG$-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p2	@DRUG$: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of @DRUG$ and heparin is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p3	@DRUG$: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and @DRUG$ is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p4	Heparin: Since @DRUG$ is contraindicated in patients with @DRUG$-induced thrombocytopenia, the co-administration of Argatroban and heparin is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p5	Heparin: Since @DRUG$ is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of @DRUG$ and heparin is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p6	Heparin: Since @DRUG$ is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of Argatroban and @DRUG$ is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p7	Heparin: Since heparin is contraindicated in patients with @DRUG$-induced thrombocytopenia, the co-administration of @DRUG$ and heparin is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p8	Heparin: Since heparin is contraindicated in patients with @DRUG$-induced thrombocytopenia, the co-administration of Argatroban and @DRUG$ is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s0.p9	Heparin: Since heparin is contraindicated in patients with heparin-induced thrombocytopenia, the co-administration of @DRUG$ and @DRUG$ is unlikely for this indication.	DDI-false
DDI-DrugBank.d148.s5.p0	@DRUG$: The safety and effectiveness of @DRUG$ with thrombolytic agents have not been established.	DDI-false
DDI-DrugBank.d148.s5.p1	@DRUG$: The safety and effectiveness of Argatroban with @DRUG$ have not been established.	DDI-false
DDI-DrugBank.d148.s5.p2	Thrombolytic agents: The safety and effectiveness of @DRUG$ with @DRUG$ have not been established.	DDI-false
DDI-DrugBank.d150.s0.p0	@DRUG$ may have life-threatening interactions with @DRUG$.	DDI-int
DDI-DrugBank.d151.s3.p0	@DRUG$ may enhance the toxicity of @DRUG$.	DDI-effect
DDI-DrugBank.d154.s1.p0	Although the mechanism of interaction between @DRUG$ and @DRUG$ is not totally known, enzyme induction and displacement of fenoprofen from plasma albumin binding sites are possibilities.	DDI-mechanism
DDI-DrugBank.d154.s1.p1	Although the mechanism of interaction between @DRUG$ and aspirin is not totally known, enzyme induction and displacement of @DRUG$ from plasma albumin binding sites are possibilities.	DDI-false
DDI-DrugBank.d154.s1.p2	Although the mechanism of interaction between fenoprofen and @DRUG$ is not totally known, enzyme induction and displacement of @DRUG$ from plasma albumin binding sites are possibilities.	DDI-false
DDI-DrugBank.d157.s1.p0	(See CLINICAL PHARMACOLOGY) Coadministration of @DRUG$ and @DRUG$ 20 mg daily resulted in a reduction of letrozole plasma levels by 38% on average.	DDI-mechanism
DDI-DrugBank.d157.s1.p1	(See CLINICAL PHARMACOLOGY) Coadministration of @DRUG$ and tamoxifen 20 mg daily resulted in a reduction of @DRUG$ plasma levels by 38% on average.	DDI-false
DDI-DrugBank.d157.s1.p2	(See CLINICAL PHARMACOLOGY) Coadministration of Femara and @DRUG$ 20 mg daily resulted in a reduction of @DRUG$ plasma levels by 38% on average.	DDI-false
DDI-DrugBank.d158.s16.p0	@DRUG$: @DRUG$ potentiate the analgesic effect of meperidine.	DDI-false
DDI-DrugBank.d158.s16.p1	@DRUG$: Amphetamines potentiate the analgesic effect of @DRUG$.	DDI-false
DDI-DrugBank.d158.s16.p2	Meperidine: @DRUG$ potentiate the analgesic effect of @DRUG$.	DDI-effect
DDI-DrugBank.d158.s19.p0	@DRUG$: @DRUG$ may delay intestinal absorption of phenobarbital;	DDI-false
DDI-DrugBank.d158.s19.p1	@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$;	DDI-false
DDI-DrugBank.d158.s19.p2	Phenobarbital: @DRUG$ may delay intestinal absorption of @DRUG$;	DDI-mechanism
DDI-DrugBank.d158.s23.p0	@DRUG$: In cases of @DRUG$ overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.	DDI-false
DDI-DrugBank.d158.s23.p1	@DRUG$: In cases of propoxyphene overdosage, @DRUG$ CNS stimulation is potentiated and fatal convulsions can occur.	DDI-false
DDI-DrugBank.d158.s23.p2	Propoxyphene: In cases of @DRUG$ overdosage, @DRUG$ CNS stimulation is potentiated and fatal convulsions can occur.	DDI-effect
DDI-DrugBank.d158.s4.p0	@DRUG$ with @DRUG$ or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-mechanism
DDI-DrugBank.d158.s4.p1	@DRUG$ with desipramine or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-mechanism
DDI-DrugBank.d158.s4.p2	@DRUG$ with desipramine or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-mechanism
DDI-DrugBank.d158.s4.p3	@DRUG$ with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	DDI-false
DDI-DrugBank.d158.s4.p4	d-amphetamine with @DRUG$ or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-false
DDI-DrugBank.d158.s4.p5	d-amphetamine with @DRUG$ or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-false
DDI-DrugBank.d158.s4.p6	d-amphetamine with @DRUG$ or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	DDI-false
DDI-DrugBank.d158.s4.p7	d-amphetamine with desipramine or @DRUG$ and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-false
DDI-DrugBank.d158.s4.p8	d-amphetamine with desipramine or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	DDI-false
DDI-DrugBank.d158.s4.p9	d-amphetamine with desipramine or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of @DRUG$ in the brain;	DDI-false
DDI-DrugBank.d16.s2.p0	Since @DRUG$ may raise the serum uric acid level, dosage adjustment of @DRUG$ may be necessary	DDI-effect
DDI-DrugBank.d160.s0.p0	The results of a study of coadministration of @DRUG$ (50 mg/kg) with an @DRUG$ containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.	DDI-mechanism
DDI-DrugBank.d160.s0.p1	The results of a study of coadministration of @DRUG$ (50 mg/kg) with an aluminum hydroxide containing @DRUG$ to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.	DDI-false
DDI-DrugBank.d160.s0.p2	The results of a study of coadministration of @DRUG$ (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of @DRUG$ of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.	DDI-false
DDI-DrugBank.d160.s0.p3	The results of a study of coadministration of @DRUG$ (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of @DRUG$ may be reduced by these antacid products.	DDI-false
DDI-DrugBank.d160.s0.p4	The results of a study of coadministration of @DRUG$ (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these @DRUG$.	DDI-false
DDI-DrugBank.d160.s0.p5	The results of a study of coadministration of ethambutol (50 mg/kg) with an @DRUG$ containing @DRUG$ to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.	DDI-false
DDI-DrugBank.d160.s0.p6	The results of a study of coadministration of ethambutol (50 mg/kg) with an @DRUG$ containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of @DRUG$ of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.	DDI-false
DDI-DrugBank.d160.s0.p7	The results of a study of coadministration of ethambutol (50 mg/kg) with an @DRUG$ containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of @DRUG$ may be reduced by these antacid products.	DDI-false
DDI-DrugBank.d160.s0.p8	The results of a study of coadministration of ethambutol (50 mg/kg) with an @DRUG$ containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these @DRUG$.	DDI-false
DDI-DrugBank.d160.s0.p9	The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing @DRUG$ to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of @DRUG$ of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these antacid products.	DDI-false
DDI-DrugBank.d160.s0.p10	The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing @DRUG$ to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of @DRUG$ may be reduced by these antacid products.	DDI-false
DDI-DrugBank.d160.s0.p11	The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing @DRUG$ to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these @DRUG$.	DDI-false
DDI-DrugBank.d160.s0.p12	The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of @DRUG$ of approximately 20% and 13%, respectively, suggesting that the oral absorption of @DRUG$ may be reduced by these antacid products.	DDI-false
DDI-DrugBank.d160.s0.p13	The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of @DRUG$ of approximately 20% and 13%, respectively, suggesting that the oral absorption of ethambutol may be reduced by these @DRUG$.	DDI-false
DDI-DrugBank.d160.s0.p14	The results of a study of coadministration of ethambutol (50 mg/kg) with an aluminum hydroxide containing antacid to 13 patients with tuberculosis showed a reduction of mean serum concentrations and urinary excretion of ethambutol of approximately 20% and 13%, respectively, suggesting that the oral absorption of @DRUG$ may be reduced by these @DRUG$.	DDI-false
DDI-DrugBank.d162.s6.p0	@DRUG$, @DRUG$: intensified electrolyte depletion, particularly hypokalemia.	DDI-false
DDI-DrugBank.d163.s10.p0	@DRUG$: @DRUG$ has not been shown to alter the pharmacokinetics of phenytoin in a study in seven healthy volunteers.	DDI-false
DDI-DrugBank.d163.s10.p1	@DRUG$: Accutane has not been shown to alter the pharmacokinetics of @DRUG$ in a study in seven healthy volunteers.	DDI-false
DDI-DrugBank.d163.s10.p2	Phenytoin: @DRUG$ has not been shown to alter the pharmacokinetics of @DRUG$ in a study in seven healthy volunteers.	DDI-false
DDI-DrugBank.d165.s11.p0	Coadministration of @DRUG$ with oral @DRUG$ or triazolam has resulted in elevated plasma concentrations of the latter two drugs.	DDI-mechanism
DDI-DrugBank.d165.s11.p1	Coadministration of @DRUG$ with oral midazolam or @DRUG$ has resulted in elevated plasma concentrations of the latter two drugs.	DDI-mechanism
DDI-DrugBank.d165.s11.p2	Coadministration of Itraconazole with oral @DRUG$ or @DRUG$ has resulted in elevated plasma concentrations of the latter two drugs.	DDI-false
DDI-DrugBank.d165.s16.p0	@DRUG$, @DRUG$ and digoxin concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.	DDI-false
DDI-DrugBank.d165.s16.p1	@DRUG$, tacrolimus and @DRUG$ concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.	DDI-false
DDI-DrugBank.d165.s16.p2	@DRUG$, tacrolimus and digoxin concentrations should be monitored at the initiation of @DRUG$ therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.	DDI-advise
DDI-DrugBank.d165.s16.p3	Cyclosporine, @DRUG$ and @DRUG$ concentrations should be monitored at the initiation of Itraconazole therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.	DDI-false
DDI-DrugBank.d165.s16.p4	Cyclosporine, @DRUG$ and digoxin concentrations should be monitored at the initiation of @DRUG$ therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.	DDI-advise
DDI-DrugBank.d165.s16.p5	Cyclosporine, tacrolimus and @DRUG$ concentrations should be monitored at the initiation of @DRUG$ therapy and frequently thereafter, and the dose of these three drug products adjusted appropriately.	DDI-advise
DDI-DrugBank.d165.s21.p0	therefore, plasma concentrations of @DRUG$ should also be monitored when it is given concurrently with @DRUG$.	DDI-advise
DDI-DrugBank.d165.s25.p0	@DRUG$ plasma concentrations should be monitored when @DRUG$ and isoniazid are coadministered.	DDI-false
DDI-DrugBank.d165.s25.p1	@DRUG$ plasma concentrations should be monitored when Itraconazole and @DRUG$ are coadministered.	DDI-false
DDI-DrugBank.d165.s25.p2	Itraconazole plasma concentrations should be monitored when @DRUG$ and @DRUG$ are coadministered.	DDI-advise
DDI-DrugBank.d165.s31.p0	The results from a study in which eight HIV-infected individuals were treated with @DRUG$, 8 +/- 0.4 mg/kg/day, showed that the pharmacokinetics of @DRUG$ were not affected during concomitant administration of Itraconazole, 100 mg b.i.d.	DDI-false
DDI-DrugBank.d165.s31.p1	The results from a study in which eight HIV-infected individuals were treated with @DRUG$, 8 +/- 0.4 mg/kg/day, showed that the pharmacokinetics of zidovudine were not affected during concomitant administration of @DRUG$, 100 mg b.i.d.	DDI-false
DDI-DrugBank.d165.s31.p2	The results from a study in which eight HIV-infected individuals were treated with zidovudine, 8 +/- 0.4 mg/kg/day, showed that the pharmacokinetics of @DRUG$ were not affected during concomitant administration of @DRUG$, 100 mg b.i.d.	DDI-false
DDI-DrugBank.d165.s9.p0	In vitro data suggest that @DRUG$ also markedly inhibits the biotransformation system mainly responsible for the metabolism of @DRUG$;	DDI-mechanism
DDI-DrugBank.d166.s0.p0	@DRUG$ has been found to temporarily raise serum concentrations of @DRUG$.	DDI-mechanism
DDI-DrugBank.d167.s2.p0	In addition, neuromuscular blocking action is enhanced by general @DRUG$, local @DRUG$ like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p1	In addition, neuromuscular blocking action is enhanced by general @DRUG$, local anesthetics like @DRUG$, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p2	In addition, neuromuscular blocking action is enhanced by general @DRUG$, local anesthetics like lidocaine, @DRUG$, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p3	In addition, neuromuscular blocking action is enhanced by general @DRUG$, local anesthetics like lidocaine, procaine, @DRUG$, metaclopramide, lithium carbonate, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p4	In addition, neuromuscular blocking action is enhanced by general @DRUG$, local anesthetics like lidocaine, procaine, beta-blockers, @DRUG$, lithium carbonate, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p5	In addition, neuromuscular blocking action is enhanced by general @DRUG$, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, @DRUG$, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p6	In addition, neuromuscular blocking action is enhanced by general @DRUG$, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and @DRUG$.	DDI-false
DDI-DrugBank.d167.s2.p7	In addition, neuromuscular blocking action is enhanced by general anesthetics, local @DRUG$ like @DRUG$, procaine, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p8	In addition, neuromuscular blocking action is enhanced by general anesthetics, local @DRUG$ like lidocaine, @DRUG$, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p9	In addition, neuromuscular blocking action is enhanced by general anesthetics, local @DRUG$ like lidocaine, procaine, @DRUG$, metaclopramide, lithium carbonate, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p10	In addition, neuromuscular blocking action is enhanced by general anesthetics, local @DRUG$ like lidocaine, procaine, beta-blockers, @DRUG$, lithium carbonate, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p11	In addition, neuromuscular blocking action is enhanced by general anesthetics, local @DRUG$ like lidocaine, procaine, beta-blockers, metaclopramide, @DRUG$, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p12	In addition, neuromuscular blocking action is enhanced by general anesthetics, local @DRUG$ like lidocaine, procaine, beta-blockers, metaclopramide, lithium carbonate, and @DRUG$.	DDI-false
DDI-DrugBank.d167.s2.p13	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like @DRUG$, @DRUG$, beta-blockers, metaclopramide, lithium carbonate, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p14	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like @DRUG$, procaine, @DRUG$, metaclopramide, lithium carbonate, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p15	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like @DRUG$, procaine, beta-blockers, @DRUG$, lithium carbonate, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p16	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like @DRUG$, procaine, beta-blockers, metaclopramide, @DRUG$, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p17	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like @DRUG$, procaine, beta-blockers, metaclopramide, lithium carbonate, and @DRUG$.	DDI-false
DDI-DrugBank.d167.s2.p18	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, @DRUG$, @DRUG$, metaclopramide, lithium carbonate, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p19	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, @DRUG$, beta-blockers, @DRUG$, lithium carbonate, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p20	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, @DRUG$, beta-blockers, metaclopramide, @DRUG$, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p21	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, @DRUG$, beta-blockers, metaclopramide, lithium carbonate, and @DRUG$.	DDI-false
DDI-DrugBank.d167.s2.p22	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, @DRUG$, @DRUG$, lithium carbonate, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p23	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, @DRUG$, metaclopramide, @DRUG$, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p24	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, @DRUG$, metaclopramide, lithium carbonate, and @DRUG$.	DDI-false
DDI-DrugBank.d167.s2.p25	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, @DRUG$, @DRUG$, and terbutaline.	DDI-false
DDI-DrugBank.d167.s2.p26	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, @DRUG$, lithium carbonate, and @DRUG$.	DDI-false
DDI-DrugBank.d167.s2.p27	In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, procaine, beta-blockers, metaclopramide, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d169.s0.p0	Results from human in vitro metabolism studies and nonclinical studies show that @DRUG$  (@DRUG$) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that lenalidomide is not likely to cause or be subject to P450-based metabolic drug interactions in man.	DDI-false
DDI-DrugBank.d169.s0.p1	Results from human in vitro metabolism studies and nonclinical studies show that @DRUG$  (lenalidomide) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that @DRUG$ is not likely to cause or be subject to P450-based metabolic drug interactions in man.	DDI-false
DDI-DrugBank.d169.s0.p2	Results from human in vitro metabolism studies and nonclinical studies show that REVLIMID  (@DRUG$) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that @DRUG$ is not likely to cause or be subject to P450-based metabolic drug interactions in man.	DDI-false
DDI-DrugBank.d169.s1.p0	Co-administration of multiple doses of 10 mg of @DRUG$ had no effect on the single dose pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d169.s1.p1	Co-administration of multiple doses of 10 mg of @DRUG$ had no effect on the single dose pharmacokinetics of R- and @DRUG$.	DDI-false
DDI-DrugBank.d169.s1.p2	Co-administration of multiple doses of 10 mg of lenalidomide had no effect on the single dose pharmacokinetics of @DRUG-DRUG$.	DDI-false
DDI-DrugBank.d17.s21.p0	(Concurrent use with @DRUG$ is not recommended, as they may provoke @DRUG$ toxicity because of reduced renal clearance.)	DDI-false
DDI-DrugBank.d17.s28.p0	(@DRUG$ may decrease arterial responsiveness to @DRUG$.	DDI-effect
DDI-DrugBank.d17.s9.p0	@DRUG$ or @DRUG$ or Corticotropin (ACTH)	DDI-false
DDI-DrugBank.d17.s9.p1	@DRUG$ or Corticosteroids or @DRUG$ (ACTH)	DDI-false
DDI-DrugBank.d17.s9.p2	@DRUG$ or Corticosteroids or Corticotropin (@DRUG$)	DDI-false
DDI-DrugBank.d17.s9.p3	Amphotericin B or @DRUG$ or @DRUG$ (ACTH)	DDI-false
DDI-DrugBank.d17.s9.p4	Amphotericin B or @DRUG$ or Corticotropin (@DRUG$)	DDI-false
DDI-DrugBank.d17.s9.p5	Amphotericin B or Corticosteroids or @DRUG$ (@DRUG$)	DDI-false
DDI-DrugBank.d170.s2.p0	The concomitant use of transdermal @DRUG$ with @DRUG$ or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-mechanism
DDI-DrugBank.d170.s2.p1	The concomitant use of transdermal @DRUG$ with ritonavir or other potent 3A4 inhibitors such as @DRUG$, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-mechanism
DDI-DrugBank.d170.s2.p2	The concomitant use of transdermal @DRUG$ with ritonavir or other potent 3A4 inhibitors such as ketoconazole, @DRUG$, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-mechanism
DDI-DrugBank.d170.s2.p3	The concomitant use of transdermal @DRUG$ with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, @DRUG$, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-mechanism
DDI-DrugBank.d170.s2.p4	The concomitant use of transdermal @DRUG$ with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, @DRUG$, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-mechanism
DDI-DrugBank.d170.s2.p5	The concomitant use of transdermal @DRUG$ with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, @DRUG$, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-mechanism
DDI-DrugBank.d170.s2.p6	The concomitant use of transdermal @DRUG$ with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in @DRUG$ plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p7	The concomitant use of transdermal fentanyl with @DRUG$ or other potent 3A4 inhibitors such as @DRUG$, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p8	The concomitant use of transdermal fentanyl with @DRUG$ or other potent 3A4 inhibitors such as ketoconazole, @DRUG$, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p9	The concomitant use of transdermal fentanyl with @DRUG$ or other potent 3A4 inhibitors such as ketoconazole, itraconazole, @DRUG$, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p10	The concomitant use of transdermal fentanyl with @DRUG$ or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, @DRUG$, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p11	The concomitant use of transdermal fentanyl with @DRUG$ or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, @DRUG$, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p12	The concomitant use of transdermal fentanyl with @DRUG$ or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in @DRUG$ plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p13	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as @DRUG$, @DRUG$, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p14	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as @DRUG$, itraconazole, @DRUG$, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p15	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as @DRUG$, itraconazole, troleandomycin, @DRUG$, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p16	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as @DRUG$, itraconazole, troleandomycin, clarithromycin, @DRUG$, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p17	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as @DRUG$, itraconazole, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in @DRUG$ plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p18	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, @DRUG$, @DRUG$, clarithromycin, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p19	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, @DRUG$, troleandomycin, @DRUG$, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p20	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, @DRUG$, troleandomycin, clarithromycin, @DRUG$, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p21	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, @DRUG$, troleandomycin, clarithromycin, nelfinavir, and nefazadone may result in an increase in @DRUG$ plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p22	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, @DRUG$, @DRUG$, nelfinavir, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p23	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, @DRUG$, clarithromycin, @DRUG$, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p24	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, @DRUG$, clarithromycin, nelfinavir, and nefazadone may result in an increase in @DRUG$ plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p25	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, @DRUG$, @DRUG$, and nefazadone may result in an increase in fentanyl plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p26	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, @DRUG$, nelfinavir, and nefazadone may result in an increase in @DRUG$ plasma concentrations.	DDI-false
DDI-DrugBank.d170.s2.p27	The concomitant use of transdermal fentanyl with ritonavir or other potent 3A4 inhibitors such as ketoconazole, itraconazole, troleandomycin, clarithromycin, @DRUG$, and nefazadone may result in an increase in @DRUG$ plasma concentrations.	DDI-false
DDI-DrugBank.d172.s10.p0	This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
DDI-DrugBank.d172.s13.p0	@DRUG$: @DRUG$ can be used with low dose aspirin.	DDI-false
DDI-DrugBank.d172.s13.p1	@DRUG$: CELEBREX can be used with low dose @DRUG$.	DDI-false
DDI-DrugBank.d172.s13.p2	Aspirin: @DRUG$ can be used with low dose @DRUG$.	DDI-advise
DDI-DrugBank.d172.s15.p0	Because of its lack of platelet effects, @DRUG$ is not a substitute for @DRUG$ for cardiovascular prophylaxis.	DDI-false
DDI-DrugBank.d172.s18.p0	@DRUG$ should be introduced at the lowest recommended dose in patients receiving @DRUG$.	DDI-advise
DDI-DrugBank.d172.s7.p0	Experience with @DRUG$ (@DRUG$) suggests the potential for interactions with furosemide and ACE inhibitors.	DDI-false
DDI-DrugBank.d172.s7.p1	Experience with @DRUG$ (NSAIDs) suggests the potential for interactions with @DRUG$ and ACE inhibitors.	DDI-int
DDI-DrugBank.d172.s7.p2	Experience with @DRUG$ (NSAIDs) suggests the potential for interactions with furosemide and @DRUG$.	DDI-int
DDI-DrugBank.d172.s7.p3	Experience with nonsteroidal anti-inflammatory drugs (@DRUG$) suggests the potential for interactions with @DRUG$ and ACE inhibitors.	DDI-int
DDI-DrugBank.d172.s7.p4	Experience with nonsteroidal anti-inflammatory drugs (@DRUG$) suggests the potential for interactions with furosemide and @DRUG$.	DDI-int
DDI-DrugBank.d172.s7.p5	Experience with nonsteroidal anti-inflammatory drugs (NSAIDs) suggests the potential for interactions with @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d172.s8.p0	The effects @DRUG$ on the pharmacokinetics and/or pharmacodynamics of @DRUG$, ketoconazole, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p1	The effects @DRUG$ on the pharmacokinetics and/or pharmacodynamics of glyburide, @DRUG$, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p2	The effects @DRUG$ on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, @DRUG$, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p3	The effects @DRUG$ on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, @DRUG$, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p4	The effects @DRUG$ on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, @DRUG$, and warfarin have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p5	The effects @DRUG$ on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, tolbutamide, and @DRUG$ have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p6	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of @DRUG$, @DRUG$, methotrexate, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p7	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of @DRUG$, ketoconazole, @DRUG$, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p8	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of @DRUG$, ketoconazole, methotrexate, @DRUG$, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p9	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of @DRUG$, ketoconazole, methotrexate, phenytoin, @DRUG$, and warfarin have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p10	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of @DRUG$, ketoconazole, methotrexate, phenytoin, tolbutamide, and @DRUG$ have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p11	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, @DRUG$, @DRUG$, phenytoin, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p12	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, @DRUG$, methotrexate, @DRUG$, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p13	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, @DRUG$, methotrexate, phenytoin, @DRUG$, and warfarin have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p14	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, @DRUG$, methotrexate, phenytoin, tolbutamide, and @DRUG$ have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p15	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, @DRUG$, @DRUG$, tolbutamide, and warfarin have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p16	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, @DRUG$, phenytoin, @DRUG$, and warfarin have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p17	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, @DRUG$, phenytoin, tolbutamide, and @DRUG$ have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p18	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, @DRUG$, @DRUG$, and warfarin have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p19	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, @DRUG$, tolbutamide, and @DRUG$ have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d172.s8.p20	The effects celecoxib on the pharmacokinetics and/or pharmacodynamics of glyburide, ketoconazole, methotrexate, phenytoin, @DRUG$, and @DRUG$ have been studied in vivo and clinically important interactions have not been found.	DDI-false
DDI-DrugBank.d174.s1.p0	Caution should be exercised when administering @DRUG$ with @DRUG$ since interactions have been seen with other NSAIDs.	DDI-advise
DDI-DrugBank.d174.s1.p1	Caution should be exercised when administering @DRUG$ with warfarin since interactions have been seen with other @DRUG$.	DDI-false
DDI-DrugBank.d174.s1.p2	Caution should be exercised when administering nabumetone with @DRUG$ since interactions have been seen with other @DRUG$.	DDI-int
DDI-DrugBank.d174.s2.p0	Concomitant administration of an @DRUG$-containing @DRUG$ had no significant effect in the bioavailability of 6MNA.	DDI-false
DDI-DrugBank.d174.s2.p1	Concomitant administration of an @DRUG$-containing antacid had no significant effect in the bioavailability of @DRUG$.	DDI-false
DDI-DrugBank.d174.s2.p2	Concomitant administration of an aluminum-containing @DRUG$ had no significant effect in the bioavailability of @DRUG$.	DDI-false
DDI-DrugBank.d175.s10.p0	Agents Affecting Sympathetic Activity The sympathetic nervous system may be especially important in supporting blood pressure in patients receiving @DRUG$ alone or with @DRUG$.	DDI-false
DDI-DrugBank.d175.s12.p0	@DRUG$ add some further antihypertensive effect to @DRUG$, but the overall response is less than additive.	DDI-effect
DDI-DrugBank.d175.s14.p0	@DRUG$ such as @DRUG$, triamterene, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.	DDI-false
DDI-DrugBank.d175.s14.p1	@DRUG$ such as spironolactone, @DRUG$, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.	DDI-false
DDI-DrugBank.d175.s14.p2	@DRUG$ such as spironolactone, triamterene, or @DRUG$, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.	DDI-false
DDI-DrugBank.d175.s14.p3	@DRUG$ such as spironolactone, triamterene, or amiloride, or @DRUG$ supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.	DDI-false
DDI-DrugBank.d175.s14.p4	Potassium-sparing diuretics such as @DRUG$, @DRUG$, or amiloride, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.	DDI-false
DDI-DrugBank.d175.s14.p5	Potassium-sparing diuretics such as @DRUG$, triamterene, or @DRUG$, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.	DDI-false
DDI-DrugBank.d175.s14.p6	Potassium-sparing diuretics such as @DRUG$, triamterene, or amiloride, or @DRUG$ supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.	DDI-false
DDI-DrugBank.d175.s14.p7	Potassium-sparing diuretics such as spironolactone, @DRUG$, or @DRUG$, or potassium supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.	DDI-false
DDI-DrugBank.d175.s14.p8	Potassium-sparing diuretics such as spironolactone, @DRUG$, or amiloride, or @DRUG$ supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.	DDI-false
DDI-DrugBank.d175.s14.p9	Potassium-sparing diuretics such as spironolactone, triamterene, or @DRUG$, or @DRUG$ supplements should be given only for documented hypokalemia, and then with caution, since they may lead to a significant increase of serum potassium.	DDI-false
DDI-DrugBank.d175.s22.p0	@DRUG$: @DRUG$ administered concurrently with captopril does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.	DDI-false
DDI-DrugBank.d175.s22.p1	@DRUG$: Furosemide administered concurrently with @DRUG$ does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.	DDI-false
DDI-DrugBank.d175.s22.p2	@DRUG$: Furosemide administered concurrently with captopril does not alter the pharmacokinetics of @DRUG$ in renally impaired hypertensive patients.	DDI-false
DDI-DrugBank.d175.s22.p3	Loop Diuretics: @DRUG$ administered concurrently with @DRUG$ does not alter the pharmacokinetics of captopril in renally impaired hypertensive patients.	DDI-false
DDI-DrugBank.d175.s22.p4	Loop Diuretics: @DRUG$ administered concurrently with captopril does not alter the pharmacokinetics of @DRUG$ in renally impaired hypertensive patients.	DDI-false
DDI-DrugBank.d175.s22.p5	Loop Diuretics: Furosemide administered concurrently with @DRUG$ does not alter the pharmacokinetics of @DRUG$ in renally impaired hypertensive patients.	DDI-false
DDI-DrugBank.d175.s8.p0	Agents Causing Renin Release @DRUG$'s effect will be augmented by @DRUG$ that cause renin release.	DDI-effect
DDI-DrugBank.d176.s12.p0	In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, @DRUG$, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p1	In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p2	In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, @DRUG$, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p3	In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, hydrochlorothiazide, @DRUG$, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p4	In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, hydrochlorothiazide, cimetidine, @DRUG$, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p5	In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, @DRUG$, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p6	In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p7	In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p8	In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p9	In separate single or multiple dose pharmacokinetic interaction studies with @DRUG$, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p10	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p11	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, @DRUG$, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p12	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, hydrochlorothiazide, @DRUG$, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p13	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, hydrochlorothiazide, cimetidine, @DRUG$, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p14	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, @DRUG$, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p15	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p16	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p17	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p18	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, @DRUG$, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p19	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, @DRUG$, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p20	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, @DRUG$, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p21	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, @DRUG$, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p22	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, @DRUG$, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p23	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p24	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p25	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p26	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, @DRUG$, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p27	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, @DRUG$, @DRUG$, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p28	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, @DRUG$, cimetidine, @DRUG$, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p29	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, @DRUG$, cimetidine, metoclopramide, @DRUG$, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p30	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, @DRUG$, cimetidine, metoclopramide, propantheline, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p31	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, @DRUG$, cimetidine, metoclopramide, propantheline, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p32	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, @DRUG$, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p33	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, @DRUG$, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p34	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, @DRUG$, @DRUG$, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p35	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, @DRUG$, metoclopramide, @DRUG$, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p36	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, @DRUG$, metoclopramide, propantheline, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p37	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, @DRUG$, metoclopramide, propantheline, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p38	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, @DRUG$, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p39	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, @DRUG$, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p40	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, @DRUG$, @DRUG$, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p41	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, @DRUG$, propantheline, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p42	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, @DRUG$, propantheline, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p43	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, @DRUG$, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p44	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, @DRUG$, propantheline, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p45	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, @DRUG$, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p46	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, @DRUG$, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p47	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, @DRUG$, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p48	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, @DRUG$, digoxin, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p49	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, @DRUG$, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p50	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, @DRUG$, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p51	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, @DRUG$, and warfarin, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p52	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and @DRUG$, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p53	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and @DRUG$, the bioavailability of fosinoprilat was not altered by coadministration of @DRUG$ with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s12.p54	In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, propantheline, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of @DRUG$ with any one of these drugs.	DDI-false
DDI-DrugBank.d176.s13.p0	In a study with concomitant administration of @DRUG$ and @DRUG$, the bioavailability of unbound fosinoprilat was not altered.	DDI-false
DDI-DrugBank.d176.s13.p1	In a study with concomitant administration of @DRUG$ and fosinopril sodium, the bioavailability of unbound @DRUG$ was not altered.	DDI-false
DDI-DrugBank.d176.s13.p2	In a study with concomitant administration of aspirin and @DRUG$, the bioavailability of unbound @DRUG$ was not altered.	DDI-false
DDI-DrugBank.d176.s4.p0	@DRUG$ (@DRUG$, amiloride,triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d176.s4.p1	@DRUG$ (spironolactone, @DRUG$,triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d176.s4.p2	@DRUG$ (spironolactone, amiloride,@DRUG$, and others) or potassium supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d176.s4.p3	@DRUG$ (spironolactone, amiloride,triamterene, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d176.s4.p4	Potassium-sparing diuretics (@DRUG$, @DRUG$,triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d176.s4.p5	Potassium-sparing diuretics (@DRUG$, amiloride,@DRUG$, and others) or potassium supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d176.s4.p6	Potassium-sparing diuretics (@DRUG$, amiloride,triamterene, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d176.s4.p7	Potassium-sparing diuretics (spironolactone, @DRUG$,@DRUG$, and others) or potassium supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d176.s4.p8	Potassium-sparing diuretics (spironolactone, @DRUG$,triamterene, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d176.s4.p9	Potassium-sparing diuretics (spironolactone, amiloride,@DRUG$, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d176.s6.p0	@DRUG$: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.	DDI-false
DDI-DrugBank.d176.s6.p1	@DRUG$: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.	DDI-false
DDI-DrugBank.d176.s6.p2	@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving @DRUG$ during therapy with lithium.	DDI-false
DDI-DrugBank.d176.s6.p3	@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with @DRUG$.	DDI-false
DDI-DrugBank.d176.s6.p4	Lithium: Increased serum @DRUG$ levels and symptoms of @DRUG$ toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.	DDI-false
DDI-DrugBank.d176.s6.p5	Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving @DRUG$ during therapy with lithium.	DDI-false
DDI-DrugBank.d176.s6.p6	Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with @DRUG$.	DDI-false
DDI-DrugBank.d176.s6.p7	Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving @DRUG$ during therapy with lithium.	DDI-false
DDI-DrugBank.d176.s6.p8	Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving ACE inhibitors during therapy with @DRUG$.	DDI-false
DDI-DrugBank.d176.s6.p9	Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving @DRUG$ during therapy with @DRUG$.	DDI-effect
DDI-DrugBank.d178.s13.p0	Coadministration of gly-buride and @DRUG$ did not result in any changes in either @DRUG$ pharmacokinetics or pharmaco-dynamics.	DDI-false
DDI-DrugBank.d179.s18.p0	- @DRUG$ (e.g., @DRUG$) (with long-term, high-dose use) or	DDI-false
DDI-DrugBank.d179.s2.p0	- @DRUG$ (e.g., @DRUG$) or	DDI-false
DDI-DrugBank.d179.s21.p0	- @DRUG$ (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p1	- @DRUG$ (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p2	- @DRUG$ (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p3	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p4	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p5	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p6	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p7	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p8	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p9	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p10	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p11	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p12	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p13	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p14	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p15	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p16	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p17	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p18	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p19	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p20	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p21	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p22	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p23	- @DRUG$ (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p24	- Phenothiazines (@DRUG$ [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p25	- Phenothiazines (@DRUG$ [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p26	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p27	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p28	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p29	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p30	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p31	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p32	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p33	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p34	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p35	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p36	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p37	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p38	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p39	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p40	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p41	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p42	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p43	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p44	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p45	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p46	- Phenothiazines (@DRUG$ [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p47	- Phenothiazines (acetophenazine [e.g., @DRUG$], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p48	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p49	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p50	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p51	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p52	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p53	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p54	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p55	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p56	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p57	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p58	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p59	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p60	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p61	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p62	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p63	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p64	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p65	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p66	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p67	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p68	- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p69	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p70	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p71	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p72	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p73	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p74	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p75	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p76	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p77	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p78	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p79	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p80	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p81	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p82	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p83	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p84	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p85	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p86	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p87	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p88	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p89	- Phenothiazines (acetophenazine [e.g., Tindal], @DRUG$ [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p90	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p91	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p92	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p93	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p94	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p95	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p96	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p97	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p98	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p99	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p100	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p101	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p102	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p103	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p104	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p105	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p106	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p107	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p108	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p109	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., @DRUG$], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p110	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p111	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p112	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p113	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p114	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p115	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p116	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p117	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p118	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p119	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p120	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p121	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p122	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p123	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p124	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p125	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p126	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p127	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p128	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], @DRUG$ [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p129	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p130	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p131	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p132	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p133	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p134	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p135	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p136	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p137	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p138	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p139	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p140	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p141	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p142	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p143	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p144	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p145	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p146	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p147	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p148	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p149	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p150	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p151	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p152	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p153	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p154	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p155	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p156	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p157	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p158	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p159	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p160	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p161	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p162	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p163	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], @DRUG$ [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p164	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p165	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p166	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p167	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p168	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p169	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p170	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p171	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p172	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p173	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p174	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p175	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p176	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p177	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p178	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p179	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., @DRUG$], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p180	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p181	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p182	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p183	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p184	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p185	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p186	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p187	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p188	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p189	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p190	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p191	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p192	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p193	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p194	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], @DRUG$ [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p195	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p196	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p197	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p198	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p199	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p200	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p201	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p202	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p203	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p204	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p205	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p206	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p207	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p208	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., @DRUG$], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p209	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p210	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p211	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p212	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p213	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p214	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p215	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p216	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p217	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p218	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p219	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p220	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p221	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], @DRUG$ [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p222	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p223	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p224	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p225	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p226	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p227	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p228	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p229	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p230	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p231	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p232	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p233	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., @DRUG$], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p234	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p235	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p236	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p237	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p238	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p239	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p240	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p241	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p242	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p243	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p244	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], @DRUG$ [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p245	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p246	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p247	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p248	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p249	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p250	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p251	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p252	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p253	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p254	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., @DRUG$], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p255	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p256	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p257	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p258	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p259	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p260	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p261	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p262	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p263	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], @DRUG$ [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p264	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p265	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p266	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p267	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p268	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p269	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p270	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p271	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., @DRUG$], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p272	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p273	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p274	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p275	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p276	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p277	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p278	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], @DRUG$ [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p279	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p280	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p281	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p282	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p283	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p284	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., @DRUG$], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p285	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p286	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p287	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p288	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p289	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], @DRUG$ [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p290	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p291	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p292	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p293	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., @DRUG$], triflupromazine [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p294	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., @DRUG$], trimeprazine [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p295	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p296	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], @DRUG$ [e.g., Vesprin], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p297	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], @DRUG$ [e.g., Temaril]) or	DDI-false
DDI-DrugBank.d179.s21.p298	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., @DRUG$], trimeprazine [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s21.p299	- Phenothiazines (acetophenazine [e.g., Tindal], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., Prolixin], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], @DRUG$ [e.g., @DRUG$]) or	DDI-false
DDI-DrugBank.d179.s23.p0	- @DRUG$ (e.g., @DRUG$) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the liver	DDI-false
DDI-DrugBank.d179.s23.p1	- @DRUG$ (e.g., Depakene) Use of @DRUG$ with these medicines may increase the chance of side effects affecting the liver	DDI-false
DDI-DrugBank.d179.s23.p2	- Valproic acid (e.g., @DRUG$) Use of @DRUG$ with these medicines may increase the chance of side effects affecting the liver	DDI-false
DDI-DrugBank.d179.s29.p0	- @DRUG$ (e.g., @DRUG$) or	DDI-false
DDI-DrugBank.d179.s34.p0	- @DRUG$ (@DRUG$s) or	DDI-false
DDI-DrugBank.d179.s35.p0	- @DRUG$ (e.g., @DRUG$) or	DDI-false
DDI-DrugBank.d179.s39.p0	- @DRUG$ (e.g., @DRUG$) Use of methyldopa with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood	DDI-false
DDI-DrugBank.d179.s39.p1	- @DRUG$ (e.g., Aldomet) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood	DDI-false
DDI-DrugBank.d179.s39.p2	- @DRUG$ (e.g., Aldomet) Use of methyldopa with @DRUG$ may increase the chance of side effects affecting the liver and/or the blood	DDI-false
DDI-DrugBank.d179.s39.p3	- Methyldopa (e.g., @DRUG$) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the blood	DDI-false
DDI-DrugBank.d179.s39.p4	- Methyldopa (e.g., @DRUG$) Use of methyldopa with @DRUG$ may increase the chance of side effects affecting the liver and/or the blood	DDI-false
DDI-DrugBank.d179.s39.p5	- Methyldopa (e.g., Aldomet) Use of @DRUG$ with @DRUG$ may increase the chance of side effects affecting the liver and/or the blood	DDI-effect
DDI-DrugBank.d179.s40.p0	- @DRUG$ (e.g., @DRUG$) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin	DDI-false
DDI-DrugBank.d179.s40.p1	- @DRUG$ (e.g., Dilantin) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin	DDI-false
DDI-DrugBank.d179.s40.p2	- @DRUG$ (e.g., Dilantin) Use of phenytoin with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of phenytoin	DDI-false
DDI-DrugBank.d179.s40.p3	- @DRUG$ (e.g., Dilantin) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$	DDI-false
DDI-DrugBank.d179.s40.p4	- Phenytoin (e.g., @DRUG$) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of phenytoin	DDI-false
DDI-DrugBank.d179.s40.p5	- Phenytoin (e.g., @DRUG$) Use of phenytoin with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of phenytoin	DDI-false
DDI-DrugBank.d179.s40.p6	- Phenytoin (e.g., @DRUG$) Use of phenytoin with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$	DDI-false
DDI-DrugBank.d179.s40.p7	- Phenytoin (e.g., Dilantin) Use of @DRUG$ with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of phenytoin	DDI-effect
DDI-DrugBank.d179.s40.p8	- Phenytoin (e.g., Dilantin) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$	DDI-false
DDI-DrugBank.d179.s40.p9	- Phenytoin (e.g., Dilantin) Use of phenytoin with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$	DDI-false
DDI-DrugBank.d179.s7.p0	- @DRUG$ (e.g., @DRUG$) or	DDI-false
DDI-DrugBank.d18.s0.p0	Tablets: The @DRUG$, including @DRUG$, produce CNS-depressant effects when administered with such medications as barbiturates or alcohol.	DDI-false
DDI-DrugBank.d18.s0.p1	Tablets: The @DRUG$, including lorazepam, produce CNS-depressant effects when administered with such medications as @DRUG$ or alcohol.	DDI-effect
DDI-DrugBank.d18.s0.p2	Tablets: The @DRUG$, including lorazepam, produce CNS-depressant effects when administered with such medications as barbiturates or @DRUG$.	DDI-effect
DDI-DrugBank.d18.s0.p3	Tablets: The benzodiazepines, including @DRUG$, produce CNS-depressant effects when administered with such medications as @DRUG$ or alcohol.	DDI-effect
DDI-DrugBank.d18.s0.p4	Tablets: The benzodiazepines, including @DRUG$, produce CNS-depressant effects when administered with such medications as barbiturates or @DRUG$.	DDI-effect
DDI-DrugBank.d18.s0.p5	Tablets: The benzodiazepines, including lorazepam, produce CNS-depressant effects when administered with such medications as @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d181.s0.p0	@DRUG$ or other @DRUG$ (concurrent use with dinoprost may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;	DDI-false
DDI-DrugBank.d181.s0.p1	@DRUG$ or other oxytocics (concurrent use with @DRUG$ may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;	DDI-effect
DDI-DrugBank.d181.s0.p2	Oxytocin or other @DRUG$ (concurrent use with @DRUG$ may result in uterine hypertonus, possibly causing uterine rupture or cervical laceration, especially in the absence of adequate cervical dilatation;	DDI-effect
DDI-DrugBank.d184.s0.p0	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p1	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p2	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p3	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p4	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p5	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p6	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p7	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p8	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p9	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p10	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p11	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p12	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), @DRUG$ (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p13	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p14	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p15	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p16	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p17	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p18	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p19	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p20	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p21	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p22	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p23	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p24	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (@DRUG$s), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p25	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p26	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p27	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p28	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p29	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p30	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p31	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p32	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p33	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p34	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p35	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), @DRUG$, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p36	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p37	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p38	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p39	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p40	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p41	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p42	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p43	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p44	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p45	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, @DRUG$ (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p46	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p47	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p48	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p49	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p50	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p51	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p52	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p53	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p54	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (@DRUG$ may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p55	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p56	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p57	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p58	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p59	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p60	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p61	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p62	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), @DRUG$ (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p63	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p64	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p65	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p66	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p67	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p68	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p69	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with @DRUG$ may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p70	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p71	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p72	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p73	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p74	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p75	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), @DRUG$, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p76	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p77	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p78	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p79	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p80	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, @DRUG$ (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p81	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p82	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p83	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p84	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with @DRUG$ may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p85	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing @DRUG$ (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p86	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p87	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral @DRUG$ containing estrogens (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p88	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (@DRUG$ may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p89	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing @DRUG$ (barbiturates may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).	DDI-false
DDI-DrugBank.d184.s0.p90	Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (@DRUG$ may decrease the effectiveness of these oral @DRUG$, and you may need to change to a different type of birth control).	DDI-effect
DDI-DrugBank.d185.s4.p0	Certain concomitant medications (such as @DRUG$, @DRUG$, St.	DDI-false
DDI-DrugBank.d185.s6.p0	With oral @DRUG$ treatment, @DRUG$ such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions	DDI-effect
DDI-DrugBank.d185.s6.p1	With oral @DRUG$ treatment, folic acid antagonists such as @DRUG$ have been noted to possibly increase the likelihood of hematologic reactions	DDI-effect
DDI-DrugBank.d185.s6.p2	With oral dapsone treatment, @DRUG$ such as @DRUG$ have been noted to possibly increase the likelihood of hematologic reactions	DDI-false
DDI-DrugBank.d186.s1.p0	A causal relationship between these events and the concomitant administration of @DRUG$ and @DRUG$ has not been established;	DDI-false
DDI-DrugBank.d186.s4.p0	In a study of 12 schizophrenic patients coadministered oral @DRUG$ and @DRUG$, plasma haloperidol levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.	DDI-mechanism
DDI-DrugBank.d186.s4.p1	In a study of 12 schizophrenic patients coadministered oral @DRUG$ and rifampin, plasma @DRUG$ levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.	DDI-false
DDI-DrugBank.d186.s4.p2	In a study of 12 schizophrenic patients coadministered oral haloperidol and @DRUG$, plasma @DRUG$ levels were decreased by a mean of 70% and mean scores on the Brief Psychiatric Rating Scale were increased from baseline.	DDI-false
DDI-DrugBank.d186.s5.p0	In 5 other schizophrenic patients treated with oral @DRUG$ and @DRUG$, discontinuation of rifampin produced a mean 3.3-fold increase in haloperidol concentrations.	DDI-false
DDI-DrugBank.d186.s5.p1	In 5 other schizophrenic patients treated with oral @DRUG$ and rifampin, discontinuation of @DRUG$ produced a mean 3.3-fold increase in haloperidol concentrations.	DDI-false
DDI-DrugBank.d186.s5.p2	In 5 other schizophrenic patients treated with oral @DRUG$ and rifampin, discontinuation of rifampin produced a mean 3.3-fold increase in @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d186.s5.p3	In 5 other schizophrenic patients treated with oral haloperidol and @DRUG$, discontinuation of @DRUG$ produced a mean 3.3-fold increase in haloperidol concentrations.	DDI-false
DDI-DrugBank.d186.s5.p4	In 5 other schizophrenic patients treated with oral haloperidol and @DRUG$, discontinuation of rifampin produced a mean 3.3-fold increase in @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d186.s5.p5	In 5 other schizophrenic patients treated with oral haloperidol and rifampin, discontinuation of @DRUG$ produced a mean 3.3-fold increase in @DRUG$ concentrations.	DDI-mechanism
DDI-DrugBank.d186.s6.p0	Thus, careful monitoring of clinical status is warranted when @DRUG$ is administered or discontinued in @DRUG$-treated patients.	DDI-advise
DDI-DrugBank.d187.s13.p0	@DRUG$: A recent case study has shown a possible increase in the plasma level of @DRUG$ when co administered with isoniazid.	DDI-false
DDI-DrugBank.d187.s13.p1	@DRUG$: A recent case study has shown a possible increase in the plasma level of valproate when co administered with @DRUG$.	DDI-false
DDI-DrugBank.d187.s13.p2	Valproate: A recent case study has shown a possible increase in the plasma level of @DRUG$ when co administered with @DRUG$.	DDI-mechanism
DDI-DrugBank.d187.s8.p0	@DRUG$: Potential interaction of @DRUG$ and Isoniazid may exist.	DDI-false
DDI-DrugBank.d187.s8.p1	@DRUG$: Potential interaction of Ketoconazole and @DRUG$ may exist.	DDI-false
DDI-DrugBank.d187.s8.p2	Ketoconazole: Potential interaction of @DRUG$ and @DRUG$ may exist.	DDI-int
DDI-DrugBank.d187.s9.p0	@DRUG$: @DRUG$ may increase serum levels of phenytoin.	DDI-false
DDI-DrugBank.d187.s9.p1	@DRUG$: Isoniazid may increase serum levels of @DRUG$.	DDI-false
DDI-DrugBank.d187.s9.p2	Phenytoin: @DRUG$ may increase serum levels of @DRUG$.	DDI-mechanism
DDI-DrugBank.d188.s1.p0	Data from a randomized trial of @DRUG$ and @DRUG$ plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;	DDI-effect
DDI-DrugBank.d188.s1.p1	Data from a randomized trial of @DRUG$ and cisplatin plus or minus @DRUG$ in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;	DDI-false
DDI-DrugBank.d188.s1.p2	Data from a randomized trial of @DRUG$ and cisplatin plus or minus pyridoxine in ovarian cancer indicated that @DRUG$ significantly reduced neurotoxicity;	DDI-false
DDI-DrugBank.d188.s1.p3	Data from a randomized trial of HEXALEN and @DRUG$ plus or minus @DRUG$ in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;	DDI-false
DDI-DrugBank.d188.s1.p4	Data from a randomized trial of HEXALEN and @DRUG$ plus or minus pyridoxine in ovarian cancer indicated that @DRUG$ significantly reduced neurotoxicity;	DDI-false
DDI-DrugBank.d188.s1.p5	Data from a randomized trial of HEXALEN and cisplatin plus or minus @DRUG$ in ovarian cancer indicated that @DRUG$ significantly reduced neurotoxicity;	DDI-false
DDI-DrugBank.d19.s7.p0	Patients taking @DRUG$ when @DRUG$ is given should be observed for the appearance of unsteady gait or marked changes in mental status;	DDI-advise
DDI-DrugBank.d190.s2.p0	Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose @DRUG$ (@DRUG$ up to 15,000 units/day) or prophylactic doses of low molecular weight heparins as indicated in the prescribing information for the specific products.	DDI-false
DDI-DrugBank.d190.s2.p1	Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose @DRUG$ (unfractionated heparin up to 15,000 units/day) or prophylactic doses of @DRUG$ as indicated in the prescribing information for the specific products.	DDI-false
DDI-DrugBank.d190.s2.p2	Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose heparin (@DRUG$ up to 15,000 units/day) or prophylactic doses of @DRUG$ as indicated in the prescribing information for the specific products.	DDI-false
DDI-DrugBank.d190.s3.p0	Concomitant use of prophylactic low dose @DRUG$ did not appear to affect safety, however, its effects on the efficacy of @DRUG$ have not been evaluated in an adequate and well-controlled clinical trial.	DDI-false
DDI-DrugBank.d191.s1.p0	@DRUG$ enhance the renal toxicity of @DRUG$ in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the zinc. 7	DDI-effect
DDI-DrugBank.d191.s1.p1	@DRUG$ enhance the renal toxicity of edetate calcium disodium in animals. 7 @DRUG$ interferes with the action of zinc insulin preparations by chelating the zinc. 7	DDI-false
DDI-DrugBank.d191.s1.p2	@DRUG$ enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of @DRUG$ preparations by chelating the zinc. 7	DDI-false
DDI-DrugBank.d191.s1.p3	@DRUG$ enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the @DRUG$. 7	DDI-false
DDI-DrugBank.d191.s1.p4	Steroids enhance the renal toxicity of @DRUG$ in animals. 7 @DRUG$ interferes with the action of zinc insulin preparations by chelating the zinc. 7	DDI-false
DDI-DrugBank.d191.s1.p5	Steroids enhance the renal toxicity of @DRUG$ in animals. 7 Edetate calcium disodium interferes with the action of @DRUG$ preparations by chelating the zinc. 7	DDI-false
DDI-DrugBank.d191.s1.p6	Steroids enhance the renal toxicity of @DRUG$ in animals. 7 Edetate calcium disodium interferes with the action of zinc insulin preparations by chelating the @DRUG$. 7	DDI-false
DDI-DrugBank.d191.s1.p7	Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 @DRUG$ interferes with the action of @DRUG$ preparations by chelating the zinc. 7	DDI-mechanism
DDI-DrugBank.d191.s1.p8	Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 @DRUG$ interferes with the action of zinc insulin preparations by chelating the @DRUG$. 7	DDI-false
DDI-DrugBank.d191.s1.p9	Steroids enhance the renal toxicity of edetate calcium disodium in animals. 7 Edetate calcium disodium interferes with the action of @DRUG$ preparations by chelating the @DRUG$. 7	DDI-false
DDI-DrugBank.d192.s0.p0	@DRUG$ can interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-effect
DDI-DrugBank.d192.s0.p1	@DRUG$ can interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-effect
DDI-DrugBank.d192.s0.p2	@DRUG$ can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p3	@DRUG$ can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-effect
DDI-DrugBank.d192.s0.p4	@DRUG$ can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p5	@DRUG$ can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-effect
DDI-DrugBank.d192.s0.p6	@DRUG$ can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p7	@DRUG$ can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d192.s0.p8	Dexbrompheniramine can interact with @DRUG$ or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p9	Dexbrompheniramine can interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p10	Dexbrompheniramine can interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p11	Dexbrompheniramine can interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p12	Dexbrompheniramine can interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p13	Dexbrompheniramine can interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p14	Dexbrompheniramine can interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d192.s0.p15	Dexbrompheniramine can interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p16	Dexbrompheniramine can interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p17	Dexbrompheniramine can interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p18	Dexbrompheniramine can interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p19	Dexbrompheniramine can interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p20	Dexbrompheniramine can interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d192.s0.p21	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p22	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p23	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p24	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p25	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d192.s0.p26	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p27	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p28	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p29	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d192.s0.p30	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p31	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p32	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d192.s0.p33	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d192.s0.p34	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d192.s0.p35	Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d193.s0.p0	A drug interaction study was performed in which @DRUG$ was administered in combination with @DRUG$.	DDI-false
DDI-DrugBank.d195.s7.p0	Based on clinical and pharmacokinetic results from the ATAC trial, @DRUG$ should not be administered with @DRUG$ (see CLINICAL PHARMACOLOGY   Drug Interactions and CLINICAL PHARMACOLOGY - Clinical Studies - Adjuvant Treatment of Breast Cancer in Postmenopausal Women subsections).	DDI-advise
DDI-DrugBank.d195.s8.p0	Co-administration of @DRUG$ and @DRUG$ resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with anastrozole alone.	DDI-mechanism
DDI-DrugBank.d195.s8.p1	Co-administration of @DRUG$ and tamoxifen resulted in a reduction of @DRUG$ plasma levels by 27% compared with those achieved with anastrozole alone.	DDI-false
DDI-DrugBank.d195.s8.p2	Co-administration of @DRUG$ and tamoxifen resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with @DRUG$ alone.	DDI-false
DDI-DrugBank.d195.s8.p3	Co-administration of anastrozole and @DRUG$ resulted in a reduction of @DRUG$ plasma levels by 27% compared with those achieved with anastrozole alone.	DDI-false
DDI-DrugBank.d195.s8.p4	Co-administration of anastrozole and @DRUG$ resulted in a reduction of anastrozole plasma levels by 27% compared with those achieved with @DRUG$ alone.	DDI-false
DDI-DrugBank.d195.s8.p5	Co-administration of anastrozole and tamoxifen resulted in a reduction of @DRUG$ plasma levels by 27% compared with those achieved with @DRUG$ alone.	DDI-false
DDI-DrugBank.d196.s36.p0	@DRUG$ contains @DRUG$.	DDI-false
DDI-DrugBank.d196.s4.p0	Nucleoside Analogues @DRUG$ Co-administration of @DRUG$ and didanosine is not recommended.	DDI-false
DDI-DrugBank.d196.s4.p1	Nucleoside Analogues @DRUG$ Co-administration of COPEGUS and @DRUG$ is not recommended.	DDI-false
DDI-DrugBank.d196.s4.p2	Nucleoside Analogues Didanosine Co-administration of @DRUG$ and @DRUG$ is not recommended.	DDI-advise
DDI-DrugBank.d196.s41.p0	@DRUG$ and @DRUG$ are excreted by the kidney, and the risk of toxic reactions to this therapy may be greater in patients with impaired renal function.	DDI-false
DDI-DrugBank.d196.s43.p0	@DRUG$ should be used with caution in patients with creatinine clearance  50 mL/min and @DRUG$ should not be administered to patients with creatinine clearance  50 mL/min	DDI-false
DDI-DrugBank.d197.s1.p0	@DRUG$/@DRUG$/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p1	@DRUG$/Sedatives/@DRUG$/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p2	@DRUG$/Sedatives/Hypnotics/@DRUG$: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p3	@DRUG$/Sedatives/Hypnotics/Opioids: Co-administration of @DRUG$ with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p4	@DRUG$/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with @DRUG$, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p5	@DRUG$/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, @DRUG$, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p6	@DRUG$/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, @DRUG$, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p7	@DRUG$/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and @DRUG$ is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p8	Anesthetics/@DRUG$/@DRUG$/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p9	Anesthetics/@DRUG$/Hypnotics/@DRUG$: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p10	Anesthetics/@DRUG$/Hypnotics/Opioids: Co-administration of @DRUG$ with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p11	Anesthetics/@DRUG$/Hypnotics/Opioids: Co-administration of PRECEDEX with @DRUG$, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p12	Anesthetics/@DRUG$/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, @DRUG$, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p13	Anesthetics/@DRUG$/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, @DRUG$, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p14	Anesthetics/@DRUG$/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and @DRUG$ is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p15	Anesthetics/Sedatives/@DRUG$/@DRUG$: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p16	Anesthetics/Sedatives/@DRUG$/Opioids: Co-administration of @DRUG$ with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p17	Anesthetics/Sedatives/@DRUG$/Opioids: Co-administration of PRECEDEX with @DRUG$, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p18	Anesthetics/Sedatives/@DRUG$/Opioids: Co-administration of PRECEDEX with anesthetics, @DRUG$, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p19	Anesthetics/Sedatives/@DRUG$/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, @DRUG$, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p20	Anesthetics/Sedatives/@DRUG$/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and @DRUG$ is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p21	Anesthetics/Sedatives/Hypnotics/@DRUG$: Co-administration of @DRUG$ with anesthetics, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p22	Anesthetics/Sedatives/Hypnotics/@DRUG$: Co-administration of PRECEDEX with @DRUG$, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p23	Anesthetics/Sedatives/Hypnotics/@DRUG$: Co-administration of PRECEDEX with anesthetics, @DRUG$, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p24	Anesthetics/Sedatives/Hypnotics/@DRUG$: Co-administration of PRECEDEX with anesthetics, sedatives, @DRUG$, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p25	Anesthetics/Sedatives/Hypnotics/@DRUG$: Co-administration of PRECEDEX with anesthetics, sedatives, hypnotics, and @DRUG$ is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p26	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of @DRUG$ with @DRUG$, sedatives, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-effect
DDI-DrugBank.d197.s1.p27	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of @DRUG$ with anesthetics, @DRUG$, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-effect
DDI-DrugBank.d197.s1.p28	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of @DRUG$ with anesthetics, sedatives, @DRUG$, and opioids is likely to lead to an enhancement of effects.	DDI-effect
DDI-DrugBank.d197.s1.p29	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of @DRUG$ with anesthetics, sedatives, hypnotics, and @DRUG$ is likely to lead to an enhancement of effects.	DDI-effect
DDI-DrugBank.d197.s1.p30	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with @DRUG$, @DRUG$, hypnotics, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p31	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with @DRUG$, sedatives, @DRUG$, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p32	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with @DRUG$, sedatives, hypnotics, and @DRUG$ is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p33	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, @DRUG$, @DRUG$, and opioids is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p34	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, @DRUG$, hypnotics, and @DRUG$ is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s1.p35	Anesthetics/Sedatives/Hypnotics/Opioids: Co-administration of PRECEDEX with anesthetics, sedatives, @DRUG$, and @DRUG$ is likely to lead to an enhancement of effects.	DDI-false
DDI-DrugBank.d197.s4.p0	However, due to possible pharmacodynamic interactions, when co-administered with @DRUG$, a reduction in dosage of @DRUG$ on the concomitant anesthetic, sedative, hypnotic or opioid may be required.	DDI-false
DDI-DrugBank.d197.s4.p1	However, due to possible pharmacodynamic interactions, when co-administered with @DRUG$, a reduction in dosage of PRECEDEX on the concomitant @DRUG$, sedative, hypnotic or opioid may be required.	DDI-false
DDI-DrugBank.d197.s4.p2	However, due to possible pharmacodynamic interactions, when co-administered with @DRUG$, a reduction in dosage of PRECEDEX on the concomitant anesthetic, @DRUG$, hypnotic or opioid may be required.	DDI-false
DDI-DrugBank.d197.s4.p3	However, due to possible pharmacodynamic interactions, when co-administered with @DRUG$, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, @DRUG$ or opioid may be required.	DDI-false
DDI-DrugBank.d197.s4.p4	However, due to possible pharmacodynamic interactions, when co-administered with @DRUG$, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, hypnotic or @DRUG$ may be required.	DDI-false
DDI-DrugBank.d197.s4.p5	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of @DRUG$ on the concomitant @DRUG$, sedative, hypnotic or opioid may be required.	DDI-advise
DDI-DrugBank.d197.s4.p6	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of @DRUG$ on the concomitant anesthetic, @DRUG$, hypnotic or opioid may be required.	DDI-advise
DDI-DrugBank.d197.s4.p7	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of @DRUG$ on the concomitant anesthetic, sedative, @DRUG$ or opioid may be required.	DDI-advise
DDI-DrugBank.d197.s4.p8	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of @DRUG$ on the concomitant anesthetic, sedative, hypnotic or @DRUG$ may be required.	DDI-advise
DDI-DrugBank.d197.s4.p9	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant @DRUG$, @DRUG$, hypnotic or opioid may be required.	DDI-false
DDI-DrugBank.d197.s4.p10	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant @DRUG$, sedative, @DRUG$ or opioid may be required.	DDI-false
DDI-DrugBank.d197.s4.p11	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant @DRUG$, sedative, hypnotic or @DRUG$ may be required.	DDI-false
DDI-DrugBank.d197.s4.p12	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, @DRUG$, @DRUG$ or opioid may be required.	DDI-false
DDI-DrugBank.d197.s4.p13	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, @DRUG$, hypnotic or @DRUG$ may be required.	DDI-false
DDI-DrugBank.d197.s4.p14	However, due to possible pharmacodynamic interactions, when co-administered with PRECEDEX, a reduction in dosage of PRECEDEX on the concomitant anesthetic, sedative, @DRUG$ or @DRUG$ may be required.	DDI-false
DDI-DrugBank.d197.s5.p0	@DRUG$: In one study of 10 healthy volunteers, administration of @DRUG$ for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with rocuronium administration.	DDI-false
DDI-DrugBank.d197.s5.p1	@DRUG$: In one study of 10 healthy volunteers, administration of PRECEDEX for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with @DRUG$ administration.	DDI-false
DDI-DrugBank.d197.s5.p2	Neuromuscular Blockers: In one study of 10 healthy volunteers, administration of @DRUG$ for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with @DRUG$ administration.	DDI-false
DDI-DrugBank.d198.s14.p0	@DRUG$ significantly prolonged the half-life of @DRUG$ to 26 hours.	DDI-mechanism
DDI-DrugBank.d198.s15.p0	Consequently, it is recommended not to exceed a single 2.5 mg @DRUG$ dose in a 72-hour period when used in combination with @DRUG$.	DDI-advise
DDI-DrugBank.d198.s22.p0	In vivo studies: @DRUG$: The blood pressure lowering effects of sublingual @DRUG$ (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.	DDI-false
DDI-DrugBank.d198.s22.p1	In vivo studies: @DRUG$: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after @DRUG$ and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.	DDI-false
DDI-DrugBank.d198.s22.p2	In vivo studies: @DRUG$: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of @DRUG$ in healthy middle-aged subjects.	DDI-false
DDI-DrugBank.d198.s22.p3	In vivo studies: Nitrates: The blood pressure lowering effects of sublingual @DRUG$ (0.4 mg) taken 1 and 4 hours after @DRUG$ and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of Vardenafil in healthy middle-aged subjects.	DDI-mechanism
DDI-DrugBank.d198.s22.p4	In vivo studies: Nitrates: The blood pressure lowering effects of sublingual @DRUG$ (0.4 mg) taken 1 and 4 hours after vardenafil and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of @DRUG$ in healthy middle-aged subjects.	DDI-false
DDI-DrugBank.d198.s22.p5	In vivo studies: Nitrates: The blood pressure lowering effects of sublingual nitrates (0.4 mg) taken 1 and 4 hours after @DRUG$ and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of @DRUG$ in healthy middle-aged subjects.	DDI-false
DDI-DrugBank.d198.s24.p0	Potentiation of the hypotensive effects of @DRUG$ for patients with ischemic heart disease has not been evaluated, and concomitant use of @DRUG$ and nitrates is contraindicated.	DDI-false
DDI-DrugBank.d198.s24.p1	Potentiation of the hypotensive effects of @DRUG$ for patients with ischemic heart disease has not been evaluated, and concomitant use of Vardenafil and @DRUG$ is contraindicated.	DDI-false
DDI-DrugBank.d198.s24.p2	Potentiation of the hypotensive effects of nitrates for patients with ischemic heart disease has not been evaluated, and concomitant use of @DRUG$ and @DRUG$ is contraindicated.	DDI-advise
DDI-DrugBank.d198.s31.p0	When @DRUG$ dosing was separated from @DRUG$ 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of Vardenafil experienced a decrease in standing systolic blood pressure below 85 mm Hg.	DDI-effect
DDI-DrugBank.d198.s31.p1	When @DRUG$ dosing was separated from terazosin 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of @DRUG$ experienced a decrease in standing systolic blood pressure below 85 mm Hg.	DDI-false
DDI-DrugBank.d198.s31.p2	When Vardenafil dosing was separated from @DRUG$ 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of @DRUG$ experienced a decrease in standing systolic blood pressure below 85 mm Hg.	DDI-false
DDI-DrugBank.d198.s34.p0	The administration of lower doses of @DRUG$ with @DRUG$ has not been completely evaluated to determine if they can be safely administered together.	DDI-false
DDI-DrugBank.d198.s37.p0	Upon administration of 10 mg of @DRUG$ with 800 mg TID @DRUG$, the Cmax and AUC of indinavir were reduced by 40% and 30%, respectively.	DDI-mechanism
DDI-DrugBank.d198.s37.p1	Upon administration of 10 mg of @DRUG$ with 800 mg TID indinavir, the Cmax and AUC of @DRUG$ were reduced by 40% and 30%, respectively.	DDI-false
DDI-DrugBank.d198.s37.p2	Upon administration of 10 mg of Vardenafil with 800 mg TID @DRUG$, the Cmax and AUC of @DRUG$ were reduced by 40% and 30%, respectively.	DDI-false
DDI-DrugBank.d198.s5.p0	@DRUG$ (500 mg t.i.d) produced a 4-fold increase in @DRUG$ AUC and a 3-fold increase in Cmax when co-administered with Vardenafil 5 mg in healthy volunteers.	DDI-mechanism
DDI-DrugBank.d198.s5.p1	@DRUG$ (500 mg t.i.d) produced a 4-fold increase in vardenafil AUC and a 3-fold increase in Cmax when co-administered with @DRUG$ 5 mg in healthy volunteers.	DDI-false
DDI-DrugBank.d198.s5.p2	Erythromycin (500 mg t.i.d) produced a 4-fold increase in @DRUG$ AUC and a 3-fold increase in Cmax when co-administered with @DRUG$ 5 mg in healthy volunteers.	DDI-false
DDI-DrugBank.d199.s0.p0	@DRUG$: When coadministered with @DRUG$, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.	DDI-false
DDI-DrugBank.d199.s0.p1	@DRUG$: When coadministered with MONUROL, @DRUG$, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.	DDI-false
DDI-DrugBank.d199.s0.p2	@DRUG$: When coadministered with MONUROL, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of @DRUG$.	DDI-false
DDI-DrugBank.d199.s0.p3	Metoclopramide: When coadministered with @DRUG$, @DRUG$, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of fosfomycin.	DDI-mechanism
DDI-DrugBank.d199.s0.p4	Metoclopramide: When coadministered with @DRUG$, metoclopramide, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of @DRUG$.	DDI-false
DDI-DrugBank.d199.s0.p5	Metoclopramide: When coadministered with MONUROL, @DRUG$, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of @DRUG$.	DDI-false
DDI-DrugBank.d199.s2.p0	@DRUG$: @DRUG$ does not affect the pharmacokinetics of fosfomycin when coadministered with MONUROL.	DDI-false
DDI-DrugBank.d199.s2.p1	@DRUG$: Cimetidine does not affect the pharmacokinetics of @DRUG$ when coadministered with MONUROL.	DDI-false
DDI-DrugBank.d199.s2.p2	@DRUG$: Cimetidine does not affect the pharmacokinetics of fosfomycin when coadministered with @DRUG$.	DDI-false
DDI-DrugBank.d199.s2.p3	Cimetidine: @DRUG$ does not affect the pharmacokinetics of @DRUG$ when coadministered with MONUROL.	DDI-false
DDI-DrugBank.d199.s2.p4	Cimetidine: @DRUG$ does not affect the pharmacokinetics of fosfomycin when coadministered with @DRUG$.	DDI-false
DDI-DrugBank.d199.s2.p5	Cimetidine: Cimetidine does not affect the pharmacokinetics of @DRUG$ when coadministered with @DRUG$.	DDI-false
DDI-DrugBank.d20.s1.p0	A pharmacokinetic study evaluating the administration of a single dose of @DRUG$ 100 mg with @DRUG$ 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of eplerenone.	DDI-mechanism
DDI-DrugBank.d20.s1.p1	A pharmacokinetic study evaluating the administration of a single dose of @DRUG$ 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of @DRUG$ and a 5.4-fold increase in AUC of eplerenone.	DDI-false
DDI-DrugBank.d20.s1.p2	A pharmacokinetic study evaluating the administration of a single dose of @DRUG$ 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of @DRUG$.	DDI-false
DDI-DrugBank.d20.s1.p3	A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with @DRUG$ 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of @DRUG$ and a 5.4-fold increase in AUC of eplerenone.	DDI-false
DDI-DrugBank.d20.s1.p4	A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with @DRUG$ 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of eplerenone and a 5.4-fold increase in AUC of @DRUG$.	DDI-false
DDI-DrugBank.d20.s1.p5	A pharmacokinetic study evaluating the administration of a single dose of INSPRA 100 mg with ketoconazole 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of @DRUG$ and a 5.4-fold increase in AUC of @DRUG$.	DDI-false
DDI-DrugBank.d20.s12.p0	Therefore, when @DRUG$ and @DRUG$ are used concomitantly, patients should be observed to determine whether the desired effect on blood pressure is obtained.	DDI-advise
DDI-DrugBank.d20.s3.p0	Administration of @DRUG$ with other CYP3A4 inhibitors (e.g., @DRUG$ 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.	DDI-mechanism
DDI-DrugBank.d20.s3.p1	Administration of @DRUG$ with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, @DRUG$ 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.	DDI-mechanism
DDI-DrugBank.d20.s3.p2	Administration of @DRUG$ with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, @DRUG$ 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.	DDI-mechanism
DDI-DrugBank.d20.s3.p3	Administration of @DRUG$ with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, @DRUG$ 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.	DDI-mechanism
DDI-DrugBank.d20.s3.p4	Administration of @DRUG$ with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of @DRUG$ ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.	DDI-false
DDI-DrugBank.d20.s3.p5	Administration of eplerenone with other CYP3A4 inhibitors (e.g., @DRUG$ 500 mg BID, @DRUG$ 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.	DDI-false
DDI-DrugBank.d20.s3.p6	Administration of eplerenone with other CYP3A4 inhibitors (e.g., @DRUG$ 500 mg BID, verapamil 240 mg QD, @DRUG$ 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.	DDI-false
DDI-DrugBank.d20.s3.p7	Administration of eplerenone with other CYP3A4 inhibitors (e.g., @DRUG$ 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, @DRUG$ 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.	DDI-false
DDI-DrugBank.d20.s3.p8	Administration of eplerenone with other CYP3A4 inhibitors (e.g., @DRUG$ 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of @DRUG$ ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.	DDI-false
DDI-DrugBank.d20.s3.p9	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, @DRUG$ 240 mg QD, @DRUG$ 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.	DDI-false
DDI-DrugBank.d20.s3.p10	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, @DRUG$ 240 mg QD, saquinavir 1200 mg TID, @DRUG$ 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.	DDI-false
DDI-DrugBank.d20.s3.p11	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, @DRUG$ 240 mg QD, saquinavir 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of @DRUG$ ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.	DDI-false
DDI-DrugBank.d20.s3.p12	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, @DRUG$ 1200 mg TID, @DRUG$ 200 mg QD) resulted in increases in Cmax of eplerenone ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.	DDI-false
DDI-DrugBank.d20.s3.p13	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, @DRUG$ 1200 mg TID, fluconazole 200 mg QD) resulted in increases in Cmax of @DRUG$ ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.	DDI-false
DDI-DrugBank.d20.s3.p14	Administration of eplerenone with other CYP3A4 inhibitors (e.g., erythromycin 500 mg BID, verapamil 240 mg QD, saquinavir 1200 mg TID, @DRUG$ 200 mg QD) resulted in increases in Cmax of @DRUG$ ranging from 1.4- to 1.6- fold and AUC from 2.0- to 2.9- fold.	DDI-false
DDI-DrugBank.d20.s5.p0	Rates of patients with maximum potassium levels  5.5 mEq/L were similar regardless of the use of @DRUG$/@DRUG$.	DDI-false
DDI-DrugBank.d20.s7.p0	In a study in diabetics with microalbuminuria @DRUG$ 200 mg combined with the @DRUG$ enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.	DDI-false
DDI-DrugBank.d20.s7.p1	In a study in diabetics with microalbuminuria @DRUG$ 200 mg combined with the ACE inhibitor @DRUG$ 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.	DDI-effect
DDI-DrugBank.d20.s7.p2	In a study in diabetics with microalbuminuria @DRUG$ 200 mg combined with the ACE inhibitor enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on @DRUG$ alone to 38%.	DDI-false
DDI-DrugBank.d20.s7.p3	In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the @DRUG$ @DRUG$ 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on enalapril alone to 38%.	DDI-false
DDI-DrugBank.d20.s7.p4	In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the @DRUG$ enalapril 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on @DRUG$ alone to 38%.	DDI-false
DDI-DrugBank.d20.s7.p5	In a study in diabetics with microalbuminuria INSPRA 200 mg combined with the ACE inhibitor @DRUG$ 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on @DRUG$ alone to 38%.	DDI-false
DDI-DrugBank.d202.s12.p0	Such individuals are referred to as  poor metabolizers  of drugs such as @DRUG$, @DRUG$, and the tricyclic antidepressants.	DDI-false
DDI-DrugBank.d202.s12.p1	Such individuals are referred to as  poor metabolizers  of drugs such as @DRUG$, dextromethorphan, and the @DRUG$.	DDI-false
DDI-DrugBank.d202.s12.p2	Such individuals are referred to as  poor metabolizers  of drugs such as debrisoquin, @DRUG$, and the @DRUG$.	DDI-false
DDI-DrugBank.d202.s15.p0	Concomitant use of @DRUG$ with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the @DRUG$ or the other drug.	DDI-false
DDI-DrugBank.d202.s16.p0	Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other @DRUG$, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-advise
DDI-DrugBank.d202.s16.p1	Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other antidepressants, @DRUG$, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-advise
DDI-DrugBank.d202.s16.p2	Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, @DRUG$, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-advise
DDI-DrugBank.d202.s16.p3	Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and @DRUG$ (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-advise
DDI-DrugBank.d202.s16.p4	Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, @DRUG$, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-advise
DDI-DrugBank.d202.s16.p5	Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, @DRUG$, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-advise
DDI-DrugBank.d202.s16.p6	Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and @DRUG$), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-advise
DDI-DrugBank.d202.s16.p7	Therefore, co-administration of @DRUG$ with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.	DDI-advise
DDI-DrugBank.d202.s16.p8	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, @DRUG$, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p9	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, phenothiazines, @DRUG$, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p10	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, phenothiazines, carbamazepine, and @DRUG$ (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p11	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, @DRUG$, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p12	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, @DRUG$, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p13	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and @DRUG$), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p14	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p15	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, @DRUG$, @DRUG$, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p16	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, @DRUG$, carbamazepine, and @DRUG$ (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p17	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, @DRUG$, carbamazepine, and Type 1C antiarrhythmics (eg, @DRUG$, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p18	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, @DRUG$, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, @DRUG$, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p19	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, @DRUG$, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and @DRUG$), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p20	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, @DRUG$, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p21	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, @DRUG$, and @DRUG$ (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p22	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, @DRUG$, and Type 1C antiarrhythmics (eg, @DRUG$, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p23	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, @DRUG$, and Type 1C antiarrhythmics (eg, propafenone, @DRUG$, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p24	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, @DRUG$, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and @DRUG$), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p25	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, @DRUG$, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p26	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and @DRUG$ (eg, @DRUG$, flecainide, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p27	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and @DRUG$ (eg, propafenone, @DRUG$, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p28	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and @DRUG$ (eg, propafenone, flecainide, and @DRUG$), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p29	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and @DRUG$ (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p30	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, @DRUG$, @DRUG$, and encainide), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p31	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, @DRUG$, flecainide, and @DRUG$), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p32	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, @DRUG$, flecainide, and encainide), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p33	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, @DRUG$, and @DRUG$), or that inhibit this enzyme (eg, quinidine), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p34	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, @DRUG$, and encainide), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s16.p35	Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and @DRUG$), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.	DDI-false
DDI-DrugBank.d202.s4.p0	The therapeutic efficacy of @DRUG$ may be compromised in these patients when @DRUG$ is discontinued.	DDI-effect
DDI-DrugBank.d204.s0.p0	When administered concurrently, the following drugs may interact with @DRUG$: @DRUG$, general: exaggeration of the hypotension induced by general anesthetics.	DDI-int
DDI-DrugBank.d204.s0.p1	When administered concurrently, the following drugs may interact with @DRUG$: Anesthetics, general: exaggeration of the hypotension induced by general @DRUG$.	DDI-false
DDI-DrugBank.d204.s0.p2	When administered concurrently, the following drugs may interact with beta-adrenergic receptor blocking agents: @DRUG$, general: exaggeration of the hypotension induced by general @DRUG$.	DDI-false
DDI-DrugBank.d204.s1.p0	@DRUG$ (oral agents and @DRUG$): hypoglycemia or hyperglycemia;	DDI-false
DDI-DrugBank.d205.s0.p0	Since @DRUG$ (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).	DDI-false
DDI-DrugBank.d205.s0.p1	Since @DRUG$ (ethosuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).	DDI-int
DDI-DrugBank.d205.s0.p2	Since @DRUG$ (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, @DRUG$ may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).	DDI-false
DDI-DrugBank.d205.s0.p3	Since @DRUG$ (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate @DRUG$ serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).	DDI-false
DDI-DrugBank.d205.s0.p4	Since @DRUG$ (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and @DRUG$ has been reported to both increase and decrease ethosuximide levels).	DDI-false
DDI-DrugBank.d205.s0.p5	Since @DRUG$ (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease @DRUG$ levels).	DDI-false
DDI-DrugBank.d205.s0.p6	Since Zarontin (@DRUG$) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).	DDI-int
DDI-DrugBank.d205.s0.p7	Since Zarontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, @DRUG$ may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).	DDI-false
DDI-DrugBank.d205.s0.p8	Since Zarontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate @DRUG$ serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).	DDI-false
DDI-DrugBank.d205.s0.p9	Since Zarontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and @DRUG$ has been reported to both increase and decrease ethosuximide levels).	DDI-false
DDI-DrugBank.d205.s0.p10	Since Zarontin (@DRUG$) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease @DRUG$ levels).	DDI-false
DDI-DrugBank.d205.s0.p11	Since Zarontin (ethosuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg, @DRUG$ may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).	DDI-false
DDI-DrugBank.d205.s0.p12	Since Zarontin (ethosuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate @DRUG$ serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).	DDI-false
DDI-DrugBank.d205.s0.p13	Since Zarontin (ethosuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and @DRUG$ has been reported to both increase and decrease ethosuximide levels).	DDI-false
DDI-DrugBank.d205.s0.p14	Since Zarontin (ethosuximide) may interact with concurrently administered @DRUG$, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease @DRUG$ levels).	DDI-false
DDI-DrugBank.d205.s0.p15	Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, @DRUG$ may elevate @DRUG$ serum levels and valproic acid has been reported to both increase and decrease ethosuximide levels).	DDI-mechanism
DDI-DrugBank.d205.s0.p16	Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, @DRUG$ may elevate phenytoin serum levels and @DRUG$ has been reported to both increase and decrease ethosuximide levels).	DDI-false
DDI-DrugBank.d205.s0.p17	Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, @DRUG$ may elevate phenytoin serum levels and valproic acid has been reported to both increase and decrease @DRUG$ levels).	DDI-false
DDI-DrugBank.d205.s0.p18	Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate @DRUG$ serum levels and @DRUG$ has been reported to both increase and decrease ethosuximide levels).	DDI-false
DDI-DrugBank.d205.s0.p19	Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate @DRUG$ serum levels and valproic acid has been reported to both increase and decrease @DRUG$ levels).	DDI-false
DDI-DrugBank.d205.s0.p20	Since Zarontin (ethosuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, ethosuximide may elevate phenytoin serum levels and @DRUG$ has been reported to both increase and decrease @DRUG$ levels).	DDI-mechanism
DDI-DrugBank.d206.s0.p0	Results of preliminary studies in humans and rats suggest that nonabsorbable @DRUG$ given concurrently with @DRUG$ may inhibit the desired lactulose-induced drop in colonic pH.	DDI-mechanism
DDI-DrugBank.d206.s0.p1	Results of preliminary studies in humans and rats suggest that nonabsorbable @DRUG$ given concurrently with lactulose may inhibit the desired @DRUG$-induced drop in colonic pH.	DDI-false
DDI-DrugBank.d206.s0.p2	Results of preliminary studies in humans and rats suggest that nonabsorbable antacids given concurrently with @DRUG$ may inhibit the desired @DRUG$-induced drop in colonic pH.	DDI-false
DDI-DrugBank.d207.s1.p0	In patients receiving a potent CYP3A4 inducer such as @DRUG$ or @DRUG$, a dose increase to 500 mg daily should be considered in the absence of severe adverse drug reaction, and clinical response and adverse events should be carefully monitored (see CLINICAL PHARMACOLOGY-Pharmacokinetics-Drug-Drug Interactions and DOSAGE AND ADMINISTRATION-Dosage Adjustment sections).	DDI-false
DDI-DrugBank.d207.s8.p0	Phase II clinical trial data, where @DRUG$ and @DRUG$ have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of vinorelbine.	DDI-false
DDI-DrugBank.d207.s8.p1	Phase II clinical trial data, where @DRUG$ and vinorelbine have been used concomitantly, indicate that @DRUG$ may exacerbate the neutropenic effect of vinorelbine.	DDI-false
DDI-DrugBank.d207.s8.p2	Phase II clinical trial data, where @DRUG$ and vinorelbine have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of @DRUG$.	DDI-false
DDI-DrugBank.d207.s8.p3	Phase II clinical trial data, where IRESSA and @DRUG$ have been used concomitantly, indicate that @DRUG$ may exacerbate the neutropenic effect of vinorelbine.	DDI-false
DDI-DrugBank.d207.s8.p4	Phase II clinical trial data, where IRESSA and @DRUG$ have been used concomitantly, indicate that IRESSA may exacerbate the neutropenic effect of @DRUG$.	DDI-false
DDI-DrugBank.d207.s8.p5	Phase II clinical trial data, where IRESSA and vinorelbine have been used concomitantly, indicate that @DRUG$ may exacerbate the neutropenic effect of @DRUG$.	DDI-effect
DDI-DrugBank.d21.s0.p0	Tissue culture and animal studies indicate that @DRUG$ can diminish or abolish the effect of @DRUG$ on malignant cells.14 This effect on methotrexate activity persists as long as plasma asparagine levels are suppressed.	DDI-effect
DDI-DrugBank.d21.s0.p1	Tissue culture and animal studies indicate that @DRUG$ can diminish or abolish the effect of methotrexate on malignant cells.14 This effect on @DRUG$ activity persists as long as plasma asparagine levels are suppressed.	DDI-false
DDI-DrugBank.d21.s0.p2	Tissue culture and animal studies indicate that ELSPAR can diminish or abolish the effect of @DRUG$ on malignant cells.14 This effect on @DRUG$ activity persists as long as plasma asparagine levels are suppressed.	DDI-false
DDI-DrugBank.d210.s10.p0	@DRUG$: Co-administration with high doses of @DRUG$ [800 mg twice daily] increased the Cmax of rofecoxib by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.	DDI-false
DDI-DrugBank.d210.s10.p1	@DRUG$: Co-administration with high doses of cimetidine [800 mg twice daily] increased the Cmax of @DRUG$ by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.	DDI-false
DDI-DrugBank.d210.s10.p2	Cimetidine: Co-administration with high doses of @DRUG$ [800 mg twice daily] increased the Cmax of @DRUG$ by 21%, the AUC0-120hr by 23% and the t1/2 by 15%.	DDI-mechanism
DDI-DrugBank.d210.s13.p0	@DRUG$: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and thiazides in some patients.	DDI-false
DDI-DrugBank.d210.s13.p1	@DRUG$: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	DDI-false
DDI-DrugBank.d210.s13.p2	@DRUG$: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	DDI-false
DDI-DrugBank.d210.s13.p3	Furosemide: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	DDI-effect
DDI-DrugBank.d210.s13.p4	Furosemide: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	DDI-effect
DDI-DrugBank.d210.s13.p5	Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and @DRUG$ in some patients.	DDI-false
DDI-DrugBank.d210.s15.p0	@DRUG$: @DRUG$ 400 mg daily did not have any clinically important effect on the pharmacokinetics of rofecoxib.	DDI-false
DDI-DrugBank.d210.s15.p1	@DRUG$: Ketoconazole 400 mg daily did not have any clinically important effect on the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d210.s15.p2	Ketoconazole: @DRUG$ 400 mg daily did not have any clinically important effect on the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d210.s18.p0	Thus, when @DRUG$ and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.	DDI-advise
DDI-DrugBank.d210.s18.p1	Thus, when @DRUG$ and lithium are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.	DDI-false
DDI-DrugBank.d210.s18.p2	Thus, when VIOXX and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.	DDI-false
DDI-DrugBank.d210.s19.p0	@DRUG$ @DRUG$ 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis.	DDI-false
DDI-DrugBank.d210.s19.p1	@DRUG$ VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of @DRUG$ as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis.	DDI-false
DDI-DrugBank.d210.s19.p2	@DRUG$ VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly @DRUG$ doses of 7.5 to 20 mg for rheumatoid arthritis.	DDI-false
DDI-DrugBank.d210.s19.p3	Methotrexate @DRUG$ 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of @DRUG$ as measured by AUC0-24hr in patients receiving single weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis.	DDI-false
DDI-DrugBank.d210.s19.p4	Methotrexate @DRUG$ 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of methotrexate as measured by AUC0-24hr in patients receiving single weekly @DRUG$ doses of 7.5 to 20 mg for rheumatoid arthritis.	DDI-false
DDI-DrugBank.d210.s19.p5	Methotrexate VIOXX 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of @DRUG$ as measured by AUC0-24hr in patients receiving single weekly @DRUG$ doses of 7.5 to 20 mg for rheumatoid arthritis.	DDI-false
DDI-DrugBank.d210.s21.p0	At 24 hours postdose, a similar proportion of patients treated with @DRUG$ alone (94%) and subsequently treated with @DRUG$ co-administered with 75 mg of rofecoxib (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).	DDI-false
DDI-DrugBank.d210.s21.p1	At 24 hours postdose, a similar proportion of patients treated with @DRUG$ alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of @DRUG$ (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).	DDI-false
DDI-DrugBank.d210.s21.p2	At 24 hours postdose, a similar proportion of patients treated with @DRUG$ alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of rofecoxib (88%) had @DRUG$ plasma concentrations below the measurable limit (5 ng/mL).	DDI-false
DDI-DrugBank.d210.s21.p3	At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with @DRUG$ co-administered with 75 mg of @DRUG$ (88%) had methotrexate plasma concentrations below the measurable limit (5 ng/mL).	DDI-mechanism
DDI-DrugBank.d210.s21.p4	At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with @DRUG$ co-administered with 75 mg of rofecoxib (88%) had @DRUG$ plasma concentrations below the measurable limit (5 ng/mL).	DDI-false
DDI-DrugBank.d210.s21.p5	At 24 hours postdose, a similar proportion of patients treated with methotrexate alone (94%) and subsequently treated with methotrexate co-administered with 75 mg of @DRUG$ (88%) had @DRUG$ plasma concentrations below the measurable limit (5 ng/mL).	DDI-false
DDI-DrugBank.d210.s23.p0	Oral @DRUG$ @DRUG$ did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and norethindrone.	DDI-false
DDI-DrugBank.d210.s23.p1	Oral @DRUG$ Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ and norethindrone.	DDI-false
DDI-DrugBank.d210.s23.p2	Oral @DRUG$ Rofecoxib did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and @DRUG$.	DDI-false
DDI-DrugBank.d210.s23.p3	Oral Contraceptives @DRUG$ did not have any clinically important effect on the pharmacokinetics of @DRUG$ and norethindrone.	DDI-false
DDI-DrugBank.d210.s23.p4	Oral Contraceptives @DRUG$ did not have any clinically important effect on the pharmacokinetics of ethinyl estradiol and @DRUG$.	DDI-false
DDI-DrugBank.d210.s23.p5	Oral Contraceptives Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d210.s27.p0	@DRUG$ @DRUG$ 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.	DDI-false
DDI-DrugBank.d210.s27.p1	@DRUG$ VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma @DRUG$ concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.	DDI-false
DDI-DrugBank.d210.s27.p2	@DRUG$ VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of @DRUG$.	DDI-false
DDI-DrugBank.d210.s27.p3	Theophylline @DRUG$ 12.5, 25, and 50 mg administered once daily for 7 days increased plasma @DRUG$ concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of theophylline.	DDI-mechanism
DDI-DrugBank.d210.s27.p4	Theophylline @DRUG$ 12.5, 25, and 50 mg administered once daily for 7 days increased plasma theophylline concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of @DRUG$.	DDI-false
DDI-DrugBank.d210.s27.p5	Theophylline VIOXX 12.5, 25, and 50 mg administered once daily for 7 days increased plasma @DRUG$ concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of @DRUG$.	DDI-false
DDI-DrugBank.d210.s9.p0	Prospective, long-term studies on concomitant administration of @DRUG$ and @DRUG$ have not been conducted.	DDI-false
DDI-DrugBank.d212.s7.p0	Pharmacokinetics of @DRUG$ were also not affected by @DRUG$.	DDI-false
DDI-DrugBank.d213.s1.p0	Serum concentration of @DRUG$ and @DRUG$ may increase when patients take antithyroid agents.	DDI-false
DDI-DrugBank.d213.s1.p1	Serum concentration of @DRUG$ and digitoxin may increase when patients take @DRUG$.	DDI-mechanism
DDI-DrugBank.d213.s1.p2	Serum concentration of digoxin and @DRUG$ may increase when patients take @DRUG$.	DDI-mechanism
DDI-DrugBank.d213.s3.p0	@DRUG$ may decrease thyroidal uptake of @DRUG$, a rebound in uptake may occur up to 5 days after sudden withdrawal of Carbimazole.	DDI-effect
DDI-DrugBank.d213.s3.p1	@DRUG$ may decrease thyroidal uptake of sodium iodide I131, a rebound in uptake may occur up to 5 days after sudden withdrawal of @DRUG$.	DDI-false
DDI-DrugBank.d213.s3.p2	Antithyroid agents may decrease thyroidal uptake of @DRUG$, a rebound in uptake may occur up to 5 days after sudden withdrawal of @DRUG$.	DDI-false
DDI-DrugBank.d215.s0.p0	Caution should be observed when @DRUG$ is coadministered with other @DRUG$, sedatives, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.	DDI-advise
DDI-DrugBank.d215.s0.p1	Caution should be observed when @DRUG$ is coadministered with other opioids, @DRUG$, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.	DDI-advise
DDI-DrugBank.d215.s0.p2	Caution should be observed when @DRUG$ is coadministered with other opioids, sedatives, @DRUG$, or anesthetics, as these agents may increase respiratory and circulatory depression.	DDI-advise
DDI-DrugBank.d215.s0.p3	Caution should be observed when @DRUG$ is coadministered with other opioids, sedatives, phenothiazines, or @DRUG$, as these agents may increase respiratory and circulatory depression.	DDI-advise
DDI-DrugBank.d215.s0.p4	Caution should be observed when anileridine is coadministered with other @DRUG$, @DRUG$, phenothiazines, or anesthetics, as these agents may increase respiratory and circulatory depression.	DDI-false
DDI-DrugBank.d215.s0.p5	Caution should be observed when anileridine is coadministered with other @DRUG$, sedatives, @DRUG$, or anesthetics, as these agents may increase respiratory and circulatory depression.	DDI-false
DDI-DrugBank.d215.s0.p6	Caution should be observed when anileridine is coadministered with other @DRUG$, sedatives, phenothiazines, or @DRUG$, as these agents may increase respiratory and circulatory depression.	DDI-false
DDI-DrugBank.d215.s0.p7	Caution should be observed when anileridine is coadministered with other opioids, @DRUG$, @DRUG$, or anesthetics, as these agents may increase respiratory and circulatory depression.	DDI-false
DDI-DrugBank.d215.s0.p8	Caution should be observed when anileridine is coadministered with other opioids, @DRUG$, phenothiazines, or @DRUG$, as these agents may increase respiratory and circulatory depression.	DDI-false
DDI-DrugBank.d215.s0.p9	Caution should be observed when anileridine is coadministered with other opioids, sedatives, @DRUG$, or @DRUG$, as these agents may increase respiratory and circulatory depression.	DDI-false
DDI-DrugBank.d216.s0.p0	CNS-Active Drugs @DRUG$ An additive effect on psychomotor performance was seen with coadministration of @DRUG$ and ethanol 0.70 g/kg for up to 4 hours after ethanol administration.	DDI-false
DDI-DrugBank.d216.s0.p1	CNS-Active Drugs @DRUG$ An additive effect on psychomotor performance was seen with coadministration of eszopiclone and @DRUG$ 0.70 g/kg for up to 4 hours after ethanol administration.	DDI-false
DDI-DrugBank.d216.s0.p2	CNS-Active Drugs @DRUG$ An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol 0.70 g/kg for up to 4 hours after @DRUG$ administration.	DDI-false
DDI-DrugBank.d216.s0.p3	CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of @DRUG$ and @DRUG$ 0.70 g/kg for up to 4 hours after ethanol administration.	DDI-effect
DDI-DrugBank.d216.s0.p4	CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of @DRUG$ and ethanol 0.70 g/kg for up to 4 hours after @DRUG$ administration.	DDI-false
DDI-DrugBank.d216.s0.p5	CNS-Active Drugs Ethanol An additive effect on psychomotor performance was seen with coadministration of eszopiclone and @DRUG$ 0.70 g/kg for up to 4 hours after @DRUG$ administration.	DDI-false
DDI-DrugBank.d217.s12.p0	@DRUG$ (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
DDI-DrugBank.d217.s12.p1	@DRUG$ (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
DDI-DrugBank.d217.s12.p2	@DRUG$ (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
DDI-DrugBank.d217.s12.p3	Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
DDI-DrugBank.d217.s12.p4	Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
DDI-DrugBank.d217.s12.p5	Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because these products may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
DDI-DrugBank.d217.s13.p0	Some @DRUG$ have also been shown to interfere with the metabolism of @DRUG$.	DDI-mechanism
DDI-DrugBank.d217.s2.p0	Therefore, monitoring of @DRUG$ plasma levels should be considered and dosage of @DRUG$ adjusted as required.	DDI-false
DDI-DrugBank.d217.s7.p0	The concomitant administration of @DRUG$ including @DRUG$ with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
DDI-DrugBank.d217.s7.p1	The concomitant administration of @DRUG$ including norfloxacin with @DRUG$ (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.	DDI-effect
DDI-DrugBank.d217.s7.p2	The concomitant administration of @DRUG$ including norfloxacin with glyburide (a @DRUG$) has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
DDI-DrugBank.d217.s7.p3	The concomitant administration of quinolones including @DRUG$ with @DRUG$ (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia.	DDI-effect
DDI-DrugBank.d217.s7.p4	The concomitant administration of quinolones including @DRUG$ with glyburide (a @DRUG$) has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
DDI-DrugBank.d217.s7.p5	The concomitant administration of quinolones including norfloxacin with @DRUG$ (a @DRUG$) has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
DDI-DrugBank.d217.s9.p0	Diminished urinary excretion of @DRUG$ has been reported during the concomitant administration of @DRUG$ and norfloxacin.	DDI-false
DDI-DrugBank.d217.s9.p1	Diminished urinary excretion of @DRUG$ has been reported during the concomitant administration of probenecid and @DRUG$.	DDI-false
DDI-DrugBank.d217.s9.p2	Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of @DRUG$ and @DRUG$.	DDI-mechanism
DDI-DrugBank.d219.s18.p0	Thus, when @DRUG$ and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.	DDI-effect
DDI-DrugBank.d219.s18.p1	Thus, when @DRUG$ and lithium are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.	DDI-false
DDI-DrugBank.d219.s18.p2	Thus, when NSAIDs and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.	DDI-false
DDI-DrugBank.d219.s2.p0	@DRUG$: The concomitant administration of @DRUG$ has no apparent effect on the extent of absorption of Lodine.	DDI-false
DDI-DrugBank.d219.s2.p1	@DRUG$: The concomitant administration of antacids has no apparent effect on the extent of absorption of @DRUG$.	DDI-false
DDI-DrugBank.d219.s2.p2	Antacids: The concomitant administration of @DRUG$ has no apparent effect on the extent of absorption of @DRUG$.	DDI-false
DDI-DrugBank.d219.s20.p0	Although in vivo studies have not been done to see if @DRUG$ clearance is changed by coadministration of @DRUG$, it is not recommended that they be coadministered.	DDI-advise
DDI-DrugBank.d219.s26.p0	However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in @DRUG$-treated patients receiving concomitant @DRUG$ therapy.	DDI-effect
DDI-DrugBank.d219.s6.p0	however, as with other @DRUG$, concomitant administration of @DRUG$ and aspirin is not generally recommended because of the potential of increased adverse effects.	DDI-false
DDI-DrugBank.d219.s6.p1	however, as with other @DRUG$, concomitant administration of Lodine and @DRUG$ is not generally recommended because of the potential of increased adverse effects.	DDI-false
DDI-DrugBank.d219.s6.p2	however, as with other NSAIDs, concomitant administration of @DRUG$ and @DRUG$ is not generally recommended because of the potential of increased adverse effects.	DDI-advise
DDI-DrugBank.d220.s1.p0	There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a @DRUG$ (@DRUG$).	DDI-false
DDI-DrugBank.d220.s11.p0	In patients taking an @DRUG$ (eg, @DRUG$, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.	DDI-false
DDI-DrugBank.d220.s11.p1	In patients taking an @DRUG$ (eg, valproic acid, @DRUG$, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.	DDI-false
DDI-DrugBank.d220.s11.p2	In patients taking an @DRUG$ (eg, valproic acid, carbamazepine, @DRUG$ or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.	DDI-false
DDI-DrugBank.d220.s11.p3	In patients taking an @DRUG$ (eg, valproic acid, carbamazepine, phenobarbital or @DRUG$), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.	DDI-false
DDI-DrugBank.d220.s11.p4	In patients taking an @DRUG$ (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of @DRUG$ may reduce seizure control by lowering the plasma levels of the anticonvulsant.	DDI-effect
DDI-DrugBank.d220.s11.p5	In patients taking an @DRUG$ (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the @DRUG$.	DDI-false
DDI-DrugBank.d220.s11.p6	In patients taking an anticonvulsant (eg, @DRUG$, @DRUG$, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.	DDI-false
DDI-DrugBank.d220.s11.p7	In patients taking an anticonvulsant (eg, @DRUG$, carbamazepine, @DRUG$ or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.	DDI-false
DDI-DrugBank.d220.s11.p8	In patients taking an anticonvulsant (eg, @DRUG$, carbamazepine, phenobarbital or @DRUG$), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.	DDI-false
DDI-DrugBank.d220.s11.p9	In patients taking an anticonvulsant (eg, @DRUG$, carbamazepine, phenobarbital or phenytoin), the concomitant use of @DRUG$ may reduce seizure control by lowering the plasma levels of the anticonvulsant.	DDI-effect
DDI-DrugBank.d220.s11.p10	In patients taking an anticonvulsant (eg, @DRUG$, carbamazepine, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the @DRUG$.	DDI-false
DDI-DrugBank.d220.s11.p11	In patients taking an anticonvulsant (eg, valproic acid, @DRUG$, @DRUG$ or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.	DDI-false
DDI-DrugBank.d220.s11.p12	In patients taking an anticonvulsant (eg, valproic acid, @DRUG$, phenobarbital or @DRUG$), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.	DDI-false
DDI-DrugBank.d220.s11.p13	In patients taking an anticonvulsant (eg, valproic acid, @DRUG$, phenobarbital or phenytoin), the concomitant use of @DRUG$ may reduce seizure control by lowering the plasma levels of the anticonvulsant.	DDI-effect
DDI-DrugBank.d220.s11.p14	In patients taking an anticonvulsant (eg, valproic acid, @DRUG$, phenobarbital or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the @DRUG$.	DDI-false
DDI-DrugBank.d220.s11.p15	In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, @DRUG$ or @DRUG$), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the anticonvulsant.	DDI-false
DDI-DrugBank.d220.s11.p16	In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, @DRUG$ or phenytoin), the concomitant use of @DRUG$ may reduce seizure control by lowering the plasma levels of the anticonvulsant.	DDI-effect
DDI-DrugBank.d220.s11.p17	In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, @DRUG$ or phenytoin), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the @DRUG$.	DDI-false
DDI-DrugBank.d220.s11.p18	In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or @DRUG$), the concomitant use of @DRUG$ may reduce seizure control by lowering the plasma levels of the anticonvulsant.	DDI-effect
DDI-DrugBank.d220.s11.p19	In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or @DRUG$), the concomitant use of Mefloquine may reduce seizure control by lowering the plasma levels of the @DRUG$.	DDI-false
DDI-DrugBank.d220.s11.p20	In patients taking an anticonvulsant (eg, valproic acid, carbamazepine, phenobarbital or phenytoin), the concomitant use of @DRUG$ may reduce seizure control by lowering the plasma levels of the @DRUG$.	DDI-false
DDI-DrugBank.d220.s4.p0	Because of the danger of a potentially fatal prolongation of the QTc interval, @DRUG$ must not be given simultaneously with or subsequent to @DRUG$.	DDI-advise
DDI-DrugBank.d221.s1.p0	Simultaneous use of @DRUG$ or @DRUG$ should be avoided.	DDI-false
DDI-DrugBank.d222.s0.p0	When @DRUG$ and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of atropine.	DDI-effect
DDI-DrugBank.d222.s0.p1	When @DRUG$ and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when @DRUG$ is used alone because pralidoxime may potentiate the effect of atropine.	DDI-false
DDI-DrugBank.d222.s0.p2	When @DRUG$ and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because @DRUG$ may potentiate the effect of atropine.	DDI-false
DDI-DrugBank.d222.s0.p3	When @DRUG$ and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of @DRUG$.	DDI-false
DDI-DrugBank.d222.s0.p4	When atropine and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when @DRUG$ is used alone because pralidoxime may potentiate the effect of atropine.	DDI-false
DDI-DrugBank.d222.s0.p5	When atropine and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because @DRUG$ may potentiate the effect of atropine.	DDI-false
DDI-DrugBank.d222.s0.p6	When atropine and @DRUG$ are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because pralidoxime may potentiate the effect of @DRUG$.	DDI-false
DDI-DrugBank.d222.s0.p7	When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when @DRUG$ is used alone because @DRUG$ may potentiate the effect of atropine.	DDI-false
DDI-DrugBank.d222.s0.p8	When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when @DRUG$ is used alone because pralidoxime may potentiate the effect of @DRUG$.	DDI-false
DDI-DrugBank.d222.s0.p9	When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected than when atropine is used alone because @DRUG$ may potentiate the effect of @DRUG$.	DDI-effect
DDI-DrugBank.d223.s16.p0	Inhibitors or substrates of CYP2D6 (i.e., @DRUG$, @DRUG$ [SSRIs]) may increase the plasma concentration of doxepin when administered concomitantly.	DDI-false
DDI-DrugBank.d223.s16.p1	Inhibitors or substrates of CYP2D6 (i.e., @DRUG$, selective serotonin reuptake inhibitors [@DRUG$]) may increase the plasma concentration of doxepin when administered concomitantly.	DDI-false
DDI-DrugBank.d223.s16.p2	Inhibitors or substrates of CYP2D6 (i.e., @DRUG$, selective serotonin reuptake inhibitors [SSRIs]) may increase the plasma concentration of @DRUG$ when administered concomitantly.	DDI-mechanism
DDI-DrugBank.d223.s16.p3	Inhibitors or substrates of CYP2D6 (i.e., quinidine, @DRUG$ [@DRUG$]) may increase the plasma concentration of doxepin when administered concomitantly.	DDI-false
DDI-DrugBank.d223.s16.p4	Inhibitors or substrates of CYP2D6 (i.e., quinidine, @DRUG$ [SSRIs]) may increase the plasma concentration of @DRUG$ when administered concomitantly.	DDI-mechanism
DDI-DrugBank.d223.s16.p5	Inhibitors or substrates of CYP2D6 (i.e., quinidine, selective serotonin reuptake inhibitors [@DRUG$]) may increase the plasma concentration of @DRUG$ when administered concomitantly.	DDI-mechanism
DDI-DrugBank.d223.s25.p0	In patients who have been reported to be well controlled on @DRUG$ receiving concurrent @DRUG$ therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.	DDI-false
DDI-DrugBank.d223.s25.p1	In patients who have been reported to be well controlled on @DRUG$ receiving concurrent cimetidine therapy, discontinuation of @DRUG$ has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.	DDI-false
DDI-DrugBank.d223.s25.p2	In patients who have been reported to be well controlled on @DRUG$ receiving concurrent cimetidine therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum @DRUG$ levels and compromise their therapeutic effects.	DDI-false
DDI-DrugBank.d223.s25.p3	In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent @DRUG$ therapy, discontinuation of @DRUG$ has been reported to decrease established steady-state serum tricyclic antidepressant levels and compromise their therapeutic effects.	DDI-false
DDI-DrugBank.d223.s25.p4	In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent @DRUG$ therapy, discontinuation of cimetidine has been reported to decrease established steady-state serum @DRUG$ levels and compromise their therapeutic effects.	DDI-false
DDI-DrugBank.d223.s25.p5	In patients who have been reported to be well controlled on tricyclic antidepressants receiving concurrent cimetidine therapy, discontinuation of @DRUG$ has been reported to decrease established steady-state serum @DRUG$ levels and compromise their therapeutic effects.	DDI-mechanism
DDI-DrugBank.d223.s26.p0	@DRUG$: It should be borne in mind that @DRUG$ ingestion may increase the danger inherent in any intentional or unintentional SINEQUAN overdosage.	DDI-false
DDI-DrugBank.d223.s26.p1	@DRUG$: It should be borne in mind that alcohol ingestion may increase the danger inherent in any intentional or unintentional @DRUG$ overdosage.	DDI-false
DDI-DrugBank.d223.s26.p2	Alcohol: It should be borne in mind that @DRUG$ ingestion may increase the danger inherent in any intentional or unintentional @DRUG$ overdosage.	DDI-mechanism
DDI-DrugBank.d223.s7.p0	@DRUG$) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).	DDI-false
DDI-DrugBank.d223.s7.p1	@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and flecainide).	DDI-false
DDI-DrugBank.d223.s7.p2	@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ propafenone and flecainide).	DDI-false
DDI-DrugBank.d223.s7.p3	@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and flecainide).	DDI-false
DDI-DrugBank.d223.s7.p4	@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and @DRUG$).	DDI-false
DDI-DrugBank.d223.s7.p5	cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, @DRUG$, and the Type 1C antiarrhythmics propafenone and flecainide).	DDI-false
DDI-DrugBank.d223.s7.p6	cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the @DRUG$ propafenone and flecainide).	DDI-false
DDI-DrugBank.d223.s7.p7	cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and flecainide).	DDI-false
DDI-DrugBank.d223.s7.p8	cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics propafenone and @DRUG$).	DDI-false
DDI-DrugBank.d223.s7.p9	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the @DRUG$ propafenone and flecainide).	DDI-false
DDI-DrugBank.d223.s7.p10	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics @DRUG$ and flecainide).	DDI-false
DDI-DrugBank.d223.s7.p11	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and @DRUG$).	DDI-false
DDI-DrugBank.d223.s7.p12	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ @DRUG$ and flecainide).	DDI-false
DDI-DrugBank.d223.s7.p13	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ propafenone and @DRUG$).	DDI-false
DDI-DrugBank.d223.s7.p14	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and @DRUG$).	DDI-false
DDI-DrugBank.d224.s8.p0	Since @DRUG$ may reduce pulse and blood pressure, caution in using drugs such as @DRUG$ (ophthalmic and systemic), antihypertensives, and cardiac glycosides is advised.	DDI-advise
DDI-DrugBank.d224.s8.p1	Since @DRUG$ may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), @DRUG$, and cardiac glycosides is advised.	DDI-advise
DDI-DrugBank.d224.s8.p2	Since @DRUG$ may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), antihypertensives, and @DRUG$ is advised.	DDI-advise
DDI-DrugBank.d224.s8.p3	Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as @DRUG$ (ophthalmic and systemic), @DRUG$, and cardiac glycosides is advised.	DDI-false
DDI-DrugBank.d224.s8.p4	Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as @DRUG$ (ophthalmic and systemic), antihypertensives, and @DRUG$ is advised.	DDI-false
DDI-DrugBank.d224.s8.p5	Since apraclonidine may reduce pulse and blood pressure, caution in using drugs such as beta-blockers (ophthalmic and systemic), @DRUG$, and @DRUG$ is advised.	DDI-false
DDI-DrugBank.d225.s0.p0	Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
DDI-DrugBank.d225.s0.p1	Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
DDI-DrugBank.d225.s0.p2	Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
DDI-DrugBank.d225.s0.p3	Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
DDI-DrugBank.d225.s0.p4	Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
DDI-DrugBank.d225.s0.p5	Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
DDI-DrugBank.d225.s0.p6	Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
DDI-DrugBank.d225.s0.p7	Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-effect
DDI-DrugBank.d225.s0.p8	Immediate and Extended Release Tablets The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-effect
DDI-DrugBank.d225.s0.p9	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p10	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p11	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p12	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p13	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p14	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p15	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p16	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
DDI-DrugBank.d225.s0.p17	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p18	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p19	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p20	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p21	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p22	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p23	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
DDI-DrugBank.d225.s0.p24	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, @DRUG$, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p25	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, @DRUG$, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p26	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p27	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p28	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p29	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
DDI-DrugBank.d225.s0.p30	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, @DRUG$, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p31	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p32	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p33	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p34	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
DDI-DrugBank.d225.s0.p35	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p36	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p37	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p38	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
DDI-DrugBank.d225.s0.p39	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p40	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p41	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
DDI-DrugBank.d225.s0.p42	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, @DRUG$, and beta adrenergic blocking agents.	DDI-false
DDI-DrugBank.d225.s0.p43	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
DDI-DrugBank.d225.s0.p44	Immediate and Extended Release Tablets The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents, some azoles and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d225.s11.p0	The effect of concomitant administration of @DRUG$ and @DRUG$ has been demonstrated in a placebo-controlled crossover study in normal volunteers.	DDI-int
DDI-DrugBank.d231.s10.p0	Tablets Simultaneous administration of @DRUG$ and @DRUG$ tablets may reduce the natriuretic and antihypertensive effects of furosemide.	DDI-effect
DDI-DrugBank.d231.s10.p1	Tablets Simultaneous administration of @DRUG$ and furosemide tablets may reduce the natriuretic and antihypertensive effects of @DRUG$.	DDI-false
DDI-DrugBank.d231.s10.p2	Tablets Simultaneous administration of sucralfate and @DRUG$ tablets may reduce the natriuretic and antihypertensive effects of @DRUG$.	DDI-false
DDI-DrugBank.d231.s12.p0	The intake of @DRUG$ and @DRUG$ should be separated by at least two hours.	DDI-advise
DDI-DrugBank.d231.s13.p0	Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of @DRUG$ and @DRUG$ temporarily reduced creatinine clearance in patients with chronic renal insufficiency.	DDI-effect
DDI-DrugBank.d231.s15.p0	Literature reports indicate that coadministration of @DRUG$ may reduce the natriuretic and antihypertensive effects of @DRUG$ in some patients by inhibiting prostaglandin synthesis.	DDI-effect
DDI-DrugBank.d234.s11.p0	An adequate period of observation must be provided for any patient in whom either @DRUG$ (such as @DRUG$) or large doses of short-acting benzodiazepines (such as  10 mg of midazolam) have been used.	DDI-false
DDI-DrugBank.d234.s11.p1	An adequate period of observation must be provided for any patient in whom either @DRUG$ (such as diazepam) or large doses of @DRUG$ (such as  10 mg of midazolam) have been used.	DDI-false
DDI-DrugBank.d234.s11.p2	An adequate period of observation must be provided for any patient in whom either @DRUG$ (such as diazepam) or large doses of short-acting benzodiazepines (such as  10 mg of @DRUG$) have been used.	DDI-false
DDI-DrugBank.d234.s11.p3	An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as @DRUG$) or large doses of @DRUG$ (such as  10 mg of midazolam) have been used.	DDI-false
DDI-DrugBank.d234.s11.p4	An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as @DRUG$) or large doses of short-acting benzodiazepines (such as  10 mg of @DRUG$) have been used.	DDI-false
DDI-DrugBank.d234.s11.p5	An adequate period of observation must be provided for any patient in whom either long-acting benzodiazepines (such as diazepam) or large doses of @DRUG$ (such as  10 mg of @DRUG$) have been used.	DDI-false
DDI-DrugBank.d235.s2.p0	Increased toxicity (CNS depression): @DRUG$, @DRUG$, tricyclic antidepressants, phenothiazines.	DDI-false
DDI-DrugBank.d235.s2.p1	Increased toxicity (CNS depression): @DRUG$, MAO inhibitors, @DRUG$, phenothiazines.	DDI-false
DDI-DrugBank.d235.s2.p2	Increased toxicity (CNS depression): @DRUG$, MAO inhibitors, tricyclic antidepressants, @DRUG$.	DDI-false
DDI-DrugBank.d235.s2.p3	Increased toxicity (CNS depression): CNS depressants, @DRUG$, @DRUG$, phenothiazines.	DDI-false
DDI-DrugBank.d235.s2.p4	Increased toxicity (CNS depression): CNS depressants, @DRUG$, tricyclic antidepressants, @DRUG$.	DDI-false
DDI-DrugBank.d235.s2.p5	Increased toxicity (CNS depression): CNS depressants, MAO inhibitors, @DRUG$, @DRUG$.	DDI-false
DDI-DrugBank.d236.s10.p0	@DRUG$: @DRUG$, as well as a metabolite of furazolidone, slow amphetamine metabolism.	DDI-false
DDI-DrugBank.d236.s10.p1	@DRUG$: MAOI antidepressants, as well as a metabolite of @DRUG$, slow amphetamine metabolism.	DDI-false
DDI-DrugBank.d236.s10.p2	@DRUG$: MAOI antidepressants, as well as a metabolite of furazolidone, slow @DRUG$ metabolism.	DDI-false
DDI-DrugBank.d236.s10.p3	MAO inhibitors: @DRUG$, as well as a metabolite of @DRUG$, slow amphetamine metabolism.	DDI-false
DDI-DrugBank.d236.s10.p4	MAO inhibitors: @DRUG$, as well as a metabolite of furazolidone, slow @DRUG$ metabolism.	DDI-mechanism
DDI-DrugBank.d236.s10.p5	MAO inhibitors: MAOI antidepressants, as well as a metabolite of @DRUG$, slow @DRUG$ metabolism.	DDI-mechanism
DDI-DrugBank.d236.s14.p0	@DRUG$: @DRUG$ may counteract the sedative effect of antihistamines.	DDI-false
DDI-DrugBank.d236.s14.p1	@DRUG$: Amphetamines may counteract the sedative effect of @DRUG$.	DDI-false
DDI-DrugBank.d236.s14.p2	Antihistamines: @DRUG$ may counteract the sedative effect of @DRUG$.	DDI-effect
DDI-DrugBank.d236.s16.p0	@DRUG$: @DRUG$ blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.	DDI-false
DDI-DrugBank.d236.s16.p1	@DRUG$: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of @DRUG$, and can be used to treat amphetamine poisoning.	DDI-false
DDI-DrugBank.d236.s16.p2	@DRUG$: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat @DRUG$ poisoning.	DDI-false
DDI-DrugBank.d236.s16.p3	Chlorpromazine: @DRUG$ blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of @DRUG$, and can be used to treat amphetamine poisoning.	DDI-effect
DDI-DrugBank.d236.s16.p4	Chlorpromazine: @DRUG$ blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat @DRUG$ poisoning.	DDI-false
DDI-DrugBank.d236.s16.p5	Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of @DRUG$, and can be used to treat @DRUG$ poisoning.	DDI-false
DDI-DrugBank.d236.s23.p0	@DRUG$: @DRUG$ may delay intestinal absorption of phenobarbital;	DDI-false
DDI-DrugBank.d236.s23.p1	@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$;	DDI-false
DDI-DrugBank.d236.s23.p2	Phenobarbital: @DRUG$ may delay intestinal absorption of @DRUG$;	DDI-mechanism
DDI-DrugBank.d236.s27.p0	@DRUG$: In cases of @DRUG$ overdosage, amphetamine CNS stimulation is potentiated and fatal convulsions can occur.	DDI-false
DDI-DrugBank.d236.s27.p1	@DRUG$: In cases of propoxyphene overdosage, @DRUG$ CNS stimulation is potentiated and fatal convulsions can occur.	DDI-false
DDI-DrugBank.d236.s27.p2	Propoxyphene: In cases of @DRUG$ overdosage, @DRUG$ CNS stimulation is potentiated and fatal convulsions can occur.	DDI-effect
DDI-DrugBank.d237.s1.p0	In some cases where serious ventricular arrhythmias, QT prolongation, and torsades de pointes have occurred when @DRUG$ was taken in conjunction with one of the cytochrome P450 3A4 inhibitors, elevated blood @DRUG$ levels were noted at the time of the QT prolongation.	DDI-false
DDI-DrugBank.d237.s12.p0	@DRUG$: In vitro data indicate that @DRUG$ and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
DDI-DrugBank.d237.s12.p1	@DRUG$: In vitro data indicate that indinavir and @DRUG$ markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
DDI-DrugBank.d237.s12.p2	@DRUG$: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of @DRUG$ which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
DDI-DrugBank.d237.s12.p3	@DRUG$: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
DDI-DrugBank.d237.s12.p4	Protease Inhibitors: In vitro data indicate that @DRUG$ and @DRUG$ markedly inhibit the metabolism of cisapride which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
DDI-DrugBank.d237.s12.p5	Protease Inhibitors: In vitro data indicate that @DRUG$ and ritonavir markedly inhibit the metabolism of @DRUG$ which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
DDI-DrugBank.d237.s12.p6	Protease Inhibitors: In vitro data indicate that @DRUG$ and ritonavir markedly inhibit the metabolism of cisapride which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
DDI-DrugBank.d237.s12.p7	Protease Inhibitors: In vitro data indicate that indinavir and @DRUG$ markedly inhibit the metabolism of @DRUG$ which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
DDI-DrugBank.d237.s12.p8	Protease Inhibitors: In vitro data indicate that indinavir and @DRUG$ markedly inhibit the metabolism of cisapride which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
DDI-DrugBank.d237.s12.p9	Protease Inhibitors: In vitro data indicate that indinavir and ritonavir markedly inhibit the metabolism of @DRUG$ which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
DDI-DrugBank.d237.s13.p0	Other: Coadministration of grapefruit juice with @DRUG$ increases the bioavailability of @DRUG$ and concomitant use should be avoided.	DDI-false
DDI-DrugBank.d237.s14.p0	@DRUG$ should not be used concomitantly with other drugs known to prolong the QT interval: certain @DRUG$, including those of Class IA (such as quinidine and procainamide) and Class III (such as sotalol);	DDI-advise
DDI-DrugBank.d237.s14.p1	@DRUG$ should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as @DRUG$ and procainamide) and Class III (such as sotalol);	DDI-advise
DDI-DrugBank.d237.s14.p2	@DRUG$ should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and @DRUG$) and Class III (such as sotalol);	DDI-advise
DDI-DrugBank.d237.s14.p3	@DRUG$ should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and procainamide) and Class III (such as @DRUG$);	DDI-advise
DDI-DrugBank.d237.s14.p4	Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain @DRUG$, including those of Class IA (such as @DRUG$ and procainamide) and Class III (such as sotalol);	DDI-false
DDI-DrugBank.d237.s14.p5	Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain @DRUG$, including those of Class IA (such as quinidine and @DRUG$) and Class III (such as sotalol);	DDI-false
DDI-DrugBank.d237.s14.p6	Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain @DRUG$, including those of Class IA (such as quinidine and procainamide) and Class III (such as @DRUG$);	DDI-false
DDI-DrugBank.d237.s14.p7	Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as @DRUG$ and @DRUG$) and Class III (such as sotalol);	DDI-false
DDI-DrugBank.d237.s14.p8	Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as @DRUG$ and procainamide) and Class III (such as @DRUG$);	DDI-false
DDI-DrugBank.d237.s14.p9	Cisapride should not be used concomitantly with other drugs known to prolong the QT interval: certain antiarrhythmics, including those of Class IA (such as quinidine and @DRUG$) and Class III (such as @DRUG$);	DDI-false
DDI-DrugBank.d237.s16.p0	certain @DRUG$ (such as @DRUG$);	DDI-false
DDI-DrugBank.d237.s3.p0	@DRUG$: Concurrent administration of certain @DRUG$, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of cisapride.	DDI-false
DDI-DrugBank.d237.s3.p1	@DRUG$: Concurrent administration of certain anticholinergic compounds, such as @DRUG$ and dicyclomine, would be expected to compromise the beneficial effects of cisapride.	DDI-false
DDI-DrugBank.d237.s3.p2	@DRUG$: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and @DRUG$, would be expected to compromise the beneficial effects of cisapride.	DDI-false
DDI-DrugBank.d237.s3.p3	@DRUG$: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of @DRUG$.	DDI-false
DDI-DrugBank.d237.s3.p4	Anticholinergics: Concurrent administration of certain @DRUG$, such as @DRUG$ and dicyclomine, would be expected to compromise the beneficial effects of cisapride.	DDI-false
DDI-DrugBank.d237.s3.p5	Anticholinergics: Concurrent administration of certain @DRUG$, such as belladonna alkaloids and @DRUG$, would be expected to compromise the beneficial effects of cisapride.	DDI-false
DDI-DrugBank.d237.s3.p6	Anticholinergics: Concurrent administration of certain @DRUG$, such as belladonna alkaloids and dicyclomine, would be expected to compromise the beneficial effects of @DRUG$.	DDI-effect
DDI-DrugBank.d237.s3.p7	Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as @DRUG$ and @DRUG$, would be expected to compromise the beneficial effects of cisapride.	DDI-false
DDI-DrugBank.d237.s3.p8	Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as @DRUG$ and dicyclomine, would be expected to compromise the beneficial effects of @DRUG$.	DDI-effect
DDI-DrugBank.d237.s3.p9	Anticholinergics: Concurrent administration of certain anticholinergic compounds, such as belladonna alkaloids and @DRUG$, would be expected to compromise the beneficial effects of @DRUG$.	DDI-effect
DDI-DrugBank.d237.s4.p0	@DRUG$ (Oral): In patients receiving oral @DRUG$, the coagulation times were increased in some cases.	DDI-false
DDI-DrugBank.d237.s9.p0	A study in 14 normal male and female volunteers suggests that coadministration of @DRUG$ and @DRUG$ can result in prolongation of the QT interval on the ECG.	DDI-effect
DDI-DrugBank.d238.s19.p0	Nevertheless, caution is indicated in the co-administration of @DRUG$ with any of the @DRUG$ and also in switching from one class to the other.	DDI-advise
DDI-DrugBank.d238.s20.p0	Of particular importance, sufficient time must elapse before initiating @DRUG$treatment in a patient being withdrawn from @DRUG$, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).	DDI-advise
DDI-DrugBank.d238.s23.p0	It is desirable to monitor @DRUG$plasma levels whenever an agent of the @DRUG$ including Anafranil is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).	DDI-false
DDI-DrugBank.d238.s23.p1	It is desirable to monitor @DRUG$plasma levels whenever an agent of the tricyclic antidepressant class including @DRUG$ is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).	DDI-false
DDI-DrugBank.d238.s23.p2	It is desirable to monitor TCAplasma levels whenever an agent of the @DRUG$ including @DRUG$ is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).	DDI-false
DDI-DrugBank.d238.s24.p0	Because @DRUG$ is highly bound to serum protein, the administration of @DRUG$ to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.	DDI-false
DDI-DrugBank.d238.s24.p1	Because @DRUG$ is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., @DRUG$, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.	DDI-false
DDI-DrugBank.d238.s24.p2	Because @DRUG$ is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., warfarin, @DRUG$) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.	DDI-false
DDI-DrugBank.d238.s24.p3	Because Anafranil is highly bound to serum protein, the administration of @DRUG$ to patients taking other drugs that are highly bound to protein (e.g., @DRUG$, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.	DDI-mechanism
DDI-DrugBank.d238.s24.p4	Because Anafranil is highly bound to serum protein, the administration of @DRUG$ to patients taking other drugs that are highly bound to protein (e.g., warfarin, @DRUG$) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.	DDI-mechanism
DDI-DrugBank.d238.s24.p5	Because Anafranil is highly bound to serum protein, the administration of Anafranil to patients taking other drugs that are highly bound to protein (e.g., @DRUG$, @DRUG$) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.	DDI-false
DDI-DrugBank.d238.s4.p0	Several @DRUG$ have been reported to block the pharmacologic effects of @DRUG$, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.	DDI-effect
DDI-DrugBank.d238.s4.p1	Several @DRUG$ have been reported to block the pharmacologic effects of guanethidine, @DRUG$, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.	DDI-effect
DDI-DrugBank.d238.s4.p2	Several @DRUG$ have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with @DRUG$ because of its structural similarity to other tricyclic antidepressants.	DDI-effect
DDI-DrugBank.d238.s4.p3	Several @DRUG$ have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other @DRUG$.	DDI-effect
DDI-DrugBank.d238.s4.p4	Several tricyclic antidepressants have been reported to block the pharmacologic effects of @DRUG$, @DRUG$, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.	DDI-false
DDI-DrugBank.d238.s4.p5	Several tricyclic antidepressants have been reported to block the pharmacologic effects of @DRUG$, clonidine, or similar agents, and such an effect may be anticipated with @DRUG$ because of its structural similarity to other tricyclic antidepressants.	DDI-false
DDI-DrugBank.d238.s4.p6	Several tricyclic antidepressants have been reported to block the pharmacologic effects of @DRUG$, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other @DRUG$.	DDI-false
DDI-DrugBank.d238.s4.p7	Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, @DRUG$, or similar agents, and such an effect may be anticipated with @DRUG$ because of its structural similarity to other tricyclic antidepressants.	DDI-false
DDI-DrugBank.d238.s4.p8	Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, @DRUG$, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other @DRUG$.	DDI-false
DDI-DrugBank.d238.s4.p9	Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with @DRUG$ because of its structural similarity to other @DRUG$.	DDI-false
DDI-DrugBank.d238.s5.p0	The plasma concentration of @DRUG$ has been reported to be increased by the concomitant administration of @DRUG$;	DDI-mechanism
DDI-DrugBank.d240.s1.p0	It may also interact with @DRUG$ or other @DRUG$ or MAOIs, which may intensify the anticholinergic action.	DDI-false
DDI-DrugBank.d240.s1.p1	It may also interact with @DRUG$ or other anticholinergic drugs or @DRUG$, which may intensify the anticholinergic action.	DDI-false
DDI-DrugBank.d240.s1.p2	It may also interact with amantadine or other @DRUG$ or @DRUG$, which may intensify the anticholinergic action.	DDI-false
DDI-DrugBank.d241.s2.p0	However, patients receiving infusions of @DRUG$ in clinical trials were maintained on @DRUG$ without evidence of increased bleeding.	DDI-false
DDI-DrugBank.d242.s1.p0	However, the systemic administration of some @DRUG$ has been shown to elevate plasma concentrations of @DRUG$, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.	DDI-mechanism
DDI-DrugBank.d242.s1.p1	However, the systemic administration of some @DRUG$ has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of @DRUG$, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.	DDI-mechanism
DDI-DrugBank.d242.s1.p2	However, the systemic administration of some @DRUG$ has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral @DRUG$ warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.	DDI-false
DDI-DrugBank.d242.s1.p3	However, the systemic administration of some @DRUG$ has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant @DRUG$ and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.	DDI-effect
DDI-DrugBank.d242.s1.p4	However, the systemic administration of some @DRUG$ has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic @DRUG$ concomitantly.	DDI-effect
DDI-DrugBank.d242.s1.p5	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of @DRUG$, interfere with the metabolism of @DRUG$, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.	DDI-false
DDI-DrugBank.d242.s1.p6	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of @DRUG$, interfere with the metabolism of caffeine, and enhance the effects of the oral @DRUG$ warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.	DDI-false
DDI-DrugBank.d242.s1.p7	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of @DRUG$, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant @DRUG$ and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.	DDI-false
DDI-DrugBank.d242.s1.p8	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of @DRUG$, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic @DRUG$ concomitantly.	DDI-false
DDI-DrugBank.d242.s1.p9	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of @DRUG$, and enhance the effects of the oral @DRUG$ warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.	DDI-false
DDI-DrugBank.d242.s1.p10	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of @DRUG$, and enhance the effects of the oral anticoagulant @DRUG$ and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.	DDI-false
DDI-DrugBank.d242.s1.p11	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of @DRUG$, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic @DRUG$ concomitantly.	DDI-false
DDI-DrugBank.d242.s1.p12	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral @DRUG$ @DRUG$ and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic cyclosporine concomitantly.	DDI-false
DDI-DrugBank.d242.s1.p13	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral @DRUG$ warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic @DRUG$ concomitantly.	DDI-false
DDI-DrugBank.d242.s1.p14	However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant @DRUG$ and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic @DRUG$ concomitantly.	DDI-false
DDI-DrugBank.d246.s0.p0	Concurrent use of @DRUG$ with @DRUG$ (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d246.s0.p1	Concurrent use of @DRUG$ with central nervous system depressants (e.g., @DRUG$, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d246.s0.p2	Concurrent use of @DRUG$ with central nervous system depressants (e.g., alcohol, @DRUG$, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d246.s0.p3	Concurrent use of @DRUG$ with central nervous system depressants (e.g., alcohol, barbiturates, @DRUG$, and antihistamines) may result in increased central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d246.s0.p4	Concurrent use of @DRUG$ with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and @DRUG$) may result in increased central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d246.s0.p5	Concurrent use of @DRUG$ with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased @DRUG$ effects.	DDI-false
DDI-DrugBank.d246.s0.p6	Concurrent use of butorphanol with @DRUG$ (e.g., @DRUG$, barbiturates, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.	DDI-false
DDI-DrugBank.d246.s0.p7	Concurrent use of butorphanol with @DRUG$ (e.g., alcohol, @DRUG$, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.	DDI-false
DDI-DrugBank.d246.s0.p8	Concurrent use of butorphanol with @DRUG$ (e.g., alcohol, barbiturates, @DRUG$, and antihistamines) may result in increased central nervous system depressant effects.	DDI-false
DDI-DrugBank.d246.s0.p9	Concurrent use of butorphanol with @DRUG$ (e.g., alcohol, barbiturates, tranquilizers, and @DRUG$) may result in increased central nervous system depressant effects.	DDI-false
DDI-DrugBank.d246.s0.p10	Concurrent use of butorphanol with @DRUG$ (e.g., alcohol, barbiturates, tranquilizers, and antihistamines) may result in increased @DRUG$ effects.	DDI-false
DDI-DrugBank.d246.s0.p11	Concurrent use of butorphanol with central nervous system depressants (e.g., @DRUG$, @DRUG$, tranquilizers, and antihistamines) may result in increased central nervous system depressant effects.	DDI-false
DDI-DrugBank.d246.s0.p12	Concurrent use of butorphanol with central nervous system depressants (e.g., @DRUG$, barbiturates, @DRUG$, and antihistamines) may result in increased central nervous system depressant effects.	DDI-false
DDI-DrugBank.d246.s0.p13	Concurrent use of butorphanol with central nervous system depressants (e.g., @DRUG$, barbiturates, tranquilizers, and @DRUG$) may result in increased central nervous system depressant effects.	DDI-false
DDI-DrugBank.d246.s0.p14	Concurrent use of butorphanol with central nervous system depressants (e.g., @DRUG$, barbiturates, tranquilizers, and antihistamines) may result in increased @DRUG$ effects.	DDI-false
DDI-DrugBank.d246.s0.p15	Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, @DRUG$, @DRUG$, and antihistamines) may result in increased central nervous system depressant effects.	DDI-false
DDI-DrugBank.d246.s0.p16	Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, @DRUG$, tranquilizers, and @DRUG$) may result in increased central nervous system depressant effects.	DDI-false
DDI-DrugBank.d246.s0.p17	Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, @DRUG$, tranquilizers, and antihistamines) may result in increased @DRUG$ effects.	DDI-false
DDI-DrugBank.d246.s0.p18	Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, @DRUG$, and @DRUG$) may result in increased central nervous system depressant effects.	DDI-false
DDI-DrugBank.d246.s0.p19	Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, @DRUG$, and antihistamines) may result in increased @DRUG$ effects.	DDI-false
DDI-DrugBank.d246.s0.p20	Concurrent use of butorphanol with central nervous system depressants (e.g., alcohol, barbiturates, tranquilizers, and @DRUG$) may result in increased @DRUG$ effects.	DDI-false
DDI-DrugBank.d246.s13.p0	The fraction of @DRUG$ absorbed is unaffected by the concomitant administration of a @DRUG$ (oxymetazoline), but the rate of absorption is decreased.	DDI-false
DDI-DrugBank.d246.s13.p1	The fraction of @DRUG$ absorbed is unaffected by the concomitant administration of a nasal vasoconstrictor (@DRUG$), but the rate of absorption is decreased.	DDI-false
DDI-DrugBank.d246.s13.p2	The fraction of STADOL NS absorbed is unaffected by the concomitant administration of a @DRUG$ (@DRUG$), but the rate of absorption is decreased.	DDI-false
DDI-DrugBank.d246.s7.p0	These results suggest that the analgesic effect of @DRUG$ may be diminished when it is administered shortly after @DRUG$ nasal spray, but by 30 minutes any such reduction in effect should be minimal.	DDI-effect
DDI-DrugBank.d246.s8.p0	The safety of using @DRUG$ and @DRUG$ (sumatriptan) Nasal Spray during the same episode of migraine has not been established.	DDI-false
DDI-DrugBank.d246.s8.p1	The safety of using @DRUG$ and IMITREX (@DRUG$) Nasal Spray during the same episode of migraine has not been established.	DDI-false
DDI-DrugBank.d246.s8.p2	The safety of using STADOL NS and @DRUG$ (@DRUG$) Nasal Spray during the same episode of migraine has not been established.	DDI-false
DDI-DrugBank.d249.s10.p0	Oral @DRUG$: @DRUG$ does not alter glucose metabolism in normal subjects nor does it alter the effects of oral hypoglycemic agents.	DDI-false
DDI-DrugBank.d249.s10.p1	Oral @DRUG$: Diclofenac does not alter glucose metabolism in normal subjects nor does it alter the effects of oral @DRUG$.	DDI-false
DDI-DrugBank.d249.s10.p2	Oral Hypoglycemics: @DRUG$ does not alter glucose metabolism in normal subjects nor does it alter the effects of oral @DRUG$.	DDI-false
DDI-DrugBank.d250.s0.p0	Certain other @DRUG$ (@DRUG$ and polymyxin) have also been reported to interfere with the nerve transmission at the neuromuscular junction.	DDI-false
DDI-DrugBank.d250.s0.p1	Certain other @DRUG$ (aminoglycosides and @DRUG$) have also been reported to interfere with the nerve transmission at the neuromuscular junction.	DDI-false
DDI-DrugBank.d250.s0.p2	Certain other antibiotics (@DRUG$ and @DRUG$) have also been reported to interfere with the nerve transmission at the neuromuscular junction.	DDI-false
DDI-DrugBank.d250.s3.p0	@DRUG$ may enhance the nephrotoxicity of @DRUG$ Parenteral.	DDI-effect
DDI-DrugBank.d250.s4.p0	The concomitant use of @DRUG$ and @DRUG$ Parenteral should be avoided.	DDI-advise
DDI-DrugBank.d252.s4.p0	The concomitant use of @DRUG$ with @DRUG$ and calcium antagonists may have additive effects on prolonging atrioventricular conduction time.	DDI-effect
DDI-DrugBank.d252.s4.p1	The concomitant use of @DRUG$ with digitalis and @DRUG$s may have additive effects on prolonging atrioventricular conduction time.	DDI-effect
DDI-DrugBank.d252.s4.p2	The concomitant use of beta-adrenergic blocking agents with @DRUG$ and @DRUG$s may have additive effects on prolonging atrioventricular conduction time.	DDI-false
DDI-DrugBank.d257.s0.p0	Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d257.s0.p1	Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d257.s0.p2	Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d257.s0.p3	Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d257.s0.p4	Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d257.s0.p5	Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d257.s0.p6	Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d257.s0.p7	Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d257.s0.p8	Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d257.s0.p9	Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d257.s0.p10	Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d257.s0.p11	Interactions with Other CNS Agents: Concurrent use of @DRUG$ with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.	DDI-effect
DDI-DrugBank.d257.s0.p12	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p13	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p14	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p15	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p16	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p17	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p18	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p19	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p20	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p21	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p22	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all @DRUG$ (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p23	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p24	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p25	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p26	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p27	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p28	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p29	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p30	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p31	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p32	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, @DRUG$, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p33	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p34	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p35	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p36	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p37	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p38	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p39	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p40	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p41	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, @DRUG$, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p42	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p43	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p44	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p45	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p46	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p47	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p48	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p49	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, @DRUG$, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p50	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p51	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p52	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general anesthetics, barbiturates, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p53	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p54	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p55	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p56	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other @DRUG$, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p57	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p58	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p59	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p60	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p61	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p62	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general @DRUG$, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p63	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p64	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p65	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p66	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p67	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, @DRUG$, tricyclic antidepressants, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p68	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, @DRUG$, @DRUG$, tranquilizers, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p69	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, @DRUG$, phenothiazines, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p70	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, @DRUG$, phenothiazines, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p71	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, @DRUG$, phenothiazines, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p72	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, @DRUG$, skeletal muscle relaxants and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p73	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p74	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, @DRUG$, tranquilizers, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p75	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, @DRUG$ and antihistamines) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p76	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, @DRUG$, skeletal muscle relaxants and @DRUG$) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d257.s0.p77	Interactions with Other CNS Agents: Concurrent use of Levo-Dromoran with all central nervous system depressants (eg, alcohol, sedatives, hypnotics, other opioids, general anesthetics, barbiturates, tricyclic antidepressants, phenothiazines, tranquilizers, @DRUG$ and @DRUG$) may result in additive central nervous system depressant effects.	DDI-false
DDI-DrugBank.d258.s12.p0	There does not appear to be an increase in adverse events in subjects who received oral @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d260.s0.p0	@DRUG$ : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p1	@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p2	@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p3	@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p4	@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p5	@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p6	@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p7	@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p8	@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p9	@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p10	@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p11	@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p12	@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p13	@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p14	@DRUG$ : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).	DDI-false
DDI-DrugBank.d260.s0.p15	Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-mechanism
DDI-DrugBank.d260.s0.p16	Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-mechanism
DDI-DrugBank.d260.s0.p17	Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-mechanism
DDI-DrugBank.d260.s0.p18	Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-mechanism
DDI-DrugBank.d260.s0.p19	Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-mechanism
DDI-DrugBank.d260.s0.p20	Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-mechanism
DDI-DrugBank.d260.s0.p21	Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-mechanism
DDI-DrugBank.d260.s0.p22	Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-mechanism
DDI-DrugBank.d260.s0.p23	Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-mechanism
DDI-DrugBank.d260.s0.p24	Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-mechanism
DDI-DrugBank.d260.s0.p25	Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-mechanism
DDI-DrugBank.d260.s0.p26	Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).	DDI-mechanism
DDI-DrugBank.d260.s0.p27	Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).	DDI-mechanism
DDI-DrugBank.d260.s0.p28	Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).	DDI-mechanism
DDI-DrugBank.d260.s0.p29	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p30	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p31	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p32	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p33	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p34	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p35	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p36	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p37	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p38	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p39	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p40	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p41	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., @DRUG$, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).	DDI-false
DDI-DrugBank.d260.s0.p42	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p43	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p44	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p45	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p46	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p47	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p48	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p49	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p50	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p51	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p52	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p53	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, @DRUG$, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).	DDI-false
DDI-DrugBank.d260.s0.p54	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p55	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p56	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p57	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p58	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p59	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p60	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p61	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p62	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p63	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p64	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, @DRUG$, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).	DDI-false
DDI-DrugBank.d260.s0.p65	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p66	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p67	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p68	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p69	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p70	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p71	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p72	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p73	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p74	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, @DRUG$, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).	DDI-false
DDI-DrugBank.d260.s0.p75	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p76	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p77	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p78	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p79	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p80	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p81	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p82	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p83	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, @DRUG$, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).	DDI-false
DDI-DrugBank.d260.s0.p84	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p85	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p86	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p87	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p88	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p89	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p90	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p91	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, @DRUG$, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).	DDI-false
DDI-DrugBank.d260.s0.p92	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p93	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p94	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p95	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p96	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p97	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p98	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, @DRUG$, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).	DDI-false
DDI-DrugBank.d260.s0.p99	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p100	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p101	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p102	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p103	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p104	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, @DRUG$, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).	DDI-false
DDI-DrugBank.d260.s0.p105	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p106	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p107	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, @DRUG$ agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p108	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p109	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, @DRUG$, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).	DDI-false
DDI-DrugBank.d260.s0.p110	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p111	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, @DRUG$ agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p112	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p113	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, @DRUG$, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).	DDI-false
DDI-DrugBank.d260.s0.p114	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, @DRUG$ agents, theophylline, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p115	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p116	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, @DRUG$, nonsteroidal anti-inflammatory agents, theophylline, and @DRUG$).	DDI-false
DDI-DrugBank.d260.s0.p117	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, @DRUG$, and zidovudine).	DDI-false
DDI-DrugBank.d260.s0.p118	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, @DRUG$ agents, theophylline, and @DRUG$).	DDI-false
DDI-DrugBank.d260.s0.p119	Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and @DRUG$).	DDI-false
DDI-DrugBank.d260.s2.p0	@DRUG$ should either be temporarily discontinued or decreased by 50% when coadministered with @DRUG$ on the day of VISTIDE infusion.	DDI-advise
DDI-DrugBank.d260.s2.p1	@DRUG$ should either be temporarily discontinued or decreased by 50% when coadministered with probenecid on the day of @DRUG$ infusion.	DDI-false
DDI-DrugBank.d260.s2.p2	Zidovudine should either be temporarily discontinued or decreased by 50% when coadministered with @DRUG$ on the day of @DRUG$ infusion.	DDI-false
DDI-DrugBank.d263.s1.p0	@DRUG$ also has no significant effect on the intracellular phosphorylation of @DRUG$, as shown in vitro in peripheral blood mononuclear cells or in two other cell lines (U937 and Molt-4).	DDI-effect
DDI-DrugBank.d263.s14.p0	Concomitant use of @DRUG$ with @DRUG$ is not recommended.	DDI-advise
DDI-DrugBank.d263.s18.p0	@DRUG$, @DRUG$, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p1	@DRUG$, Foscarnet, and @DRUG$: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p2	@DRUG$, Foscarnet, and Aminoglycosides: Drugs such as @DRUG$, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p3	@DRUG$, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, @DRUG$, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p4	@DRUG$, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and @DRUG$ may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p5	@DRUG$, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other @DRUG$-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p6	@DRUG$, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of @DRUG$ (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p7	Amphotericin, @DRUG$, and @DRUG$: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p8	Amphotericin, @DRUG$, and Aminoglycosides: Drugs such as @DRUG$, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p9	Amphotericin, @DRUG$, and Aminoglycosides: Drugs such as amphotericin, @DRUG$, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p10	Amphotericin, @DRUG$, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and @DRUG$ may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p11	Amphotericin, @DRUG$, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other @DRUG$-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p12	Amphotericin, @DRUG$, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of @DRUG$ (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p13	Amphotericin, Foscarnet, and @DRUG$: Drugs such as @DRUG$, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p14	Amphotericin, Foscarnet, and @DRUG$: Drugs such as amphotericin, @DRUG$, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p15	Amphotericin, Foscarnet, and @DRUG$: Drugs such as amphotericin, foscarnet, and @DRUG$ may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p16	Amphotericin, Foscarnet, and @DRUG$: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other @DRUG$-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p17	Amphotericin, Foscarnet, and @DRUG$: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of @DRUG$ (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p18	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as @DRUG$, @DRUG$, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p19	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as @DRUG$, foscarnet, and @DRUG$ may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p20	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as @DRUG$, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other @DRUG$-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-effect
DDI-DrugBank.d263.s18.p21	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as @DRUG$, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of @DRUG$ (thereby raising systemic exposure).	DDI-mechanism
DDI-DrugBank.d263.s18.p22	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, @DRUG$, and @DRUG$ may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s18.p23	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, @DRUG$, and aminoglycosides may increase the risk of developing peripheral neuropathy or other @DRUG$-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-effect
DDI-DrugBank.d263.s18.p24	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, @DRUG$, and aminoglycosides may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of @DRUG$ (thereby raising systemic exposure).	DDI-mechanism
DDI-DrugBank.d263.s18.p25	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and @DRUG$ may increase the risk of developing peripheral neuropathy or other @DRUG$-associated adverse events by interfering with the renal clearance of zalcitabine (thereby raising systemic exposure).	DDI-effect
DDI-DrugBank.d263.s18.p26	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and @DRUG$ may increase the risk of developing peripheral neuropathy or other HIVID-associated adverse events by interfering with the renal clearance of @DRUG$ (thereby raising systemic exposure).	DDI-mechanism
DDI-DrugBank.d263.s18.p27	Amphotericin, Foscarnet, and Aminoglycosides: Drugs such as amphotericin, foscarnet, and aminoglycosides may increase the risk of developing peripheral neuropathy or other @DRUG$-associated adverse events by interfering with the renal clearance of @DRUG$ (thereby raising systemic exposure).	DDI-false
DDI-DrugBank.d263.s20.p0	@DRUG$ or @DRUG$: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.	DDI-false
DDI-DrugBank.d263.s20.p1	@DRUG$ or Cimetidine: Concomitant administration of @DRUG$ or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.	DDI-false
DDI-DrugBank.d263.s20.p2	@DRUG$ or Cimetidine: Concomitant administration of probenecid or @DRUG$ decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.	DDI-false
DDI-DrugBank.d263.s20.p3	@DRUG$ or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of @DRUG$, most likely by inhibition of renal tubular secretion of zalcitabine.	DDI-false
DDI-DrugBank.d263.s20.p4	@DRUG$ or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of @DRUG$.	DDI-false
DDI-DrugBank.d263.s20.p5	Probenecid or @DRUG$: Concomitant administration of @DRUG$ or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.	DDI-false
DDI-DrugBank.d263.s20.p6	Probenecid or @DRUG$: Concomitant administration of probenecid or @DRUG$ decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.	DDI-false
DDI-DrugBank.d263.s20.p7	Probenecid or @DRUG$: Concomitant administration of probenecid or cimetidine decreases the elimination of @DRUG$, most likely by inhibition of renal tubular secretion of zalcitabine.	DDI-false
DDI-DrugBank.d263.s20.p8	Probenecid or @DRUG$: Concomitant administration of probenecid or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of @DRUG$.	DDI-false
DDI-DrugBank.d263.s20.p9	Probenecid or Cimetidine: Concomitant administration of @DRUG$ or @DRUG$ decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of zalcitabine.	DDI-false
DDI-DrugBank.d263.s20.p10	Probenecid or Cimetidine: Concomitant administration of @DRUG$ or cimetidine decreases the elimination of @DRUG$, most likely by inhibition of renal tubular secretion of zalcitabine.	DDI-mechanism
DDI-DrugBank.d263.s20.p11	Probenecid or Cimetidine: Concomitant administration of @DRUG$ or cimetidine decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of @DRUG$.	DDI-false
DDI-DrugBank.d263.s20.p12	Probenecid or Cimetidine: Concomitant administration of probenecid or @DRUG$ decreases the elimination of @DRUG$, most likely by inhibition of renal tubular secretion of zalcitabine.	DDI-mechanism
DDI-DrugBank.d263.s20.p13	Probenecid or Cimetidine: Concomitant administration of probenecid or @DRUG$ decreases the elimination of zalcitabine, most likely by inhibition of renal tubular secretion of @DRUG$.	DDI-false
DDI-DrugBank.d263.s20.p14	Probenecid or Cimetidine: Concomitant administration of probenecid or cimetidine decreases the elimination of @DRUG$, most likely by inhibition of renal tubular secretion of @DRUG$.	DDI-false
DDI-DrugBank.d263.s5.p0	@DRUG$ inhibited @DRUG$ phosphorylation at high concentration ratios (10 and 100);	DDI-effect
DDI-DrugBank.d263.s7.p0	These in vitro studies suggest that concomitant administration of @DRUG$ and @DRUG$ in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of zalcitabine.	DDI-effect
DDI-DrugBank.d263.s7.p1	These in vitro studies suggest that concomitant administration of @DRUG$ and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated @DRUG$, which may lead to a decreased antiretroviral effect of zalcitabine.	DDI-false
DDI-DrugBank.d263.s7.p2	These in vitro studies suggest that concomitant administration of @DRUG$ and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased @DRUG$ effect of zalcitabine.	DDI-false
DDI-DrugBank.d263.s7.p3	These in vitro studies suggest that concomitant administration of @DRUG$ and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of @DRUG$.	DDI-false
DDI-DrugBank.d263.s7.p4	These in vitro studies suggest that concomitant administration of zalcitabine and @DRUG$ in humans may result in sub-therapeutic concentrations of active phosphorylated @DRUG$, which may lead to a decreased antiretroviral effect of zalcitabine.	DDI-false
DDI-DrugBank.d263.s7.p5	These in vitro studies suggest that concomitant administration of zalcitabine and @DRUG$ in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased @DRUG$ effect of zalcitabine.	DDI-false
DDI-DrugBank.d263.s7.p6	These in vitro studies suggest that concomitant administration of zalcitabine and @DRUG$ in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased antiretroviral effect of @DRUG$.	DDI-false
DDI-DrugBank.d263.s7.p7	These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated @DRUG$, which may lead to a decreased @DRUG$ effect of zalcitabine.	DDI-false
DDI-DrugBank.d263.s7.p8	These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated @DRUG$, which may lead to a decreased antiretroviral effect of @DRUG$.	DDI-false
DDI-DrugBank.d263.s7.p9	These in vitro studies suggest that concomitant administration of zalcitabine and lamivudine in humans may result in sub-therapeutic concentrations of active phosphorylated zalcitabine, which may lead to a decreased @DRUG$ effect of @DRUG$.	DDI-false
DDI-DrugBank.d263.s9.p0	Concomitant use of @DRUG$ and @DRUG$ is not recommended.	DDI-advise
DDI-DrugBank.d265.s0.p0	@DRUG$ may add to or potentiate the action of other @DRUG$.	DDI-effect
DDI-DrugBank.d265.s7.p0	@DRUG$ and related drugs may increase the responsiveness to @DRUG$.	DDI-effect
DDI-DrugBank.d267.s2.p0	There are no clinical data on concomitant use of @DRUG$ and other nondepolarizing @DRUG$.	DDI-false
DDI-DrugBank.d267.s3.p0	@DRUG$, @DRUG$, and halothane decrease the ED50 of NUROMAX by 30% to 45%.	DDI-false
DDI-DrugBank.d267.s3.p1	@DRUG$, enflurane, and @DRUG$ decrease the ED50 of NUROMAX by 30% to 45%.	DDI-false
DDI-DrugBank.d267.s3.p2	@DRUG$, enflurane, and halothane decrease the ED50 of @DRUG$ by 30% to 45%.	DDI-mechanism
DDI-DrugBank.d267.s3.p3	Isoflurane, @DRUG$, and @DRUG$ decrease the ED50 of NUROMAX by 30% to 45%.	DDI-false
DDI-DrugBank.d267.s3.p4	Isoflurane, @DRUG$, and halothane decrease the ED50 of @DRUG$ by 30% to 45%.	DDI-mechanism
DDI-DrugBank.d267.s3.p5	Isoflurane, enflurane, and @DRUG$ decrease the ED50 of @DRUG$ by 30% to 45%.	DDI-mechanism
DDI-DrugBank.d269.s10.p0	Due to wide interindividual variability in the dose adjustment required, it is recommended that @DRUG$ concentrations be monitored closely after initiation of @DRUG$ therapy and that the dose of cyclosporine be adjusted as appropriate.	DDI-advise
DDI-DrugBank.d269.s10.p1	Due to wide interindividual variability in the dose adjustment required, it is recommended that @DRUG$ concentrations be monitored closely after initiation of carvedilol therapy and that the dose of @DRUG$ be adjusted as appropriate.	DDI-false
DDI-DrugBank.d269.s10.p2	Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of @DRUG$ therapy and that the dose of @DRUG$ be adjusted as appropriate.	DDI-advise
DDI-DrugBank.d269.s13.p0	Therefore, increased monitoring of @DRUG$ is recommended when initiating, adjusting, or discontinuing @DRUG$.	DDI-advise
DDI-DrugBank.d269.s17.p0	As with other @DRUG$, if @DRUG$ is to be administered orally with calcium channel blockers of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.	DDI-false
DDI-DrugBank.d269.s17.p1	As with other @DRUG$, if COREG is to be administered orally with @DRUG$ of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.	DDI-false
DDI-DrugBank.d269.s17.p2	As with other @DRUG$, if COREG is to be administered orally with calcium channel blockers of the @DRUG$ or diltiazem type, it is recommended that ECG and blood pressure be monitored.	DDI-false
DDI-DrugBank.d269.s17.p3	As with other @DRUG$, if COREG is to be administered orally with calcium channel blockers of the verapamil or @DRUG$ type, it is recommended that ECG and blood pressure be monitored.	DDI-false
DDI-DrugBank.d269.s17.p4	As with other agents with b-blocking properties, if @DRUG$ is to be administered orally with @DRUG$ of the verapamil or diltiazem type, it is recommended that ECG and blood pressure be monitored.	DDI-false
DDI-DrugBank.d269.s17.p5	As with other agents with b-blocking properties, if @DRUG$ is to be administered orally with calcium channel blockers of the @DRUG$ or diltiazem type, it is recommended that ECG and blood pressure be monitored.	DDI-advise
DDI-DrugBank.d269.s17.p6	As with other agents with b-blocking properties, if @DRUG$ is to be administered orally with calcium channel blockers of the verapamil or @DRUG$ type, it is recommended that ECG and blood pressure be monitored.	DDI-advise
DDI-DrugBank.d269.s17.p7	As with other agents with b-blocking properties, if COREG is to be administered orally with @DRUG$ of the @DRUG$ or diltiazem type, it is recommended that ECG and blood pressure be monitored.	DDI-false
DDI-DrugBank.d269.s17.p8	As with other agents with b-blocking properties, if COREG is to be administered orally with @DRUG$ of the verapamil or @DRUG$ type, it is recommended that ECG and blood pressure be monitored.	DDI-false
DDI-DrugBank.d269.s17.p9	As with other agents with b-blocking properties, if COREG is to be administered orally with calcium channel blockers of the @DRUG$ or @DRUG$ type, it is recommended that ECG and blood pressure be monitored.	DDI-false
DDI-DrugBank.d269.s5.p0	When concomitant treatment with @DRUG$ and @DRUG$ is to be terminated, the b-blocking agent should be discontinued first.	DDI-advise
DDI-DrugBank.d269.s5.p1	When concomitant treatment with @DRUG$ and clonidine is to be terminated, the @DRUG$ should be discontinued first.	DDI-false
DDI-DrugBank.d269.s5.p2	When concomitant treatment with agents with b-blocking properties and @DRUG$ is to be terminated, the @DRUG$ should be discontinued first.	DDI-false
DDI-DrugBank.d269.s7.p0	@DRUG$: Modest increases in mean trough @DRUG$ concentrations were observed following initiation of carvedilol treatment in 21 renal transplant patients suffering from chronic vascular rejection.	DDI-false
DDI-DrugBank.d269.s7.p1	@DRUG$: Modest increases in mean trough cyclosporine concentrations were observed following initiation of @DRUG$ treatment in 21 renal transplant patients suffering from chronic vascular rejection.	DDI-false
DDI-DrugBank.d269.s7.p2	Cyclosporine: Modest increases in mean trough @DRUG$ concentrations were observed following initiation of @DRUG$ treatment in 21 renal transplant patients suffering from chronic vascular rejection.	DDI-mechanism
DDI-DrugBank.d27.s2.p0	However, in clinical studies the consequences of concomitant @DRUG$ on the pharmacodynamics of @DRUG$ were negligible.	DDI-false
DDI-DrugBank.d270.s18.p0	@DRUG$ exposure was significantly decreased by @DRUG$;	DDI-mechanism
DDI-DrugBank.d270.s20.p0	Alternatives to @DRUG$,such as @DRUG$, should be considered.	DDI-false
DDI-DrugBank.d270.s25.p0	@DRUG$ @DRUG$	DDI-false
DDI-DrugBank.d270.s26.p0	Oral @DRUG$ and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking @DRUG$, since nevirapinemay lower the plasma levels of thesemedications.	DDI-advise
DDI-DrugBank.d270.s36.p0	@DRUG$ and @DRUG$ should not beadministered concomitantly becausedecreases in ketoconazole plasmaconcentrations may reduce the efficacy of the drug.	DDI-advise
DDI-DrugBank.d270.s36.p1	@DRUG$ and ketoconazole should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy of the drug.	DDI-false
DDI-DrugBank.d270.s36.p2	Nevirapine and @DRUG$ should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy of the drug.	DDI-false
DDI-DrugBank.d270.s42.p0	@DRUG$ levels may be decreased; increased dosages may be required to prevent symptoms of @DRUG$ withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s42.p1	@DRUG$ levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. @DRUG$ maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s42.p2	@DRUG$ levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning @DRUG$ therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s42.p3	@DRUG$ levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and @DRUG$ dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s42.p4	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of @DRUG$ withdrawal. @DRUG$ maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s42.p5	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of @DRUG$ withdrawal. Methadone maintained patients beginning @DRUG$ therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s42.p6	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of @DRUG$ withdrawal. Methadone maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and @DRUG$ dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s42.p7	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. @DRUG$ maintained patients beginning @DRUG$ therapy should be monitored forevidence of withdrawal and methadone dose should be adjusted accordingly.	DDI-advise
DDI-DrugBank.d270.s42.p8	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. @DRUG$ maintained patients beginning nevirapine therapy should be monitored forevidence of withdrawal and @DRUG$ dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s42.p9	Methadone levels may be decreased; increased dosages may be required to prevent symptoms of opiate withdrawal. Methadone maintained patients beginning @DRUG$ therapy should be monitored forevidence of withdrawal and @DRUG$ dose should be adjusted accordingly.	DDI-false
DDI-DrugBank.d270.s45.p0	The appropriate dose for @DRUG$ incombination with @DRUG$, with respectto safety and efficacy, has not been established.	DDI-false
DDI-DrugBank.d270.s75.p0	@DRUG$, @DRUG$, sirolimus	DDI-false
DDI-DrugBank.d270.s75.p1	@DRUG$, tacrolimus, @DRUG$	DDI-false
DDI-DrugBank.d270.s75.p2	Cyclosporin, @DRUG$, @DRUG$	DDI-false
DDI-DrugBank.d272.s1.p0	@DRUG$ may interact with @DRUG$, butyrophenones, and certain other agents.	DDI-int
DDI-DrugBank.d272.s1.p1	@DRUG$ may interact with dopamine antagonists, @DRUG$, and certain other agents.	DDI-int
DDI-DrugBank.d272.s1.p2	Bromocriptine mesylate may interact with @DRUG$, @DRUG$, and certain other agents.	DDI-false
DDI-DrugBank.d273.s0.p0	Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between @DRUG$ and other @DRUG$ have not been determined.	DDI-false
DDI-DrugBank.d274.s3.p0	There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p1	There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p2	There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p3	There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p4	There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p5	There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p6	There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p7	There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p8	There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p9	There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p10	There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, @DRUG$, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p11	There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p12	There was no evidence of drug interactions in clinical studies in which @DRUG$ was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.	DDI-false
DDI-DrugBank.d274.s3.p13	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p14	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p15	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p16	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p17	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p18	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p19	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p20	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p21	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p22	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, @DRUG$, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p23	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p24	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including @DRUG$, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.	DDI-false
DDI-DrugBank.d274.s3.p25	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p26	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p27	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p28	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p29	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p30	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p31	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p32	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p33	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, @DRUG$, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p34	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p35	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, @DRUG$, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.	DDI-false
DDI-DrugBank.d274.s3.p36	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p37	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p38	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p39	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p40	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p41	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p42	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p43	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, @DRUG$, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p44	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p45	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, @DRUG$, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.	DDI-false
DDI-DrugBank.d274.s3.p46	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p47	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p48	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p49	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p50	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p51	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p52	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, @DRUG$, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p53	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p54	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, @DRUG$, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.	DDI-false
DDI-DrugBank.d274.s3.p55	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, @DRUG$, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p56	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p57	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p58	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p59	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p60	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, @DRUG$, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p61	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p62	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, @DRUG$, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.	DDI-false
DDI-DrugBank.d274.s3.p63	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, @DRUG$, atropine, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p64	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p65	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p66	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p67	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, protamine, @DRUG$, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p68	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p69	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, @DRUG$, morphine, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.	DDI-false
DDI-DrugBank.d274.s3.p70	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, @DRUG$, heparin, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p71	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p72	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p73	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, @DRUG$, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p74	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p75	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, @DRUG$, atropine, heparin, protamine, potassium chloride, folic acid, and @DRUG$.	DDI-false
DDI-DrugBank.d274.s3.p76	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, @DRUG$, protamine, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p77	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, @DRUG$, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p78	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, @DRUG$, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p79	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, @DRUG$, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p80	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, @DRUG$, heparin, protamine, potassium chloride, folic acid, and @DRUG$.	DDI-false
DDI-DrugBank.d274.s3.p81	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, @DRUG$, potassium chloride, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p82	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, @DRUG$, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p83	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, potassium chloride, @DRUG$, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p84	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, @DRUG$, protamine, potassium chloride, folic acid, and @DRUG$.	DDI-false
DDI-DrugBank.d274.s3.p85	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, @DRUG$, folic acid, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p86	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, @DRUG$, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p87	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, @DRUG$, potassium chloride, folic acid, and @DRUG$.	DDI-false
DDI-DrugBank.d274.s3.p88	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, @DRUG$, @DRUG$, and acetaminophen.	DDI-false
DDI-DrugBank.d274.s3.p89	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, @DRUG$, folic acid, and @DRUG$.	DDI-false
DDI-DrugBank.d274.s3.p90	There was no evidence of drug interactions in clinical studies in which dobutamine was administered concurrently with other drugs, including digitalis preparations, furosemide, spironolactone, lidocaine, glyceryl trinitrate, isosorbide dinitrate, morphine, atropine, heparin, protamine, potassium chloride, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d276.s1.p0	The mechanism for this interaction probably is adsorption of @DRUG$ onto the surface of @DRUG$.	DDI-mechanism
DDI-DrugBank.d276.s3.p0	The resulting increase in @DRUG$ serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract @DRUG$.	DDI-false
DDI-DrugBank.d277.s1.p0	@DRUG$, @DRUG$ and carbamazepine are ge nerally classified as enzyme inducers;	DDI-false
DDI-DrugBank.d277.s1.p1	@DRUG$, phenobarbital and @DRUG$ are ge nerally classified as enzyme inducers;	DDI-false
DDI-DrugBank.d277.s1.p2	Phenytoin, @DRUG$ and @DRUG$ are ge nerally classified as enzyme inducers;	DDI-false
DDI-DrugBank.d277.s10.p0	Effects of other Antiepilepsy Drugs (@DRUG$) on @DRUG$ : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.	DDI-false
DDI-DrugBank.d277.s10.p1	Effects of other Antiepilepsy Drugs (@DRUG$) on GABITRIL : @DRUG$: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.	DDI-false
DDI-DrugBank.d277.s10.p2	Effects of other Antiepilepsy Drugs (@DRUG$) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.	DDI-false
DDI-DrugBank.d277.s10.p3	Effects of other Antiepilepsy Drugs (@DRUG$) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.	DDI-false
DDI-DrugBank.d277.s10.p4	Effects of other Antiepilepsy Drugs (@DRUG$) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing @DRUG$.	DDI-false
DDI-DrugBank.d277.s10.p5	Effects of other Antiepilepsy Drugs (AEDs) on @DRUG$ : @DRUG$: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.	DDI-false
DDI-DrugBank.d277.s10.p6	Effects of other Antiepilepsy Drugs (AEDs) on @DRUG$ : Carbamazepine: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.	DDI-false
DDI-DrugBank.d277.s10.p7	Effects of other Antiepilepsy Drugs (AEDs) on @DRUG$ : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.	DDI-false
DDI-DrugBank.d277.s10.p8	Effects of other Antiepilepsy Drugs (AEDs) on @DRUG$ : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing @DRUG$.	DDI-false
DDI-DrugBank.d277.s10.p9	Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : @DRUG$: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing AEDs.	DDI-false
DDI-DrugBank.d277.s10.p10	Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : @DRUG$: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.	DDI-false
DDI-DrugBank.d277.s10.p11	Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : @DRUG$: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing @DRUG$.	DDI-false
DDI-DrugBank.d277.s10.p12	Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.	DDI-mechanism
DDI-DrugBank.d277.s10.p13	Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking carbamazepine with or without other enzyme- inducing @DRUG$.	DDI-false
DDI-DrugBank.d277.s10.p14	Effects of other Antiepilepsy Drugs (AEDs) on GABITRIL : Carbamazepine: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing @DRUG$.	DDI-false
DDI-DrugBank.d277.s12.p0	@DRUG$ (@DRUG$): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.	DDI-false
DDI-DrugBank.d277.s12.p1	@DRUG$ (Primidone): Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.	DDI-false
DDI-DrugBank.d277.s12.p2	@DRUG$ (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ (primidone) with or without other enzyme-inducing AEDs.	DDI-false
DDI-DrugBank.d277.s12.p3	@DRUG$ (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (@DRUG$) with or without other enzyme-inducing AEDs.	DDI-false
DDI-DrugBank.d277.s12.p4	@DRUG$ (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing @DRUG$.	DDI-false
DDI-DrugBank.d277.s12.p5	Phenobarbital (@DRUG$): Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing AEDs.	DDI-false
DDI-DrugBank.d277.s12.p6	Phenobarbital (@DRUG$): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ (primidone) with or without other enzyme-inducing AEDs.	DDI-false
DDI-DrugBank.d277.s12.p7	Phenobarbital (@DRUG$): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (@DRUG$) with or without other enzyme-inducing AEDs.	DDI-false
DDI-DrugBank.d277.s12.p8	Phenobarbital (@DRUG$): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing @DRUG$.	DDI-false
DDI-DrugBank.d277.s12.p9	Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking @DRUG$ (primidone) with or without other enzyme-inducing AEDs.	DDI-mechanism
DDI-DrugBank.d277.s12.p10	Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking phenobarbital (@DRUG$) with or without other enzyme-inducing AEDs.	DDI-mechanism
DDI-DrugBank.d277.s12.p11	Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking phenobarbital (primidone) with or without other enzyme-inducing @DRUG$.	DDI-false
DDI-DrugBank.d277.s12.p12	Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ (@DRUG$) with or without other enzyme-inducing AEDs.	DDI-false
DDI-DrugBank.d277.s12.p13	Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ (primidone) with or without other enzyme-inducing @DRUG$.	DDI-false
DDI-DrugBank.d277.s12.p14	Phenobarbital (Primidone): Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenobarbital (@DRUG$) with or without other enzyme-inducing @DRUG$.	DDI-false
DDI-DrugBank.d277.s19.p0	@DRUG$: Concomitant administration of @DRUG$ did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of digoxin.	DDI-false
DDI-DrugBank.d277.s19.p1	@DRUG$: Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of @DRUG$ or the mean daily trough serum level of digoxin.	DDI-false
DDI-DrugBank.d277.s19.p2	@DRUG$: Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of @DRUG$.	DDI-false
DDI-DrugBank.d277.s19.p3	Digoxin: Concomitant administration of @DRUG$ did not affect the steady-state pharmacokinetics of @DRUG$ or the mean daily trough serum level of digoxin.	DDI-false
DDI-DrugBank.d277.s19.p4	Digoxin: Concomitant administration of @DRUG$ did not affect the steady-state pharmacokinetics of digoxin or the mean daily trough serum level of @DRUG$.	DDI-false
DDI-DrugBank.d277.s19.p5	Digoxin: Concomitant administration of tiagabine did not affect the steady-state pharmacokinetics of @DRUG$ or the mean daily trough serum level of @DRUG$.	DDI-false
DDI-DrugBank.d277.s20.p0	@DRUG$ or @DRUG$: No significant differences were observed in the pharmacokinetics of triazolam (0.125 mg) and tiagabine (10 mg) when given together as a single dose.	DDI-false
DDI-DrugBank.d277.s20.p1	@DRUG$ or Triazolam: No significant differences were observed in the pharmacokinetics of @DRUG$ (0.125 mg) and tiagabine (10 mg) when given together as a single dose.	DDI-false
DDI-DrugBank.d277.s20.p2	@DRUG$ or Triazolam: No significant differences were observed in the pharmacokinetics of triazolam (0.125 mg) and @DRUG$ (10 mg) when given together as a single dose.	DDI-false
DDI-DrugBank.d277.s20.p3	Ethanol or @DRUG$: No significant differences were observed in the pharmacokinetics of @DRUG$ (0.125 mg) and tiagabine (10 mg) when given together as a single dose.	DDI-false
DDI-DrugBank.d277.s20.p4	Ethanol or @DRUG$: No significant differences were observed in the pharmacokinetics of triazolam (0.125 mg) and @DRUG$ (10 mg) when given together as a single dose.	DDI-false
DDI-DrugBank.d277.s20.p5	Ethanol or Triazolam: No significant differences were observed in the pharmacokinetics of @DRUG$ (0.125 mg) and @DRUG$ (10 mg) when given together as a single dose.	DDI-false
DDI-DrugBank.d277.s22.p0	@DRUG$ has shown no clinically important potentiation of the pharmacodynamic effects of triazo lam or @DRUG$.	DDI-false
DDI-DrugBank.d277.s23.p0	Because of the possible additive effects of drugs that may depress the nervous system, @DRUG$ or @DRUG$ should be used cautiously in combination with tiagabine.	DDI-false
DDI-DrugBank.d277.s23.p1	Because of the possible additive effects of drugs that may depress the nervous system, @DRUG$ or triazolam should be used cautiously in combination with @DRUG$.	DDI-advise
DDI-DrugBank.d277.s23.p2	Because of the possible additive effects of drugs that may depress the nervous system, ethanol or @DRUG$ should be used cautiously in combination with @DRUG$.	DDI-advise
DDI-DrugBank.d277.s25.p0	@DRUG$ : @DRUG$ pharmacokinetics were not significantly different before and after tiagabine multiple-dose regimens.	DDI-false
DDI-DrugBank.d277.s25.p1	@DRUG$ : Antipyrine pharmacokinetics were not significantly different before and after @DRUG$ multiple-dose regimens.	DDI-false
DDI-DrugBank.d277.s25.p2	Antipyrine : @DRUG$ pharmacokinetics were not significantly different before and after @DRUG$ multiple-dose regimens.	DDI-false
DDI-DrugBank.d277.s3.p0	@DRUG$ is considered to be a non-enzyme inducing @DRUG$.	DDI-false
DDI-DrugBank.d277.s8.p0	@DRUG$ or @DRUG$ : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or primidone.	DDI-false
DDI-DrugBank.d277.s8.p1	@DRUG$ or Primidone : No formal pharmacokinetic studies have been performed examining the addition of @DRUG$ to regimens containing phenobarbital or primidone.	DDI-false
DDI-DrugBank.d277.s8.p2	@DRUG$ or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing @DRUG$ or primidone.	DDI-false
DDI-DrugBank.d277.s8.p3	@DRUG$ or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or @DRUG$.	DDI-false
DDI-DrugBank.d277.s8.p4	Phenobarbital or @DRUG$ : No formal pharmacokinetic studies have been performed examining the addition of @DRUG$ to regimens containing phenobarbital or primidone.	DDI-false
DDI-DrugBank.d277.s8.p5	Phenobarbital or @DRUG$ : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing @DRUG$ or primidone.	DDI-false
DDI-DrugBank.d277.s8.p6	Phenobarbital or @DRUG$ : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing phenobarbital or @DRUG$.	DDI-false
DDI-DrugBank.d277.s8.p7	Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of @DRUG$ to regimens containing @DRUG$ or primidone.	DDI-false
DDI-DrugBank.d277.s8.p8	Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of @DRUG$ to regimens containing phenobarbital or @DRUG$.	DDI-false
DDI-DrugBank.d277.s8.p9	Phenobarbital or Primidone : No formal pharmacokinetic studies have been performed examining the addition of tiagabine to regimens containing @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d279.s0.p0	The adverse effects of @DRUG$, such as myelosuppression and diarrhea, would be expected to be exacerbated by other @DRUG$ having similar adverse effects.	DDI-effect
DDI-DrugBank.d279.s11.p0	In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by @DRUG$, the physician may wish to withhold @DRUG$ during dosing with CAMPTOSAR and, certainly, during periods of active vomiting or diarrhea.	DDI-false
DDI-DrugBank.d279.s11.p1	In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by @DRUG$, the physician may wish to withhold diuretics during dosing with @DRUG$ and, certainly, during periods of active vomiting or diarrhea.	DDI-false
DDI-DrugBank.d279.s11.p2	In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by CAMPTOSAR, the physician may wish to withhold @DRUG$ during dosing with @DRUG$ and, certainly, during periods of active vomiting or diarrhea.	DDI-effect
DDI-DrugBank.d28.s3.p0	However, 10 patients who switched from therapy with @DRUG$ to @DRUG$  did not report any serious and unexpected adverse reactions thought to be related to treatment.	DDI-false
DDI-DrugBank.d281.s0.p0	@DRUG$ may decrease renal tubular secretion of @DRUG$ when used concurrently, resulting in increased and more prolonged cephalosporin blood levels.	DDI-mechanism
DDI-DrugBank.d281.s0.p1	@DRUG$ may decrease renal tubular secretion of cephalosporins when used concurrently, resulting in increased and more prolonged @DRUG$ blood levels.	DDI-false
DDI-DrugBank.d281.s0.p2	Probenecid may decrease renal tubular secretion of @DRUG$ when used concurrently, resulting in increased and more prolonged @DRUG$ blood levels.	DDI-false
DDI-DrugBank.d283.s14.p0	A single dose of @DRUG$ had no clinically important effect on the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d283.s16.p0	The @DRUG$ Cmax values were not significantly affected by @DRUG$.	DDI-false
DDI-DrugBank.d283.s3.p0	@DRUG$: The combined use of @DRUG$ and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.	DDI-false
DDI-DrugBank.d283.s3.p1	@DRUG$: The combined use of TRICOR and @DRUG$ should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.	DDI-false
DDI-DrugBank.d283.s3.p2	HMG-CoA reductase inhibitors: The combined use of @DRUG$ and @DRUG$ should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.	DDI-advise
DDI-DrugBank.d284.s3.p0	Concomitant treatment with @DRUG$ (@DRUG$, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.	DDI-false
DDI-DrugBank.d284.s3.p1	Concomitant treatment with @DRUG$ (aminophylline, @DRUG$), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.	DDI-false
DDI-DrugBank.d284.s3.p2	Concomitant treatment with @DRUG$ (aminophylline, theophylline), @DRUG$, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.	DDI-false
DDI-DrugBank.d284.s3.p3	Concomitant treatment with @DRUG$ (aminophylline, theophylline), steroids, or @DRUG$ may potentiate any hypokalemic effect of adrenergic agonists.	DDI-false
DDI-DrugBank.d284.s3.p4	Concomitant treatment with @DRUG$ (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of @DRUG$.	DDI-effect
DDI-DrugBank.d284.s3.p5	Concomitant treatment with methylxanthines (@DRUG$, @DRUG$), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.	DDI-false
DDI-DrugBank.d284.s3.p6	Concomitant treatment with methylxanthines (@DRUG$, theophylline), @DRUG$, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.	DDI-false
DDI-DrugBank.d284.s3.p7	Concomitant treatment with methylxanthines (@DRUG$, theophylline), steroids, or @DRUG$ may potentiate any hypokalemic effect of adrenergic agonists.	DDI-false
DDI-DrugBank.d284.s3.p8	Concomitant treatment with methylxanthines (@DRUG$, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of @DRUG$.	DDI-effect
DDI-DrugBank.d284.s3.p9	Concomitant treatment with methylxanthines (aminophylline, @DRUG$), @DRUG$, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.	DDI-false
DDI-DrugBank.d284.s3.p10	Concomitant treatment with methylxanthines (aminophylline, @DRUG$), steroids, or @DRUG$ may potentiate any hypokalemic effect of adrenergic agonists.	DDI-false
DDI-DrugBank.d284.s3.p11	Concomitant treatment with methylxanthines (aminophylline, @DRUG$), steroids, or diuretics may potentiate any hypokalemic effect of @DRUG$.	DDI-effect
DDI-DrugBank.d284.s3.p12	Concomitant treatment with methylxanthines (aminophylline, theophylline), @DRUG$, or @DRUG$ may potentiate any hypokalemic effect of adrenergic agonists.	DDI-false
DDI-DrugBank.d284.s3.p13	Concomitant treatment with methylxanthines (aminophylline, theophylline), @DRUG$, or diuretics may potentiate any hypokalemic effect of @DRUG$.	DDI-effect
DDI-DrugBank.d284.s3.p14	Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or @DRUG$ may potentiate any hypokalemic effect of @DRUG$.	DDI-effect
DDI-DrugBank.d284.s5.p0	Although the clinical significance of these effects is not known, caution is advised in the co-administration of @DRUG$ with @DRUG$.	DDI-advise
DDI-DrugBank.d284.s6.p0	@DRUG$, as with other @DRUG$, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.	DDI-false
DDI-DrugBank.d284.s6.p1	@DRUG$, as with other beta2-agonists, should be administered with extreme caution to patients being treated with @DRUG$, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.	DDI-advise
DDI-DrugBank.d284.s6.p2	@DRUG$, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, @DRUG$, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.	DDI-advise
DDI-DrugBank.d284.s6.p3	@DRUG$, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
DDI-DrugBank.d284.s6.p4	BROVANA, as with other @DRUG$, should be administered with extreme caution to patients being treated with @DRUG$, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.	DDI-advise
DDI-DrugBank.d284.s6.p5	BROVANA, as with other @DRUG$, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, @DRUG$, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.	DDI-advise
DDI-DrugBank.d284.s6.p6	BROVANA, as with other @DRUG$, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
DDI-DrugBank.d284.s6.p7	BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with @DRUG$, @DRUG$, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.	DDI-false
DDI-DrugBank.d284.s6.p8	BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with @DRUG$, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-effect
DDI-DrugBank.d284.s6.p9	BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, @DRUG$, or drugs known to prolong the QTc interval because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-effect
DDI-DrugBank.d286.s0.p0	@DRUG$ may increase the action of @DRUG$, amphetamines, procainamide, and quinidine.	DDI-effect
DDI-DrugBank.d286.s0.p1	@DRUG$ may increase the action of tricyclics, @DRUG$, procainamide, and quinidine.	DDI-effect
DDI-DrugBank.d286.s0.p2	@DRUG$ may increase the action of tricyclics, amphetamines, @DRUG$, and quinidine.	DDI-effect
DDI-DrugBank.d286.s0.p3	@DRUG$ may increase the action of tricyclics, amphetamines, procainamide, and @DRUG$.	DDI-effect
DDI-DrugBank.d286.s0.p4	Ethoxzolamide may increase the action of @DRUG$, @DRUG$, procainamide, and quinidine.	DDI-false
DDI-DrugBank.d286.s0.p5	Ethoxzolamide may increase the action of @DRUG$, amphetamines, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d286.s0.p6	Ethoxzolamide may increase the action of @DRUG$, amphetamines, procainamide, and @DRUG$.	DDI-false
DDI-DrugBank.d286.s0.p7	Ethoxzolamide may increase the action of tricyclics, @DRUG$, @DRUG$, and quinidine.	DDI-false
DDI-DrugBank.d286.s0.p8	Ethoxzolamide may increase the action of tricyclics, @DRUG$, procainamide, and @DRUG$.	DDI-false
DDI-DrugBank.d286.s0.p9	Ethoxzolamide may increase the action of tricyclics, amphetamines, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d286.s2.p0	Coadministration of @DRUG$ with other @DRUG$, amphotericin B, and corticosteroids may cause hypokalemia.	DDI-effect
DDI-DrugBank.d286.s2.p1	Coadministration of @DRUG$ with other diuretics, @DRUG$, and corticosteroids may cause hypokalemia.	DDI-effect
DDI-DrugBank.d286.s2.p2	Coadministration of @DRUG$ with other diuretics, amphotericin B, and @DRUG$ may cause hypokalemia.	DDI-effect
DDI-DrugBank.d286.s2.p3	Coadministration of ethoxzolamide with other @DRUG$, @DRUG$, and corticosteroids may cause hypokalemia.	DDI-false
DDI-DrugBank.d286.s2.p4	Coadministration of ethoxzolamide with other @DRUG$, amphotericin B, and @DRUG$ may cause hypokalemia.	DDI-false
DDI-DrugBank.d286.s2.p5	Coadministration of ethoxzolamide with other diuretics, @DRUG$, and @DRUG$ may cause hypokalemia.	DDI-false
DDI-DrugBank.d288.s1.p0	Pharmacokinetic data from these patients demonstrated a decrease in @DRUG$ clearance of approximately 33% when @DRUG$ was administered following cisplatin.	DDI-false
DDI-DrugBank.d288.s1.p1	Pharmacokinetic data from these patients demonstrated a decrease in @DRUG$ clearance of approximately 33% when TAXOL was administered following @DRUG$.	DDI-false
DDI-DrugBank.d288.s1.p2	Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when @DRUG$ was administered following @DRUG$.	DDI-mechanism
DDI-DrugBank.d289.s13.p0	Co-administration of @DRUG$ decreased the plasma concentrations of @DRUG$ (a CYP3A4 substrate) by approximately 50%.	DDI-mechanism
DDI-DrugBank.d289.s14.p0	@DRUG$: Co-administration of @DRUG$ and bosentan has not been studied in man.	DDI-false
DDI-DrugBank.d289.s14.p1	@DRUG$: Co-administration of tacrolimus and @DRUG$ has not been studied in man.	DDI-false
DDI-DrugBank.d289.s14.p2	Tacrolimus: Co-administration of @DRUG$ and @DRUG$ has not been studied in man.	DDI-false
DDI-DrugBank.d289.s15.p0	Co-administration of @DRUG$ and @DRUG$ resulted in markedly increased plasma concentrations of bosentan in animals.	DDI-mechanism
DDI-DrugBank.d289.s15.p1	Co-administration of @DRUG$ and bosentan resulted in markedly increased plasma concentrations of @DRUG$ in animals.	DDI-false
DDI-DrugBank.d289.s15.p2	Co-administration of tacrolimus and @DRUG$ resulted in markedly increased plasma concentrations of @DRUG$ in animals.	DDI-false
DDI-DrugBank.d289.s21.p0	@DRUG$ is also expected to reduce plasma concentrations of other oral @DRUG$ that are predominantly metabolized by CYP2C9 or CYP3A4.	DDI-mechanism
DDI-DrugBank.d289.s23.p0	@DRUG$: Co-administration of @DRUG$ 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.	DDI-false
DDI-DrugBank.d289.s23.p1	@DRUG$: Co-administration of bosentan 125 mg b.i.d. and @DRUG$, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.	DDI-false
DDI-DrugBank.d289.s23.p2	@DRUG$: Co-administration of bosentan 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of @DRUG$ by approximately 2-fold.	DDI-false
DDI-DrugBank.d289.s23.p3	Ketoconazole: Co-administration of @DRUG$ 125 mg b.i.d. and @DRUG$, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan by approximately 2-fold.	DDI-mechanism
DDI-DrugBank.d289.s23.p4	Ketoconazole: Co-administration of @DRUG$ 125 mg b.i.d. and ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of @DRUG$ by approximately 2-fold.	DDI-false
DDI-DrugBank.d289.s23.p5	Ketoconazole: Co-administration of bosentan 125 mg b.i.d. and @DRUG$, a potent CYP3A4 inhibitor, increased the plasma concentrations of @DRUG$ by approximately 2-fold.	DDI-false
DDI-DrugBank.d289.s25.p0	@DRUG$ and Other @DRUG$: Co-administration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.	DDI-false
DDI-DrugBank.d289.s25.p1	@DRUG$ and Other Statins: Co-administration of @DRUG$ decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.	DDI-false
DDI-DrugBank.d289.s25.p2	@DRUG$ and Other Statins: Co-administration of bosentan decreased the plasma concentrations of @DRUG$ (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.	DDI-false
DDI-DrugBank.d289.s25.p3	Simvastatin and Other @DRUG$: Co-administration of @DRUG$ decreased the plasma concentrations of simvastatin (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.	DDI-false
DDI-DrugBank.d289.s25.p4	Simvastatin and Other @DRUG$: Co-administration of bosentan decreased the plasma concentrations of @DRUG$ (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.	DDI-false
DDI-DrugBank.d289.s25.p5	Simvastatin and Other Statins: Co-administration of @DRUG$ decreased the plasma concentrations of @DRUG$ (a CYP3A4 substrate), and its active  -hydroxy acid metabolite, by approximately 50%.	DDI-mechanism
DDI-DrugBank.d289.s30.p0	@DRUG$: Co-administration of @DRUG$ 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.	DDI-false
DDI-DrugBank.d289.s30.p1	@DRUG$: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both @DRUG$ (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.	DDI-false
DDI-DrugBank.d289.s30.p2	@DRUG$: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and @DRUG$ (a CYP3A4 substrate) by 29 and 38%, respectively.	DDI-false
DDI-DrugBank.d289.s30.p3	Warfarin: Co-administration of @DRUG$ 500 mg b.i.d. for 6 days decreased the plasma concentrations of both @DRUG$ (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29 and 38%, respectively.	DDI-mechanism
DDI-DrugBank.d289.s30.p4	Warfarin: Co-administration of @DRUG$ 500 mg b.i.d. for 6 days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and @DRUG$ (a CYP3A4 substrate) by 29 and 38%, respectively.	DDI-mechanism
DDI-DrugBank.d289.s30.p5	Warfarin: Co-administration of bosentan 500 mg b.i.d. for 6 days decreased the plasma concentrations of both @DRUG$ (a CYP2C9 substrate) and @DRUG$ (a CYP3A4 substrate) by 29 and 38%, respectively.	DDI-false
DDI-DrugBank.d289.s31.p0	Clinical experience with concomitant administration of @DRUG$ and @DRUG$ in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.	DDI-false
DDI-DrugBank.d289.s31.p1	Clinical experience with concomitant administration of @DRUG$ and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or @DRUG$ dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.	DDI-false
DDI-DrugBank.d289.s31.p2	Clinical experience with concomitant administration of @DRUG$ and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the @DRUG$ dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.	DDI-false
DDI-DrugBank.d289.s31.p3	Clinical experience with concomitant administration of @DRUG$ and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.	DDI-false
DDI-DrugBank.d289.s31.p4	Clinical experience with concomitant administration of bosentan and @DRUG$ in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or @DRUG$ dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.	DDI-false
DDI-DrugBank.d289.s31.p5	Clinical experience with concomitant administration of bosentan and @DRUG$ in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the @DRUG$ dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.	DDI-false
DDI-DrugBank.d289.s31.p6	Clinical experience with concomitant administration of bosentan and @DRUG$ in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.	DDI-false
DDI-DrugBank.d289.s31.p7	Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or @DRUG$ dose (baseline vs. end of the clinical studies), and the need to change the @DRUG$ dose during the trials due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients.	DDI-false
DDI-DrugBank.d289.s31.p8	Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or @DRUG$ dose (baseline vs. end of the clinical studies), and the need to change the warfarin dose during the trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.	DDI-false
DDI-DrugBank.d289.s31.p9	Clinical experience with concomitant administration of bosentan and warfarin in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or warfarin dose (baseline vs. end of the clinical studies), and the need to change the @DRUG$ dose during the trials due to changes in INR or due to adverse events was similar among @DRUG$- and placebo-treated patients.	DDI-false
DDI-DrugBank.d289.s8.p0	Therefore, @DRUG$, including oral, injectable, transdermal, and implantable forms, may not be reliable when @DRUG$ is co-administered.	DDI-effect
DDI-DrugBank.d29.s13.p0	Coadministration of oral @DRUG$, @DRUG$, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.	DDI-false
DDI-DrugBank.d29.s13.p1	Coadministration of oral @DRUG$, diazepam, @DRUG$, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.	DDI-false
DDI-DrugBank.d29.s13.p2	Coadministration of oral @DRUG$, diazepam, phenytoin, or @DRUG$ did not seem to change the pharmacokinetic profile of esomeprazole.	DDI-false
DDI-DrugBank.d29.s13.p3	Coadministration of oral @DRUG$, diazepam, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of @DRUG$.	DDI-false
DDI-DrugBank.d29.s13.p4	Coadministration of oral contraceptives, @DRUG$, @DRUG$, or quinidine did not seem to change the pharmacokinetic profile of esomeprazole.	DDI-false
DDI-DrugBank.d29.s13.p5	Coadministration of oral contraceptives, @DRUG$, phenytoin, or @DRUG$ did not seem to change the pharmacokinetic profile of esomeprazole.	DDI-false
DDI-DrugBank.d29.s13.p6	Coadministration of oral contraceptives, @DRUG$, phenytoin, or quinidine did not seem to change the pharmacokinetic profile of @DRUG$.	DDI-false
DDI-DrugBank.d29.s13.p7	Coadministration of oral contraceptives, diazepam, @DRUG$, or @DRUG$ did not seem to change the pharmacokinetic profile of esomeprazole.	DDI-false
DDI-DrugBank.d29.s13.p8	Coadministration of oral contraceptives, diazepam, @DRUG$, or quinidine did not seem to change the pharmacokinetic profile of @DRUG$.	DDI-false
DDI-DrugBank.d29.s13.p9	Coadministration of oral contraceptives, diazepam, phenytoin, or @DRUG$ did not seem to change the pharmacokinetic profile of @DRUG$.	DDI-false
DDI-DrugBank.d29.s4.p0	Post-marketing reports of changes in prothrombin measures have been received among patients on concomitant @DRUG$ and @DRUG$ therapy.	DDI-false
DDI-DrugBank.d29.s7.p0	@DRUG$ may potentially interfere with CYP2C19, the major @DRUG$ metabolizing enzyme.	DDI-false
DDI-DrugBank.d291.s0.p0	When @DRUG$ or @DRUG$ is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of anticoagulants of the coumarin type.	DDI-false
DDI-DrugBank.d291.s0.p1	When @DRUG$ or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - @DRUG$ and Bezalip retard may enhance the action of anticoagulants of the coumarin type.	DDI-false
DDI-DrugBank.d291.s0.p2	When @DRUG$ or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and @DRUG$ may enhance the action of anticoagulants of the coumarin type.	DDI-false
DDI-DrugBank.d291.s0.p3	When @DRUG$ or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of @DRUG$.	DDI-false
DDI-DrugBank.d291.s0.p4	When Bezalip or @DRUG$ is used at the same time as other medicines or substances the following interactions must be taken into account: - @DRUG$ and Bezalip retard may enhance the action of anticoagulants of the coumarin type.	DDI-false
DDI-DrugBank.d291.s0.p5	When Bezalip or @DRUG$ is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and @DRUG$ may enhance the action of anticoagulants of the coumarin type.	DDI-false
DDI-DrugBank.d291.s0.p6	When Bezalip or @DRUG$ is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and Bezalip retard may enhance the action of @DRUG$.	DDI-false
DDI-DrugBank.d291.s0.p7	When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - @DRUG$ and @DRUG$ may enhance the action of anticoagulants of the coumarin type.	DDI-false
DDI-DrugBank.d291.s0.p8	When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - @DRUG$ and Bezalip retard may enhance the action of @DRUG$.	DDI-effect
DDI-DrugBank.d291.s0.p9	When Bezalip or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and @DRUG$ may enhance the action of @DRUG$.	DDI-effect
DDI-DrugBank.d295.s1.p0	Coadministration of @DRUG$ with @DRUG$, adefovir dipivoxil,or tenofovir disoproxil fumarate did not result in significant drug interactions.	DDI-false
DDI-DrugBank.d295.s1.p1	Coadministration of @DRUG$ with lamivudine, @DRUG$,or tenofovir disoproxil fumarate did not result in significant drug interactions.	DDI-false
DDI-DrugBank.d295.s1.p2	Coadministration of @DRUG$ with lamivudine, adefovir dipivoxil,or @DRUG$ did not result in significant drug interactions.	DDI-false
DDI-DrugBank.d295.s1.p3	Coadministration of entecavir with @DRUG$, @DRUG$,or tenofovir disoproxil fumarate did not result in significant drug interactions.	DDI-false
DDI-DrugBank.d295.s1.p4	Coadministration of entecavir with @DRUG$, adefovir dipivoxil,or @DRUG$ did not result in significant drug interactions.	DDI-false
DDI-DrugBank.d295.s1.p5	Coadministration of entecavir with lamivudine, @DRUG$,or @DRUG$ did not result in significant drug interactions.	DDI-false
DDI-DrugBank.d295.s2.p0	The effects of coadministration of @DRUG$ with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when @DRUG$ is coadministered with such drugs.	DDI-false
DDI-DrugBank.d297.s5.p0	There is insufficient experience to assess the safety and efficacy of @DRUG$ administered concurrently with @DRUG$, and therefore such use is not recommended.	DDI-advise
DDI-DrugBank.d299.s5.p0	@DRUG$: The pharmacokinetics of @DRUG$ were not affected by coadministration of propranolol.	DDI-false
DDI-DrugBank.d299.s5.p1	@DRUG$: The pharmacokinetics of almotriptan were not affected by coadministration of @DRUG$.	DDI-false
DDI-DrugBank.d299.s5.p2	Propanolol: The pharmacokinetics of @DRUG$ were not affected by coadministration of @DRUG$.	DDI-false
DDI-DrugBank.d299.s7.p0	If concomitant treatment with @DRUG$ and an @DRUG$ is clinically warranted, appropriate observation of the patient is advised.	DDI-advise
DDI-DrugBank.d3.s1.p0	@DRUG$, @DRUG$, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p1	@DRUG$, Digoxin, @DRUG$, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p2	@DRUG$, Digoxin, Salicylate, and @DRUG$ The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p3	@DRUG$, Digoxin, Salicylate, and Heparin The in vitro binding of @DRUG$ to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p4	@DRUG$, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by @DRUG$ (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p5	@DRUG$, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when @DRUG$ plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p6	Warfarin, @DRUG$, @DRUG$, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p7	Warfarin, @DRUG$, Salicylate, and @DRUG$ The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p8	Warfarin, @DRUG$, Salicylate, and Heparin The in vitro binding of @DRUG$ to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p9	Warfarin, @DRUG$, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by @DRUG$ (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p10	Warfarin, @DRUG$, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when @DRUG$ plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p11	Warfarin, Digoxin, @DRUG$, and @DRUG$ The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p12	Warfarin, Digoxin, @DRUG$, and Heparin The in vitro binding of @DRUG$ to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p13	Warfarin, Digoxin, @DRUG$, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by @DRUG$ (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p14	Warfarin, Digoxin, @DRUG$, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when @DRUG$ plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p15	Warfarin, Digoxin, Salicylate, and @DRUG$ The in vitro binding of @DRUG$ to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p16	Warfarin, Digoxin, Salicylate, and @DRUG$ The in vitro binding of warfarin to plasma proteins is only slightly reduced by @DRUG$ (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p17	Warfarin, Digoxin, Salicylate, and @DRUG$ The in vitro binding of warfarin to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when @DRUG$ plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p18	Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of @DRUG$ to plasma proteins is only slightly reduced by @DRUG$ (99.5% control vs 99.3%) when ketorolac plasma concentrations reach 5 to10 m g/mL.	DDI-mechanism
DDI-DrugBank.d3.s1.p19	Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of @DRUG$ to plasma proteins is only slightly reduced by ketorolac tromethamine (99.5% control vs 99.3%) when @DRUG$ plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s1.p20	Warfarin, Digoxin, Salicylate, and Heparin The in vitro binding of warfarin to plasma proteins is only slightly reduced by @DRUG$ (99.5% control vs 99.3%) when @DRUG$ plasma concentrations reach 5 to10 m g/mL.	DDI-false
DDI-DrugBank.d3.s10.p0	Therefore, concomitant use of @DRUG$ and @DRUG$ is contraindicated.	DDI-advise
DDI-DrugBank.d3.s13.p0	@DRUG$: Concomitant administration of @DRUG$ and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.	DDI-false
DDI-DrugBank.d3.s13.p1	@DRUG$: Concomitant administration of methotrexate and some @DRUG$ has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.	DDI-false
DDI-DrugBank.d3.s13.p2	@DRUG$: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of @DRUG$, enhancing the toxicity of methotrexate.	DDI-false
DDI-DrugBank.d3.s13.p3	@DRUG$: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of @DRUG$.	DDI-false
DDI-DrugBank.d3.s13.p4	Methotrexate: Concomitant administration of @DRUG$ and some @DRUG$ has been reported to reduce the clearance of methotrexate, enhancing the toxicity of methotrexate.	DDI-mechanism
DDI-DrugBank.d3.s13.p5	Methotrexate: Concomitant administration of @DRUG$ and some NSAIDs has been reported to reduce the clearance of @DRUG$, enhancing the toxicity of methotrexate.	DDI-false
DDI-DrugBank.d3.s13.p6	Methotrexate: Concomitant administration of @DRUG$ and some NSAIDs has been reported to reduce the clearance of methotrexate, enhancing the toxicity of @DRUG$.	DDI-false
DDI-DrugBank.d3.s13.p7	Methotrexate: Concomitant administration of methotrexate and some @DRUG$ has been reported to reduce the clearance of @DRUG$, enhancing the toxicity of methotrexate.	DDI-false
DDI-DrugBank.d3.s13.p8	Methotrexate: Concomitant administration of methotrexate and some @DRUG$ has been reported to reduce the clearance of methotrexate, enhancing the toxicity of @DRUG$.	DDI-false
DDI-DrugBank.d3.s13.p9	Methotrexate: Concomitant administration of methotrexate and some NSAIDs has been reported to reduce the clearance of @DRUG$, enhancing the toxicity of @DRUG$.	DDI-false
DDI-DrugBank.d3.s18.p0	@DRUG$: Sporadic cases of seizures have been reported during concomitant use of @DRUG$ and antiepileptic drugs (phenytoin, carbamazepine).	DDI-false
DDI-DrugBank.d3.s18.p1	@DRUG$: Sporadic cases of seizures have been reported during concomitant use of TORADOL and @DRUG$ (phenytoin, carbamazepine).	DDI-false
DDI-DrugBank.d3.s18.p2	@DRUG$: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (@DRUG$, carbamazepine).	DDI-false
DDI-DrugBank.d3.s18.p3	@DRUG$: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (phenytoin, @DRUG$).	DDI-false
DDI-DrugBank.d3.s18.p4	Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of @DRUG$ and @DRUG$ (phenytoin, carbamazepine).	DDI-effect
DDI-DrugBank.d3.s18.p5	Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of @DRUG$ and antiepileptic drugs (@DRUG$, carbamazepine).	DDI-effect
DDI-DrugBank.d3.s18.p6	Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of @DRUG$ and antiepileptic drugs (phenytoin, @DRUG$).	DDI-effect
DDI-DrugBank.d3.s18.p7	Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and @DRUG$ (@DRUG$, carbamazepine).	DDI-false
DDI-DrugBank.d3.s18.p8	Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and @DRUG$ (phenytoin, @DRUG$).	DDI-false
DDI-DrugBank.d3.s18.p9	Antiepileptic Drugs: Sporadic cases of seizures have been reported during concomitant use of TORADOL and antiepileptic drugs (@DRUG$, @DRUG$).	DDI-false
DDI-DrugBank.d3.s21.p0	Do not mix @DRUG$ and @DRUG$ in the same syringe.	DDI-false
DDI-DrugBank.d3.s9.p0	@DRUG$: Concomitant administration of @DRUG$ ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.	DDI-false
DDI-DrugBank.d3.s9.p1	@DRUG$: Concomitant administration of TORADOL ORAL and @DRUG$ resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.	DDI-false
DDI-DrugBank.d3.s9.p2	@DRUG$: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of @DRUG$ and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.	DDI-false
DDI-DrugBank.d3.s9.p3	@DRUG$: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in @DRUG$ plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.	DDI-false
DDI-DrugBank.d3.s9.p4	Probenecid: Concomitant administration of @DRUG$ ORAL and @DRUG$ resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.	DDI-mechanism
DDI-DrugBank.d3.s9.p5	Probenecid: Concomitant administration of @DRUG$ ORAL and probenecid resulted in decreased clearance of @DRUG$ and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.	DDI-false
DDI-DrugBank.d3.s9.p6	Probenecid: Concomitant administration of @DRUG$ ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in @DRUG$ plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.	DDI-false
DDI-DrugBank.d3.s9.p7	Probenecid: Concomitant administration of TORADOL ORAL and @DRUG$ resulted in decreased clearance of @DRUG$ and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.	DDI-false
DDI-DrugBank.d3.s9.p8	Probenecid: Concomitant administration of TORADOL ORAL and @DRUG$ resulted in decreased clearance of ketorolac and significant increases in @DRUG$ plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.	DDI-false
DDI-DrugBank.d3.s9.p9	Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of @DRUG$ and significant increases in @DRUG$ plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.	DDI-false
DDI-DrugBank.d30.s1.p0	@DRUG$, an inducer of drug metabolism, decreased the concentrations of @DRUG$ and its active metabolite.	DDI-mechanism
DDI-DrugBank.d30.s8.p0	As with other drugs that block angiotensin II or its effects, concomitant use of @DRUG$ (e.g., @DRUG$, triamterene, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.	DDI-false
DDI-DrugBank.d30.s8.p1	As with other drugs that block angiotensin II or its effects, concomitant use of @DRUG$ (e.g., spironolactone, @DRUG$, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.	DDI-false
DDI-DrugBank.d30.s8.p2	As with other drugs that block angiotensin II or its effects, concomitant use of @DRUG$ (e.g., spironolactone, triamterene, @DRUG$), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.	DDI-false
DDI-DrugBank.d30.s8.p3	As with other drugs that block angiotensin II or its effects, concomitant use of @DRUG$ (e.g., spironolactone, triamterene, amiloride), @DRUG$ supplements, or salt substitutes containing potassium may lead to increases in serum potassium.	DDI-false
DDI-DrugBank.d30.s8.p4	As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., @DRUG$, @DRUG$, amiloride), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.	DDI-false
DDI-DrugBank.d30.s8.p5	As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., @DRUG$, triamterene, @DRUG$), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.	DDI-false
DDI-DrugBank.d30.s8.p6	As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., @DRUG$, triamterene, amiloride), @DRUG$ supplements, or salt substitutes containing potassium may lead to increases in serum potassium.	DDI-false
DDI-DrugBank.d30.s8.p7	As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, @DRUG$, @DRUG$), potassium supplements, or salt substitutes containing potassium may lead to increases in serum potassium.	DDI-false
DDI-DrugBank.d30.s8.p8	As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, @DRUG$, amiloride), @DRUG$ supplements, or salt substitutes containing potassium may lead to increases in serum potassium.	DDI-false
DDI-DrugBank.d30.s8.p9	As with other drugs that block angiotensin II or its effects, concomitant use of potassium-sparing diuretics (e.g., spironolactone, triamterene, @DRUG$), @DRUG$ supplements, or salt substitutes containing potassium may lead to increases in serum potassium.	DDI-false
DDI-DrugBank.d30.s9.p0	As with other @DRUG$, the antihypertensive effect of @DRUG$ may be blunted by the non-steroidal anti-inflammatory drug indomethacin	DDI-false
DDI-DrugBank.d30.s9.p1	As with other @DRUG$, the antihypertensive effect of losartan may be blunted by the @DRUG$ indomethacin	DDI-false
DDI-DrugBank.d30.s9.p2	As with other @DRUG$, the antihypertensive effect of losartan may be blunted by the non-steroidal anti-inflammatory drug @DRUG$	DDI-false
DDI-DrugBank.d30.s9.p3	As with other antihypertensive agents, the antihypertensive effect of @DRUG$ may be blunted by the @DRUG$ indomethacin	DDI-false
DDI-DrugBank.d30.s9.p4	As with other antihypertensive agents, the antihypertensive effect of @DRUG$ may be blunted by the non-steroidal anti-inflammatory drug @DRUG$	DDI-effect
DDI-DrugBank.d30.s9.p5	As with other antihypertensive agents, the antihypertensive effect of losartan may be blunted by the @DRUG$ @DRUG$	DDI-false
DDI-DrugBank.d305.s3.p0	Binding to plasma proteins is reduced by @DRUG$ and clotibrate and increased by @DRUG$.	DDI-false
DDI-DrugBank.d305.s5.p0	The combination of therapeutic doses of intravenous @DRUG$ and @DRUG$ in halothane a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.	DDI-false
DDI-DrugBank.d305.s5.p1	The combination of therapeutic doses of intravenous @DRUG$ and verapamil in @DRUG$ a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.	DDI-false
DDI-DrugBank.d305.s5.p2	The combination of therapeutic doses of intravenous dantrolene sodium and @DRUG$ in @DRUG$ a-chloralose anesthetized swine has resulted in ventricular fibrillation and cardiovascular collapse in association with marked hyperkalemia.	DDI-false
DDI-DrugBank.d305.s6.p0	It is recommended that the combination of intravenous @DRUG$ and @DRUG$, such as verapamil, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.	DDI-advise
DDI-DrugBank.d305.s6.p1	It is recommended that the combination of intravenous @DRUG$ and calcium channel blockers, such as @DRUG$, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.	DDI-advise
DDI-DrugBank.d305.s6.p2	It is recommended that the combination of intravenous dantrolene sodium and @DRUG$, such as @DRUG$, not be used together during the management of malignant hyperthermia crisis until the relevance of these findings to humans is established.	DDI-false
DDI-DrugBank.d307.s45.p0	@DRUG$s: After repeated co-administration of @DRUG$, the AUC of felodipine was lowered by 28% [90% CI: 20-33].	DDI-false
DDI-DrugBank.d307.s45.p1	@DRUG$s: After repeated co-administration of Trileptal, the AUC of @DRUG$ was lowered by 28% [90% CI: 20-33].	DDI-false
DDI-DrugBank.d307.s45.p2	Calcium Antagonists: After repeated co-administration of @DRUG$, the AUC of @DRUG$ was lowered by 28% [90% CI: 20-33].	DDI-mechanism
DDI-DrugBank.d307.s46.p0	@DRUG$ produced a decrease of 20% [90% CI: 18-27] of the plasma levels of @DRUG$.	DDI-false
DDI-DrugBank.d307.s48.p0	Results with @DRUG$ wshow no evidence of interaction with either single or repeated doses of @DRUG$.	DDI-false
DDI-DrugBank.d307.s7.p0	Increases of 22% with @DRUG$ and 47% with @DRUG$ were observed.	DDI-false
DDI-DrugBank.d308.s0.p0	THE POTENTIATING ACTION OF @DRUG$ MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH @DRUG$ SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.	DDI-effect
DDI-DrugBank.d308.s0.p1	THE POTENTIATING ACTION OF @DRUG$ MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS @DRUG$, NON-NARCOTIC ANALGESICS AND BARBITURATES.	DDI-effect
DDI-DrugBank.d308.s0.p2	THE POTENTIATING ACTION OF @DRUG$ MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, @DRUG$ AND BARBITURATES.	DDI-effect
DDI-DrugBank.d308.s0.p3	THE POTENTIATING ACTION OF @DRUG$ MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND @DRUG$.	DDI-effect
DDI-DrugBank.d308.s0.p4	THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH @DRUG$ SUCH AS @DRUG$, NON-NARCOTIC ANALGESICS AND BARBITURATES.	DDI-false
DDI-DrugBank.d308.s0.p5	THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH @DRUG$ SUCH AS NARCOTICS, @DRUG$ AND BARBITURATES.	DDI-false
DDI-DrugBank.d308.s0.p6	THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH @DRUG$ SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND @DRUG$.	DDI-false
DDI-DrugBank.d308.s0.p7	THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS @DRUG$, @DRUG$ AND BARBITURATES.	DDI-false
DDI-DrugBank.d308.s0.p8	THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS @DRUG$, NON-NARCOTIC ANALGESICS AND @DRUG$.	DDI-false
DDI-DrugBank.d308.s0.p9	THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, @DRUG$ AND @DRUG$.	DDI-false
DDI-DrugBank.d309.s1.p0	Patients receiving @DRUG$ should be advised against the concurrent use of other @DRUG$.	DDI-advise
DDI-DrugBank.d309.s2.p0	@DRUG$ prolong and intensify the anticholinergic effects of @DRUG$.	DDI-effect
DDI-DrugBank.d31.s0.p0	@DRUG$ should be used with caution in patients receiving @DRUG$.	DDI-advise
DDI-DrugBank.d31.s6.p0	@DRUG$, @DRUG$, and nadolol (low hepatic clearance or no first-pass metabolism) are unlikely to be affected.	DDI-false
DDI-DrugBank.d31.s6.p1	@DRUG$, atenolol, and @DRUG$ (low hepatic clearance or no first-pass metabolism) are unlikely to be affected.	DDI-false
DDI-DrugBank.d31.s6.p2	Acebutolol, @DRUG$, and @DRUG$ (low hepatic clearance or no first-pass metabolism) are unlikely to be affected.	DDI-false
DDI-DrugBank.d310.s4.p0	This effect may be mediated by the known inhibition of hepatic cytochrome P- 450 by @DRUG$, which could decrease first pass metabolism of @DRUG$.	DDI-false
DDI-DrugBank.d312.s2.p0	@DRUG$ concentrations were similar in patients receiving bolus-IFL alone and in combination with @DRUG$.	DDI-false
DDI-DrugBank.d314.s1.p0	@DRUG$ injection and potassium-depleting agents: When @DRUG$ are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, diuretics), patients should be observed closely for development of hypokalemia.	DDI-false
DDI-DrugBank.d314.s1.p1	@DRUG$ injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., @DRUG$, diuretics), patients should be observed closely for development of hypokalemia.	DDI-false
DDI-DrugBank.d314.s1.p2	@DRUG$ injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, @DRUG$), patients should be observed closely for development of hypokalemia.	DDI-false
DDI-DrugBank.d314.s1.p3	Amphotericin B injection and potassium-depleting agents: When @DRUG$ are administered concomitantly with potassium-depleting agents (e.g., @DRUG$, diuretics), patients should be observed closely for development of hypokalemia.	DDI-advise
DDI-DrugBank.d314.s1.p4	Amphotericin B injection and potassium-depleting agents: When @DRUG$ are administered concomitantly with potassium-depleting agents (e.g., amphotericin B, @DRUG$), patients should be observed closely for development of hypokalemia.	DDI-advise
DDI-DrugBank.d314.s1.p5	Amphotericin B injection and potassium-depleting agents: When corticosteroids are administered concomitantly with potassium-depleting agents (e.g., @DRUG$, @DRUG$), patients should be observed closely for development of hypokalemia.	DDI-false
DDI-DrugBank.d314.s10.p0	@DRUG$: @DRUG$ may increase the clearance of corticosteroids.	DDI-false
DDI-DrugBank.d314.s10.p1	@DRUG$: Cholestyramine may increase the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d314.s10.p2	Cholestyramine: @DRUG$ may increase the clearance of @DRUG$.	DDI-mechanism
DDI-DrugBank.d314.s15.p0	@DRUG$: Patients on @DRUG$ may be at increased risk of arrhythmias due to hypokalemia.	DDI-false
DDI-DrugBank.d314.s22.p0	@DRUG$: @DRUG$ has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of corticosteroid side effects.	DDI-false
DDI-DrugBank.d314.s22.p1	@DRUG$: Ketoconazole has been reported to decrease the metabolism of certain @DRUG$ by up to 60%, leading to increased risk of corticosteroid side effects.	DDI-false
DDI-DrugBank.d314.s22.p2	@DRUG$: Ketoconazole has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of @DRUG$ side effects.	DDI-false
DDI-DrugBank.d314.s22.p3	Ketoconazole: @DRUG$ has been reported to decrease the metabolism of certain @DRUG$ by up to 60%, leading to increased risk of corticosteroid side effects.	DDI-mechanism
DDI-DrugBank.d314.s22.p4	Ketoconazole: @DRUG$ has been reported to decrease the metabolism of certain corticosteroids by up to 60%, leading to increased risk of @DRUG$ side effects.	DDI-false
DDI-DrugBank.d314.s22.p5	Ketoconazole: Ketoconazole has been reported to decrease the metabolism of certain @DRUG$ by up to 60%, leading to increased risk of @DRUG$ side effects.	DDI-false
DDI-DrugBank.d314.s24.p0	@DRUG$ (@DRUG$): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.	DDI-false
DDI-DrugBank.d314.s24.p1	@DRUG$ (NSAIDS): Concomitant use of @DRUG$ (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.	DDI-false
DDI-DrugBank.d314.s24.p2	@DRUG$ (NSAIDS): Concomitant use of aspirin (or other @DRUG$) and corticosteroids increases the risk of gastrointestinal side effects.	DDI-false
DDI-DrugBank.d314.s24.p3	@DRUG$ (NSAIDS): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and @DRUG$ increases the risk of gastrointestinal side effects.	DDI-false
DDI-DrugBank.d314.s24.p4	Nonsteroidal anti-inflammatory agents (@DRUG$): Concomitant use of @DRUG$ (or other nonsteroidal antiinflammatory agents) and corticosteroids increases the risk of gastrointestinal side effects.	DDI-false
DDI-DrugBank.d314.s24.p5	Nonsteroidal anti-inflammatory agents (@DRUG$): Concomitant use of aspirin (or other @DRUG$) and corticosteroids increases the risk of gastrointestinal side effects.	DDI-false
DDI-DrugBank.d314.s24.p6	Nonsteroidal anti-inflammatory agents (@DRUG$): Concomitant use of aspirin (or other nonsteroidal antiinflammatory agents) and @DRUG$ increases the risk of gastrointestinal side effects.	DDI-false
DDI-DrugBank.d314.s24.p7	Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of @DRUG$ (or other @DRUG$) and corticosteroids increases the risk of gastrointestinal side effects.	DDI-false
DDI-DrugBank.d314.s24.p8	Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of @DRUG$ (or other nonsteroidal antiinflammatory agents) and @DRUG$ increases the risk of gastrointestinal side effects.	DDI-effect
DDI-DrugBank.d314.s24.p9	Nonsteroidal anti-inflammatory agents (NSAIDS): Concomitant use of aspirin (or other @DRUG$) and @DRUG$ increases the risk of gastrointestinal side effects.	DDI-effect
DDI-DrugBank.d314.s32.p0	Routine administration of @DRUG$ or toxoids should be deferred until @DRUG$ therapy is discontinued if possible.	DDI-advise
DDI-DrugBank.d314.s5.p0	If possible, @DRUG$ should be withdrawn at least 24 hours before initiating @DRUG$ therapy.	DDI-advise
DDI-DrugBank.d314.s6.p0	@DRUG$, oral: Co-administration of @DRUG$ and warfarin usually results in inhibition of response to warfarin, although there have been some conflicting reports.	DDI-false
DDI-DrugBank.d314.s6.p1	@DRUG$, oral: Co-administration of corticosteroids and @DRUG$ usually results in inhibition of response to warfarin, although there have been some conflicting reports.	DDI-false
DDI-DrugBank.d314.s6.p2	@DRUG$, oral: Co-administration of corticosteroids and warfarin usually results in inhibition of response to @DRUG$, although there have been some conflicting reports.	DDI-false
DDI-DrugBank.d314.s6.p3	Anticoagulants, oral: Co-administration of @DRUG$ and @DRUG$ usually results in inhibition of response to warfarin, although there have been some conflicting reports.	DDI-effect
DDI-DrugBank.d314.s6.p4	Anticoagulants, oral: Co-administration of @DRUG$ and warfarin usually results in inhibition of response to @DRUG$, although there have been some conflicting reports.	DDI-false
DDI-DrugBank.d314.s6.p5	Anticoagulants, oral: Co-administration of corticosteroids and @DRUG$ usually results in inhibition of response to @DRUG$, although there have been some conflicting reports.	DDI-false
DDI-DrugBank.d315.s0.p0	@DRUG$: Coadministration of @DRUG$, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.	DDI-false
DDI-DrugBank.d315.s0.p1	@DRUG$: Coadministration of digoxin, a P-glycoprotein substrate, with oral @DRUG$ resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.	DDI-false
DDI-DrugBank.d315.s0.p2	@DRUG$: Coadministration of digoxin, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in @DRUG$ Cmax and AUC values.	DDI-false
DDI-DrugBank.d315.s0.p3	Digoxin: Coadministration of @DRUG$, a P-glycoprotein substrate, with oral @DRUG$ resulted in a reduction in clearance and an increase in digoxin Cmax and AUC values.	DDI-mechanism
DDI-DrugBank.d315.s0.p4	Digoxin: Coadministration of @DRUG$, a P-glycoprotein substrate, with oral conivaptan resulted in a reduction in clearance and an increase in @DRUG$ Cmax and AUC values.	DDI-false
DDI-DrugBank.d315.s0.p5	Digoxin: Coadministration of digoxin, a P-glycoprotein substrate, with oral @DRUG$ resulted in a reduction in clearance and an increase in @DRUG$ Cmax and AUC values.	DDI-false
DDI-DrugBank.d316.s1.p0	Co-administration of CYP3A4 inhibitors (eg, @DRUG$, @DRUG$, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.	DDI-false
DDI-DrugBank.d316.s1.p1	Co-administration of CYP3A4 inhibitors (eg, @DRUG$, itraconazole, @DRUG$, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.	DDI-false
DDI-DrugBank.d316.s1.p2	Co-administration of CYP3A4 inhibitors (eg, @DRUG$, itraconazole, erythromycin, grapefruit juice, @DRUG$) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.	DDI-false
DDI-DrugBank.d316.s1.p3	Co-administration of CYP3A4 inhibitors (eg, @DRUG$, itraconazole, erythromycin, grapefruit juice, cimetidine) with @DRUG$ may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.	DDI-false
DDI-DrugBank.d316.s1.p4	Co-administration of CYP3A4 inhibitors (eg, @DRUG$, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of @DRUG$, either due to an increase in bioavailability or due to a decrease in metabolism.	DDI-false
DDI-DrugBank.d316.s1.p5	Co-administration of CYP3A4 inhibitors (eg, ketoconazole, @DRUG$, @DRUG$, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.	DDI-false
DDI-DrugBank.d316.s1.p6	Co-administration of CYP3A4 inhibitors (eg, ketoconazole, @DRUG$, erythromycin, grapefruit juice, @DRUG$) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.	DDI-false
DDI-DrugBank.d316.s1.p7	Co-administration of CYP3A4 inhibitors (eg, ketoconazole, @DRUG$, erythromycin, grapefruit juice, cimetidine) with @DRUG$ may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.	DDI-false
DDI-DrugBank.d316.s1.p8	Co-administration of CYP3A4 inhibitors (eg, ketoconazole, @DRUG$, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of @DRUG$, either due to an increase in bioavailability or due to a decrease in metabolism.	DDI-false
DDI-DrugBank.d316.s1.p9	Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, @DRUG$, grapefruit juice, @DRUG$) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.	DDI-false
DDI-DrugBank.d316.s1.p10	Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, @DRUG$, grapefruit juice, cimetidine) with @DRUG$ may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.	DDI-false
DDI-DrugBank.d316.s1.p11	Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, @DRUG$, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of @DRUG$, either due to an increase in bioavailability or due to a decrease in metabolism.	DDI-false
DDI-DrugBank.d316.s1.p12	Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, @DRUG$) with @DRUG$ may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.	DDI-false
DDI-DrugBank.d316.s1.p13	Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, @DRUG$) with felodipine may lead to several- fold increases in the plasma levels of @DRUG$, either due to an increase in bioavailability or due to a decrease in metabolism.	DDI-false
DDI-DrugBank.d316.s1.p14	Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with @DRUG$ may lead to several- fold increases in the plasma levels of @DRUG$, either due to an increase in bioavailability or due to a decrease in metabolism.	DDI-false
DDI-DrugBank.d316.s12.p0	In controlled clinical trials, however, @DRUG$ including @DRUG$ were concurrently administered with felodipine and were well tolerated.	DDI-false
DDI-DrugBank.d316.s12.p1	In controlled clinical trials, however, @DRUG$ including metoprolol were concurrently administered with @DRUG$ and were well tolerated.	DDI-false
DDI-DrugBank.d316.s12.p2	In controlled clinical trials, however, beta blockers including @DRUG$ were concurrently administered with @DRUG$ and were well tolerated.	DDI-false
DDI-DrugBank.d316.s14.p0	@DRUG$: In a pharmacokinetic study, maximum plasma concentrations of @DRUG$ were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.	DDI-false
DDI-DrugBank.d316.s14.p1	@DRUG$: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term @DRUG$ therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.	DDI-false
DDI-DrugBank.d316.s14.p2	@DRUG$: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, @DRUG$, carbamazepine, or phenobarbital) than in healthy volunteers.	DDI-false
DDI-DrugBank.d316.s14.p3	@DRUG$: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, @DRUG$, or phenobarbital) than in healthy volunteers.	DDI-false
DDI-DrugBank.d316.s14.p4	@DRUG$: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or @DRUG$) than in healthy volunteers.	DDI-false
DDI-DrugBank.d316.s14.p5	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of @DRUG$ were considerably lower in epileptic patients on long-term @DRUG$ therapy (eg, phenytoin, carbamazepine, or phenobarbital) than in healthy volunteers.	DDI-mechanism
DDI-DrugBank.d316.s14.p6	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of @DRUG$ were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, @DRUG$, carbamazepine, or phenobarbital) than in healthy volunteers.	DDI-mechanism
DDI-DrugBank.d316.s14.p7	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of @DRUG$ were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, @DRUG$, or phenobarbital) than in healthy volunteers.	DDI-mechanism
DDI-DrugBank.d316.s14.p8	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of @DRUG$ were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, carbamazepine, or @DRUG$) than in healthy volunteers.	DDI-mechanism
DDI-DrugBank.d316.s14.p9	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term @DRUG$ therapy (eg, @DRUG$, carbamazepine, or phenobarbital) than in healthy volunteers.	DDI-false
DDI-DrugBank.d316.s14.p10	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term @DRUG$ therapy (eg, phenytoin, @DRUG$, or phenobarbital) than in healthy volunteers.	DDI-false
DDI-DrugBank.d316.s14.p11	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term @DRUG$ therapy (eg, phenytoin, carbamazepine, or @DRUG$) than in healthy volunteers.	DDI-false
DDI-DrugBank.d316.s14.p12	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, @DRUG$, @DRUG$, or phenobarbital) than in healthy volunteers.	DDI-false
DDI-DrugBank.d316.s14.p13	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, @DRUG$, carbamazepine, or @DRUG$) than in healthy volunteers.	DDI-false
DDI-DrugBank.d316.s14.p14	Anticonvulsants: In a pharmacokinetic study, maximum plasma concentrations of felodipine were considerably lower in epileptic patients on long-term anticonvulsant therapy (eg, phenytoin, @DRUG$, or @DRUG$) than in healthy volunteers.	DDI-false
DDI-DrugBank.d316.s18.p0	When given concomitantly with @DRUG$, the @DRUG$ blood concentration should be followed and the tacrolimus dose may need to be adjusted.	DDI-false
DDI-DrugBank.d316.s19.p0	Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when @DRUG$ was given concomitantly with @DRUG$ or spironolactone.	DDI-false
DDI-DrugBank.d316.s19.p1	Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when @DRUG$ was given concomitantly with indomethacin or @DRUG$.	DDI-false
DDI-DrugBank.d316.s19.p2	Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when felodipine was given concomitantly with @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d316.s3.p0	These effects have been observed with co-administration of @DRUG$ (a potent @DRUG$ inhibitor).	DDI-false
DDI-DrugBank.d316.s4.p0	Caution should be used when @DRUG$ inhibitors are co-administered with @DRUG$.	DDI-false
DDI-DrugBank.d316.s8.p0	Grapefruit juice Co-administration of @DRUG$ with grapefruit juice resulted in more than 2-fold increase in the AUC and Cmax, but no prolongation in the half- life of @DRUG$.	DDI-false
DDI-DrugBank.d316.s9.p0	Cimetidine Co-administration of @DRUG$ with @DRUG$ (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of felodipine.	DDI-false
DDI-DrugBank.d316.s9.p1	Cimetidine Co-administration of @DRUG$ with cimetidine (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of @DRUG$.	DDI-false
DDI-DrugBank.d316.s9.p2	Cimetidine Co-administration of felodipine with @DRUG$ (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of @DRUG$.	DDI-false
DDI-DrugBank.d318.s0.p0	When administered concurrently, the following drugs may interact with @DRUG$: @DRUG$: may enhance the potential for renal toxicity, bronchospasm and hypotension.	DDI-effect
DDI-DrugBank.d318.s12.p0	@DRUG$: @DRUG$-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., tubocurarine).	DDI-false
DDI-DrugBank.d318.s12.p1	@DRUG$: amphotericin B-induced hypokalemia may enhance the curariform effect of @DRUG$ (e.g., tubocurarine).	DDI-false
DDI-DrugBank.d318.s12.p2	@DRUG$: amphotericin B-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., @DRUG$).	DDI-false
DDI-DrugBank.d318.s12.p3	Skeletal muscle relaxants: @DRUG$-induced hypokalemia may enhance the curariform effect of @DRUG$ (e.g., tubocurarine).	DDI-effect
DDI-DrugBank.d318.s12.p4	Skeletal muscle relaxants: @DRUG$-induced hypokalemia may enhance the curariform effect of skeletal muscle relaxants (e.g., @DRUG$).	DDI-effect
DDI-DrugBank.d318.s12.p5	Skeletal muscle relaxants: amphotericin B-induced hypokalemia may enhance the curariform effect of @DRUG$ (e.g., @DRUG$).	DDI-false
DDI-DrugBank.d318.s14.p0	@DRUG$: acute pulmonary toxicity has been reported in patients receiving intravenous @DRUG$ and leukocyte transfusions.	DDI-false
DDI-DrugBank.d318.s14.p1	@DRUG$: acute pulmonary toxicity has been reported in patients receiving intravenous amphotericin B and @DRUG$.	DDI-false
DDI-DrugBank.d318.s14.p2	Leukocyte transfusions: acute pulmonary toxicity has been reported in patients receiving intravenous @DRUG$ and @DRUG$.	DDI-effect
DDI-DrugBank.d32.s0.p0	@DRUG$: Twelve healthy male volunteers were administered one 200-mg @DRUG$ capsule twice daily for 6 days.	DDI-false
DDI-DrugBank.d320.s5.p0	@DRUG$ e.g., @DRUG$;	DDI-false
DDI-DrugBank.d320.s6.p0	and @DRUG$ e.g., @DRUG$), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and clarithromycin).	DDI-false
DDI-DrugBank.d320.s6.p1	and @DRUG$ e.g., verapamil), CYP1A2 inducers (@DRUG$) and CYP1A2 inhibitors (furafylline and clarithromycin).	DDI-false
DDI-DrugBank.d320.s6.p2	and @DRUG$ e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (@DRUG$ and clarithromycin).	DDI-false
DDI-DrugBank.d320.s6.p3	and @DRUG$ e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and @DRUG$).	DDI-false
DDI-DrugBank.d320.s6.p4	and calcium channel antagonists e.g., @DRUG$), CYP1A2 inducers (@DRUG$) and CYP1A2 inhibitors (furafylline and clarithromycin).	DDI-false
DDI-DrugBank.d320.s6.p5	and calcium channel antagonists e.g., @DRUG$), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (@DRUG$ and clarithromycin).	DDI-false
DDI-DrugBank.d320.s6.p6	and calcium channel antagonists e.g., @DRUG$), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (furafylline and @DRUG$).	DDI-false
DDI-DrugBank.d320.s6.p7	and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (@DRUG$) and CYP1A2 inhibitors (@DRUG$ and clarithromycin).	DDI-false
DDI-DrugBank.d320.s6.p8	and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (@DRUG$) and CYP1A2 inhibitors (furafylline and @DRUG$).	DDI-false
DDI-DrugBank.d320.s6.p9	and calcium channel antagonists e.g., verapamil), CYP1A2 inducers (omeprazole) and CYP1A2 inhibitors (@DRUG$ and @DRUG$).	DDI-false
DDI-DrugBank.d321.s1.p0	@DRUG$: In the fed state, @DRUG$ (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.	DDI-false
DDI-DrugBank.d321.s1.p1	@DRUG$: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of @DRUG$ by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.	DDI-false
DDI-DrugBank.d321.s1.p2	@DRUG$: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given @DRUG$ alone.	DDI-false
DDI-DrugBank.d321.s1.p3	Praziquantel: In the fed state, @DRUG$ (40 mg/kg) increased mean maximum plasma concentration and area under the curve of @DRUG$ by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given albendazole alone.	DDI-mechanism
DDI-DrugBank.d321.s1.p4	Praziquantel: In the fed state, @DRUG$ (40 mg/kg) increased mean maximum plasma concentration and area under the curve of albendazole sulfoxide by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given @DRUG$ alone.	DDI-false
DDI-DrugBank.d321.s1.p5	Praziquantel: In the fed state, praziquantel (40 mg/kg) increased mean maximum plasma concentration and area under the curve of @DRUG$ by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given @DRUG$ alone.	DDI-false
DDI-DrugBank.d324.s10.p0	@DRUG$: Coadministration of a single dose of @DRUG$ 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.	DDI-false
DDI-DrugBank.d324.s10.p1	@DRUG$: Coadministration of a single dose of zaleplon 10 mg and multiple doses of @DRUG$ ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.	DDI-false
DDI-DrugBank.d324.s10.p2	@DRUG$: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either @DRUG$ or venlafaxine.	DDI-false
DDI-DrugBank.d324.s10.p3	@DRUG$: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or @DRUG$.	DDI-false
DDI-DrugBank.d324.s10.p4	Venlafaxine: Coadministration of a single dose of @DRUG$ 10 mg and multiple doses of @DRUG$ ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.	DDI-false
DDI-DrugBank.d324.s10.p5	Venlafaxine: Coadministration of a single dose of @DRUG$ 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either @DRUG$ or venlafaxine.	DDI-false
DDI-DrugBank.d324.s10.p6	Venlafaxine: Coadministration of a single dose of @DRUG$ 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or @DRUG$.	DDI-false
DDI-DrugBank.d324.s10.p7	Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of @DRUG$ ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either @DRUG$ or venlafaxine.	DDI-false
DDI-DrugBank.d324.s10.p8	Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of @DRUG$ ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or @DRUG$.	DDI-false
DDI-DrugBank.d324.s10.p9	Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d324.s19.p0	Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of @DRUG$ because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, @DRUG$ and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose.	DDI-false
DDI-DrugBank.d324.s19.p1	Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of @DRUG$ because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and @DRUG$, account for only 9% of the urinary recovery of a zaleplon dose.	DDI-false
DDI-DrugBank.d324.s19.p2	Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of @DRUG$ because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a @DRUG$ dose.	DDI-false
DDI-DrugBank.d324.s19.p3	Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, @DRUG$ and @DRUG$, account for only 9% of the urinary recovery of a zaleplon dose.	DDI-false
DDI-DrugBank.d324.s19.p4	Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, @DRUG$ and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a @DRUG$ dose.	DDI-false
DDI-DrugBank.d324.s19.p5	Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and @DRUG$, account for only 9% of the urinary recovery of a @DRUG$ dose.	DDI-false
DDI-DrugBank.d324.s22.p0	Other strong selective CYP3A4 inhibitors such as @DRUG$ can also be expected to increase the exposure of @DRUG$.	DDI-mechanism
DDI-DrugBank.d324.s26.p0	There is no pharmacokinetic interaction between @DRUG$ and @DRUG$ following the administration of a single dose (10 mg and 50 mg, respectively) of each drug.	DDI-false
DDI-DrugBank.d324.s35.p0	@DRUG$: Multiple oral doses of @DRUG$ (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.	DDI-false
DDI-DrugBank.d324.s35.p1	@DRUG$: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of @DRUG$ (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.	DDI-false
DDI-DrugBank.d324.s35.p2	@DRUG$: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of @DRUG$.	DDI-false
DDI-DrugBank.d324.s35.p3	Warfarin: Multiple oral doses of @DRUG$ (20 mg q24h for 13 days) did not affect the pharmacokinetics of @DRUG$ (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.	DDI-false
DDI-DrugBank.d324.s35.p4	Warfarin: Multiple oral doses of @DRUG$ (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of @DRUG$.	DDI-false
DDI-DrugBank.d324.s35.p5	Warfarin: Multiple oral doses of Sonata (20 mg q24h for 13 days) did not affect the pharmacokinetics of @DRUG$ (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of @DRUG$.	DDI-false
DDI-DrugBank.d325.s13.p0	Administration of @DRUG$ to patients receiving @DRUG$ has been reported to lead to hypotension and bradycardia.	DDI-effect
DDI-DrugBank.d325.s7.p0	@DRUG$ (such as @DRUG$) and phenothiazines can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.	DDI-false
DDI-DrugBank.d325.s7.p1	@DRUG$ (such as haloperidol) and @DRUG$ can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.	DDI-false
DDI-DrugBank.d325.s7.p2	@DRUG$ (such as haloperidol) and phenothiazines can suppress the @DRUG$rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.	DDI-effect
DDI-DrugBank.d325.s7.p3	Butyrophenones (such as @DRUG$) and @DRUG$ can suppress the dopaminergic renal and mesenteric vasodilation induced with low dose dopamine infusion.	DDI-false
DDI-DrugBank.d325.s7.p4	Butyrophenones (such as @DRUG$) and phenothiazines can suppress the @DRUG$rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.	DDI-effect
DDI-DrugBank.d325.s7.p5	Butyrophenones (such as haloperidol) and @DRUG$ can suppress the @DRUG$rgic renal and mesenteric vasodilation induced with low dose dopamine infusion.	DDI-effect
DDI-DrugBank.d328.s22.p0	@DRUG$ (450 mg BID for 7 days) had no effect on @DRUG$ pharmacokinetics.	DDI-false
DDI-DrugBank.d328.s26.p0	@DRUG$ therapy should be monitored, particularly during the first few weeks, after initiating therapy with @DRUG$ in patients receiving warfarin or similar agents.	DDI-false
DDI-DrugBank.d328.s26.p1	@DRUG$ therapy should be monitored, particularly during the first few weeks, after initiating therapy with BEXTRA in patients receiving @DRUG$ or similar agents.	DDI-false
DDI-DrugBank.d328.s26.p2	Anticoagulant therapy should be monitored, particularly during the first few weeks, after initiating therapy with @DRUG$ in patients receiving @DRUG$ or similar agents.	DDI-advise
DDI-DrugBank.d328.s27.p0	@DRUG$ and @DRUG$: Ketoconazole and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.	DDI-false
DDI-DrugBank.d328.s27.p1	@DRUG$ and Ketoconazole: @DRUG$ and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.	DDI-false
DDI-DrugBank.d328.s27.p2	@DRUG$ and Ketoconazole: Ketoconazole and @DRUG$ are predominantly CYP 3A4 and 2C9 inhibitors, respectively.	DDI-false
DDI-DrugBank.d328.s27.p3	Fluconazole and @DRUG$: @DRUG$ and fluconazole are predominantly CYP 3A4 and 2C9 inhibitors, respectively.	DDI-false
DDI-DrugBank.d328.s27.p4	Fluconazole and @DRUG$: Ketoconazole and @DRUG$ are predominantly CYP 3A4 and 2C9 inhibitors, respectively.	DDI-false
DDI-DrugBank.d328.s27.p5	Fluconazole and Ketoconazole: @DRUG$ and @DRUG$ are predominantly CYP 3A4 and 2C9 inhibitors, respectively.	DDI-false
DDI-DrugBank.d328.s28.p0	Concomitant single dose administration of @DRUG$ 20 mg with multiple doses of @DRUG$ and fluconazole produced a significant increase in exposure of valdecoxib.	DDI-mechanism
DDI-DrugBank.d328.s28.p1	Concomitant single dose administration of @DRUG$ 20 mg with multiple doses of ketoconazole and @DRUG$ produced a significant increase in exposure of valdecoxib.	DDI-mechanism
DDI-DrugBank.d328.s28.p2	Concomitant single dose administration of @DRUG$ 20 mg with multiple doses of ketoconazole and fluconazole produced a significant increase in exposure of @DRUG$.	DDI-false
DDI-DrugBank.d328.s28.p3	Concomitant single dose administration of valdecoxib 20 mg with multiple doses of @DRUG$ and @DRUG$ produced a significant increase in exposure of valdecoxib.	DDI-false
DDI-DrugBank.d328.s28.p4	Concomitant single dose administration of valdecoxib 20 mg with multiple doses of @DRUG$ and fluconazole produced a significant increase in exposure of @DRUG$.	DDI-false
DDI-DrugBank.d328.s28.p5	Concomitant single dose administration of valdecoxib 20 mg with multiple doses of ketoconazole and @DRUG$ produced a significant increase in exposure of @DRUG$.	DDI-false
DDI-DrugBank.d328.s38.p0	@DRUG$ steady state plasma concentrations (40 mg BID) were not affected significantly with multiple doses of @DRUG$ (40 mg QD).	DDI-false
DDI-DrugBank.d328.s41.p0	However, because higher doses (up to 360 mg QD) of @DRUG$ are tolerated in Zollinger-Ellison (ZE) patients, no dose adjustment for @DRUG$ is recommended at current doses.	DDI-false
DDI-DrugBank.d328.s6.p0	In a parallel group drug interaction study comparing the intravenous prodrug form of @DRUG$ at 40 mg BID (n=10) vs placebo (n=9), @DRUG$ had no effect on in vitro aspirin-mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.	DDI-false
DDI-DrugBank.d328.s6.p1	In a parallel group drug interaction study comparing the intravenous prodrug form of @DRUG$ at 40 mg BID (n=10) vs placebo (n=9), valdecoxib had no effect on in vitro @DRUG$-mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.	DDI-false
DDI-DrugBank.d328.s6.p2	In a parallel group drug interaction study comparing the intravenous prodrug form of valdecoxib at 40 mg BID (n=10) vs placebo (n=9), @DRUG$ had no effect on in vitro @DRUG$-mediated inhibition of arachidonate- or collagen-stimulated platelet aggregation.	DDI-false
DDI-DrugBank.d328.s9.p0	This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
DDI-DrugBank.d329.s0.p0	When @DRUG$ is co-administered with @DRUG$ (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of ertapenem.	DDI-false
DDI-DrugBank.d329.s0.p1	When @DRUG$ is co-administered with probenecid (500 mg p.o. every 6 hours), @DRUG$ competes for active tubular secretion and reduces the renal clearance of ertapenem.	DDI-false
DDI-DrugBank.d329.s0.p2	When @DRUG$ is co-administered with probenecid (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of @DRUG$.	DDI-false
DDI-DrugBank.d329.s0.p3	When ertapenem is co-administered with @DRUG$ (500 mg p.o. every 6 hours), @DRUG$ competes for active tubular secretion and reduces the renal clearance of ertapenem.	DDI-false
DDI-DrugBank.d329.s0.p4	When ertapenem is co-administered with @DRUG$ (500 mg p.o. every 6 hours), probenecid competes for active tubular secretion and reduces the renal clearance of @DRUG$.	DDI-false
DDI-DrugBank.d329.s0.p5	When ertapenem is co-administered with probenecid (500 mg p.o. every 6 hours), @DRUG$ competes for active tubular secretion and reduces the renal clearance of @DRUG$.	DDI-mechanism
DDI-DrugBank.d330.s5.p0	Oral @DRUG$ may enhance the effect of @DRUG$ in anticoagulants by decreasing vitamin K availability.	DDI-effect
DDI-DrugBank.d330.s5.p1	Oral @DRUG$ may enhance the effect of coumarin in @DRUG$ by decreasing vitamin K availability.	DDI-effect
DDI-DrugBank.d330.s5.p2	Oral neomycin sulfate may enhance the effect of @DRUG$ in @DRUG$ by decreasing vitamin K availability.	DDI-false
DDI-DrugBank.d331.s4.p0	- @DRUG$: Pretreatment with @DRUG$ reduces both the natriuresis and hyperreninemia produced by bumetanide.	DDI-false
DDI-DrugBank.d331.s4.p1	- @DRUG$: Pretreatment with probenecid reduces both the natriuresis and hyperreninemia produced by @DRUG$.	DDI-false
DDI-DrugBank.d331.s4.p2	- Probenecid: Pretreatment with @DRUG$ reduces both the natriuresis and hyperreninemia produced by @DRUG$.	DDI-effect
DDI-DrugBank.d333.s7.p0	Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-effect
DDI-DrugBank.d333.s7.p1	Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-effect
DDI-DrugBank.d333.s7.p2	Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-effect
DDI-DrugBank.d333.s7.p3	Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, barbiturates, @DRUG$, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-effect
DDI-DrugBank.d333.s7.p4	Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-effect
DDI-DrugBank.d333.s7.p5	Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-effect
DDI-DrugBank.d333.s7.p6	Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-effect
DDI-DrugBank.d333.s7.p7	Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-effect
DDI-DrugBank.d333.s7.p8	Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-effect
DDI-DrugBank.d333.s7.p9	Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.	DDI-effect
DDI-DrugBank.d333.s7.p10	Pharmacodynamic Interactions: The CNS-depressant action of the @DRUG$ of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.	DDI-effect
DDI-DrugBank.d333.s7.p11	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p12	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p13	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, @DRUG$, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p14	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p15	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p16	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p17	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p18	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p19	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p20	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by @DRUG$, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.	DDI-false
DDI-DrugBank.d333.s7.p21	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p22	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, @DRUG$, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p23	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p24	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p25	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p26	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p27	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p28	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p29	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, @DRUG$, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.	DDI-false
DDI-DrugBank.d333.s7.p30	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, @DRUG$, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p31	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p32	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p33	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p34	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p35	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p36	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p37	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, @DRUG$, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.	DDI-false
DDI-DrugBank.d333.s7.p38	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, @DRUG$, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p39	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, @DRUG$, antianxiety agents, the @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p40	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, @DRUG$, antianxiety agents, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p41	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, @DRUG$, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p42	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, @DRUG$, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p43	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, @DRUG$, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p44	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, @DRUG$, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.	DDI-false
DDI-DrugBank.d333.s7.p45	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p46	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p47	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p48	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p49	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p50	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, @DRUG$, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.	DDI-false
DDI-DrugBank.d333.s7.p51	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG-DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p52	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG-DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p53	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG$, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p54	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG$, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p55	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.	DDI-false
DDI-DrugBank.d333.s7.p56	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, @DRUG-DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p57	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, @DRUG$, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p58	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p59	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.	DDI-false
DDI-DrugBank.d333.s7.p60	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, @DRUG$ and the tricyclic antidepressants, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p61	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the @DRUG$, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p62	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.	DDI-false
DDI-DrugBank.d333.s7.p63	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the @DRUG$, and by other anticonvulsant drugs.	DDI-false
DDI-DrugBank.d333.s7.p64	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, @DRUG$ and the tricyclic antidepressants, and by other @DRUG$.	DDI-false
DDI-DrugBank.d333.s7.p65	Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the @DRUG$, and by other @DRUG$.	DDI-false
DDI-DrugBank.d334.s15.p0	Use of @DRUG$ with @DRUG$ (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-effect
DDI-DrugBank.d334.s15.p1	Use of @DRUG$ with potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-effect
DDI-DrugBank.d334.s15.p2	Use of @DRUG$ with potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-effect
DDI-DrugBank.d334.s15.p3	Use of @DRUG$ with potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-effect
DDI-DrugBank.d334.s15.p4	Use of @DRUG$ with potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-effect
DDI-DrugBank.d334.s15.p5	Use of PRINIVIL with @DRUG$ (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
DDI-DrugBank.d334.s15.p6	Use of PRINIVIL with @DRUG$ (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
DDI-DrugBank.d334.s15.p7	Use of PRINIVIL with @DRUG$ (e.g., spironolactone, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
DDI-DrugBank.d334.s15.p8	Use of PRINIVIL with @DRUG$ (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
DDI-DrugBank.d334.s15.p9	Use of PRINIVIL with potassium-sparing diuretics (e.g., @DRUG$, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
DDI-DrugBank.d334.s15.p10	Use of PRINIVIL with potassium-sparing diuretics (e.g., @DRUG$, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
DDI-DrugBank.d334.s15.p11	Use of PRINIVIL with potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
DDI-DrugBank.d334.s15.p12	Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
DDI-DrugBank.d334.s15.p13	Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
DDI-DrugBank.d334.s15.p14	Use of PRINIVIL with potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
DDI-DrugBank.d334.s4.p0	Studies with @DRUG$ in combination with @DRUG$ indicate that the dose of the ACE inhibitor can be reduced when it is given with a diuretic.	DDI-false
DDI-DrugBank.d334.s4.p1	Studies with @DRUG$ in combination with diuretics indicate that the dose of the @DRUG$ can be reduced when it is given with a diuretic.	DDI-false
DDI-DrugBank.d334.s4.p2	Studies with @DRUG$ in combination with diuretics indicate that the dose of the ACE inhibitor can be reduced when it is given with a @DRUG$.	DDI-false
DDI-DrugBank.d334.s4.p3	Studies with ACE inhibitors in combination with @DRUG$ indicate that the dose of the @DRUG$ can be reduced when it is given with a diuretic.	DDI-false
DDI-DrugBank.d334.s4.p4	Studies with ACE inhibitors in combination with @DRUG$ indicate that the dose of the ACE inhibitor can be reduced when it is given with a @DRUG$.	DDI-false
DDI-DrugBank.d334.s4.p5	Studies with ACE inhibitors in combination with diuretics indicate that the dose of the @DRUG$ can be reduced when it is given with a @DRUG$.	DDI-advise
DDI-DrugBank.d334.s9.p0	In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of @DRUG$ alone were compared to @DRUG$ given concomitantly with indomethacin, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.	DDI-false
DDI-DrugBank.d334.s9.p1	In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of @DRUG$ alone were compared to PRINIVIL given concomitantly with @DRUG$, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.	DDI-false
DDI-DrugBank.d334.s9.p2	In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of @DRUG$ alone were compared to PRINIVIL given concomitantly with indomethacin, the use of @DRUG$ was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.	DDI-false
DDI-DrugBank.d334.s9.p3	In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to @DRUG$ given concomitantly with @DRUG$, the use of indomethacin was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.	DDI-false
DDI-DrugBank.d334.s9.p4	In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to @DRUG$ given concomitantly with indomethacin, the use of @DRUG$ was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.	DDI-false
DDI-DrugBank.d334.s9.p5	In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of PRINIVIL alone were compared to PRINIVIL given concomitantly with @DRUG$, the use of @DRUG$ was associated with a reduced antihypertensive effect, although the difference between the two regimens was not significant.	DDI-false
DDI-DrugBank.d335.s1.p0	Animal experience indicates that @DRUG$ prolongs the sleeping time after @DRUG$ or after ethyl alcohol, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.	DDI-effect
DDI-DrugBank.d335.s1.p1	Animal experience indicates that @DRUG$ prolongs the sleeping time after hexobarbital or after @DRUG$, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.	DDI-effect
DDI-DrugBank.d335.s1.p2	Animal experience indicates that @DRUG$ prolongs the sleeping time after hexobarbital or after ethyl alcohol, increases the inhibitory effects of @DRUG$, but does not exhibit monoamine oxidase inhibition.	DDI-effect
DDI-DrugBank.d335.s1.p3	Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after @DRUG$ or after @DRUG$, increases the inhibitory effects of chlorpromazine, but does not exhibit monoamine oxidase inhibition.	DDI-false
DDI-DrugBank.d335.s1.p4	Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after @DRUG$ or after ethyl alcohol, increases the inhibitory effects of @DRUG$, but does not exhibit monoamine oxidase inhibition.	DDI-false
DDI-DrugBank.d335.s1.p5	Animal experience indicates that clorazepate dipotassium prolongs the sleeping time after hexobarbital or after @DRUG$, increases the inhibitory effects of @DRUG$, but does not exhibit monoamine oxidase inhibition.	DDI-false
DDI-DrugBank.d335.s3.p0	The actions of the @DRUG$ may be potentiated by @DRUG$, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.	DDI-effect
DDI-DrugBank.d335.s3.p1	The actions of the @DRUG$ may be potentiated by barbiturates, @DRUG$, phenothiazines, monoamine oxidase inhibitors or other antidepressants.	DDI-effect
DDI-DrugBank.d335.s3.p2	The actions of the @DRUG$ may be potentiated by barbiturates, narcotics, @DRUG$, monoamine oxidase inhibitors or other antidepressants.	DDI-effect
DDI-DrugBank.d335.s3.p3	The actions of the @DRUG$ may be potentiated by barbiturates, narcotics, phenothiazines, @DRUG$ or other antidepressants.	DDI-effect
DDI-DrugBank.d335.s3.p4	The actions of the @DRUG$ may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other @DRUG$.	DDI-effect
DDI-DrugBank.d335.s3.p5	The actions of the benzodiazepines may be potentiated by @DRUG$, @DRUG$, phenothiazines, monoamine oxidase inhibitors or other antidepressants.	DDI-false
DDI-DrugBank.d335.s3.p6	The actions of the benzodiazepines may be potentiated by @DRUG$, narcotics, @DRUG$, monoamine oxidase inhibitors or other antidepressants.	DDI-false
DDI-DrugBank.d335.s3.p7	The actions of the benzodiazepines may be potentiated by @DRUG$, narcotics, phenothiazines, @DRUG$ or other antidepressants.	DDI-false
DDI-DrugBank.d335.s3.p8	The actions of the benzodiazepines may be potentiated by @DRUG$, narcotics, phenothiazines, monoamine oxidase inhibitors or other @DRUG$.	DDI-false
DDI-DrugBank.d335.s3.p9	The actions of the benzodiazepines may be potentiated by barbiturates, @DRUG$, @DRUG$, monoamine oxidase inhibitors or other antidepressants.	DDI-false
DDI-DrugBank.d335.s3.p10	The actions of the benzodiazepines may be potentiated by barbiturates, @DRUG$, phenothiazines, @DRUG$ or other antidepressants.	DDI-false
DDI-DrugBank.d335.s3.p11	The actions of the benzodiazepines may be potentiated by barbiturates, @DRUG$, phenothiazines, monoamine oxidase inhibitors or other @DRUG$.	DDI-false
DDI-DrugBank.d335.s3.p12	The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, @DRUG$, @DRUG$ or other antidepressants.	DDI-false
DDI-DrugBank.d335.s3.p13	The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, @DRUG$, monoamine oxidase inhibitors or other @DRUG$.	DDI-false
DDI-DrugBank.d335.s3.p14	The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, @DRUG$ or other @DRUG$.	DDI-false
DDI-DrugBank.d338.s5.p0	@DRUG$: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of @DRUG$ to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.	DDI-false
DDI-DrugBank.d338.s5.p1	@DRUG$: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of estazolam to the major circulating metabolite @DRUG$ and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.	DDI-false
DDI-DrugBank.d338.s5.p2	@DRUG$: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of estazolam to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other @DRUG$ is catalyzed by CYP3A.	DDI-false
DDI-DrugBank.d338.s5.p3	Estazolam: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of @DRUG$ to the major circulating metabolite @DRUG$ and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.	DDI-false
DDI-DrugBank.d338.s5.p4	Estazolam: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of @DRUG$ to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other @DRUG$ is catalyzed by CYP3A.	DDI-false
DDI-DrugBank.d338.s5.p5	Estazolam: Interaction with Drugs that Inhibit Metabolism via Cytochrome P450 3A (CYP3A): The metabolism of estazolam to the major circulating metabolite @DRUG$ and the metabolism of other @DRUG$ is catalyzed by CYP3A.	DDI-false
DDI-DrugBank.d338.s9.p0	Drug Interaction with @DRUG$: A multiple-dose study was conducted to assess the effect of @DRUG$ 20 mg BID on the pharmacokinetics of estazolam 2 mg QHS after seven days.	DDI-false
DDI-DrugBank.d338.s9.p1	Drug Interaction with @DRUG$: A multiple-dose study was conducted to assess the effect of fluoxetine 20 mg BID on the pharmacokinetics of @DRUG$ 2 mg QHS after seven days.	DDI-false
DDI-DrugBank.d338.s9.p2	Drug Interaction with Fluoxetine: A multiple-dose study was conducted to assess the effect of @DRUG$ 20 mg BID on the pharmacokinetics of @DRUG$ 2 mg QHS after seven days.	DDI-false
DDI-DrugBank.d339.s3.p0	Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using @DRUG$ but not with those using @DRUG$.	DDI-false
DDI-DrugBank.d34.s0.p0	Although acid-base and electrolyte disturbances were not reported in the clinical trials with @DRUG$, these disturbances have been reported with oral @DRUG$ and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose salicylate therapy).	DDI-effect
DDI-DrugBank.d34.s0.p1	Although acid-base and electrolyte disturbances were not reported in the clinical trials with @DRUG$, these disturbances have been reported with oral carbonic anhydrase inhibitors and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose @DRUG$ therapy).	DDI-false
DDI-DrugBank.d34.s0.p2	Although acid-base and electrolyte disturbances were not reported in the clinical trials with dorzolamide, these disturbances have been reported with oral @DRUG$ and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose @DRUG$ therapy).	DDI-false
DDI-DrugBank.d340.s22.p0	@DRUG$: Coadministration of @DRUG$ with VIRACEPT resulted in a 35% increase in nelfinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s22.p1	@DRUG$: Coadministration of ketoconazole with @DRUG$ resulted in a 35% increase in nelfinavir plasma A.C.	DDI-false
DDI-DrugBank.d340.s22.p2	@DRUG$: Coadministration of ketoconazole with VIRACEPT resulted in a 35% increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s22.p3	Ketoconazole: Coadministration of @DRUG$ with @DRUG$ resulted in a 35% increase in nelfinavir plasma A.C.	DDI-mechanism
DDI-DrugBank.d340.s22.p4	Ketoconazole: Coadministration of @DRUG$ with VIRACEPT resulted in a 35% increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s22.p5	Ketoconazole: Coadministration of ketoconazole with @DRUG$ resulted in a 35% increase in @DRUG$ plasma A.C.	DDI-false
DDI-DrugBank.d340.s27.p0	A dose adjustment is not needed when @DRUG$ is administered with @DRUG$.	DDI-advise
DDI-DrugBank.d340.s31.p0	It is recommended that the dose of @DRUG$ be reduced to one-half the usual dose when administered with @DRUG$.	DDI-advise
DDI-DrugBank.d341.s1.p0	However, it was observed that the pharmacokinetics of @DRUG$  was unaltered by concomitant @DRUG$ in rheumatoid arthritis patients.	DDI-false
DDI-DrugBank.d342.s0.p0	This drug may interact with @DRUG$ or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p1	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p2	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p3	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p4	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p5	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p6	This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d342.s0.p7	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p8	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p9	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p10	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p11	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p12	This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d342.s0.p13	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p14	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p15	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p16	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p17	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d342.s0.p18	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p19	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p20	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p21	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d342.s0.p22	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p23	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p24	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d342.s0.p25	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
DDI-DrugBank.d342.s0.p26	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d342.s0.p27	This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
DDI-DrugBank.d345.s13.p0	No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: @DRUG$, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p1	No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, @DRUG$, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p2	No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, clindamycin, @DRUG$, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p3	No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, clindamycin, clofibrate, @DRUG$, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p4	No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, @DRUG$ (niacin), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p5	No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (@DRUG$), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p6	No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), @DRUG$, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p7	No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, @DRUG$ or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p8	No depressant effect on blood levels in humans was noted when @DRUG$ was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or @DRUG$.	DDI-false
DDI-DrugBank.d345.s13.p9	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, @DRUG$, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p10	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, clindamycin, @DRUG$, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p11	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, clindamycin, clofibrate, @DRUG$, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p12	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, clindamycin, clofibrate, methyldopa, @DRUG$ (niacin), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p13	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, clindamycin, clofibrate, methyldopa, nicotinic acid (@DRUG$), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p14	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), @DRUG$, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p15	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, @DRUG$ or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p16	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: @DRUG$, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or @DRUG$.	DDI-false
DDI-DrugBank.d345.s13.p17	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, @DRUG$, @DRUG$, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p18	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, @DRUG$, clofibrate, @DRUG$, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p19	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, @DRUG$, clofibrate, methyldopa, @DRUG$ (niacin), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p20	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, @DRUG$, clofibrate, methyldopa, nicotinic acid (@DRUG$), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p21	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, @DRUG$, clofibrate, methyldopa, nicotinic acid (niacin), @DRUG$, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p22	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, @DRUG$, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, @DRUG$ or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p23	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, @DRUG$, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or @DRUG$.	DDI-false
DDI-DrugBank.d345.s13.p24	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, @DRUG$, @DRUG$, nicotinic acid (niacin), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p25	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, @DRUG$, methyldopa, @DRUG$ (niacin), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p26	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, @DRUG$, methyldopa, nicotinic acid (@DRUG$), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p27	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, @DRUG$, methyldopa, nicotinic acid (niacin), @DRUG$, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p28	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, @DRUG$, methyldopa, nicotinic acid (niacin), tolbutamide, @DRUG$ or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p29	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, @DRUG$, methyldopa, nicotinic acid (niacin), tolbutamide, phenytoin or @DRUG$.	DDI-false
DDI-DrugBank.d345.s13.p30	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, @DRUG$, @DRUG$ (niacin), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p31	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, @DRUG$, nicotinic acid (@DRUG$), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p32	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, @DRUG$, nicotinic acid (niacin), @DRUG$, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p33	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, @DRUG$, nicotinic acid (niacin), tolbutamide, @DRUG$ or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p34	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, @DRUG$, nicotinic acid (niacin), tolbutamide, phenytoin or @DRUG$.	DDI-false
DDI-DrugBank.d345.s13.p35	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, @DRUG$ (@DRUG$), tolbutamide, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p36	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, @DRUG$ (niacin), @DRUG$, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p37	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, @DRUG$ (niacin), tolbutamide, @DRUG$ or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p38	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, @DRUG$ (niacin), tolbutamide, phenytoin or @DRUG$.	DDI-false
DDI-DrugBank.d345.s13.p39	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (@DRUG$), @DRUG$, phenytoin or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p40	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (@DRUG$), tolbutamide, @DRUG$ or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p41	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (@DRUG$), tolbutamide, phenytoin or @DRUG$.	DDI-false
DDI-DrugBank.d345.s13.p42	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), @DRUG$, @DRUG$ or warfarin.	DDI-false
DDI-DrugBank.d345.s13.p43	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), @DRUG$, phenytoin or @DRUG$.	DDI-false
DDI-DrugBank.d345.s13.p44	No depressant effect on blood levels in humans was noted when colestipol hydrochloride was administered with any of the following drugs: aspirin, clindamycin, clofibrate, methyldopa, nicotinic acid (niacin), tolbutamide, @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d345.s17.p0	@DRUG$ may also interfere with the absorption of oral @DRUG$ supplements and hydrocortisone.	DDI-mechanism
DDI-DrugBank.d345.s17.p1	@DRUG$ may also interfere with the absorption of oral phosphate supplements and @DRUG$.	DDI-mechanism
DDI-DrugBank.d345.s17.p2	Bile acid binding resins may also interfere with the absorption of oral @DRUG$ supplements and @DRUG$.	DDI-false
DDI-DrugBank.d345.s6.p0	However, in a follow-up study in normal subjects, single-dose administration of @DRUG$ and @DRUG$ and twice-a-day administration for 5 days of both agents did not affect the extent of propranolol absorption, but had a small yet statistically significant effect on its rate of absorption;	DDI-false
DDI-DrugBank.d345.s6.p1	However, in a follow-up study in normal subjects, single-dose administration of @DRUG$ and propranolol and twice-a-day administration for 5 days of both agents did not affect the extent of @DRUG$ absorption, but had a small yet statistically significant effect on its rate of absorption;	DDI-false
DDI-DrugBank.d345.s6.p2	However, in a follow-up study in normal subjects, single-dose administration of colestipol hydrochloride and @DRUG$ and twice-a-day administration for 5 days of both agents did not affect the extent of @DRUG$ absorption, but had a small yet statistically significant effect on its rate of absorption;	DDI-false
DDI-DrugBank.d346.s4.p0	Patients taking @DRUG$ may not benefit from @DRUG$ containing medicines, such as cough and cold preparations, antidiarrheal preparations, and opioid analgesics.	DDI-effect
DDI-DrugBank.d346.s4.p1	Patients taking @DRUG$ may not benefit from opioid containing medicines, such as cough and cold preparations, antidiarrheal preparations, and @DRUG$.	DDI-effect
DDI-DrugBank.d346.s4.p2	Patients taking REVIA may not benefit from @DRUG$ containing medicines, such as cough and cold preparations, antidiarrheal preparations, and @DRUG$.	DDI-false
DDI-DrugBank.d347.s1.p0	Concomitant administration of @DRUG$ and @DRUG$, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-mechanism
DDI-DrugBank.d347.s1.p1	Concomitant administration of @DRUG$ and calcium carbonate, @DRUG$, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-mechanism
DDI-DrugBank.d347.s1.p2	Concomitant administration of @DRUG$ and calcium carbonate, cimetidine, @DRUG$, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-mechanism
DDI-DrugBank.d347.s1.p3	Concomitant administration of @DRUG$ and calcium carbonate, cimetidine, omeprazole, or an @DRUG$/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-mechanism
DDI-DrugBank.d347.s1.p4	Concomitant administration of @DRUG$ and calcium carbonate, cimetidine, omeprazole, or an estrogen/@DRUG$ oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-mechanism
DDI-DrugBank.d347.s1.p5	Concomitant administration of @DRUG$ and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral @DRUG$ produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-mechanism
DDI-DrugBank.d347.s1.p6	Concomitant administration of @DRUG$ and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of @DRUG$, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p7	Concomitant administration of FACTIVE and @DRUG$, @DRUG$, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p8	Concomitant administration of FACTIVE and @DRUG$, cimetidine, @DRUG$, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p9	Concomitant administration of FACTIVE and @DRUG$, cimetidine, omeprazole, or an @DRUG$/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p10	Concomitant administration of FACTIVE and @DRUG$, cimetidine, omeprazole, or an estrogen/@DRUG$ oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p11	Concomitant administration of FACTIVE and @DRUG$, cimetidine, omeprazole, or an estrogen/progesterone oral @DRUG$ produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p12	Concomitant administration of FACTIVE and @DRUG$, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of @DRUG$, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p13	Concomitant administration of FACTIVE and calcium carbonate, @DRUG$, @DRUG$, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p14	Concomitant administration of FACTIVE and calcium carbonate, @DRUG$, omeprazole, or an @DRUG$/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p15	Concomitant administration of FACTIVE and calcium carbonate, @DRUG$, omeprazole, or an estrogen/@DRUG$ oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p16	Concomitant administration of FACTIVE and calcium carbonate, @DRUG$, omeprazole, or an estrogen/progesterone oral @DRUG$ produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p17	Concomitant administration of FACTIVE and calcium carbonate, @DRUG$, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of @DRUG$, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p18	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, @DRUG$, or an @DRUG$/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p19	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, @DRUG$, or an estrogen/@DRUG$ oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p20	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, @DRUG$, or an estrogen/progesterone oral @DRUG$ produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p21	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, @DRUG$, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of @DRUG$, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p22	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an @DRUG$/@DRUG$ oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p23	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an @DRUG$/progesterone oral @DRUG$ produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p24	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an @DRUG$/progesterone oral contraceptive produced minor changes in the pharmacokinetics of @DRUG$, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p25	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/@DRUG$ oral @DRUG$ produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p26	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/@DRUG$ oral contraceptive produced minor changes in the pharmacokinetics of @DRUG$, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s1.p27	Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral @DRUG$ produced minor changes in the pharmacokinetics of @DRUG$, which were considered to be without clinical significance.	DDI-false
DDI-DrugBank.d347.s2.p0	Concomitant administration of @DRUG$ with @DRUG$ resulted in a 45% increase in systemic exposure to gemifloxacin.	DDI-mechanism
DDI-DrugBank.d347.s2.p1	Concomitant administration of @DRUG$ with probenecid resulted in a 45% increase in systemic exposure to @DRUG$.	DDI-false
DDI-DrugBank.d347.s2.p2	Concomitant administration of FACTIVE with @DRUG$ resulted in a 45% increase in systemic exposure to @DRUG$.	DDI-false
DDI-DrugBank.d350.s3.p0	Clinical studies in healthy volunteers show that the pharmacokinetics of @DRUG$ are not altered by @DRUG$, amphotericin B, mycophenolate, nelfinavir, or tacrolimus.	DDI-false
DDI-DrugBank.d350.s3.p1	Clinical studies in healthy volunteers show that the pharmacokinetics of @DRUG$ are not altered by itraconazole, @DRUG$, mycophenolate, nelfinavir, or tacrolimus.	DDI-false
DDI-DrugBank.d350.s3.p2	Clinical studies in healthy volunteers show that the pharmacokinetics of @DRUG$ are not altered by itraconazole, amphotericin B, @DRUG$, nelfinavir, or tacrolimus.	DDI-false
DDI-DrugBank.d350.s3.p3	Clinical studies in healthy volunteers show that the pharmacokinetics of @DRUG$ are not altered by itraconazole, amphotericin B, mycophenolate, @DRUG$, or tacrolimus.	DDI-false
DDI-DrugBank.d350.s3.p4	Clinical studies in healthy volunteers show that the pharmacokinetics of @DRUG$ are not altered by itraconazole, amphotericin B, mycophenolate, nelfinavir, or @DRUG$.	DDI-false
DDI-DrugBank.d350.s3.p5	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by @DRUG$, @DRUG$, mycophenolate, nelfinavir, or tacrolimus.	DDI-false
DDI-DrugBank.d350.s3.p6	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by @DRUG$, amphotericin B, @DRUG$, nelfinavir, or tacrolimus.	DDI-false
DDI-DrugBank.d350.s3.p7	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by @DRUG$, amphotericin B, mycophenolate, @DRUG$, or tacrolimus.	DDI-false
DDI-DrugBank.d350.s3.p8	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by @DRUG$, amphotericin B, mycophenolate, nelfinavir, or @DRUG$.	DDI-false
DDI-DrugBank.d350.s3.p9	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, @DRUG$, @DRUG$, nelfinavir, or tacrolimus.	DDI-false
DDI-DrugBank.d350.s3.p10	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, @DRUG$, mycophenolate, @DRUG$, or tacrolimus.	DDI-false
DDI-DrugBank.d350.s3.p11	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, @DRUG$, mycophenolate, nelfinavir, or @DRUG$.	DDI-false
DDI-DrugBank.d350.s3.p12	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, @DRUG$, @DRUG$, or tacrolimus.	DDI-false
DDI-DrugBank.d350.s3.p13	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, @DRUG$, nelfinavir, or @DRUG$.	DDI-false
DDI-DrugBank.d350.s3.p14	Clinical studies in healthy volunteers show that the pharmacokinetics of CANCIDAS are not altered by itraconazole, amphotericin B, mycophenolate, @DRUG$, or @DRUG$.	DDI-false
DDI-DrugBank.d350.s4.p0	@DRUG$ has no effect on the pharmacokinetics of @DRUG$, amphotericin B, or the active metabolite of mycophenolate.	DDI-false
DDI-DrugBank.d350.s4.p1	@DRUG$ has no effect on the pharmacokinetics of itraconazole, @DRUG$, or the active metabolite of mycophenolate.	DDI-false
DDI-DrugBank.d350.s4.p2	CANCIDAS has no effect on the pharmacokinetics of @DRUG$, @DRUG$, or the active metabolite of mycophenolate.	DDI-false
DDI-DrugBank.d352.s0.p0	@DRUG$ requirements (i.e., @DRUG$) may be altered.	DDI-false
DDI-DrugBank.d352.s4.p0	Concurrent use of @DRUG$ may antagonize the anorectic effect of @DRUG$.	DDI-effect
DDI-DrugBank.d353.s0.p0	@DRUG$:Clinical evidence has shown that @DRUG$ can be formed with concurrent ingestion of acitretin and ethanol.	DDI-false
DDI-DrugBank.d353.s0.p1	@DRUG$:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of @DRUG$ and ethanol.	DDI-false
DDI-DrugBank.d353.s0.p2	@DRUG$:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of acitretin and @DRUG$.	DDI-false
DDI-DrugBank.d353.s0.p3	Ethanol:Clinical evidence has shown that @DRUG$ can be formed with concurrent ingestion of @DRUG$ and ethanol.	DDI-false
DDI-DrugBank.d353.s0.p4	Ethanol:Clinical evidence has shown that @DRUG$ can be formed with concurrent ingestion of acitretin and @DRUG$.	DDI-false
DDI-DrugBank.d353.s0.p5	Ethanol:Clinical evidence has shown that etretinate can be formed with concurrent ingestion of @DRUG$ and @DRUG$.	DDI-mechanism
DDI-DrugBank.d353.s1.p0	@DRUG$: In a study of 7 healthy male volunteers, @DRUG$ treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.	DDI-false
DDI-DrugBank.d353.s1.p1	@DRUG$: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of @DRUG$ (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.	DDI-false
DDI-DrugBank.d353.s1.p2	@DRUG$: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a @DRUG$ similar to chlorpropamide) in 3 of the 7 subjects.	DDI-false
DDI-DrugBank.d353.s1.p3	@DRUG$: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to @DRUG$) in 3 of the 7 subjects.	DDI-false
DDI-DrugBank.d353.s1.p4	Glibenclamide: In a study of 7 healthy male volunteers, @DRUG$ treatment potentiated the blood glucose lowering effect of @DRUG$ (a sulfonylurea similar to chlorpropamide) in 3 of the 7 subjects.	DDI-effect
DDI-DrugBank.d353.s1.p5	Glibenclamide: In a study of 7 healthy male volunteers, @DRUG$ treatment potentiated the blood glucose lowering effect of glibenclamide (a @DRUG$ similar to chlorpropamide) in 3 of the 7 subjects.	DDI-false
DDI-DrugBank.d353.s1.p6	Glibenclamide: In a study of 7 healthy male volunteers, @DRUG$ treatment potentiated the blood glucose lowering effect of glibenclamide (a sulfonylurea similar to @DRUG$) in 3 of the 7 subjects.	DDI-false
DDI-DrugBank.d353.s1.p7	Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of @DRUG$ (a @DRUG$ similar to chlorpropamide) in 3 of the 7 subjects.	DDI-false
DDI-DrugBank.d353.s1.p8	Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of @DRUG$ (a sulfonylurea similar to @DRUG$) in 3 of the 7 subjects.	DDI-false
DDI-DrugBank.d353.s1.p9	Glibenclamide: In a study of 7 healthy male volunteers, acitretin treatment potentiated the blood glucose lowering effect of glibenclamide (a @DRUG$ similar to @DRUG$) in 3 of the 7 subjects.	DDI-false
DDI-DrugBank.d353.s10.p0	@DRUG$: If @DRUG$ is given concurrently with phenytoin, the protein binding of phenytoin may be reduced.	DDI-false
DDI-DrugBank.d353.s10.p1	@DRUG$: If acitretin is given concurrently with @DRUG$, the protein binding of phenytoin may be reduced.	DDI-false
DDI-DrugBank.d353.s10.p2	@DRUG$: If acitretin is given concurrently with phenytoin, the protein binding of @DRUG$ may be reduced.	DDI-false
DDI-DrugBank.d353.s10.p3	Phenytoin: If @DRUG$ is given concurrently with @DRUG$, the protein binding of phenytoin may be reduced.	DDI-mechanism
DDI-DrugBank.d353.s10.p4	Phenytoin: If @DRUG$ is given concurrently with phenytoin, the protein binding of @DRUG$ may be reduced.	DDI-false
DDI-DrugBank.d353.s10.p5	Phenytoin: If acitretin is given concurrently with @DRUG$, the protein binding of @DRUG$ may be reduced.	DDI-false
DDI-DrugBank.d353.s12.p0	@DRUG$ and oral @DRUG$: Concomitant administration of vitamin A and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.	DDI-false
DDI-DrugBank.d353.s12.p1	@DRUG$ and oral retinoids: Concomitant administration of @DRUG$ and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.	DDI-false
DDI-DrugBank.d353.s12.p2	@DRUG$ and oral retinoids: Concomitant administration of vitamin A and/or other oral @DRUG$ with acitretin must be avoided because of the risk of hypervitaminosis A.	DDI-false
DDI-DrugBank.d353.s12.p3	@DRUG$ and oral retinoids: Concomitant administration of vitamin A and/or other oral retinoids with @DRUG$ must be avoided because of the risk of hypervitaminosis A.	DDI-false
DDI-DrugBank.d353.s12.p4	Vitamin A and oral @DRUG$: Concomitant administration of @DRUG$ and/or other oral retinoids with acitretin must be avoided because of the risk of hypervitaminosis A.	DDI-false
DDI-DrugBank.d353.s12.p5	Vitamin A and oral @DRUG$: Concomitant administration of vitamin A and/or other oral @DRUG$ with acitretin must be avoided because of the risk of hypervitaminosis A.	DDI-false
DDI-DrugBank.d353.s12.p6	Vitamin A and oral @DRUG$: Concomitant administration of vitamin A and/or other oral retinoids with @DRUG$ must be avoided because of the risk of hypervitaminosis A.	DDI-false
DDI-DrugBank.d353.s12.p7	Vitamin A and oral retinoids: Concomitant administration of @DRUG$ and/or other oral @DRUG$ with acitretin must be avoided because of the risk of hypervitaminosis A.	DDI-false
DDI-DrugBank.d353.s12.p8	Vitamin A and oral retinoids: Concomitant administration of @DRUG$ and/or other oral retinoids with @DRUG$ must be avoided because of the risk of hypervitaminosis A.	DDI-advise
DDI-DrugBank.d353.s12.p9	Vitamin A and oral retinoids: Concomitant administration of vitamin A and/or other oral @DRUG$ with @DRUG$ must be avoided because of the risk of hypervitaminosis A.	DDI-advise
DDI-DrugBank.d353.s13.p0	Other: There appears to be no pharmacokinetic interaction between @DRUG$ and @DRUG$, digoxin, or glyburide.	DDI-false
DDI-DrugBank.d353.s13.p1	Other: There appears to be no pharmacokinetic interaction between @DRUG$ and cimetidine, @DRUG$, or glyburide.	DDI-false
DDI-DrugBank.d353.s13.p2	Other: There appears to be no pharmacokinetic interaction between @DRUG$ and cimetidine, digoxin, or @DRUG$.	DDI-false
DDI-DrugBank.d353.s13.p3	Other: There appears to be no pharmacokinetic interaction between acitretin and @DRUG$, @DRUG$, or glyburide.	DDI-false
DDI-DrugBank.d353.s13.p4	Other: There appears to be no pharmacokinetic interaction between acitretin and @DRUG$, digoxin, or @DRUG$.	DDI-false
DDI-DrugBank.d353.s13.p5	Other: There appears to be no pharmacokinetic interaction between acitretin and cimetidine, @DRUG$, or @DRUG$.	DDI-false
DDI-DrugBank.d353.s2.p0	Repeating the study with 6 healthy male volunteers in the absence of @DRUG$ did not detect an effect of @DRUG$ on glucose tolerance.	DDI-false
DDI-DrugBank.d353.s8.p0	@DRUG$: An increased risk of hepatitis has been reported to result from combined use of @DRUG$ and etretinate.	DDI-false
DDI-DrugBank.d353.s8.p1	@DRUG$: An increased risk of hepatitis has been reported to result from combined use of methotrexate and @DRUG$.	DDI-false
DDI-DrugBank.d353.s8.p2	Methotrexate: An increased risk of hepatitis has been reported to result from combined use of @DRUG$ and @DRUG$.	DDI-effect
DDI-DrugBank.d355.s3.p0	In diabetic patients, the metabolic effects of @DRUG$ may decrease blood glucose and therefore, @DRUG$ requirements.	DDI-effect
DDI-DrugBank.d356.s0.p0	When @DRUG$ HCl is administered concomitantly with an @DRUG$, the risk of hyperkalemia may be increased.	DDI-effect
DDI-DrugBank.d358.s0.p0	Since @DRUG$ is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when @DRUG$ is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as omeprazole.	DDI-false
DDI-DrugBank.d358.s0.p1	Since @DRUG$ is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as @DRUG$ and erythromycin or inhibitors of CYP2C19 such as omeprazole.	DDI-false
DDI-DrugBank.d358.s0.p2	Since @DRUG$ is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and @DRUG$ or inhibitors of CYP2C19 such as omeprazole.	DDI-false
DDI-DrugBank.d358.s0.p3	Since @DRUG$ is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as @DRUG$.	DDI-false
DDI-DrugBank.d358.s0.p4	Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when @DRUG$ is coadministered with inhibitors of C.P.A. such as @DRUG$ and erythromycin or inhibitors of CYP2C19 such as omeprazole.	DDI-advise
DDI-DrugBank.d358.s0.p5	Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when @DRUG$ is coadministered with inhibitors of C.P.A. such as ketoconazole and @DRUG$ or inhibitors of CYP2C19 such as omeprazole.	DDI-advise
DDI-DrugBank.d358.s0.p6	Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when @DRUG$ is coadministered with inhibitors of C.P.A. such as ketoconazole and erythromycin or inhibitors of CYP2C19 such as @DRUG$.	DDI-advise
DDI-DrugBank.d358.s0.p7	Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as @DRUG$ and @DRUG$ or inhibitors of CYP2C19 such as omeprazole.	DDI-false
DDI-DrugBank.d358.s0.p8	Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as @DRUG$ and erythromycin or inhibitors of CYP2C19 such as @DRUG$.	DDI-false
DDI-DrugBank.d358.s0.p9	Since PLETAL is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when PLETAL is coadministered with inhibitors of C.P.A. such as ketoconazole and @DRUG$ or inhibitors of CYP2C19 such as @DRUG$.	DDI-false
DDI-DrugBank.d360.s2.p0	A possible interaction has been suggested with @DRUG$ and the herbal supplement St. Johns Wort based on some reports of oral @DRUG$ users experiencing breakthrough bleeding shortly after starting St. Johns Wort.	DDI-false
DDI-DrugBank.d362.s4.p0	In another drug interaction study, co-administration of orally inhaled @DRUG$ and oral @DRUG$, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.	DDI-mechanism
DDI-DrugBank.d362.s4.p1	In another drug interaction study, co-administration of orally inhaled @DRUG$ and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of @DRUG$ by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.	DDI-false
DDI-DrugBank.d362.s4.p2	In another drug interaction study, co-administration of orally inhaled @DRUG$ and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of @DRUG$ remained unchanged.	DDI-false
DDI-DrugBank.d362.s4.p3	In another drug interaction study, co-administration of orally inhaled ciclesonide and oral @DRUG$, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of @DRUG$ by approximately 3.6-fold at steady state, while levels of ciclesonide remained unchanged.	DDI-false
DDI-DrugBank.d362.s4.p4	In another drug interaction study, co-administration of orally inhaled ciclesonide and oral @DRUG$, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of des-ciclesonide by approximately 3.6-fold at steady state, while levels of @DRUG$ remained unchanged.	DDI-false
DDI-DrugBank.d362.s4.p5	In another drug interaction study, co-administration of orally inhaled ciclesonide and oral ketoconazole, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of @DRUG$ by approximately 3.6-fold at steady state, while levels of @DRUG$ remained unchanged.	DDI-false
DDI-DrugBank.d362.s5.p0	Therefore, @DRUG$ should be administered with caution with intranasal @DRUG$.	DDI-advise
DDI-DrugBank.d363.s2.p0	Like @DRUG$, @DRUG$ does not predispose to premature ventricular arrhythmias in the presence of exogenously infused epinephrine in swine.	DDI-false
DDI-DrugBank.d363.s2.p1	Like @DRUG$, desflurane does not predispose to premature ventricular arrhythmias in the presence of exogenously infused @DRUG$ in swine.	DDI-false
DDI-DrugBank.d363.s2.p2	Like isoflurane, @DRUG$ does not predispose to premature ventricular arrhythmias in the presence of exogenously infused @DRUG$ in swine.	DDI-false
DDI-DrugBank.d364.s0.p0	Because @DRUG$ is metabolized by a variety of hepatic CYP drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d364.s10.p0	Coadministration of @DRUG$ and strong CYP3A4 inhibitors, such as @DRUG$, telithromycin, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.	DDI-advise
DDI-DrugBank.d364.s10.p1	Coadministration of @DRUG$ and strong CYP3A4 inhibitors, such as clarithromycin, @DRUG$, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.	DDI-advise
DDI-DrugBank.d364.s10.p2	Coadministration of @DRUG$ and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, @DRUG$, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.	DDI-advise
DDI-DrugBank.d364.s10.p3	Coadministration of @DRUG$ and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, @DRUG$, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.	DDI-advise
DDI-DrugBank.d364.s10.p4	Coadministration of @DRUG$ and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, voriconazole, and @DRUG$ has not been evaluated but should be undertaken with caution because of similar potential drug interactions.	DDI-advise
DDI-DrugBank.d364.s10.p5	Coadministration of alosetron and strong CYP3A4 inhibitors, such as @DRUG$, @DRUG$, protease inhibitors, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.	DDI-false
DDI-DrugBank.d364.s10.p6	Coadministration of alosetron and strong CYP3A4 inhibitors, such as @DRUG$, telithromycin, @DRUG$, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.	DDI-false
DDI-DrugBank.d364.s10.p7	Coadministration of alosetron and strong CYP3A4 inhibitors, such as @DRUG$, telithromycin, protease inhibitors, @DRUG$, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.	DDI-false
DDI-DrugBank.d364.s10.p8	Coadministration of alosetron and strong CYP3A4 inhibitors, such as @DRUG$, telithromycin, protease inhibitors, voriconazole, and @DRUG$ has not been evaluated but should be undertaken with caution because of similar potential drug interactions.	DDI-false
DDI-DrugBank.d364.s10.p9	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, @DRUG$, @DRUG$, voriconazole, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.	DDI-false
DDI-DrugBank.d364.s10.p10	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, @DRUG$, protease inhibitors, @DRUG$, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.	DDI-false
DDI-DrugBank.d364.s10.p11	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, @DRUG$, protease inhibitors, voriconazole, and @DRUG$ has not been evaluated but should be undertaken with caution because of similar potential drug interactions.	DDI-false
DDI-DrugBank.d364.s10.p12	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, @DRUG$, @DRUG$, and itraconazole has not been evaluated but should be undertaken with caution because of similar potential drug interactions.	DDI-false
DDI-DrugBank.d364.s10.p13	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, @DRUG$, voriconazole, and @DRUG$ has not been evaluated but should be undertaken with caution because of similar potential drug interactions.	DDI-false
DDI-DrugBank.d364.s10.p14	Coadministration of alosetron and strong CYP3A4 inhibitors, such as clarithromycin, telithromycin, protease inhibitors, @DRUG$, and @DRUG$ has not been evaluated but should be undertaken with caution because of similar potential drug interactions.	DDI-false
DDI-DrugBank.d364.s15.p0	Although not studied with @DRUG$, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as @DRUG$, procainamide, and hydralazine.	DDI-effect
DDI-DrugBank.d364.s15.p1	Although not studied with @DRUG$, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, @DRUG$, and hydralazine.	DDI-effect
DDI-DrugBank.d364.s15.p2	Although not studied with @DRUG$, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, procainamide, and @DRUG$.	DDI-effect
DDI-DrugBank.d364.s15.p3	Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as @DRUG$, @DRUG$, and hydralazine.	DDI-false
DDI-DrugBank.d364.s15.p4	Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as @DRUG$, procainamide, and @DRUG$.	DDI-false
DDI-DrugBank.d364.s15.p5	Although not studied with alosetron, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as isoniazid, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d364.s18.p0	A clinical interaction study was also conducted with @DRUG$ and the CYP3A4 substrate @DRUG$.	DDI-false
DDI-DrugBank.d364.s8.p0	@DRUG$ increased mean @DRUG$ plasma concentrations (AUC) by 29%.	DDI-mechanism
DDI-DrugBank.d367.s3.p0	@DRUG$ has been administered without any evidence of an adverse drug interaction to patients receiving @DRUG$, beta-blocking agents, and nonsteroidal anti-inflammatory drugs.	DDI-false
DDI-DrugBank.d367.s3.p1	@DRUG$ has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, @DRUG$s, and nonsteroidal anti-inflammatory drugs.	DDI-false
DDI-DrugBank.d367.s3.p2	@DRUG$ has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, beta-blocking agents, and @DRUG$.	DDI-false
DDI-DrugBank.d367.s3.p3	Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving @DRUG$, @DRUG$s, and nonsteroidal anti-inflammatory drugs.	DDI-false
DDI-DrugBank.d367.s3.p4	Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving @DRUG$, beta-blocking agents, and @DRUG$.	DDI-false
DDI-DrugBank.d367.s3.p5	Doxazosin mesylate has been administered without any evidence of an adverse drug interaction to patients receiving thiazide diuretics, @DRUG$s, and @DRUG$.	DDI-false
DDI-DrugBank.d367.s4.p0	In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of @DRUG$ on day 1 of a four-day regimen of oral @DRUG$ (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.	DDI-mechanism
DDI-DrugBank.d367.s4.p1	In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of @DRUG$ on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of @DRUG$ (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.	DDI-false
DDI-DrugBank.d367.s4.p2	In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of @DRUG$ on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of @DRUG$.	DDI-false
DDI-DrugBank.d367.s4.p3	In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral @DRUG$ (400 mg twice daily) resulted in a 10% increase in mean AUC of @DRUG$ (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin.	DDI-false
DDI-DrugBank.d367.s4.p4	In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral @DRUG$ (400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of @DRUG$.	DDI-false
DDI-DrugBank.d367.s4.p5	In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral cimetidine (400 mg twice daily) resulted in a 10% increase in mean AUC of @DRUG$ (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of @DRUG$.	DDI-false
DDI-DrugBank.d368.s11.p0	@DRUG$ may prevent the urinary antiseptic effect of @DRUG$.	DDI-effect
DDI-DrugBank.d371.s1.p0	In vitro studies have shown that the metabolism of @DRUG$ may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as @DRUG$, terfenadine, ketoconazole, erythromycin, and troleandomycin.	DDI-mechanism
DDI-DrugBank.d371.s1.p1	In vitro studies have shown that the metabolism of @DRUG$ may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, @DRUG$, ketoconazole, erythromycin, and troleandomycin.	DDI-mechanism
DDI-DrugBank.d371.s1.p2	In vitro studies have shown that the metabolism of @DRUG$ may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, @DRUG$, erythromycin, and troleandomycin.	DDI-mechanism
DDI-DrugBank.d371.s1.p3	In vitro studies have shown that the metabolism of @DRUG$ may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, @DRUG$, and troleandomycin.	DDI-mechanism
DDI-DrugBank.d371.s1.p4	In vitro studies have shown that the metabolism of @DRUG$ may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and @DRUG$.	DDI-mechanism
DDI-DrugBank.d371.s1.p5	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as @DRUG$, @DRUG$, ketoconazole, erythromycin, and troleandomycin.	DDI-false
DDI-DrugBank.d371.s1.p6	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as @DRUG$, terfenadine, @DRUG$, erythromycin, and troleandomycin.	DDI-false
DDI-DrugBank.d371.s1.p7	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as @DRUG$, terfenadine, ketoconazole, @DRUG$, and troleandomycin.	DDI-false
DDI-DrugBank.d371.s1.p8	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as @DRUG$, terfenadine, ketoconazole, erythromycin, and @DRUG$.	DDI-false
DDI-DrugBank.d371.s1.p9	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, @DRUG$, @DRUG$, erythromycin, and troleandomycin.	DDI-false
DDI-DrugBank.d371.s1.p10	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, @DRUG$, ketoconazole, @DRUG$, and troleandomycin.	DDI-false
DDI-DrugBank.d371.s1.p11	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, @DRUG$, ketoconazole, erythromycin, and @DRUG$.	DDI-false
DDI-DrugBank.d371.s1.p12	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, @DRUG$, @DRUG$, and troleandomycin.	DDI-false
DDI-DrugBank.d371.s1.p13	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, @DRUG$, erythromycin, and @DRUG$.	DDI-false
DDI-DrugBank.d371.s1.p14	In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d373.s1.p0	Long Acting @DRUG$: @DRUG$ may be safely co-administered with nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.	DDI-false
DDI-DrugBank.d373.s1.p1	Long Acting @DRUG$: Nifedipine may be safely co-administered with @DRUG$, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.	DDI-false
DDI-DrugBank.d373.s1.p2	Long Acting Nitrates: @DRUG$ may be safely co-administered with @DRUG$, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.	DDI-false
DDI-DrugBank.d373.s13.p0	The effect may be mediated by the known inhibition of @DRUG$ on hepatic cytochrome P-450, the enzyme system probably responsible for the first-pass metabolism of @DRUG$.	DDI-false
DDI-DrugBank.d376.s0.p0	May interact with addictive medications, especially @DRUG$ with habituating potential (prolonged concurrent use may increase the risk of habituation), @DRUG$ or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or ethinamate).	DDI-false
DDI-DrugBank.d376.s0.p1	May interact with addictive medications, especially @DRUG$ with habituating potential (prolonged concurrent use may increase the risk of habituation), alcohol or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or @DRUG$).	DDI-false
DDI-DrugBank.d376.s0.p2	May interact with addictive medications, especially central nervous system (CNS) depressants with habituating potential (prolonged concurrent use may increase the risk of habituation), @DRUG$ or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or @DRUG$).	DDI-false
DDI-DrugBank.d377.s0.p0	@DRUG$ potentiates other @DRUG$ such as succinylcholine or organophosphate and carbamate insecticides.	DDI-effect
DDI-DrugBank.d377.s0.p1	@DRUG$ potentiates other cholinesterase inhibitors such as @DRUG$ or organophosphate and carbamate insecticides.	DDI-effect
DDI-DrugBank.d377.s0.p2	@DRUG$ potentiates other cholinesterase inhibitors such as succinylcholine or @DRUG$s.	DDI-effect
DDI-DrugBank.d377.s0.p3	@DRUG$ potentiates other cholinesterase inhibitors such as succinylcholine or organophosphate and @DRUG$s.	DDI-effect
DDI-DrugBank.d377.s0.p4	Phospholine Iodide potentiates other @DRUG$ such as @DRUG$ or organophosphate and carbamate insecticides.	DDI-false
DDI-DrugBank.d377.s0.p5	Phospholine Iodide potentiates other @DRUG$ such as succinylcholine or @DRUG$s.	DDI-false
DDI-DrugBank.d377.s0.p6	Phospholine Iodide potentiates other @DRUG$ such as succinylcholine or organophosphate and @DRUG$s.	DDI-false
DDI-DrugBank.d377.s0.p7	Phospholine Iodide potentiates other cholinesterase inhibitors such as @DRUG$ or @DRUG$s.	DDI-false
DDI-DrugBank.d377.s0.p8	Phospholine Iodide potentiates other cholinesterase inhibitors such as @DRUG$ or organophosphate and @DRUG$s.	DDI-false
DDI-DrugBank.d377.s0.p9	Phospholine Iodide potentiates other cholinesterase inhibitors such as succinylcholine or @DRUG-DRUG$s.	DDI-false
DDI-DrugBank.d379.s1.p0	It is, however, possible that concomitant use of other known @DRUG$ such as @DRUG$, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p1	It is, however, possible that concomitant use of other known @DRUG$ such as griseofulvin, @DRUG$, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p2	It is, however, possible that concomitant use of other known @DRUG$ such as griseofulvin, thiazide diuretics, @DRUG$, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p3	It is, however, possible that concomitant use of other known @DRUG$ such as griseofulvin, thiazide diuretics, sulfonylureas, @DRUG$, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p4	It is, however, possible that concomitant use of other known @DRUG$ such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, @DRUG$ and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p5	It is, however, possible that concomitant use of other known @DRUG$ such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and @DRUG$ might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p6	It is, however, possible that concomitant use of other known @DRUG$ such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.	DDI-effect
DDI-DrugBank.d379.s1.p7	It is, however, possible that concomitant use of other known photosensitizing agents such as @DRUG$, @DRUG$, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p8	It is, however, possible that concomitant use of other known photosensitizing agents such as @DRUG$, thiazide diuretics, @DRUG$, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p9	It is, however, possible that concomitant use of other known photosensitizing agents such as @DRUG$, thiazide diuretics, sulfonylureas, @DRUG$, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p10	It is, however, possible that concomitant use of other known photosensitizing agents such as @DRUG$, thiazide diuretics, sulfonylureas, phenothiazines, @DRUG$ and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p11	It is, however, possible that concomitant use of other known photosensitizing agents such as @DRUG$, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and @DRUG$ might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p12	It is, however, possible that concomitant use of other known photosensitizing agents such as @DRUG$, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.	DDI-effect
DDI-DrugBank.d379.s1.p13	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, @DRUG$, @DRUG$, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p14	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, @DRUG$, sulfonylureas, @DRUG$, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p15	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, @DRUG$, sulfonylureas, phenothiazines, @DRUG$ and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p16	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, @DRUG$, sulfonylureas, phenothiazines, sulfonamides and @DRUG$ might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p17	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, @DRUG$, sulfonylureas, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.	DDI-effect
DDI-DrugBank.d379.s1.p18	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, @DRUG$, @DRUG$, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p19	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, @DRUG$, phenothiazines, @DRUG$ and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p20	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, @DRUG$, phenothiazines, sulfonamides and @DRUG$ might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p21	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, @DRUG$, phenothiazines, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.	DDI-effect
DDI-DrugBank.d379.s1.p22	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, @DRUG$, @DRUG$ and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p23	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, @DRUG$, sulfonamides and @DRUG$ might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p24	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, @DRUG$, sulfonamides and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.	DDI-effect
DDI-DrugBank.d379.s1.p25	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, @DRUG$ and @DRUG$ might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.	DDI-false
DDI-DrugBank.d379.s1.p26	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, @DRUG$ and tetracyclines might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.	DDI-effect
DDI-DrugBank.d379.s1.p27	It is, however, possible that concomitant use of other known photosensitizing agents such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and @DRUG$ might increase the photosensitivity reaction of actinic keratoses treated with the @DRUG$ for Topical Solution.	DDI-effect
DDI-DrugBank.d380.s3.p0	Based on anecdotal reports, there may be an interaction between @DRUG$ and @DRUG$.	DDI-int
DDI-DrugBank.d380.s4.p0	There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of @DRUG$ and @DRUG$ by addicts.	DDI-effect
DDI-DrugBank.d382.s10.p0	The oral @DRUG$ doses should be reduced by approximately 50% when coadministered with @DRUG$, to achieve exposures of dexamethasone similar to those obtained when it is given without Aprepitant.	DDI-advise
DDI-DrugBank.d382.s10.p1	The oral @DRUG$ doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of @DRUG$ similar to those obtained when it is given without Aprepitant.	DDI-false
DDI-DrugBank.d382.s10.p2	The oral @DRUG$ doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of dexamethasone similar to those obtained when it is given without @DRUG$.	DDI-false
DDI-DrugBank.d382.s10.p3	The oral dexamethasone doses should be reduced by approximately 50% when coadministered with @DRUG$, to achieve exposures of @DRUG$ similar to those obtained when it is given without Aprepitant.	DDI-false
DDI-DrugBank.d382.s10.p4	The oral dexamethasone doses should be reduced by approximately 50% when coadministered with @DRUG$, to achieve exposures of dexamethasone similar to those obtained when it is given without @DRUG$.	DDI-false
DDI-DrugBank.d382.s10.p5	The oral dexamethasone doses should be reduced by approximately 50% when coadministered with Aprepitant, to achieve exposures of @DRUG$ similar to those obtained when it is given without @DRUG$.	DDI-false
DDI-DrugBank.d382.s16.p0	Although there was no effect of @DRUG$ on the plasma AUC of @DRUG$ determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.	DDI-false
DDI-DrugBank.d382.s16.p1	Although there was no effect of @DRUG$ on the plasma AUC of R(+) or @DRUG$ determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.	DDI-false
DDI-DrugBank.d382.s16.p2	Although there was no effect of @DRUG$ on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in @DRUG$ (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.	DDI-false
DDI-DrugBank.d382.s16.p3	Although there was no effect of @DRUG$ on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with @DRUG$.	DDI-false
DDI-DrugBank.d382.s16.p4	Although there was no effect of Aprepitant on the plasma AUC of @DRUG-DRUG$ determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.	DDI-false
DDI-DrugBank.d382.s16.p5	Although there was no effect of Aprepitant on the plasma AUC of @DRUG$ determined on Day 3, there was a 34% decrease in @DRUG$ (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.	DDI-false
DDI-DrugBank.d382.s16.p6	Although there was no effect of Aprepitant on the plasma AUC of @DRUG$ determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with @DRUG$.	DDI-false
DDI-DrugBank.d382.s16.p7	Although there was no effect of Aprepitant on the plasma AUC of R(+) or @DRUG$ determined on Day 3, there was a 34% decrease in @DRUG$ (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with Aprepitant.	DDI-false
DDI-DrugBank.d382.s16.p8	Although there was no effect of Aprepitant on the plasma AUC of R(+) or @DRUG$ determined on Day 3, there was a 34% decrease in S(-)warfarin (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with @DRUG$.	DDI-false
DDI-DrugBank.d382.s16.p9	Although there was no effect of Aprepitant on the plasma AUC of R(+) or S(-) warfarin determined on Day 3, there was a 34% decrease in @DRUG$ (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with @DRUG$.	DDI-mechanism
DDI-DrugBank.d382.s17.p0	In patients on chronic @DRUG$ therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of @DRUG$ with each chemotherapy cycle.	DDI-advise
DDI-DrugBank.d382.s18.p0	@DRUG$: @DRUG$, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.	DDI-false
DDI-DrugBank.d382.s18.p1	@DRUG$: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of @DRUG$ (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.	DDI-false
DDI-DrugBank.d382.s18.p2	@DRUG$: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of @DRUG$ 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.	DDI-false
DDI-DrugBank.d382.s18.p3	@DRUG$: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of @DRUG$ and on Days 4,8, and 15.	DDI-false
DDI-DrugBank.d382.s18.p4	Tolbutamide: @DRUG$, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of @DRUG$ (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.	DDI-false
DDI-DrugBank.d382.s18.p5	Tolbutamide: @DRUG$, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of @DRUG$ 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.	DDI-false
DDI-DrugBank.d382.s18.p6	Tolbutamide: @DRUG$, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of @DRUG$ and on Days 4,8, and 15.	DDI-false
DDI-DrugBank.d382.s18.p7	Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of @DRUG$ (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of @DRUG$ 500 mg was admini,stered orally prior to the administration of the 3-day regimen of Aprepitant and on Days 4,8, and 15.	DDI-false
DDI-DrugBank.d382.s18.p8	Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of @DRUG$ (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of tolbutamide 500 mg was admini,stered orally prior to the administration of the 3-day regimen of @DRUG$ and on Days 4,8, and 15.	DDI-false
DDI-DrugBank.d382.s18.p9	Tolbutamide: Aprepitant, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of @DRUG$ 500 mg was admini,stered orally prior to the administration of the 3-day regimen of @DRUG$ and on Days 4,8, and 15.	DDI-mechanism
DDI-DrugBank.d382.s25.p0	@DRUG$ increased the AUC of @DRUG$ by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.	DDI-mechanism
DDI-DrugBank.d382.s25.p1	@DRUG$ increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of @DRUG$ by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.	DDI-mechanism
DDI-DrugBank.d382.s25.p2	@DRUG$ increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of @DRUG$ on Days 1 through 3.	DDI-false
DDI-DrugBank.d382.s25.p3	Aprepitant increased the AUC of @DRUG$ by 25% on Day 4 and decreased the AUC of @DRUG$ by 19% on Day 8 relative to the dosing of Aprepitant on Days 1 through 3.	DDI-false
DDI-DrugBank.d382.s25.p4	Aprepitant increased the AUC of @DRUG$ by 25% on Day 4 and decreased the AUC of midazolam by 19% on Day 8 relative to the dosing of @DRUG$ on Days 1 through 3.	DDI-false
DDI-DrugBank.d382.s25.p5	Aprepitant increased the AUC of midazolam by 25% on Day 4 and decreased the AUC of @DRUG$ by 19% on Day 8 relative to the dosing of @DRUG$ on Days 1 through 3.	DDI-false
DDI-DrugBank.d382.s30.p0	therefore, coadministration of @DRUG$ with drugs that inhibit CYP3A4 activity may result in increased plasma concentrations of @DRUG$.	DDI-false
DDI-DrugBank.d382.s34.p0	therefore, coadministration of @DRUG$ with drugs that strongly induce CYP3A4 activity (e.g., @DRUG$, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.	DDI-mechanism
DDI-DrugBank.d382.s34.p1	therefore, coadministration of @DRUG$ with drugs that strongly induce CYP3A4 activity (e.g., rifampin, @DRUG$, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.	DDI-false
DDI-DrugBank.d382.s34.p2	therefore, coadministration of @DRUG$ with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, @DRUG$) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.	DDI-mechanism
DDI-DrugBank.d382.s34.p3	therefore, coadministration of @DRUG$ with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of @DRUG$ that may result in decreased efficacy of Aprepitant.	DDI-mechanism
DDI-DrugBank.d382.s34.p4	therefore, coadministration of @DRUG$ with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of @DRUG$.	DDI-false
DDI-DrugBank.d382.s34.p5	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., @DRUG$, @DRUG$, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.	DDI-false
DDI-DrugBank.d382.s34.p6	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., @DRUG$, carbamazepine, @DRUG$) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.	DDI-false
DDI-DrugBank.d382.s34.p7	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., @DRUG$, carbamazepine, phenytoin) may result in reduced plasma concentrations of @DRUG$ that may result in decreased efficacy of Aprepitant.	DDI-false
DDI-DrugBank.d382.s34.p8	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., @DRUG$, carbamazepine, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of @DRUG$.	DDI-false
DDI-DrugBank.d382.s34.p9	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, @DRUG$, @DRUG$) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of Aprepitant.	DDI-false
DDI-DrugBank.d382.s34.p10	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, @DRUG$, phenytoin) may result in reduced plasma concentrations of @DRUG$ that may result in decreased efficacy of Aprepitant.	DDI-false
DDI-DrugBank.d382.s34.p11	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, @DRUG$, phenytoin) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of @DRUG$.	DDI-false
DDI-DrugBank.d382.s34.p12	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, @DRUG$) may result in reduced plasma concentrations of @DRUG$ that may result in decreased efficacy of Aprepitant.	DDI-false
DDI-DrugBank.d382.s34.p13	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, @DRUG$) may result in reduced plasma concentrations of aprepitant that may result in decreased efficacy of @DRUG$.	DDI-false
DDI-DrugBank.d382.s34.p14	therefore, coadministration of Aprepitant with drugs that strongly induce CYP3A4 activity (e.g., rifampin, carbamazepine, phenytoin) may result in reduced plasma concentrations of @DRUG$ that may result in decreased efficacy of @DRUG$.	DDI-false
DDI-DrugBank.d382.s43.p0	@DRUG$: Coadministration of once daily doses of @DRUG$, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.	DDI-false
DDI-DrugBank.d382.s43.p1	@DRUG$: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with @DRUG$ 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.	DDI-false
DDI-DrugBank.d382.s43.p2	@DRUG$: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both @DRUG$ and paroxetine.	DDI-false
DDI-DrugBank.d382.s43.p3	@DRUG$: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and @DRUG$.	DDI-false
DDI-DrugBank.d382.s43.p4	Paroxetine: Coadministration of once daily doses of @DRUG$, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with @DRUG$ 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and paroxetine.	DDI-mechanism
DDI-DrugBank.d382.s43.p5	Paroxetine: Coadministration of once daily doses of @DRUG$, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both @DRUG$ and paroxetine.	DDI-false
DDI-DrugBank.d382.s43.p6	Paroxetine: Coadministration of once daily doses of @DRUG$, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and @DRUG$.	DDI-false
DDI-DrugBank.d382.s43.p7	Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with @DRUG$ 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both @DRUG$ and paroxetine.	DDI-false
DDI-DrugBank.d382.s43.p8	Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with @DRUG$ 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both aprepitant and @DRUG$.	DDI-false
DDI-DrugBank.d382.s43.p9	Paroxetine: Coadministration of once daily doses of aprepitant, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with paroxetine 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d382.s5.p0	Coadministration of @DRUG$ with these drugs or other drugs that are known to be metabolized by CYP2C9, such as @DRUG$, may result in lower plasma concentrations of these drugs.	DDI-mechanism
DDI-DrugBank.d382.s6.p0	@DRUG$ is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of @DRUG$ with digoxin in a clinical drug interaction study.	DDI-false
DDI-DrugBank.d382.s6.p1	@DRUG$ is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of Aprepitant with @DRUG$ in a clinical drug interaction study.	DDI-false
DDI-DrugBank.d382.s6.p2	Aprepitant is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of @DRUG$ with @DRUG$ in a clinical drug interaction study.	DDI-false
DDI-DrugBank.d387.s0.p0	Potential drug interactions for @DRUG$ include, increased sedation if @DRUG$ is combined with other CNS depressant drugs.	DDI-false
DDI-DrugBank.d387.s0.p1	Potential drug interactions for @DRUG$ include, increased sedation if doxylamine is combined with other @DRUG$.	DDI-false
DDI-DrugBank.d387.s0.p2	Potential drug interactions for doxylamine include, increased sedation if @DRUG$ is combined with other @DRUG$.	DDI-effect
DDI-DrugBank.d388.s1.p0	Patients treated with @DRUG$ plus @DRUG$ should, therefore, be observed closely for evidence of marked bradycardia or hypotension which may present as vertigo, syncope/presyncope, or orthostatic changes in blood pressure without compensatory tachycardia.	DDI-advise
DDI-DrugBank.d388.s5.p0	No significant interactions with @DRUG$, @DRUG$, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.	DDI-false
DDI-DrugBank.d388.s5.p1	No significant interactions with @DRUG$, hydrochlorothiazide, @DRUG$, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.	DDI-false
DDI-DrugBank.d388.s5.p2	No significant interactions with @DRUG$, hydrochlorothiazide, hydralazine, @DRUG$, oral contraceptives, tolbutamide, or warfarin have been observed.	DDI-false
DDI-DrugBank.d388.s5.p3	No significant interactions with @DRUG$, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral @DRUG$, tolbutamide, or warfarin have been observed.	DDI-false
DDI-DrugBank.d388.s5.p4	No significant interactions with @DRUG$, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, @DRUG$, or warfarin have been observed.	DDI-false
DDI-DrugBank.d388.s5.p5	No significant interactions with @DRUG$, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or @DRUG$ have been observed.	DDI-false
DDI-DrugBank.d388.s5.p6	No significant interactions with digoxin, @DRUG$, @DRUG$, sulfinpyrazone, oral contraceptives, tolbutamide, or warfarin have been observed.	DDI-false
DDI-DrugBank.d388.s5.p7	No significant interactions with digoxin, @DRUG$, hydralazine, @DRUG$, oral contraceptives, tolbutamide, or warfarin have been observed.	DDI-false
DDI-DrugBank.d388.s5.p8	No significant interactions with digoxin, @DRUG$, hydralazine, sulfinpyrazone, oral @DRUG$, tolbutamide, or warfarin have been observed.	DDI-false
DDI-DrugBank.d388.s5.p9	No significant interactions with digoxin, @DRUG$, hydralazine, sulfinpyrazone, oral contraceptives, @DRUG$, or warfarin have been observed.	DDI-false
DDI-DrugBank.d388.s5.p10	No significant interactions with digoxin, @DRUG$, hydralazine, sulfinpyrazone, oral contraceptives, tolbutamide, or @DRUG$ have been observed.	DDI-false
DDI-DrugBank.d388.s5.p11	No significant interactions with digoxin, hydrochlorothiazide, @DRUG$, @DRUG$, oral contraceptives, tolbutamide, or warfarin have been observed.	DDI-false
DDI-DrugBank.d388.s5.p12	No significant interactions with digoxin, hydrochlorothiazide, @DRUG$, sulfinpyrazone, oral @DRUG$, tolbutamide, or warfarin have been observed.	DDI-false
DDI-DrugBank.d388.s5.p13	No significant interactions with digoxin, hydrochlorothiazide, @DRUG$, sulfinpyrazone, oral contraceptives, @DRUG$, or warfarin have been observed.	DDI-false
DDI-DrugBank.d388.s5.p14	No significant interactions with digoxin, hydrochlorothiazide, @DRUG$, sulfinpyrazone, oral contraceptives, tolbutamide, or @DRUG$ have been observed.	DDI-false
DDI-DrugBank.d388.s5.p15	No significant interactions with digoxin, hydrochlorothiazide, hydralazine, @DRUG$, oral @DRUG$, tolbutamide, or warfarin have been observed.	DDI-false
DDI-DrugBank.d388.s5.p16	No significant interactions with digoxin, hydrochlorothiazide, hydralazine, @DRUG$, oral contraceptives, @DRUG$, or warfarin have been observed.	DDI-false
DDI-DrugBank.d388.s5.p17	No significant interactions with digoxin, hydrochlorothiazide, hydralazine, @DRUG$, oral contraceptives, tolbutamide, or @DRUG$ have been observed.	DDI-false
DDI-DrugBank.d388.s5.p18	No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral @DRUG$, @DRUG$, or warfarin have been observed.	DDI-false
DDI-DrugBank.d388.s5.p19	No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral @DRUG$, tolbutamide, or @DRUG$ have been observed.	DDI-false
DDI-DrugBank.d388.s5.p20	No significant interactions with digoxin, hydrochlorothiazide, hydralazine, sulfinpyrazone, oral contraceptives, @DRUG$, or @DRUG$ have been observed.	DDI-false
DDI-DrugBank.d389.s1.p0	@DRUG$ prolong and intensify the anticholinergic effects of @DRUG$.	DDI-effect
DDI-DrugBank.d389.s3.p0	Effects of @DRUG$ are increased with @DRUG$ and beta adrenergic blockers.	DDI-effect
DDI-DrugBank.d389.s3.p1	Effects of @DRUG$ are increased with MAO inhibitors and @DRUG$.	DDI-effect
DDI-DrugBank.d389.s3.p2	Effects of sympathomimetics are increased with @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d393.s0.p0	Pharmacokinetic interaction studies with @DRUG$ in adults were conducted with @DRUG$, antipyrine, ketoconazole, erythromycin and azithromycin.	DDI-false
DDI-DrugBank.d393.s0.p1	Pharmacokinetic interaction studies with @DRUG$ in adults were conducted with pseudoephedrine, @DRUG$, ketoconazole, erythromycin and azithromycin.	DDI-false
DDI-DrugBank.d393.s0.p2	Pharmacokinetic interaction studies with @DRUG$ in adults were conducted with pseudoephedrine, antipyrine, @DRUG$, erythromycin and azithromycin.	DDI-false
DDI-DrugBank.d393.s0.p3	Pharmacokinetic interaction studies with @DRUG$ in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, @DRUG$ and azithromycin.	DDI-false
DDI-DrugBank.d393.s0.p4	Pharmacokinetic interaction studies with @DRUG$ in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, erythromycin and @DRUG$.	DDI-false
DDI-DrugBank.d393.s0.p5	Pharmacokinetic interaction studies with cetirizine in adults were conducted with @DRUG$, @DRUG$, ketoconazole, erythromycin and azithromycin.	DDI-false
DDI-DrugBank.d393.s0.p6	Pharmacokinetic interaction studies with cetirizine in adults were conducted with @DRUG$, antipyrine, @DRUG$, erythromycin and azithromycin.	DDI-false
DDI-DrugBank.d393.s0.p7	Pharmacokinetic interaction studies with cetirizine in adults were conducted with @DRUG$, antipyrine, ketoconazole, @DRUG$ and azithromycin.	DDI-false
DDI-DrugBank.d393.s0.p8	Pharmacokinetic interaction studies with cetirizine in adults were conducted with @DRUG$, antipyrine, ketoconazole, erythromycin and @DRUG$.	DDI-false
DDI-DrugBank.d393.s0.p9	Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, @DRUG$, @DRUG$, erythromycin and azithromycin.	DDI-false
DDI-DrugBank.d393.s0.p10	Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, @DRUG$, ketoconazole, @DRUG$ and azithromycin.	DDI-false
DDI-DrugBank.d393.s0.p11	Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, @DRUG$, ketoconazole, erythromycin and @DRUG$.	DDI-false
DDI-DrugBank.d393.s0.p12	Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, @DRUG$, @DRUG$ and azithromycin.	DDI-false
DDI-DrugBank.d393.s0.p13	Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, @DRUG$, erythromycin and @DRUG$.	DDI-false
DDI-DrugBank.d393.s0.p14	Pharmacokinetic interaction studies with cetirizine in adults were conducted with pseudoephedrine, antipyrine, ketoconazole, @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d393.s3.p0	The disposition of @DRUG$ was not altered by concomitant @DRUG$ administration.	DDI-false
DDI-DrugBank.d395.s2.p0	@DRUG$: @DRUG$ is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of methylxanthines.	DDI-false
DDI-DrugBank.d395.s2.p1	@DRUG$: Enoxacin is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of @DRUG$.	DDI-false
DDI-DrugBank.d395.s2.p2	Caffeine: @DRUG$ is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of @DRUG$.	DDI-mechanism
DDI-DrugBank.d395.s25.p0	Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when @DRUG$ or its derivatives and @DRUG$ are given concomitantly.	DDI-advise
DDI-DrugBank.d395.s6.p0	@DRUG$: Elevated serum levels of @DRUG$ have been reported with concomitant use of cyclosporine with other members of the quinolone class.	DDI-false
DDI-DrugBank.d395.s6.p1	@DRUG$: Elevated serum levels of cyclosporine have been reported with concomitant use of @DRUG$ with other members of the quinolone class.	DDI-false
DDI-DrugBank.d395.s6.p2	@DRUG$: Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with other members of the @DRUG$.	DDI-false
DDI-DrugBank.d395.s6.p3	Cyclosporine: Elevated serum levels of @DRUG$ have been reported with concomitant use of @DRUG$ with other members of the quinolone class.	DDI-false
DDI-DrugBank.d395.s6.p4	Cyclosporine: Elevated serum levels of @DRUG$ have been reported with concomitant use of cyclosporine with other members of the @DRUG$.	DDI-false
DDI-DrugBank.d395.s6.p5	Cyclosporine: Elevated serum levels of cyclosporine have been reported with concomitant use of @DRUG$ with other members of the @DRUG$.	DDI-mechanism
DDI-DrugBank.d395.s8.p0	If signs and symptoms suggestive of @DRUG$ toxicity occur when @DRUG$ and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.	DDI-false
DDI-DrugBank.d395.s8.p1	If signs and symptoms suggestive of @DRUG$ toxicity occur when enoxacin and @DRUG$ are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.	DDI-false
DDI-DrugBank.d395.s8.p2	If signs and symptoms suggestive of @DRUG$ toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum @DRUG$ levels and adjust digoxin doses appropriately.	DDI-false
DDI-DrugBank.d395.s8.p3	If signs and symptoms suggestive of @DRUG$ toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust @DRUG$ doses appropriately.	DDI-false
DDI-DrugBank.d395.s8.p4	If signs and symptoms suggestive of digoxin toxicity occur when @DRUG$ and @DRUG$ are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust digoxin doses appropriately.	DDI-effect
DDI-DrugBank.d395.s8.p5	If signs and symptoms suggestive of digoxin toxicity occur when @DRUG$ and digoxin are given concomitantly, physicians are advised to obtain serum @DRUG$ levels and adjust digoxin doses appropriately.	DDI-false
DDI-DrugBank.d395.s8.p6	If signs and symptoms suggestive of digoxin toxicity occur when @DRUG$ and digoxin are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust @DRUG$ doses appropriately.	DDI-false
DDI-DrugBank.d395.s8.p7	If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and @DRUG$ are given concomitantly, physicians are advised to obtain serum @DRUG$ levels and adjust digoxin doses appropriately.	DDI-false
DDI-DrugBank.d395.s8.p8	If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and @DRUG$ are given concomitantly, physicians are advised to obtain serum digoxin levels and adjust @DRUG$ doses appropriately.	DDI-false
DDI-DrugBank.d395.s8.p9	If signs and symptoms suggestive of digoxin toxicity occur when enoxacin and digoxin are given concomitantly, physicians are advised to obtain serum @DRUG$ levels and adjust @DRUG$ doses appropriately.	DDI-false
DDI-DrugBank.d396.s0.p0	Patients receiving other @DRUG$, @DRUG$, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.	DDI-false
DDI-DrugBank.d396.s0.p1	Patients receiving other @DRUG$, antipsychotics, @DRUG$, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.	DDI-false
DDI-DrugBank.d396.s0.p2	Patients receiving other @DRUG$, antipsychotics, antianxiety agents, or other @DRUG$ (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.	DDI-false
DDI-DrugBank.d396.s0.p3	Patients receiving other @DRUG$, antipsychotics, antianxiety agents, or other CNS depressants (including @DRUG$) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.	DDI-false
DDI-DrugBank.d396.s0.p4	Patients receiving other @DRUG$, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with @DRUG$ and acetaminophen tablets may exhibit an additive CNS depression.	DDI-effect
DDI-DrugBank.d396.s0.p5	Patients receiving other @DRUG$, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and @DRUG$ tablets may exhibit an additive CNS depression.	DDI-false
DDI-DrugBank.d396.s0.p6	Patients receiving other narcotic analgesics, @DRUG$, @DRUG$, or other CNS depressants (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.	DDI-false
DDI-DrugBank.d396.s0.p7	Patients receiving other narcotic analgesics, @DRUG$, antianxiety agents, or other @DRUG$ (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.	DDI-false
DDI-DrugBank.d396.s0.p8	Patients receiving other narcotic analgesics, @DRUG$, antianxiety agents, or other CNS depressants (including @DRUG$) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.	DDI-false
DDI-DrugBank.d396.s0.p9	Patients receiving other narcotic analgesics, @DRUG$, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with @DRUG$ and acetaminophen tablets may exhibit an additive CNS depression.	DDI-effect
DDI-DrugBank.d396.s0.p10	Patients receiving other narcotic analgesics, @DRUG$, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone and @DRUG$ tablets may exhibit an additive CNS depression.	DDI-false
DDI-DrugBank.d396.s0.p11	Patients receiving other narcotic analgesics, antipsychotics, @DRUG$, or other @DRUG$ (including alcohol) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.	DDI-false
DDI-DrugBank.d396.s0.p12	Patients receiving other narcotic analgesics, antipsychotics, @DRUG$, or other CNS depressants (including @DRUG$) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.	DDI-false
DDI-DrugBank.d396.s0.p13	Patients receiving other narcotic analgesics, antipsychotics, @DRUG$, or other CNS depressants (including alcohol) concomitantly with @DRUG$ and acetaminophen tablets may exhibit an additive CNS depression.	DDI-effect
DDI-DrugBank.d396.s0.p14	Patients receiving other narcotic analgesics, antipsychotics, @DRUG$, or other CNS depressants (including alcohol) concomitantly with hydrocodone and @DRUG$ tablets may exhibit an additive CNS depression.	DDI-false
DDI-DrugBank.d396.s0.p15	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other @DRUG$ (including @DRUG$) concomitantly with hydrocodone and acetaminophen tablets may exhibit an additive CNS depression.	DDI-false
DDI-DrugBank.d396.s0.p16	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other @DRUG$ (including alcohol) concomitantly with @DRUG$ and acetaminophen tablets may exhibit an additive CNS depression.	DDI-effect
DDI-DrugBank.d396.s0.p17	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other @DRUG$ (including alcohol) concomitantly with hydrocodone and @DRUG$ tablets may exhibit an additive CNS depression.	DDI-false
DDI-DrugBank.d396.s0.p18	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including @DRUG$) concomitantly with @DRUG$ and acetaminophen tablets may exhibit an additive CNS depression.	DDI-effect
DDI-DrugBank.d396.s0.p19	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including @DRUG$) concomitantly with hydrocodone and @DRUG$ tablets may exhibit an additive CNS depression.	DDI-false
DDI-DrugBank.d396.s0.p20	Patients receiving other narcotic analgesics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with @DRUG$ and @DRUG$ tablets may exhibit an additive CNS depression.	DDI-false
DDI-DrugBank.d396.s3.p0	The concurrent use of @DRUG$ with @DRUG$ may produce paralytic ileus.	DDI-effect
DDI-DrugBank.d397.s10.p0	@DRUG$ has been reported to significantly alter the metabolism of nonsedating @DRUG$ terfenadine and astemizole when taken concomitantly.	DDI-false
DDI-DrugBank.d397.s10.p1	@DRUG$ has been reported to significantly alter the metabolism of nonsedating antihistamines @DRUG$ and astemizole when taken concomitantly.	DDI-mechanism
DDI-DrugBank.d397.s10.p2	@DRUG$ has been reported to significantly alter the metabolism of nonsedating antihistamines terfenadine and @DRUG$ when taken concomitantly.	DDI-mechanism
DDI-DrugBank.d397.s10.p3	Erythromycin has been reported to significantly alter the metabolism of nonsedating @DRUG$ @DRUG$ and astemizole when taken concomitantly.	DDI-false
DDI-DrugBank.d397.s10.p4	Erythromycin has been reported to significantly alter the metabolism of nonsedating @DRUG$ terfenadine and @DRUG$ when taken concomitantly.	DDI-false
DDI-DrugBank.d397.s10.p5	Erythromycin has been reported to significantly alter the metabolism of nonsedating antihistamines @DRUG$ and @DRUG$ when taken concomitantly.	DDI-false
DDI-DrugBank.d397.s2.p0	Concomitant administration of @DRUG$ and @DRUG$ has been reported to result in elevated digoxin serum levels.	DDI-mechanism
DDI-DrugBank.d397.s2.p1	Concomitant administration of @DRUG$ and digoxin has been reported to result in elevated @DRUG$ serum levels.	DDI-false
DDI-DrugBank.d397.s2.p2	Concomitant administration of erythromycin and @DRUG$ has been reported to result in elevated @DRUG$ serum levels.	DDI-false
DDI-DrugBank.d397.s8.p0	There have been reports of interactions of @DRUG$ with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-int
DDI-DrugBank.d397.s8.p1	There have been reports of interactions of @DRUG$ with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-int
DDI-DrugBank.d397.s8.p2	There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-int
DDI-DrugBank.d397.s8.p3	There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-int
DDI-DrugBank.d397.s8.p4	There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-int
DDI-DrugBank.d397.s8.p5	There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-int
DDI-DrugBank.d397.s8.p6	There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-int
DDI-DrugBank.d397.s8.p7	There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-int
DDI-DrugBank.d397.s8.p8	There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.	DDI-int
DDI-DrugBank.d397.s8.p9	There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.	DDI-int
DDI-DrugBank.d397.s8.p10	There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.	DDI-int
DDI-DrugBank.d397.s8.p11	There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.	DDI-int
DDI-DrugBank.d397.s8.p12	There have been reports of interactions of @DRUG$ with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.	DDI-int
DDI-DrugBank.d397.s8.p13	There have been reports of interactions of erythromycin with @DRUG$, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p14	There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p15	There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p16	There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p17	There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p18	There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p19	There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p20	There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p21	There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p22	There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p23	There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p24	There have been reports of interactions of erythromycin with @DRUG$, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.	DDI-false
DDI-DrugBank.d397.s8.p25	There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p26	There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p27	There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p28	There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p29	There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p30	There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p31	There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p32	There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p33	There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p34	There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p35	There have been reports of interactions of erythromycin with carbamazepine, @DRUG$, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.	DDI-false
DDI-DrugBank.d397.s8.p36	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p37	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p38	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p39	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p40	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p41	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p42	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p43	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p44	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p45	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, @DRUG$, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.	DDI-false
DDI-DrugBank.d397.s8.p46	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p47	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p48	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p49	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p50	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p51	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p52	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p53	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p54	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, @DRUG$, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.	DDI-false
DDI-DrugBank.d397.s8.p55	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p56	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p57	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p58	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p59	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p60	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p61	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p62	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, @DRUG$, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.	DDI-false
DDI-DrugBank.d397.s8.p63	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p64	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p65	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p66	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p67	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p68	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p69	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, @DRUG$, cisapride, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.	DDI-false
DDI-DrugBank.d397.s8.p70	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p71	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p72	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p73	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p74	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p75	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, @DRUG$, disopyramide, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.	DDI-false
DDI-DrugBank.d397.s8.p76	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, @DRUG$, bromocriptine, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p77	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, @DRUG$, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p78	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, @DRUG$, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p79	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, @DRUG$, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p80	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, @DRUG$, lovastatin, bromocriptine, valproate, terfenadine, and @DRUG$.	DDI-false
DDI-DrugBank.d397.s8.p81	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, @DRUG$, valproate, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p82	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, @DRUG$, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p83	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, @DRUG$, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p84	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, @DRUG$, bromocriptine, valproate, terfenadine, and @DRUG$.	DDI-false
DDI-DrugBank.d397.s8.p85	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, @DRUG$, terfenadine, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p86	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, @DRUG$, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p87	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, @DRUG$, valproate, terfenadine, and @DRUG$.	DDI-false
DDI-DrugBank.d397.s8.p88	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, @DRUG$, and astemizole.	DDI-false
DDI-DrugBank.d397.s8.p89	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, @DRUG$, terfenadine, and @DRUG$.	DDI-false
DDI-DrugBank.d397.s8.p90	There have been reports of interactions of erythromycin with carbamazepine, cyclosporine, tacrolimus, hexobarbital, phenytoin, alfentanil, cisapride, disopyramide, lovastatin, bromocriptine, valproate, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d40.s15.p0	Similarly, the effects of @DRUG$ on @DRUG$, valproic acid and sodium plasma valproate concentrations are unpredictable	DDI-effect
DDI-DrugBank.d40.s15.p1	Similarly, the effects of @DRUG$ on phenobarbital, @DRUG$ and sodium plasma valproate concentrations are unpredictable	DDI-effect
DDI-DrugBank.d40.s15.p2	Similarly, the effects of @DRUG$ on phenobarbital, valproic acid and sodium plasma @DRUG$ concentrations are unpredictable	DDI-effect
DDI-DrugBank.d40.s15.p3	Similarly, the effects of phenytoin on @DRUG$, @DRUG$ and sodium plasma valproate concentrations are unpredictable	DDI-false
DDI-DrugBank.d40.s15.p4	Similarly, the effects of phenytoin on @DRUG$, valproic acid and sodium plasma @DRUG$ concentrations are unpredictable	DDI-false
DDI-DrugBank.d40.s15.p5	Similarly, the effects of phenytoin on phenobarbital, @DRUG$ and sodium plasma @DRUG$ concentrations are unpredictable	DDI-false
DDI-DrugBank.d40.s5.p0	The most significant drug interactions following administration of @DRUG$ are expected to occur with drugs that interact with @DRUG$.	DDI-false
DDI-DrugBank.d400.s12.p0	Thus, when @DRUG$ and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.	DDI-advise
DDI-DrugBank.d400.s12.p1	Thus, when @DRUG$ and lithium are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.	DDI-false
DDI-DrugBank.d400.s12.p2	Thus, when NSAIDs and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.	DDI-false
DDI-DrugBank.d400.s13.p0	@DRUG$: The effects of @DRUG$ and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.	DDI-false
DDI-DrugBank.d400.s13.p1	@DRUG$: The effects of warfarin and @DRUG$ on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.	DDI-false
DDI-DrugBank.d400.s13.p2	Warfarin: The effects of @DRUG$ and @DRUG$ on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone.	DDI-effect
DDI-DrugBank.d404.s10.p0	However, in vivo drug interaction studies of @DRUG$ with @DRUG$ have not been investigated.	DDI-false
DDI-DrugBank.d404.s4.p0	@DRUG$: @DRUG$ are known to induce hypercalcemia by the reduction of calcium excretion in urine.	DDI-false
DDI-DrugBank.d404.s8.p0	@DRUG$: @DRUG$ may inhibit both synthetic and catabolic enzymes of vitamin D.	DDI-false
DDI-DrugBank.d404.s8.p1	@DRUG$: Ketoconazole may inhibit both synthetic and catabolic enzymes of @DRUG$.	DDI-false
DDI-DrugBank.d404.s8.p2	Ketoconazole: @DRUG$ may inhibit both synthetic and catabolic enzymes of @DRUG$.	DDI-mechanism
DDI-DrugBank.d407.s1.p0	An immune response to @DRUG$ may interfere with subsequent diagnostic serum tests that utilize @DRUG$	DDI-false
DDI-DrugBank.d409.s0.p0	Because the @DRUG$ have been shown to depress plasma prothrombin activity, patients who are on @DRUG$ therapy may require downward adjustment of their anticoagulant dosage.	DDI-advise
DDI-DrugBank.d409.s0.p1	Because the @DRUG$ have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their @DRUG$ dosage.	DDI-false
DDI-DrugBank.d409.s0.p2	Because the tetracyclines have been shown to depress plasma prothrombin activity, patients who are on @DRUG$ therapy may require downward adjustment of their @DRUG$ dosage.	DDI-false
DDI-DrugBank.d410.s3.p0	@DRUG$: Although the results of a clinical study did not indicate a safe problem associated with the administration of @DRUG$  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.	DDI-false
DDI-DrugBank.d410.s3.p1	@DRUG$: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (@DRUG$) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.	DDI-false
DDI-DrugBank.d410.s3.p2	@DRUG$: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving @DRUG$, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.	DDI-false
DDI-DrugBank.d410.s3.p3	@DRUG$: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that @DRUG$ may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.	DDI-false
DDI-DrugBank.d410.s3.p4	@DRUG$: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of @DRUG$ by blocking the vasodilating property of epinephrine.	DDI-false
DDI-DrugBank.d410.s3.p5	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of @DRUG$  (@DRUG$) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.	DDI-false
DDI-DrugBank.d410.s3.p6	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of @DRUG$  (dihydroergotamine mesylate) Injection, USP to subjects already receiving @DRUG$, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.	DDI-false
DDI-DrugBank.d410.s3.p7	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of @DRUG$  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that @DRUG$ may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.	DDI-false
DDI-DrugBank.d410.s3.p8	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of @DRUG$  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of @DRUG$ by blocking the vasodilating property of epinephrine.	DDI-false
DDI-DrugBank.d410.s3.p9	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (@DRUG$) Injection, USP to subjects already receiving @DRUG$, there have been reports that propranolol may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.	DDI-false
DDI-DrugBank.d410.s3.p10	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (@DRUG$) Injection, USP to subjects already receiving propranolol, there have been reports that @DRUG$ may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.	DDI-false
DDI-DrugBank.d410.s3.p11	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (@DRUG$) Injection, USP to subjects already receiving propranolol, there have been reports that propranolol may potentiate the vasoconstrictive action of @DRUG$ by blocking the vasodilating property of epinephrine.	DDI-false
DDI-DrugBank.d410.s3.p12	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving @DRUG$, there have been reports that @DRUG$ may potentiate the vasoconstrictive action of ergotamine by blocking the vasodilating property of epinephrine.	DDI-false
DDI-DrugBank.d410.s3.p13	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving @DRUG$, there have been reports that propranolol may potentiate the vasoconstrictive action of @DRUG$ by blocking the vasodilating property of epinephrine.	DDI-false
DDI-DrugBank.d410.s3.p14	Beta Blockers: Although the results of a clinical study did not indicate a safe problem associated with the administration of D.H.E. 45  (dihydroergotamine mesylate) Injection, USP to subjects already receiving propranolol, there have been reports that @DRUG$ may potentiate the vasoconstrictive action of @DRUG$ by blocking the vasodilating property of epinephrine.	DDI-effect
DDI-DrugBank.d410.s4.p0	@DRUG$: @DRUG$ may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to ergot therapy.	DDI-false
DDI-DrugBank.d410.s4.p1	@DRUG$: Nicotine may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to @DRUG$ therapy.	DDI-false
DDI-DrugBank.d410.s4.p2	Nicotine: @DRUG$ may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to @DRUG$ therapy.	DDI-effect
DDI-DrugBank.d410.s7.p0	@DRUG$: Weakness hyperreflexia, and incoordination have been reported rarely when @DRUG$ have been co-administered with SSRIs (e. g.	DDI-false
DDI-DrugBank.d410.s7.p1	@DRUG$: Weakness hyperreflexia, and incoordination have been reported rarely when 5-HT1 agonists have been co-administered with @DRUG$ (e. g.	DDI-false
DDI-DrugBank.d410.s7.p2	SSRIs: Weakness hyperreflexia, and incoordination have been reported rarely when @DRUG$ have been co-administered with @DRUG$ (e. g.	DDI-effect
DDI-DrugBank.d411.s15.p0	@DRUG$ (123I and 131I), @DRUG$: Uptake of radiolabeled ions may be decreased.	DDI-false
DDI-DrugBank.d411.s3.p0	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-mechanism
DDI-DrugBank.d411.s3.p1	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-mechanism
DDI-DrugBank.d411.s3.p2	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-mechanism
DDI-DrugBank.d411.s3.p3	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-mechanism
DDI-DrugBank.d411.s3.p4	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-mechanism
DDI-DrugBank.d411.s3.p5	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-mechanism
DDI-DrugBank.d411.s3.p6	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-mechanism
DDI-DrugBank.d411.s3.p7	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-mechanism
DDI-DrugBank.d411.s3.p8	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-mechanism
DDI-DrugBank.d411.s3.p9	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-mechanism
DDI-DrugBank.d411.s3.p10	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-mechanism
DDI-DrugBank.d411.s3.p11	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-mechanism
DDI-DrugBank.d411.s3.p12	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-mechanism
DDI-DrugBank.d411.s3.p13	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.	DDI-mechanism
DDI-DrugBank.d411.s3.p14	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.	DDI-mechanism
DDI-DrugBank.d411.s3.p15	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.	DDI-mechanism
DDI-DrugBank.d411.s3.p16	Binding to Serum Proteins: The following agents may either inhibit @DRUG$ binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.	DDI-mechanism
DDI-DrugBank.d411.s3.p17	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p18	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p19	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p20	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p21	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p22	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p23	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p24	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p25	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p26	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p27	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p28	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p29	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p30	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p31	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p32	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: @DRUG$ and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.	DDI-false
DDI-DrugBank.d411.s3.p33	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p34	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p35	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p36	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p37	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p38	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p39	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p40	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p41	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p42	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p43	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p44	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p45	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p46	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p47	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related @DRUG$, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.	DDI-false
DDI-DrugBank.d411.s3.p48	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p49	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p50	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p51	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p52	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p53	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p54	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p55	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p56	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p57	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p58	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p59	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p60	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p61	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, @DRUG$, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.	DDI-false
DDI-DrugBank.d411.s3.p62	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p63	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p64	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p65	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p66	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p67	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p68	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p69	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p70	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p71	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p72	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p73	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p74	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, @DRUG$, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.	DDI-false
DDI-DrugBank.d411.s3.p75	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p76	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p77	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p78	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p79	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p80	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p81	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p82	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p83	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p84	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p85	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p86	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, @DRUG$ and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.	DDI-false
DDI-DrugBank.d411.s3.p87	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p88	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p89	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p90	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p91	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p92	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p93	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p94	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p95	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p96	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p97	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and @DRUG$, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.	DDI-false
DDI-DrugBank.d411.s3.p98	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p99	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p100	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p101	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p102	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p103	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p104	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p105	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p106	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p107	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, @DRUG$, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.	DDI-false
DDI-DrugBank.d411.s3.p108	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p109	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p110	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p111	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p112	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p113	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p114	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p115	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p116	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, @DRUG$, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.	DDI-false
DDI-DrugBank.d411.s3.p117	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p118	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p119	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p120	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p121	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p122	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p123	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p124	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, @DRUG$, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.	DDI-false
DDI-DrugBank.d411.s3.p125	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p126	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p127	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p128	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p129	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p130	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p131	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, @DRUG$, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.	DDI-false
DDI-DrugBank.d411.s3.p132	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p133	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p134	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p135	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p136	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p137	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, @DRUG$, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.	DDI-false
DDI-DrugBank.d411.s3.p138	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, @DRUG$, phenylbutazone, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p139	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, @DRUG$, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p140	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, @DRUG$, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p141	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, @DRUG$, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p142	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, @DRUG$, perphenazine, phenylbutazone, phenytoin, salicylates, @DRUG$.	DDI-false
DDI-DrugBank.d411.s3.p143	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, @DRUG$, phenytoin, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p144	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, @DRUG$, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p145	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, @DRUG$, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p146	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, @DRUG$, phenylbutazone, phenytoin, salicylates, @DRUG$.	DDI-false
DDI-DrugBank.d411.s3.p147	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, @DRUG$, salicylates, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p148	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, @DRUG$, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p149	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, @DRUG$, phenytoin, salicylates, @DRUG$.	DDI-false
DDI-DrugBank.d411.s3.p150	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, @DRUG$, tamoxifen.	DDI-false
DDI-DrugBank.d411.s3.p151	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, @DRUG$, salicylates, @DRUG$.	DDI-false
DDI-DrugBank.d411.s3.p152	Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, @DRUG$, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p0	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p1	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p2	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p3	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p4	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p5	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p6	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p7	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p8	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p9	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p10	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p11	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p12	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p13	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p14	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p15	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p16	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p17	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p18	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p19	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p20	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p21	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p22	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p23	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p24	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p25	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p26	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p27	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p28	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p29	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p30	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p31	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p32	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: @DRUG$, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p33	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p34	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p35	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p36	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p37	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p38	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p39	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p40	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p41	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p42	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p43	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p44	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p45	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p46	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p47	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p48	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p49	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p50	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p51	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p52	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p53	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p54	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p55	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p56	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p57	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p58	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p59	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p60	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p61	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p62	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p63	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p64	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, @DRUG$, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p65	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p66	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p67	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p68	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p69	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p70	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p71	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p72	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p73	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p74	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p75	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p76	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p77	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p78	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p79	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p80	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p81	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p82	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p83	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p84	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p85	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p86	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p87	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p88	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p89	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p90	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p91	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p92	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p93	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p94	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p95	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, @DRUG$, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p96	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p97	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p98	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p99	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p100	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p101	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p102	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p103	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p104	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p105	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p106	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p107	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p108	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p109	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p110	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p111	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p112	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p113	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p114	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p115	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p116	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p117	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p118	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p119	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p120	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p121	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p122	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p123	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p124	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p125	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, @DRUG$ and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p126	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p127	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p128	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p129	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p130	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p131	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p132	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p133	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p134	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p135	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p136	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p137	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p138	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p139	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p140	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p141	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p142	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p143	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p144	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p145	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p146	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p147	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p148	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p149	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p150	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p151	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p152	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p153	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p154	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (@DRUG$, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p155	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p156	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p157	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p158	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p159	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p160	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p161	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p162	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p163	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p164	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p165	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p166	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p167	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p168	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p169	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p170	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p171	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p172	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p173	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p174	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p175	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p176	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p177	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p178	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p179	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p180	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p181	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p182	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p183	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p184	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p185	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p186	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p187	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p188	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p189	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p190	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p191	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p192	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p193	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p194	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p195	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p196	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p197	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p198	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p199	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p200	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p201	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p202	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p203	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p204	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p205	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p206	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p207	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p208	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p209	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, @DRUG$), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p210	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p211	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p212	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p213	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p214	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p215	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p216	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p217	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p218	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p219	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p220	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p221	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p222	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p223	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p224	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p225	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p226	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p227	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p228	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p229	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p230	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p231	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p232	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p233	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p234	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p235	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), @DRUG$, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p236	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p237	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p238	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p239	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p240	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p241	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p242	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p243	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p244	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p245	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p246	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p247	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p248	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p249	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p250	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p251	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p252	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p253	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p254	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p255	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p256	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p257	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p258	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p259	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p260	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, @DRUG$, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p261	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p262	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p263	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p264	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p265	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p266	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p267	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p268	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p269	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p270	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p271	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p272	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p273	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p274	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p275	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p276	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p277	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p278	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p279	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p280	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p281	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p282	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p283	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p284	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, @DRUG$, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p285	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p286	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p287	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p288	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p289	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p290	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p291	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p292	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p293	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p294	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p295	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p296	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p297	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p298	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p299	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p300	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p301	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p302	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p303	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p304	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p305	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p306	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p307	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, @DRUG$, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p308	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p309	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p310	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p311	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p312	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p313	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p314	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p315	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p316	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p317	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p318	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p319	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p320	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p321	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p322	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p323	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p324	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p325	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p326	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p327	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p328	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p329	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, @DRUG$, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p330	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p331	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p332	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p333	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p334	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p335	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p336	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p337	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p338	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p339	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p340	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p341	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p342	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p343	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p344	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p345	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p346	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p347	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p348	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p349	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p350	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p351	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p352	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p353	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p354	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p355	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p356	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p357	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p358	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p359	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p360	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p361	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p362	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p363	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p364	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p365	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p366	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p367	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p368	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p369	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p370	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and @DRUG$, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p371	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p372	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p373	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p374	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p375	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p376	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p377	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p378	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p379	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p380	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p381	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p382	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p383	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p384	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p385	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p386	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p387	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p388	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p389	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, @DRUG$, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p390	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p391	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p392	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p393	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p394	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p395	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p396	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p397	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p398	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p399	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p400	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p401	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p402	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p403	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p404	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p405	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p406	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p407	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, @DRUG$, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p408	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p409	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p410	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p411	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p412	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p413	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p414	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p415	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p416	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p417	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p418	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p419	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p420	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p421	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p422	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p423	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p424	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p425	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p426	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p427	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p428	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p429	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p430	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p431	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p432	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p433	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p434	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p435	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p436	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p437	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p438	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p439	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p440	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, @DRUG$, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p441	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p442	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p443	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p444	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p445	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p446	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p447	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p448	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p449	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p450	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p451	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p452	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p453	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p454	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p455	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, @DRUG$, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p456	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p457	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p458	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p459	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p460	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p461	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p462	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p463	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p464	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p465	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p466	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p467	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p468	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p469	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, @DRUG$, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p470	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p471	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p472	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p473	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p474	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p475	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p476	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p477	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p478	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p479	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p480	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p481	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p482	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, @DRUG$, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p483	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p484	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p485	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p486	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p487	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p488	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p489	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p490	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p491	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p492	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p493	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p494	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, @DRUG$, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p495	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p496	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p497	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p498	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p499	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p500	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p501	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p502	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p503	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p504	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p505	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, @DRUG$, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p506	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p507	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p508	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p509	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p510	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p511	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p512	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p513	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p514	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p515	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, @DRUG$, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p516	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p517	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p518	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p519	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p520	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p521	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p522	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p523	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p524	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, @DRUG$, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p525	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p526	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p527	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p528	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p529	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p530	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p531	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p532	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, @DRUG$, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p533	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p534	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p535	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p536	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p537	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p538	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p539	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, @DRUG$, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p540	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p541	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p542	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p543	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p544	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p545	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, @DRUG$, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p546	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p547	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p548	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p549	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p550	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, @DRUG$, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p551	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, @DRUG$, sulfonamides, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p552	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p553	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p554	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, @DRUG$, somatostatin analogs, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p555	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, @DRUG$, sulfonylureas, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p556	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p557	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, @DRUG$, sulfonamides, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p558	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, @DRUG$, thiazide diuretics.	DDI-false
DDI-DrugBank.d411.s4.p559	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, @DRUG$, sulfonylureas, @DRUG$.	DDI-false
DDI-DrugBank.d411.s4.p560	Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, @DRUG$.	DDI-false
DDI-DrugBank.d411.s7.p0	@DRUG$ (Oral): The hypoprothrombinemic effect of @DRUG$ may be potentiated, apparently by increased catabloism of vitamin K-dependent clotting factors.	DDI-false
DDI-DrugBank.d412.s17.p0	When patients being treated with @DRUG$ have a positive urine test for @DRUG$ using these techniques confirmation should be made by using more specific methods such as a gas chromatographic-mass spectrometer technique.	DDI-false
DDI-DrugBank.d413.s20.p0	@DRUG$: @DRUG$s plasma half-life may be prolonged by allopurinol, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.	DDI-false
DDI-DrugBank.d413.s20.p1	@DRUG$: Chlorpropamides plasma half-life may be prolonged by @DRUG$, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.	DDI-false
DDI-DrugBank.d413.s20.p2	@DRUG$: Chlorpropamides plasma half-life may be prolonged by allopurinol, since @DRUG$ and chlorpropamide may compete for excretion in the renal tubule.	DDI-false
DDI-DrugBank.d413.s20.p3	@DRUG$: Chlorpropamides plasma half-life may be prolonged by allopurinol, since allopurinol and @DRUG$ may compete for excretion in the renal tubule.	DDI-false
DDI-DrugBank.d413.s20.p4	Chlorpropamide: @DRUG$s plasma half-life may be prolonged by @DRUG$, since allopurinol and chlorpropamide may compete for excretion in the renal tubule.	DDI-mechanism
DDI-DrugBank.d413.s20.p5	Chlorpropamide: @DRUG$s plasma half-life may be prolonged by allopurinol, since @DRUG$ and chlorpropamide may compete for excretion in the renal tubule.	DDI-false
DDI-DrugBank.d413.s20.p6	Chlorpropamide: @DRUG$s plasma half-life may be prolonged by allopurinol, since allopurinol and @DRUG$ may compete for excretion in the renal tubule.	DDI-false
DDI-DrugBank.d413.s20.p7	Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by @DRUG$, since @DRUG$ and chlorpropamide may compete for excretion in the renal tubule.	DDI-false
DDI-DrugBank.d413.s20.p8	Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by @DRUG$, since allopurinol and @DRUG$ may compete for excretion in the renal tubule.	DDI-false
DDI-DrugBank.d413.s20.p9	Chlorpropamide: Chlorpropamides plasma half-life may be prolonged by allopurinol, since @DRUG$ and @DRUG$ may compete for excretion in the renal tubule.	DDI-mechanism
DDI-DrugBank.d415.s11.p0	During concomitant therapy with @DRUG$, the patient should be observed closely for signs of renal failure, as well as to assure @DRUG$ efficacy.	DDI-false
DDI-DrugBank.d415.s12.p0	@DRUG$: @DRUG$ produced an elevation of plasma lithium levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.	DDI-false
DDI-DrugBank.d415.s12.p1	@DRUG$: Ibuprofen produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.	DDI-false
DDI-DrugBank.d415.s12.p2	@DRUG$: Ibuprofen produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance in a study of eleven normal volunteers.	DDI-false
DDI-DrugBank.d415.s12.p3	Lithium: @DRUG$ produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance in a study of eleven normal volunteers.	DDI-mechanism
DDI-DrugBank.d415.s12.p4	Lithium: @DRUG$ produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance in a study of eleven normal volunteers.	DDI-false
DDI-DrugBank.d415.s12.p5	Lithium: Ibuprofen produced an elevation of plasma @DRUG$ levels and a reduction in renal @DRUG$ clearance in a study of eleven normal volunteers.	DDI-false
DDI-DrugBank.d415.s15.p0	Thus, when @DRUG$ and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of lithium toxicity.	DDI-advise
DDI-DrugBank.d415.s15.p1	Thus, when @DRUG$ and lithium are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.	DDI-false
DDI-DrugBank.d415.s15.p2	Thus, when ibuprofen and @DRUG$ are administered concurrently, subjects should be observed carefully for signs of @DRUG$ toxicity.	DDI-false
DDI-DrugBank.d415.s3.p0	Single dose bioavailability studies in normal volunteers have failed to wshow an effect of @DRUG$ on @DRUG$ blood levels.	DDI-false
DDI-DrugBank.d415.s9.p0	@DRUG$: Clinical studies, as well as random observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and thiazides in some patients.	DDI-false
DDI-DrugBank.d415.s9.p1	@DRUG$: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	DDI-false
DDI-DrugBank.d415.s9.p2	@DRUG$: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	DDI-false
DDI-DrugBank.d415.s9.p3	Furosemide: Clinical studies, as well as random observations, have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	DDI-effect
DDI-DrugBank.d415.s9.p4	Furosemide: Clinical studies, as well as random observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	DDI-effect
DDI-DrugBank.d415.s9.p5	Furosemide: Clinical studies, as well as random observations, have shown that ibuprofen can reduce the natriuretic effect of @DRUG$ and @DRUG$ in some patients.	DDI-false
DDI-DrugBank.d416.s3.p0	Therefore, patients receiving @DRUG$ will have erroneously low ERPF and Tm @DRUG$ values.	DDI-effect
DDI-DrugBank.d417.s0.p0	@DRUG$ should not be administered concomitantly with potent @DRUG$ such as furosemide and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.	DDI-advise
DDI-DrugBank.d417.s0.p1	@DRUG$ should not be administered concomitantly with potent loop diuretics such as @DRUG$ and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.	DDI-advise
DDI-DrugBank.d417.s0.p2	@DRUG$ should not be administered concomitantly with potent loop diuretics such as furosemide and @DRUG$ as the potential for ototoxicity is enhanced by the combination.	DDI-advise
DDI-DrugBank.d417.s0.p3	Netilmicin should not be administered concomitantly with potent @DRUG$ such as @DRUG$ and ethacrynic acid as the potential for ototoxicity is enhanced by the combination.	DDI-false
DDI-DrugBank.d417.s0.p4	Netilmicin should not be administered concomitantly with potent @DRUG$ such as furosemide and @DRUG$ as the potential for ototoxicity is enhanced by the combination.	DDI-false
DDI-DrugBank.d417.s0.p5	Netilmicin should not be administered concomitantly with potent loop diuretics such as @DRUG$ and @DRUG$ as the potential for ototoxicity is enhanced by the combination.	DDI-false
DDI-DrugBank.d419.s0.p0	The concurrent administration of @DRUG$ and @DRUG$ increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving ampicillin alone.	DDI-effect
DDI-DrugBank.d419.s0.p1	The concurrent administration of @DRUG$ and ampicillin increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving @DRUG$ alone.	DDI-false
DDI-DrugBank.d419.s0.p2	The concurrent administration of allopurinol and @DRUG$ increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving @DRUG$ alone.	DDI-false
DDI-DrugBank.d42.s4.p0	In patients taking @DRUG$, @DRUG$, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p1	In patients taking @DRUG$, nifedipine, @DRUG$, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p2	In patients taking @DRUG$, nifedipine, diltiazem, @DRUG$, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p3	In patients taking @DRUG$, nifedipine, diltiazem, ACE inhibitors, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p4	In patients taking @DRUG$, nifedipine, diltiazem, ACE inhibitors, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p5	In patients taking @DRUG$, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p6	In patients taking @DRUG$, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d42.s4.p7	In patients taking furosemide, @DRUG$, @DRUG$, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p8	In patients taking furosemide, @DRUG$, diltiazem, @DRUG$, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p9	In patients taking furosemide, @DRUG$, diltiazem, ACE inhibitors, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p10	In patients taking furosemide, @DRUG$, diltiazem, ACE inhibitors, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p11	In patients taking furosemide, @DRUG$, diltiazem, ACE inhibitors, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p12	In patients taking furosemide, @DRUG$, diltiazem, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d42.s4.p13	In patients taking furosemide, nifedipine, @DRUG$, @DRUG$, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p14	In patients taking furosemide, nifedipine, @DRUG$, ACE inhibitors, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p15	In patients taking furosemide, nifedipine, @DRUG$, ACE inhibitors, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p16	In patients taking furosemide, nifedipine, @DRUG$, ACE inhibitors, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p17	In patients taking furosemide, nifedipine, @DRUG$, ACE inhibitors, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d42.s4.p18	In patients taking furosemide, nifedipine, diltiazem, @DRUG$, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p19	In patients taking furosemide, nifedipine, diltiazem, @DRUG$, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p20	In patients taking furosemide, nifedipine, diltiazem, @DRUG$, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p21	In patients taking furosemide, nifedipine, diltiazem, @DRUG$, verapamil, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d42.s4.p22	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, @DRUG$, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p23	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, @DRUG$, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p24	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, @DRUG$, glyburide, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d42.s4.p25	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, @DRUG$, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of hydrodolasetron.	DDI-false
DDI-DrugBank.d42.s4.p26	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, @DRUG$, propranolol, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d42.s4.p27	In patients taking furosemide, nifedipine, diltiazem, ACE inhibitors, verapamil, glyburide, @DRUG$, and various chemotherapy agents, no effect was shown on the clearance of @DRUG$.	DDI-false
DDI-DrugBank.d42.s5.p0	Clearance of @DRUG$ decreased by about 27% when @DRUG$ was administered intravenously concomitantly with atenolol.	DDI-false
DDI-DrugBank.d42.s5.p1	Clearance of @DRUG$ decreased by about 27% when dolasetron mesylate was administered intravenously concomitantly with @DRUG$.	DDI-false
DDI-DrugBank.d42.s5.p2	Clearance of hydrodolasetron decreased by about 27% when @DRUG$ was administered intravenously concomitantly with @DRUG$.	DDI-mechanism
DDI-DrugBank.d420.s12.p0	Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using @DRUG$, but not with those using @DRUG$.	DDI-false
DDI-DrugBank.d420.s3.p0	If @DRUG$ are required during @DRUG$ therapy, OMNICEF should be taken at least 2 hours before or after the antacid.	DDI-false
DDI-DrugBank.d420.s3.p1	If @DRUG$ are required during OMNICEF therapy, @DRUG$ should be taken at least 2 hours before or after the antacid.	DDI-false
DDI-DrugBank.d420.s3.p2	If @DRUG$ are required during OMNICEF therapy, OMNICEF should be taken at least 2 hours before or after the @DRUG$.	DDI-false
DDI-DrugBank.d420.s3.p3	If antacids are required during @DRUG$ therapy, @DRUG$ should be taken at least 2 hours before or after the antacid.	DDI-false
DDI-DrugBank.d420.s3.p4	If antacids are required during @DRUG$ therapy, OMNICEF should be taken at least 2 hours before or after the @DRUG$.	DDI-false
DDI-DrugBank.d420.s3.p5	If antacids are required during OMNICEF therapy, @DRUG$ should be taken at least 2 hours before or after the @DRUG$.	DDI-advise
DDI-DrugBank.d420.s5.p0	@DRUG$ and Foods Fortified With @DRUG$ Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p1	@DRUG$ and Foods Fortified With Iron Concomitant administration of @DRUG$ with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p2	@DRUG$ and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic @DRUG$ containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p3	@DRUG$ and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental @DRUG$ (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p4	@DRUG$ and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or @DRUG$ supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p5	@DRUG$ and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental @DRUG$ reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p6	Iron Supplements and Foods Fortified With @DRUG$ Concomitant administration of @DRUG$ with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p7	Iron Supplements and Foods Fortified With @DRUG$ Concomitant administration of cefdinir with a therapeutic @DRUG$ containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p8	Iron Supplements and Foods Fortified With @DRUG$ Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental @DRUG$ (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p9	Iron Supplements and Foods Fortified With @DRUG$ Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or @DRUG$ supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p10	Iron Supplements and Foods Fortified With @DRUG$ Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental @DRUG$ reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p11	Iron Supplements and Foods Fortified With Iron Concomitant administration of @DRUG$ with a therapeutic @DRUG$ containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p12	Iron Supplements and Foods Fortified With Iron Concomitant administration of @DRUG$ with a therapeutic iron supplement containing 60 mg of elemental @DRUG$ (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.	DDI-mechanism
DDI-DrugBank.d420.s5.p13	Iron Supplements and Foods Fortified With Iron Concomitant administration of @DRUG$ with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or @DRUG$ supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p14	Iron Supplements and Foods Fortified With Iron Concomitant administration of @DRUG$ with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental @DRUG$ reduced extent of absorption by 80% and 31%, respectively.	DDI-mechanism
DDI-DrugBank.d420.s5.p15	Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic @DRUG$ containing 60 mg of elemental @DRUG$ (as FeSO4) or vitamins supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p16	Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic @DRUG$ containing 60 mg of elemental iron (as FeSO4) or @DRUG$ supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p17	Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic @DRUG$ containing 60 mg of elemental iron (as FeSO4) or vitamins supplemented with 10 mg of elemental @DRUG$ reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p18	Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental @DRUG$ (as FeSO4) or @DRUG$ supplemented with 10 mg of elemental iron reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p19	Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental @DRUG$ (as FeSO4) or vitamins supplemented with 10 mg of elemental @DRUG$ reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s5.p20	Iron Supplements and Foods Fortified With Iron Concomitant administration of cefdinir with a therapeutic iron supplement containing 60 mg of elemental iron (as FeSO4) or @DRUG$ supplemented with 10 mg of elemental @DRUG$ reduced extent of absorption by 80% and 31%, respectively.	DDI-false
DDI-DrugBank.d420.s6.p0	If @DRUG$ are required during @DRUG$ therapy, OMNICEF should be taken at least 2 hours before or after the supplement.	DDI-false
DDI-DrugBank.d420.s6.p1	If @DRUG$ are required during OMNICEF therapy, @DRUG$ should be taken at least 2 hours before or after the supplement.	DDI-advise
DDI-DrugBank.d420.s6.p2	If iron supplements are required during @DRUG$ therapy, @DRUG$ should be taken at least 2 hours before or after the supplement.	DDI-false
DDI-DrugBank.d422.s3.p0	@DRUG$ concentrations were equivocally higher when given with @DRUG$, but this is not likely to be clinically important.	DDI-mechanism
DDI-DrugBank.d422.s4.p0	When @DRUG$ and @DRUG$ were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in digoxin blood levels at some time points.	DDI-mechanism
DDI-DrugBank.d422.s4.p1	When @DRUG$ and BREVIBLOC were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in @DRUG$ blood levels at some time points.	DDI-false
DDI-DrugBank.d422.s4.p2	When digoxin and @DRUG$ were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in @DRUG$ blood levels at some time points.	DDI-false
DDI-DrugBank.d423.s3.p0	At least 3 weeks should elapse between discontinuation of @DRUG$ and initiation of treatment with a @DRUG$.	DDI-advise
DDI-DrugBank.d423.s6.p0	@DRUG$ should not be administered with other @DRUG$.	DDI-advise
DDI-DrugBank.d424.s3.p0	@DRUG$: Coadministration of @DRUG$ and MEPRON Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.	DDI-false
DDI-DrugBank.d424.s3.p1	@DRUG$: Coadministration of rifampin and @DRUG$ Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.	DDI-false
DDI-DrugBank.d424.s3.p2	@DRUG$: Coadministration of rifampin and MEPRON Suspension results in a significant decrease in average steady- state plasma @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d424.s3.p3	Rifampin: Coadministration of @DRUG$ and @DRUG$ Suspension results in a significant decrease in average steady- state plasma atovaquone concentrations.	DDI-mechanism
DDI-DrugBank.d424.s3.p4	Rifampin: Coadministration of @DRUG$ and MEPRON Suspension results in a significant decrease in average steady- state plasma @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d424.s3.p5	Rifampin: Coadministration of rifampin and @DRUG$ Suspension results in a significant decrease in average steady- state plasma @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d424.s6.p0	No interaction trials have been conducted with @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d425.s5.p0	Therefore, intake of supplemental @DRUG$ should not exceed 1000 micrograms ( g, sometimes mcg) per day to prevent @DRUG$ from masking symptoms of vitamin B12 deficiency.	DDI-false
DDI-DrugBank.d426.s1.p0	Due to a theoretical risk of a pharmacodynamic interaction, use of @DRUG$-containing or @DRUG$ (like dihydroergotamine or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).	DDI-false
DDI-DrugBank.d426.s1.p1	Due to a theoretical risk of a pharmacodynamic interaction, use of @DRUG$-containing or ergot-type medications (like @DRUG$ or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).	DDI-false
DDI-DrugBank.d426.s1.p2	Due to a theoretical risk of a pharmacodynamic interaction, use of @DRUG$-containing or ergot-type medications (like dihydroergotamine or @DRUG$) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).	DDI-false
DDI-DrugBank.d426.s1.p3	Due to a theoretical risk of a pharmacodynamic interaction, use of @DRUG$-containing or ergot-type medications (like dihydroergotamine or methysergide) and @DRUG$ within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).	DDI-advise
DDI-DrugBank.d426.s1.p4	Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or @DRUG$ (like @DRUG$ or methysergide) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).	DDI-false
DDI-DrugBank.d426.s1.p5	Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or @DRUG$) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).	DDI-false
DDI-DrugBank.d426.s1.p6	Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or methysergide) and @DRUG$ within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).	DDI-advise
DDI-DrugBank.d426.s1.p7	Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like @DRUG$ or @DRUG$) and FROVA within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).	DDI-false
DDI-DrugBank.d426.s1.p8	Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like @DRUG$ or methysergide) and @DRUG$ within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).	DDI-advise
DDI-DrugBank.d426.s1.p9	Due to a theoretical risk of a pharmacodynamic interaction, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or @DRUG$) and @DRUG$ within 24 hours of each other should be avoided (see  a href= frova_od.htm#CI CONTRAINDICATIONS).	DDI-advise
DDI-DrugBank.d426.s3.p0	@DRUG$ (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
DDI-DrugBank.d426.s3.p1	@DRUG$ (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
DDI-DrugBank.d426.s3.p2	@DRUG$ (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
DDI-DrugBank.d426.s3.p3	@DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
DDI-DrugBank.d426.s3.p4	@DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
DDI-DrugBank.d426.s3.p5	@DRUG$ (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
DDI-DrugBank.d426.s3.p6	Selective serotonin reuptake inhibitors (@DRUG$) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
DDI-DrugBank.d426.s3.p7	Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
DDI-DrugBank.d426.s3.p8	Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
DDI-DrugBank.d426.s3.p9	Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
DDI-DrugBank.d426.s3.p10	Selective serotonin reuptake inhibitors (@DRUG$) (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
DDI-DrugBank.d426.s3.p11	Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
DDI-DrugBank.d426.s3.p12	Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
DDI-DrugBank.d426.s3.p13	Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
DDI-DrugBank.d426.s3.p14	Selective serotonin reuptake inhibitors (SSRIs) (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
DDI-DrugBank.d426.s3.p15	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
DDI-DrugBank.d426.s3.p16	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
DDI-DrugBank.d426.s3.p17	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
DDI-DrugBank.d426.s3.p18	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
DDI-DrugBank.d426.s3.p19	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
DDI-DrugBank.d426.s3.p20	Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
DDI-DrugBank.d427.s0.p0	Elevated plasma levels of @DRUG$ have been reported with concomitant @DRUG$ use.	DDI-mechanism
DDI-DrugBank.d427.s1.p0	There have been reports of @DRUG$-related side effects in patients on concomitant therapy with @DRUG$ and theophylline.	DDI-false
DDI-DrugBank.d427.s1.p1	There have been reports of @DRUG$-related side effects in patients on concomitant therapy with quinolones and @DRUG$.	DDI-false
DDI-DrugBank.d427.s1.p2	There have been reports of theophylline-related side effects in patients on concomitant therapy with @DRUG$ and @DRUG$.	DDI-effect
DDI-DrugBank.d427.s11.p0	and @DRUG$ , (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of quinolones, resulting in systemic levels considerably lower than desired.	DDI-false
DDI-DrugBank.d427.s11.p1	and @DRUG$ , (Didanosine), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of @DRUG$, resulting in systemic levels considerably lower than desired.	DDI-mechanism
DDI-DrugBank.d427.s11.p2	and Videx , (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of @DRUG$, resulting in systemic levels considerably lower than desired.	DDI-mechanism
DDI-DrugBank.d427.s13.p0	Elevated serum levels of @DRUG$ have been reported with the concomitant use of some @DRUG$ and cyclosporine.	DDI-false
DDI-DrugBank.d427.s13.p1	Elevated serum levels of @DRUG$ have been reported with the concomitant use of some quinolones and @DRUG$.	DDI-false
DDI-DrugBank.d427.s13.p2	Elevated serum levels of cyclosporine have been reported with the concomitant use of some @DRUG$ and @DRUG$.	DDI-mechanism
DDI-DrugBank.d427.s7.p0	@DRUG$ interferes with the therapeutic action of @DRUG$.	DDI-effect
DDI-DrugBank.d427.s8.p0	@DRUG$ containing @DRUG$, aluminum, or calcium;	DDI-false
DDI-DrugBank.d427.s8.p1	@DRUG$ containing magnesium, @DRUG$, or calcium;	DDI-false
DDI-DrugBank.d427.s8.p2	@DRUG$ containing magnesium, aluminum, or @DRUG$;	DDI-false
DDI-DrugBank.d427.s8.p3	Antacids containing @DRUG$, @DRUG$, or calcium;	DDI-false
DDI-DrugBank.d427.s8.p4	Antacids containing @DRUG$, aluminum, or @DRUG$;	DDI-false
DDI-DrugBank.d427.s8.p5	Antacids containing magnesium, @DRUG$, or @DRUG$;	DDI-false
DDI-DrugBank.d429.s2.p0	@DRUG$: @DRUG$ can inhibit the metabolism of chloroquine, increasing its plasma level.	DDI-false
DDI-DrugBank.d429.s2.p1	@DRUG$: Cimetidine can inhibit the metabolism of @DRUG$, increasing its plasma level.	DDI-false
DDI-DrugBank.d429.s2.p2	Cimetidine: @DRUG$ can inhibit the metabolism of @DRUG$, increasing its plasma level.	DDI-mechanism
DDI-DrugBank.d429.s4.p0	@DRUG$: In a study of healthy volunteers, @DRUG$ significantly reduced the bioavailability of ampicillin.	DDI-false
DDI-DrugBank.d429.s4.p1	@DRUG$: In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of @DRUG$.	DDI-false
DDI-DrugBank.d429.s4.p2	Ampicillin: In a study of healthy volunteers, @DRUG$ significantly reduced the bioavailability of @DRUG$.	DDI-mechanism
DDI-DrugBank.d43.s15.p0	To avoid this interaction, @DRUG$ or @DRUG$ should be given 1 hour prior to dosing with VIDEX.	DDI-false
DDI-DrugBank.d43.s15.p1	To avoid this interaction, @DRUG$ or indinavir should be given 1 hour prior to dosing with @DRUG$.	DDI-advise
DDI-DrugBank.d43.s15.p2	To avoid this interaction, delavirdine or @DRUG$ should be given 1 hour prior to dosing with @DRUG$.	DDI-advise
DDI-DrugBank.d43.s7.p0	A 21 (17)% decrease in the steady-state AUC of @DRUG$ was observed when @DRUG$ was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).	DDI-false
DDI-DrugBank.d43.s7.p1	A 21 (17)% decrease in the steady-state AUC of @DRUG$ was observed when VIDEX was administered 2 hours prior to @DRUG$, but not when the two drugs were administered simultaneously (n = 12).	DDI-false
DDI-DrugBank.d43.s7.p2	A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when @DRUG$ was administered 2 hours prior to @DRUG$, but not when the two drugs were administered simultaneously (n = 12).	DDI-mechanism
DDI-DrugBank.d43.s8.p0	@DRUG$s: @DRUG$ should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p1	@DRUG$s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with @DRUG$ because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p2	@DRUG$s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of @DRUG$ are decreased when administered with antacids containing magnesium, calcium, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p3	@DRUG$s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with @DRUG$ containing magnesium, calcium, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p4	@DRUG$s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing @DRUG$, calcium, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p5	@DRUG$s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, @DRUG$, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p6	@DRUG$s: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or @DRUG$.	DDI-false
DDI-DrugBank.d43.s8.p7	Quinolone Antibiotics: @DRUG$ should be administered at least 2 hours after or 6 hours before dosing with @DRUG$ because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or aluminum.	DDI-advise
DDI-DrugBank.d43.s8.p8	Quinolone Antibiotics: @DRUG$ should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of @DRUG$ are decreased when administered with antacids containing magnesium, calcium, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p9	Quinolone Antibiotics: @DRUG$ should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with @DRUG$ containing magnesium, calcium, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p10	Quinolone Antibiotics: @DRUG$ should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing @DRUG$, calcium, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p11	Quinolone Antibiotics: @DRUG$ should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, @DRUG$, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p12	Quinolone Antibiotics: @DRUG$ should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or @DRUG$.	DDI-false
DDI-DrugBank.d43.s8.p13	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with @DRUG$ because plasma concentrations of @DRUG$ are decreased when administered with antacids containing magnesium, calcium, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p14	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with @DRUG$ because plasma concentrations of ciprofloxacin are decreased when administered with @DRUG$ containing magnesium, calcium, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p15	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with @DRUG$ because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing @DRUG$, calcium, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p16	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with @DRUG$ because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, @DRUG$, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p17	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with @DRUG$ because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, calcium, or @DRUG$.	DDI-false
DDI-DrugBank.d43.s8.p18	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of @DRUG$ are decreased when administered with @DRUG$ containing magnesium, calcium, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p19	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of @DRUG$ are decreased when administered with antacids containing @DRUG$, calcium, or aluminum.	DDI-mechanism
DDI-DrugBank.d43.s8.p20	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of @DRUG$ are decreased when administered with antacids containing magnesium, @DRUG$, or aluminum.	DDI-mechanism
DDI-DrugBank.d43.s8.p21	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of @DRUG$ are decreased when administered with antacids containing magnesium, calcium, or @DRUG$.	DDI-mechanism
DDI-DrugBank.d43.s8.p22	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with @DRUG$ containing @DRUG$, calcium, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p23	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with @DRUG$ containing magnesium, @DRUG$, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p24	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with @DRUG$ containing magnesium, calcium, or @DRUG$.	DDI-false
DDI-DrugBank.d43.s8.p25	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing @DRUG$, @DRUG$, or aluminum.	DDI-false
DDI-DrugBank.d43.s8.p26	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing @DRUG$, calcium, or @DRUG$.	DDI-false
DDI-DrugBank.d43.s8.p27	Quinolone Antibiotics: VIDEX should be administered at least 2 hours after or 6 hours before dosing with ciprofloxacin because plasma concentrations of ciprofloxacin are decreased when administered with antacids containing magnesium, @DRUG$, or @DRUG$.	DDI-false
DDI-DrugBank.d434.s15.p0	In order to maintain @DRUG$ levels, limit adverse experiences, and achieve the @DRUG$ dose of 3600 mg/day, a phenytoin dose reduction of approximately 40% was necessary for eight of these 10 subjects.	DDI-false
DDI-DrugBank.d434.s15.p1	In order to maintain @DRUG$ levels, limit adverse experiences, and achieve the felbamate dose of 3600 mg/day, a @DRUG$ dose reduction of approximately 40% was necessary for eight of these 10 subjects.	DDI-false
DDI-DrugBank.d434.s15.p2	In order to maintain phenytoin levels, limit adverse experiences, and achieve the @DRUG$ dose of 3600 mg/day, a @DRUG$ dose reduction of approximately 40% was necessary for eight of these 10 subjects.	DDI-advise
DDI-DrugBank.d434.s16.p0	In a controlled clinical trial, a 20% reduction of the @DRUG$ dose at the initiation of @DRUG$  therapy resulted in phenytoin levels comparable to those prior to Felbatol  administration.	DDI-false
DDI-DrugBank.d434.s16.p1	In a controlled clinical trial, a 20% reduction of the @DRUG$ dose at the initiation of Felbatol  therapy resulted in @DRUG$ levels comparable to those prior to Felbatol  administration.	DDI-false
DDI-DrugBank.d434.s16.p2	In a controlled clinical trial, a 20% reduction of the @DRUG$ dose at the initiation of Felbatol  therapy resulted in phenytoin levels comparable to those prior to @DRUG$  administration.	DDI-false
DDI-DrugBank.d434.s16.p3	In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of @DRUG$  therapy resulted in @DRUG$ levels comparable to those prior to Felbatol  administration.	DDI-false
DDI-DrugBank.d434.s16.p4	In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of @DRUG$  therapy resulted in phenytoin levels comparable to those prior to @DRUG$  administration.	DDI-false
DDI-DrugBank.d434.s16.p5	In a controlled clinical trial, a 20% reduction of the phenytoin dose at the initiation of Felbatol  therapy resulted in @DRUG$ levels comparable to those prior to @DRUG$  administration.	DDI-false
DDI-DrugBank.d434.s21.p0	In clinical trials, similar changes in @DRUG$ and @DRUG$ were seen.	DDI-false
DDI-DrugBank.d434.s27.p0	The ratios of the AUCs of unbound @DRUG$ to the AUCs of the total @DRUG$ were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of Felbatol , respectively.	DDI-false
DDI-DrugBank.d434.s27.p1	The ratios of the AUCs of unbound @DRUG$ to the AUCs of the total valproate were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of @DRUG$ , respectively.	DDI-false
DDI-DrugBank.d434.s27.p2	The ratios of the AUCs of unbound valproate to the AUCs of the total @DRUG$ were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of @DRUG$ , respectively.	DDI-false
DDI-DrugBank.d434.s36.p0	Effects of @DRUG$ on @DRUG$  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.	DDI-false
DDI-DrugBank.d434.s36.p1	Effects of @DRUG$ on Felbatol  The coadministration of @DRUG$ (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.	DDI-false
DDI-DrugBank.d434.s36.p2	Effects of @DRUG$ on Felbatol  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at @DRUG$ daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.	DDI-false
DDI-DrugBank.d434.s36.p3	Effects of Erythromycin on @DRUG$  The coadministration of @DRUG$ (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at felbamate daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.	DDI-false
DDI-DrugBank.d434.s36.p4	Effects of Erythromycin on @DRUG$  The coadministration of erythromycin (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at @DRUG$ daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.	DDI-false
DDI-DrugBank.d434.s36.p5	Effects of Erythromycin on Felbatol  The coadministration of @DRUG$ (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at @DRUG$ daily doses of 3000 or 3600 mg/day in 10 otherwise healthy subjects with epilepsy.	DDI-false
DDI-DrugBank.d437.s13.p0	Laboratory Tests: The combination of @DRUG$ and low-dose @DRUG$ has been associated with elevations of cholesterol and triglycerides, SGOT (AST), and SGPT (ALT) in some patients.	DDI-effect
DDI-DrugBank.d437.s5.p0	@DRUG$ steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant @DRUG$.	DDI-mechanism
DDI-DrugBank.d437.s8.p0	@DRUG$ steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant @DRUG$.	DDI-mechanism
DDI-DrugBank.d438.s11.p0	@DRUG$: The mean steady-state trough serum @DRUG$ concentrations prior to and during concomitant gabapentin administration (400 mg TID;	DDI-false
DDI-DrugBank.d438.s11.p1	@DRUG$: The mean steady-state trough serum valproic acid concentrations prior to and during concomitant @DRUG$ administration (400 mg TID;	DDI-false
DDI-DrugBank.d438.s11.p2	Valproic Acid: The mean steady-state trough serum @DRUG$ concentrations prior to and during concomitant @DRUG$ administration (400 mg TID;	DDI-false
DDI-DrugBank.d438.s27.p0	@DRUG$ pharmacokinetic parameter values were not affected by administration of @DRUG$  2 hours after morphine.	DDI-false
DDI-DrugBank.d438.s27.p1	@DRUG$ pharmacokinetic parameter values were not affected by administration of Neurontin  2 hours after @DRUG$.	DDI-false
DDI-DrugBank.d438.s27.p2	Morphine pharmacokinetic parameter values were not affected by administration of @DRUG$  2 hours after @DRUG$.	DDI-false
DDI-DrugBank.d438.s29.p0	@DRUG$: In the presence of @DRUG$ at 300 mg QID (N=12) the mean apparent oral clearance of gabapentin fell by 14% and creatinine clearance fell by 10%.	DDI-false
DDI-DrugBank.d438.s29.p1	@DRUG$: In the presence of cimetidine at 300 mg QID (N=12) the mean apparent oral clearance of @DRUG$ fell by 14% and creatinine clearance fell by 10%.	DDI-false
DDI-DrugBank.d438.s29.p2	Cimetidine: In the presence of @DRUG$ at 300 mg QID (N=12) the mean apparent oral clearance of @DRUG$ fell by 14% and creatinine clearance fell by 10%.	DDI-mechanism
DDI-DrugBank.d438.s32.p0	The effect of @DRUG$ on @DRUG$ was not evaluated.	DDI-false
DDI-DrugBank.d438.s35.p0	The Cmax of @DRUG$ was 13% higher when it was coadministered with @DRUG$;	DDI-mechanism
DDI-DrugBank.d438.s39.p0	It is recommended that @DRUG$ be taken at least 2 hours following @DRUG$ administration.	DDI-advise
DDI-DrugBank.d438.s43.p0	Drug/Laboratory Tests Interactions Because false positive readings were reported with the Ames N-Multistix SG dipstick test for urinary protein when @DRUG$ was added to other @DRUG$, the more specific sulfosalicylic acid precipitation procedure is recommended to determine the presence of urine protein	DDI-false
DDI-DrugBank.d439.s0.p0	@DRUG$ may accentuate the electrolyte loss associated with @DRUG$ therapy.	DDI-effect
DDI-DrugBank.d440.s13.p0	However, since @DRUG$, @DRUG$, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.	DDI-false
DDI-DrugBank.d440.s13.p1	However, since @DRUG$, NSAIDs, and @DRUG$ are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.	DDI-false
DDI-DrugBank.d440.s13.p2	However, since @DRUG$, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of @DRUG$ or NSAIDs with Ibandronate.	DDI-false
DDI-DrugBank.d440.s13.p3	However, since @DRUG$, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or @DRUG$ with Ibandronate.	DDI-false
DDI-DrugBank.d440.s13.p4	However, since @DRUG$, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with @DRUG$.	DDI-false
DDI-DrugBank.d440.s13.p5	However, since aspirin, @DRUG$, and @DRUG$ are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with Ibandronate.	DDI-false
DDI-DrugBank.d440.s13.p6	However, since aspirin, @DRUG$, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of @DRUG$ or NSAIDs with Ibandronate.	DDI-false
DDI-DrugBank.d440.s13.p7	However, since aspirin, @DRUG$, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or @DRUG$ with Ibandronate.	DDI-false
DDI-DrugBank.d440.s13.p8	However, since aspirin, @DRUG$, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with @DRUG$.	DDI-false
DDI-DrugBank.d440.s13.p9	However, since aspirin, NSAIDs, and @DRUG$ are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of @DRUG$ or NSAIDs with Ibandronate.	DDI-false
DDI-DrugBank.d440.s13.p10	However, since aspirin, NSAIDs, and @DRUG$ are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or @DRUG$ with Ibandronate.	DDI-false
DDI-DrugBank.d440.s13.p11	However, since aspirin, NSAIDs, and @DRUG$ are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or NSAIDs with @DRUG$.	DDI-false
DDI-DrugBank.d440.s13.p12	However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of @DRUG$ or @DRUG$ with Ibandronate.	DDI-false
DDI-DrugBank.d440.s13.p13	However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of @DRUG$ or NSAIDs with @DRUG$.	DDI-advise
DDI-DrugBank.d440.s13.p14	However, since aspirin, NSAIDs, and bisphosphonates are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of aspirin or @DRUG$ with @DRUG$.	DDI-advise
DDI-DrugBank.d440.s4.p0	Of over 3500 patients enrolled in the @DRUG$ osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily @DRUG$ and PPIs).	DDI-false
DDI-DrugBank.d440.s4.p1	Of over 3500 patients enrolled in the @DRUG$ osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily H2 blockers and @DRUG$).	DDI-false
DDI-DrugBank.d440.s4.p2	Of over 3500 patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily @DRUG$ and @DRUG$).	DDI-false
DDI-DrugBank.d440.s7.p0	Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with @DRUG$ 150 mg once monthly was similar to that in patients treated with @DRUG$ 2.5 mg once daily.	DDI-false
DDI-DrugBank.d441.s5.p0	@DRUG$: Co-administration of @DRUG$ and serotonergic agents was not associated with serotonin syndrome in Phase 1, 2 or 3 studies.	DDI-false
DDI-DrugBank.d441.s5.p1	@DRUG$: Co-administration of linezolid and @DRUG$ was not associated with serotonin syndrome in Phase 1, 2 or 3 studies.	DDI-false
DDI-DrugBank.d441.s5.p2	Serotonergic Agents: Co-administration of @DRUG$ and @DRUG$ was not associated with serotonin syndrome in Phase 1, 2 or 3 studies.	DDI-false
DDI-DrugBank.d441.s6.p0	Spontaneous reports of serotonin syndrome associated with co-administration of @DRUG$ and @DRUG$, including antidepressants such as selective serotonin reuptake inhibitors (SSRIs), have been reported.	DDI-effect
DDI-DrugBank.d441.s6.p1	Spontaneous reports of serotonin syndrome associated with co-administration of @DRUG$ and serotonergic agents, including @DRUG$ such as selective serotonin reuptake inhibitors (SSRIs), have been reported.	DDI-effect
DDI-DrugBank.d441.s6.p2	Spontaneous reports of serotonin syndrome associated with co-administration of @DRUG$ and serotonergic agents, including antidepressants such as @DRUG$ (SSRIs), have been reported.	DDI-effect
DDI-DrugBank.d441.s6.p3	Spontaneous reports of serotonin syndrome associated with co-administration of @DRUG$ and serotonergic agents, including antidepressants such as selective serotonin reuptake inhibitors (@DRUG$), have been reported.	DDI-effect
DDI-DrugBank.d441.s6.p4	Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and @DRUG$, including @DRUG$ such as selective serotonin reuptake inhibitors (SSRIs), have been reported.	DDI-false
DDI-DrugBank.d441.s6.p5	Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and @DRUG$, including antidepressants such as @DRUG$ (SSRIs), have been reported.	DDI-false
DDI-DrugBank.d441.s6.p6	Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and @DRUG$, including antidepressants such as selective serotonin reuptake inhibitors (@DRUG$), have been reported.	DDI-false
DDI-DrugBank.d441.s6.p7	Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including @DRUG$ such as @DRUG$ (SSRIs), have been reported.	DDI-false
DDI-DrugBank.d441.s6.p8	Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including @DRUG$ such as selective serotonin reuptake inhibitors (@DRUG$), have been reported.	DDI-false
DDI-DrugBank.d441.s6.p9	Spontaneous reports of serotonin syndrome associated with co-administration of ZYVOX and serotonergic agents, including antidepressants such as @DRUG$ (@DRUG$), have been reported.	DDI-false
DDI-DrugBank.d441.s7.p0	Patients who are treated with @DRUG$ and concomitant @DRUG$ should be closely observed for signs and symptoms of serotonin syndrome (e.g., cognitive dysfunction, hyperpyrexia, hyperreflexia, incoordination).	DDI-effect
DDI-DrugBank.d442.s0.p0	Increases in prothrombin time have been noted in patients receiving long- term @DRUG$ therapy after @DRUG$ was initiated.	DDI-effect
DDI-DrugBank.d443.s4.p0	@DRUG$ Agents: @DRUG$ is contraindicated in patients who are hypersensitive to nonsteroidal anti-inflammatory agents.	DDI-false
DDI-DrugBank.d443.s4.p1	@DRUG$ Agents: Aspirin is contraindicated in patients who are hypersensitive to @DRUG$ agents.	DDI-false
DDI-DrugBank.d443.s4.p2	Nonsteroidal Antiinflammatory Agents: @DRUG$ is contraindicated in patients who are hypersensitive to @DRUG$ agents.	DDI-advise
DDI-DrugBank.d448.s1.p0	Concomitant use of @DRUG$ with @DRUG$, tricyclic antidepressants, barbiturates, or other central nervous system depressants may have an additive effect.	DDI-effect
DDI-DrugBank.d448.s1.p1	Concomitant use of @DRUG$ with alcohol, @DRUG$, barbiturates, or other central nervous system depressants may have an additive effect.	DDI-effect
DDI-DrugBank.d448.s1.p2	Concomitant use of @DRUG$ with alcohol, tricyclic antidepressants, @DRUG$, or other central nervous system depressants may have an additive effect.	DDI-effect
DDI-DrugBank.d448.s1.p3	Concomitant use of @DRUG$ with alcohol, tricyclic antidepressants, barbiturates, or other @DRUG$ may have an additive effect.	DDI-effect
DDI-DrugBank.d448.s1.p4	Concomitant use of antihistamines with @DRUG$, @DRUG$, barbiturates, or other central nervous system depressants may have an additive effect.	DDI-false
DDI-DrugBank.d448.s1.p5	Concomitant use of antihistamines with @DRUG$, tricyclic antidepressants, @DRUG$, or other central nervous system depressants may have an additive effect.	DDI-false
DDI-DrugBank.d448.s1.p6	Concomitant use of antihistamines with @DRUG$, tricyclic antidepressants, barbiturates, or other @DRUG$ may have an additive effect.	DDI-false
DDI-DrugBank.d448.s1.p7	Concomitant use of antihistamines with alcohol, @DRUG$, @DRUG$, or other central nervous system depressants may have an additive effect.	DDI-false
DDI-DrugBank.d448.s1.p8	Concomitant use of antihistamines with alcohol, @DRUG$, barbiturates, or other @DRUG$ may have an additive effect.	DDI-false
DDI-DrugBank.d448.s1.p9	Concomitant use of antihistamines with alcohol, tricyclic antidepressants, @DRUG$, or other @DRUG$ may have an additive effect.	DDI-false
DDI-DrugBank.d448.s4.p0	@DRUG$ may also interact with @DRUG$.	DDI-int
DDI-DrugBank.d448.s6.p0	@DRUG$ increase the rate of absorption of @DRUG$, while kaolin decreases it.	DDI-mechanism
DDI-DrugBank.d448.s6.p1	@DRUG$ increase the rate of absorption of pseudoephedrine, while @DRUG$ decreases it.	DDI-false
DDI-DrugBank.d448.s6.p2	Antacids increase the rate of absorption of @DRUG$, while @DRUG$ decreases it.	DDI-mechanism
DDI-DrugBank.d449.s1.p0	@DRUG$, @DRUG$, cimetidine (consider Xanax dose reduction).	DDI-false
DDI-DrugBank.d449.s1.p1	@DRUG$, fluvoxamine, @DRUG$ (consider Xanax dose reduction).	DDI-false
DDI-DrugBank.d449.s1.p2	@DRUG$, fluvoxamine, cimetidine (consider @DRUG$ dose reduction).	DDI-advise
DDI-DrugBank.d449.s1.p3	Nafazodone, @DRUG$, @DRUG$ (consider Xanax dose reduction).	DDI-false
DDI-DrugBank.d449.s1.p4	Nafazodone, @DRUG$, cimetidine (consider @DRUG$ dose reduction).	DDI-advise
DDI-DrugBank.d449.s1.p5	Nafazodone, fluvoxamine, @DRUG$ (consider @DRUG$ dose reduction).	DDI-advise
DDI-DrugBank.d45.s1.p0	Other @DRUG$ (including @DRUG$) used in combination with anakinra may also result in similar toxicities.	DDI-false
DDI-DrugBank.d45.s1.p1	Other @DRUG$ (including REMICADE) used in combination with @DRUG$ may also result in similar toxicities.	DDI-effect
DDI-DrugBank.d45.s1.p2	Other TNFa-blocking agents (including @DRUG$) used in combination with @DRUG$ may also result in similar toxicities.	DDI-effect
DDI-DrugBank.d45.s8.p0	Serum @DRUG$ concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including @DRUG$, antibiotics (metronidazole or ciprofloxacin) and aminosalicylates.	DDI-false
DDI-DrugBank.d45.s8.p1	Serum @DRUG$ concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, @DRUG$ (metronidazole or ciprofloxacin) and aminosalicylates.	DDI-false
DDI-DrugBank.d45.s8.p2	Serum @DRUG$ concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, antibiotics (@DRUG$ or ciprofloxacin) and aminosalicylates.	DDI-false
DDI-DrugBank.d45.s8.p3	Serum @DRUG$ concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, antibiotics (metronidazole or @DRUG$) and aminosalicylates.	DDI-false
DDI-DrugBank.d45.s8.p4	Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including @DRUG$, @DRUG$ (metronidazole or ciprofloxacin) and aminosalicylates.	DDI-false
DDI-DrugBank.d45.s8.p5	Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including @DRUG$, antibiotics (@DRUG$ or ciprofloxacin) and aminosalicylates.	DDI-false
DDI-DrugBank.d45.s8.p6	Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including @DRUG$, antibiotics (metronidazole or @DRUG$) and aminosalicylates.	DDI-false
DDI-DrugBank.d45.s8.p7	Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, @DRUG$ (@DRUG$ or ciprofloxacin) and aminosalicylates.	DDI-false
DDI-DrugBank.d45.s8.p8	Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, @DRUG$ (metronidazole or @DRUG$) and aminosalicylates.	DDI-false
DDI-DrugBank.d45.s8.p9	Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, antibiotics (@DRUG$ or @DRUG$) and aminosalicylates.	DDI-false
DDI-DrugBank.d450.s10.p0	Concomitant use of @DRUG$ and @DRUG$ increases the risk of cardiac arrhythmias.	DDI-effect
DDI-DrugBank.d450.s5.p0	@DRUG$ and @DRUG$, by decreasing gut motility, may increase digoxin absorption.	DDI-false
DDI-DrugBank.d450.s5.p1	@DRUG$ and diphenoxylate, by decreasing gut motility, may increase @DRUG$ absorption.	DDI-mechanism
DDI-DrugBank.d450.s5.p2	Propantheline and @DRUG$, by decreasing gut motility, may increase @DRUG$ absorption.	DDI-mechanism
DDI-DrugBank.d454.s4.p0	- Concomitant use of @DRUG$ may reduce the efficacy of @DRUG$.	DDI-effect
DDI-DrugBank.d455.s10.p0	These include @DRUG$, @DRUG$, and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).	DDI-false
DDI-DrugBank.d455.s10.p1	These include @DRUG$, cholestyramine, and some @DRUG$ (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).	DDI-false
DDI-DrugBank.d455.s10.p2	These include @DRUG$, cholestyramine, and some antibiotics (e.g. @DRUG$, rifamipicin, ampicillin and chloramphenicol).	DDI-false
DDI-DrugBank.d455.s10.p3	These include @DRUG$, cholestyramine, and some antibiotics (e.g. erythromycin, rifamipicin, @DRUG$ and chloramphenicol).	DDI-false
DDI-DrugBank.d455.s10.p4	These include @DRUG$, cholestyramine, and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and @DRUG$).	DDI-false
DDI-DrugBank.d455.s10.p5	These include probenecid, @DRUG$, and some @DRUG$ (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).	DDI-false
DDI-DrugBank.d455.s10.p6	These include probenecid, @DRUG$, and some antibiotics (e.g. @DRUG$, rifamipicin, ampicillin and chloramphenicol).	DDI-false
DDI-DrugBank.d455.s10.p7	These include probenecid, @DRUG$, and some antibiotics (e.g. erythromycin, rifamipicin, @DRUG$ and chloramphenicol).	DDI-false
DDI-DrugBank.d455.s10.p8	These include probenecid, @DRUG$, and some antibiotics (e.g. erythromycin, rifamipicin, ampicillin and @DRUG$).	DDI-false
DDI-DrugBank.d455.s10.p9	These include probenecid, cholestyramine, and some @DRUG$ (e.g. @DRUG$, rifamipicin, ampicillin and chloramphenicol).	DDI-false
DDI-DrugBank.d455.s10.p10	These include probenecid, cholestyramine, and some @DRUG$ (e.g. erythromycin, rifamipicin, @DRUG$ and chloramphenicol).	DDI-false
DDI-DrugBank.d455.s10.p11	These include probenecid, cholestyramine, and some @DRUG$ (e.g. erythromycin, rifamipicin, ampicillin and @DRUG$).	DDI-false
DDI-DrugBank.d455.s10.p12	These include probenecid, cholestyramine, and some antibiotics (e.g. @DRUG$, rifamipicin, @DRUG$ and chloramphenicol).	DDI-false
DDI-DrugBank.d455.s10.p13	These include probenecid, cholestyramine, and some antibiotics (e.g. @DRUG$, rifamipicin, ampicillin and @DRUG$).	DDI-false
DDI-DrugBank.d455.s10.p14	These include probenecid, cholestyramine, and some antibiotics (e.g. erythromycin, rifamipicin, @DRUG$ and @DRUG$).	DDI-false
DDI-DrugBank.d455.s11.p0	No interaction with the @DRUG$ @DRUG$ was shown in a single-dose study with entacapone without coadministered levodopa/dopa-decarboxylase inhibitor.	DDI-false
DDI-DrugBank.d455.s11.p1	No interaction with the @DRUG$ imipramine was shown in a single-dose study with @DRUG$ without coadministered levodopa/dopa-decarboxylase inhibitor.	DDI-false
DDI-DrugBank.d455.s11.p2	No interaction with the @DRUG$ imipramine was shown in a single-dose study with entacapone without coadministered @DRUG$/dopa-decarboxylase inhibitor.	DDI-false
DDI-DrugBank.d455.s11.p3	No interaction with the @DRUG$ imipramine was shown in a single-dose study with entacapone without coadministered levodopa/@DRUG$.	DDI-false
DDI-DrugBank.d455.s11.p4	No interaction with the tricyclic antidepressant @DRUG$ was shown in a single-dose study with @DRUG$ without coadministered levodopa/dopa-decarboxylase inhibitor.	DDI-false
DDI-DrugBank.d455.s11.p5	No interaction with the tricyclic antidepressant @DRUG$ was shown in a single-dose study with entacapone without coadministered @DRUG$/dopa-decarboxylase inhibitor.	DDI-false
DDI-DrugBank.d455.s11.p6	No interaction with the tricyclic antidepressant @DRUG$ was shown in a single-dose study with entacapone without coadministered levodopa/@DRUG$.	DDI-false
DDI-DrugBank.d455.s11.p7	No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with @DRUG$ without coadministered @DRUG$/dopa-decarboxylase inhibitor.	DDI-false
DDI-DrugBank.d455.s11.p8	No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with @DRUG$ without coadministered levodopa/@DRUG$.	DDI-false
DDI-DrugBank.d455.s11.p9	No interaction with the tricyclic antidepressant imipramine was shown in a single-dose study with entacapone without coadministered @DRUG$/@DRUG$.	DDI-false
DDI-DrugBank.d456.s6.p0	Other CYP3A4 inducers include, but are not limited to, @DRUG$, @DRUG$, phenytoin, carbamazepine, phenobarbital and St. Johns Wort.	DDI-false
DDI-DrugBank.d456.s6.p1	Other CYP3A4 inducers include, but are not limited to, @DRUG$, rifapentine, @DRUG$, carbamazepine, phenobarbital and St. Johns Wort.	DDI-false
DDI-DrugBank.d456.s6.p2	Other CYP3A4 inducers include, but are not limited to, @DRUG$, rifapentine, phenytoin, @DRUG$, phenobarbital and St. Johns Wort.	DDI-false
DDI-DrugBank.d456.s6.p3	Other CYP3A4 inducers include, but are not limited to, @DRUG$, rifapentine, phenytoin, carbamazepine, @DRUG$ and St. Johns Wort.	DDI-false
DDI-DrugBank.d456.s6.p4	Other CYP3A4 inducers include, but are not limited to, rifabutin, @DRUG$, @DRUG$, carbamazepine, phenobarbital and St. Johns Wort.	DDI-false
DDI-DrugBank.d456.s6.p5	Other CYP3A4 inducers include, but are not limited to, rifabutin, @DRUG$, phenytoin, @DRUG$, phenobarbital and St. Johns Wort.	DDI-false
DDI-DrugBank.d456.s6.p6	Other CYP3A4 inducers include, but are not limited to, rifabutin, @DRUG$, phenytoin, carbamazepine, @DRUG$ and St. Johns Wort.	DDI-false
DDI-DrugBank.d456.s6.p7	Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine, @DRUG$, @DRUG$, phenobarbital and St. Johns Wort.	DDI-false
DDI-DrugBank.d456.s6.p8	Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine, @DRUG$, carbamazepine, @DRUG$ and St. Johns Wort.	DDI-false
DDI-DrugBank.d456.s6.p9	Other CYP3A4 inducers include, but are not limited to, rifabutin, rifapentine, phenytoin, @DRUG$, @DRUG$ and St. Johns Wort.	DDI-false
DDI-DrugBank.d457.s0.p0	@DRUG$ may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	DDI-effect
DDI-DrugBank.d457.s0.p1	@DRUG$ may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	DDI-effect
DDI-DrugBank.d457.s0.p2	@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers.	DDI-effect
DDI-DrugBank.d457.s0.p3	@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers.	DDI-effect
DDI-DrugBank.d457.s0.p4	@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, @DRUG$, anticoagulants, and beta blockers.	DDI-effect
DDI-DrugBank.d457.s0.p5	@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, @DRUG$, and beta blockers.	DDI-effect
DDI-DrugBank.d457.s0.p6	@DRUG$ may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and @DRUG$.	DDI-effect
DDI-DrugBank.d457.s0.p7	Barbiturates may decrease the effectiveness of oral @DRUG$, certain @DRUG$, quinidine, theophylline, corticosteroids, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d457.s0.p8	Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d457.s0.p9	Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d457.s0.p10	Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, @DRUG$, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d457.s0.p11	Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, corticosteroids, @DRUG$, and beta blockers.	DDI-false
DDI-DrugBank.d457.s0.p12	Barbiturates may decrease the effectiveness of oral @DRUG$, certain antibiotics, quinidine, theophylline, corticosteroids, anticoagulants, and @DRUG$.	DDI-false
DDI-DrugBank.d457.s0.p13	Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, @DRUG$, theophylline, corticosteroids, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d457.s0.p14	Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, @DRUG$, corticosteroids, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d457.s0.p15	Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, @DRUG$, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d457.s0.p16	Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, corticosteroids, @DRUG$, and beta blockers.	DDI-false
DDI-DrugBank.d457.s0.p17	Barbiturates may decrease the effectiveness of oral contraceptives, certain @DRUG$, quinidine, theophylline, corticosteroids, anticoagulants, and @DRUG$.	DDI-false
DDI-DrugBank.d457.s0.p18	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, @DRUG$, corticosteroids, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d457.s0.p19	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, @DRUG$, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d457.s0.p20	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, @DRUG$, and beta blockers.	DDI-false
DDI-DrugBank.d457.s0.p21	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, @DRUG$, theophylline, corticosteroids, anticoagulants, and @DRUG$.	DDI-false
DDI-DrugBank.d457.s0.p22	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, @DRUG$, anticoagulants, and beta blockers.	DDI-false
DDI-DrugBank.d457.s0.p23	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, corticosteroids, @DRUG$, and beta blockers.	DDI-false
DDI-DrugBank.d457.s0.p24	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, @DRUG$, corticosteroids, anticoagulants, and @DRUG$.	DDI-false
DDI-DrugBank.d457.s0.p25	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, @DRUG$, @DRUG$, and beta blockers.	DDI-false
DDI-DrugBank.d457.s0.p26	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, @DRUG$, anticoagulants, and @DRUG$.	DDI-false
DDI-DrugBank.d457.s0.p27	Barbiturates may decrease the effectiveness of oral contraceptives, certain antibiotics, quinidine, theophylline, corticosteroids, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d458.s10.p0	@DRUG$ tablets may alter the metabolism of @DRUG$, tacrolimus, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.	DDI-mechanism
DDI-DrugBank.d458.s10.p1	@DRUG$ tablets may alter the metabolism of cyclosporine, @DRUG$, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.	DDI-mechanism
DDI-DrugBank.d458.s10.p2	@DRUG$ tablets may alter the metabolism of cyclosporine, tacrolimus, and @DRUG$, resulting in elevated plasma concentrations of the latter drugs.	DDI-mechanism
DDI-DrugBank.d458.s10.p3	Ketoconazole tablets may alter the metabolism of @DRUG$, @DRUG$, and methylprednisolone, resulting in elevated plasma concentrations of the latter drugs.	DDI-false
DDI-DrugBank.d458.s10.p4	Ketoconazole tablets may alter the metabolism of @DRUG$, tacrolimus, and @DRUG$, resulting in elevated plasma concentrations of the latter drugs.	DDI-false
DDI-DrugBank.d458.s10.p5	Ketoconazole tablets may alter the metabolism of cyclosporine, @DRUG$, and @DRUG$, resulting in elevated plasma concentrations of the latter drugs.	DDI-false
DDI-DrugBank.d458.s20.p0	In simultaneous treatment with @DRUG$ and @DRUG$, the anticoagulant effect should be carefully titrated and monitored.	DDI-advise
DDI-DrugBank.d458.s30.p0	Also, there were no clinically significant differences in adverse events when @DRUG$ was administered with or without @DRUG$.	DDI-false
DDI-DrugBank.d46.s15.p0	- @DRUG$: Generally should not be given with @DRUG$.	DDI-advise
DDI-DrugBank.d460.s14.p0	Certain drugs, including @DRUG$ (@DRUG$), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.	DDI-false
DDI-DrugBank.d460.s14.p1	Certain drugs, including @DRUG$ (NSAIDs), @DRUG$, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.	DDI-false
DDI-DrugBank.d460.s14.p2	Certain drugs, including @DRUG$ (NSAIDs), salicylates, @DRUG$, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.	DDI-false
DDI-DrugBank.d460.s14.p3	Certain drugs, including @DRUG$ (NSAIDs), salicylates, monoamine oxidase inhibitors, and @DRUG$ may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.	DDI-false
DDI-DrugBank.d460.s14.p4	Certain drugs, including @DRUG$ (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.	DDI-effect
DDI-DrugBank.d460.s14.p5	Certain drugs, including @DRUG$ (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral @DRUG$.	DDI-effect
DDI-DrugBank.d460.s14.p6	Certain drugs, including nonsteroidal anti-inflammatory agents (@DRUG$), @DRUG$, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.	DDI-false
DDI-DrugBank.d460.s14.p7	Certain drugs, including nonsteroidal anti-inflammatory agents (@DRUG$), salicylates, @DRUG$, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.	DDI-false
DDI-DrugBank.d460.s14.p8	Certain drugs, including nonsteroidal anti-inflammatory agents (@DRUG$), salicylates, monoamine oxidase inhibitors, and @DRUG$ may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.	DDI-false
DDI-DrugBank.d460.s14.p9	Certain drugs, including nonsteroidal anti-inflammatory agents (@DRUG$), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.	DDI-effect
DDI-DrugBank.d460.s14.p10	Certain drugs, including nonsteroidal anti-inflammatory agents (@DRUG$), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral @DRUG$.	DDI-effect
DDI-DrugBank.d460.s14.p11	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), @DRUG$, @DRUG$, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.	DDI-false
DDI-DrugBank.d460.s14.p12	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), @DRUG$, monoamine oxidase inhibitors, and @DRUG$ may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.	DDI-false
DDI-DrugBank.d460.s14.p13	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), @DRUG$, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.	DDI-effect
DDI-DrugBank.d460.s14.p14	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), @DRUG$, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral @DRUG$.	DDI-effect
DDI-DrugBank.d460.s14.p15	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, @DRUG$, and @DRUG$ may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.	DDI-false
DDI-DrugBank.d460.s14.p16	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, @DRUG$, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.	DDI-effect
DDI-DrugBank.d460.s14.p17	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, @DRUG$, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral @DRUG$.	DDI-effect
DDI-DrugBank.d460.s14.p18	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and @DRUG$ may potentiate the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.	DDI-effect
DDI-DrugBank.d460.s14.p19	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and @DRUG$ may potentiate the hypoglycemic action of Starlix and other oral @DRUG$.	DDI-effect
DDI-DrugBank.d460.s14.p20	Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of @DRUG$ and other oral @DRUG$.	DDI-false
DDI-DrugBank.d460.s15.p0	Certain drugs including @DRUG$, @DRUG$, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.	DDI-false
DDI-DrugBank.d460.s15.p1	Certain drugs including @DRUG$, corticosteroids, @DRUG$, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.	DDI-false
DDI-DrugBank.d460.s15.p2	Certain drugs including @DRUG$, corticosteroids, thyroid products, and @DRUG$ may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.	DDI-false
DDI-DrugBank.d460.s15.p3	Certain drugs including @DRUG$, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.	DDI-effect
DDI-DrugBank.d460.s15.p4	Certain drugs including @DRUG$, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral @DRUG$.	DDI-effect
DDI-DrugBank.d460.s15.p5	Certain drugs including thiazides, @DRUG$, @DRUG$, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.	DDI-false
DDI-DrugBank.d460.s15.p6	Certain drugs including thiazides, @DRUG$, thyroid products, and @DRUG$ may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.	DDI-false
DDI-DrugBank.d460.s15.p7	Certain drugs including thiazides, @DRUG$, thyroid products, and sympathomimetics may reduce the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.	DDI-effect
DDI-DrugBank.d460.s15.p8	Certain drugs including thiazides, @DRUG$, thyroid products, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral @DRUG$.	DDI-effect
DDI-DrugBank.d460.s15.p9	Certain drugs including thiazides, corticosteroids, @DRUG$, and @DRUG$ may reduce the hypoglycemic action of Starlix and other oral antidiabetic drugs.	DDI-false
DDI-DrugBank.d460.s15.p10	Certain drugs including thiazides, corticosteroids, @DRUG$, and sympathomimetics may reduce the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.	DDI-effect
DDI-DrugBank.d460.s15.p11	Certain drugs including thiazides, corticosteroids, @DRUG$, and sympathomimetics may reduce the hypoglycemic action of Starlix and other oral @DRUG$.	DDI-effect
DDI-DrugBank.d460.s15.p12	Certain drugs including thiazides, corticosteroids, thyroid products, and @DRUG$ may reduce the hypoglycemic action of @DRUG$ and other oral antidiabetic drugs.	DDI-effect
DDI-DrugBank.d460.s15.p13	Certain drugs including thiazides, corticosteroids, thyroid products, and @DRUG$ may reduce the hypoglycemic action of Starlix and other oral @DRUG$.	DDI-effect
DDI-DrugBank.d460.s15.p14	Certain drugs including thiazides, corticosteroids, thyroid products, and sympathomimetics may reduce the hypoglycemic action of @DRUG$ and other oral @DRUG$.	DDI-false
DDI-DrugBank.d460.s7.p0	@DRUG$: When healthy subjects were administered @DRUG$ 120 mg three times daily before meals for four days in combination with a single dose of warfarin 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.	DDI-false
DDI-DrugBank.d460.s7.p1	@DRUG$: When healthy subjects were administered Starlix 120 mg three times daily before meals for four days in combination with a single dose of @DRUG$ 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.	DDI-false
DDI-DrugBank.d460.s7.p2	Warfarin: When healthy subjects were administered @DRUG$ 120 mg three times daily before meals for four days in combination with a single dose of @DRUG$ 30 mg on day 2, there were no alterations in the pharmacokinetics of either agent.	DDI-false
DDI-DrugBank.d461.s0.p0	Additive depressant effect when used with general @DRUG$, @DRUG$, antianxiety drugs, hypnotics, alcohol, and other opiate analgesics.	DDI-false
DDI-DrugBank.d461.s0.p1	Additive depressant effect when used with general @DRUG$, sedatives, @DRUG$, hypnotics, alcohol, and other opiate analgesics.	DDI-false
DDI-DrugBank.d461.s0.p2	Additive depressant effect when used with general @DRUG$, sedatives, antianxiety drugs, @DRUG$, alcohol, and other opiate analgesics.	DDI-false
DDI-DrugBank.d461.s0.p3	Additive depressant effect when used with general @DRUG$, sedatives, antianxiety drugs, hypnotics, @DRUG$, and other opiate analgesics.	DDI-false
DDI-DrugBank.d461.s0.p4	Additive depressant effect when used with general @DRUG$, sedatives, antianxiety drugs, hypnotics, alcohol, and other @DRUG$.	DDI-false
DDI-DrugBank.d461.s0.p5	Additive depressant effect when used with general anesthetics, @DRUG$, @DRUG$, hypnotics, alcohol, and other opiate analgesics.	DDI-false
DDI-DrugBank.d461.s0.p6	Additive depressant effect when used with general anesthetics, @DRUG$, antianxiety drugs, @DRUG$, alcohol, and other opiate analgesics.	DDI-false
DDI-DrugBank.d461.s0.p7	Additive depressant effect when used with general anesthetics, @DRUG$, antianxiety drugs, hypnotics, @DRUG$, and other opiate analgesics.	DDI-false
DDI-DrugBank.d461.s0.p8	Additive depressant effect when used with general anesthetics, @DRUG$, antianxiety drugs, hypnotics, alcohol, and other @DRUG$.	DDI-false
DDI-DrugBank.d461.s0.p9	Additive depressant effect when used with general anesthetics, sedatives, @DRUG$, @DRUG$, alcohol, and other opiate analgesics.	DDI-false
DDI-DrugBank.d461.s0.p10	Additive depressant effect when used with general anesthetics, sedatives, @DRUG$, hypnotics, @DRUG$, and other opiate analgesics.	DDI-false
DDI-DrugBank.d461.s0.p11	Additive depressant effect when used with general anesthetics, sedatives, @DRUG$, hypnotics, alcohol, and other @DRUG$.	DDI-false
DDI-DrugBank.d461.s0.p12	Additive depressant effect when used with general anesthetics, sedatives, antianxiety drugs, @DRUG$, @DRUG$, and other opiate analgesics.	DDI-false
DDI-DrugBank.d461.s0.p13	Additive depressant effect when used with general anesthetics, sedatives, antianxiety drugs, @DRUG$, alcohol, and other @DRUG$.	DDI-false
DDI-DrugBank.d461.s0.p14	Additive depressant effect when used with general anesthetics, sedatives, antianxiety drugs, hypnotics, @DRUG$, and other @DRUG$.	DDI-false
DDI-DrugBank.d463.s5.p0	In vitro, @DRUG$ does not displace tightly bound drugs like @DRUG$, propranolol, and warfarin from serum proteins.	DDI-false
DDI-DrugBank.d463.s5.p1	In vitro, @DRUG$ does not displace tightly bound drugs like phenytoin, @DRUG$, and warfarin from serum proteins.	DDI-false
DDI-DrugBank.d463.s5.p2	In vitro, @DRUG$ does not displace tightly bound drugs like phenytoin, propranolol, and @DRUG$ from serum proteins.	DDI-false
DDI-DrugBank.d463.s5.p3	In vitro, buspirone does not displace tightly bound drugs like @DRUG$, @DRUG$, and warfarin from serum proteins.	DDI-false
DDI-DrugBank.d463.s5.p4	In vitro, buspirone does not displace tightly bound drugs like @DRUG$, propranolol, and @DRUG$ from serum proteins.	DDI-false
DDI-DrugBank.d463.s5.p5	In vitro, buspirone does not displace tightly bound drugs like phenytoin, @DRUG$, and @DRUG$ from serum proteins.	DDI-false
DDI-DrugBank.d466.s0.p0	Drug Interaction with @DRUG$ and @DRUG$ Fexofenadine has been shown to exhibit minimal (ca. 5%) metabolism.	DDI-false
DDI-DrugBank.d466.s0.p1	Drug Interaction with @DRUG$ and Ketoconazole @DRUG$ has been shown to exhibit minimal (ca. 5%) metabolism.	DDI-false
DDI-DrugBank.d466.s0.p2	Drug Interaction with Erythromycin and @DRUG$ @DRUG$ has been shown to exhibit minimal (ca. 5%) metabolism.	DDI-false
DDI-DrugBank.d466.s19.p0	Drug Interactions with @DRUG$ Administration of 120 mg of @DRUG$ (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s19.p1	Drug Interactions with @DRUG$ Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an @DRUG$ and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s19.p2	Drug Interactions with @DRUG$ Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and @DRUG$ containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s19.p3	Drug Interactions with @DRUG$ Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing @DRUG$ (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s19.p4	Drug Interactions with @DRUG$ Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (@DRUG$ ) decreased fexofenadine AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s19.p5	Drug Interactions with @DRUG$ Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased @DRUG$ AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s19.p6	Drug Interactions with Antacids Administration of 120 mg of @DRUG$ (2 x 60 mg capsule) within 15 minutes of an @DRUG$ and magnesium containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.	DDI-mechanism
DDI-DrugBank.d466.s19.p7	Drug Interactions with Antacids Administration of 120 mg of @DRUG$ (2 x 60 mg capsule) within 15 minutes of an aluminum and @DRUG$ containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.	DDI-mechanism
DDI-DrugBank.d466.s19.p8	Drug Interactions with Antacids Administration of 120 mg of @DRUG$ (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing @DRUG$ (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.	DDI-mechanism
DDI-DrugBank.d466.s19.p9	Drug Interactions with Antacids Administration of 120 mg of @DRUG$ (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (@DRUG$ ) decreased fexofenadine AUC by 41% and cmax by 43%.	DDI-mechanism
DDI-DrugBank.d466.s19.p10	Drug Interactions with Antacids Administration of 120 mg of @DRUG$ (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (Maalox ) decreased @DRUG$ AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s19.p11	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an @DRUG$ and @DRUG$ containing antacid (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s19.p12	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an @DRUG$ and magnesium containing @DRUG$ (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s19.p13	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an @DRUG$ and magnesium containing antacid (@DRUG$ ) decreased fexofenadine AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s19.p14	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an @DRUG$ and magnesium containing antacid (Maalox ) decreased @DRUG$ AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s19.p15	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and @DRUG$ containing @DRUG$ (Maalox ) decreased fexofenadine AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s19.p16	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and @DRUG$ containing antacid (@DRUG$ ) decreased fexofenadine AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s19.p17	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and @DRUG$ containing antacid (Maalox ) decreased @DRUG$ AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s19.p18	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing @DRUG$ (@DRUG$ ) decreased fexofenadine AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s19.p19	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing @DRUG$ (Maalox ) decreased @DRUG$ AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s19.p20	Drug Interactions with Antacids Administration of 120 mg of fexofenadine hydrochloride (2 x 60 mg capsule) within 15 minutes of an aluminum and magnesium containing antacid (@DRUG$ ) decreased @DRUG$ AUC by 41% and cmax by 43%.	DDI-false
DDI-DrugBank.d466.s27.p0	Therefore, to maximize the effects of @DRUG$, it is recommended that @DRUG$ should be taken with water	DDI-false
DDI-DrugBank.d466.s5.p0	The findings of these studies are summarized in the following table: Effects on steady-state @DRUG$ pharmacokinetics after 7 days of co-administration with @DRUG$ 120 mg every 12 hours (two times the recommended twice daily dose) in healthy volunteers (n=24)	DDI-false
DDI-DrugBank.d467.s2.p0	On the basis of the metabolism of @DRUG$ by cytochrome P450 3A4, @DRUG$, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.	DDI-false
DDI-DrugBank.d467.s2.p1	On the basis of the metabolism of @DRUG$ by cytochrome P450 3A4, ketoconazole, @DRUG$, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.	DDI-false
DDI-DrugBank.d467.s2.p2	On the basis of the metabolism of @DRUG$ by cytochrome P450 3A4, ketoconazole, itraconazole, @DRUG$, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.	DDI-false
DDI-DrugBank.d467.s2.p3	On the basis of the metabolism of @DRUG$ by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, @DRUG$, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.	DDI-false
DDI-DrugBank.d467.s2.p4	On the basis of the metabolism of @DRUG$ by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d467.s2.p5	On the basis of the metabolism of bexarotene by cytochrome P450 3A4, @DRUG$, @DRUG$, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.	DDI-false
DDI-DrugBank.d467.s2.p6	On the basis of the metabolism of bexarotene by cytochrome P450 3A4, @DRUG$, itraconazole, @DRUG$, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.	DDI-false
DDI-DrugBank.d467.s2.p7	On the basis of the metabolism of bexarotene by cytochrome P450 3A4, @DRUG$, itraconazole, erythromycin, @DRUG$, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.	DDI-false
DDI-DrugBank.d467.s2.p8	On the basis of the metabolism of bexarotene by cytochrome P450 3A4, @DRUG$, itraconazole, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma @DRUG$ concentrations.	DDI-mechanism
DDI-DrugBank.d467.s2.p9	On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, @DRUG$, @DRUG$, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.	DDI-false
DDI-DrugBank.d467.s2.p10	On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, @DRUG$, erythromycin, @DRUG$, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.	DDI-false
DDI-DrugBank.d467.s2.p11	On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, @DRUG$, erythromycin, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma @DRUG$ concentrations.	DDI-mechanism
DDI-DrugBank.d467.s2.p12	On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, @DRUG$, @DRUG$, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma bexarotene concentrations.	DDI-false
DDI-DrugBank.d467.s2.p13	On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, @DRUG$, gemfibrozil, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma @DRUG$ concentrations.	DDI-mechanism
DDI-DrugBank.d467.s2.p14	On the basis of the metabolism of bexarotene by cytochrome P450 3A4, ketoconazole, itraconazole, erythromycin, @DRUG$, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma @DRUG$ concentrations.	DDI-mechanism
DDI-DrugBank.d467.s3.p0	Furthermore, @DRUG$, @DRUG$, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.	DDI-false
DDI-DrugBank.d467.s3.p1	Furthermore, @DRUG$, phenytoin, @DRUG$, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.	DDI-false
DDI-DrugBank.d467.s3.p2	Furthermore, @DRUG$, phenytoin, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma @DRUG$ concentrations.	DDI-mechanism
DDI-DrugBank.d467.s3.p3	Furthermore, rifampin, @DRUG$, @DRUG$, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma bexarotene concentrations.	DDI-false
DDI-DrugBank.d467.s3.p4	Furthermore, rifampin, @DRUG$, phenobarbital, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma @DRUG$ concentrations.	DDI-mechanism
DDI-DrugBank.d467.s3.p5	Furthermore, rifampin, phenytoin, @DRUG$, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma @DRUG$ concentrations.	DDI-mechanism
DDI-DrugBank.d468.s4.p0	@DRUG$: Some @DRUG$ may increase the concentration of digitalis preparations in the blood.	DDI-false
DDI-DrugBank.d468.s4.p1	@DRUG$: Some calcium blockers may increase the concentration of @DRUG$ in the blood.	DDI-false
DDI-DrugBank.d468.s4.p2	Digoxin: Some @DRUG$ may increase the concentration of @DRUG$ in the blood.	DDI-mechanism
DDI-DrugBank.d468.s8.p0	@DRUG$: Concomitant administration of @DRUG$ and cyclosporine levels.	DDI-false
DDI-DrugBank.d468.s8.p1	@DRUG$: Concomitant administration of nicardipine and @DRUG$ levels.	DDI-false
DDI-DrugBank.d468.s8.p2	Cyclosporine: Concomitant administration of @DRUG$ and @DRUG$ levels.	DDI-false
DDI-DrugBank.d468.s9.p0	Plasma concentrations of @DRUG$ should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with @DRUG$.	DDI-advise
DDI-DrugBank.d47.s3.p0	In addition, the beneficial effects of @DRUG$ in Parkinsons disease have been reported to be reversed by @DRUG$ and papaverine.	DDI-effect
DDI-DrugBank.d47.s3.p1	In addition, the beneficial effects of @DRUG$ in Parkinsons disease have been reported to be reversed by phenytoin and @DRUG$.	DDI-effect
DDI-DrugBank.d47.s3.p2	In addition, the beneficial effects of levodopa in Parkinsons disease have been reported to be reversed by @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d47.s7.p0	Although @DRUG$ may increase the bioavailability of @DRUG$ by increasing gastric emptying, metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.	DDI-mechanism
DDI-DrugBank.d47.s7.p1	Although @DRUG$ may increase the bioavailability of levodopa by increasing gastric emptying, @DRUG$ may also adversely affect disease control by its dopamine receptor antagonistic properties.	DDI-false
DDI-DrugBank.d47.s7.p2	Although metoclopramide may increase the bioavailability of @DRUG$ by increasing gastric emptying, @DRUG$ may also adversely affect disease control by its dopamine receptor antagonistic properties.	DDI-false
DDI-DrugBank.d476.s7.p0	There was no effect of @DRUG$ on prothrombin time in patients on stable doses of @DRUG$.	DDI-false
DDI-DrugBank.d477.s2.p0	@DRUG$ may decrease the hypotensive effect of @DRUG$.	DDI-effect
DDI-DrugBank.d478.s5.p0	If concomitant treatment with @DRUG$ and an @DRUG$ is clinically warranted, appropriate observation of the patient is advised.	DDI-advise
DDI-DrugBank.d48.s11.p0	@DRUG$/@DRUG$: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.	DDI-false
DDI-DrugBank.d48.s11.p1	@DRUG$/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by @DRUG$ or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.	DDI-false
DDI-DrugBank.d48.s11.p2	@DRUG$/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or @DRUG$ (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.	DDI-false
DDI-DrugBank.d48.s11.p3	@DRUG$/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, @DRUG$ and omeprazole) is likely to reduce dasatinib exposure.	DDI-false
DDI-DrugBank.d48.s11.p4	@DRUG$/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and @DRUG$) is likely to reduce dasatinib exposure.	DDI-false
DDI-DrugBank.d48.s11.p5	@DRUG$/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce @DRUG$ exposure.	DDI-false
DDI-DrugBank.d48.s11.p6	H2 Blockers/@DRUG$: Long-term suppression of gastric acid secretion by @DRUG$ or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.	DDI-false
DDI-DrugBank.d48.s11.p7	H2 Blockers/@DRUG$: Long-term suppression of gastric acid secretion by H2 blockers or @DRUG$ (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.	DDI-false
DDI-DrugBank.d48.s11.p8	H2 Blockers/@DRUG$: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, @DRUG$ and omeprazole) is likely to reduce dasatinib exposure.	DDI-false
DDI-DrugBank.d48.s11.p9	H2 Blockers/@DRUG$: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and @DRUG$) is likely to reduce dasatinib exposure.	DDI-false
DDI-DrugBank.d48.s11.p10	H2 Blockers/@DRUG$: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce @DRUG$ exposure.	DDI-false
DDI-DrugBank.d48.s11.p11	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by @DRUG$ or @DRUG$ (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.	DDI-false
DDI-DrugBank.d48.s11.p12	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by @DRUG$ or proton pump inhibitors (eg, @DRUG$ and omeprazole) is likely to reduce dasatinib exposure.	DDI-false
DDI-DrugBank.d48.s11.p13	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by @DRUG$ or proton pump inhibitors (eg, famotidine and @DRUG$) is likely to reduce dasatinib exposure.	DDI-false
DDI-DrugBank.d48.s11.p14	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by @DRUG$ or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce @DRUG$ exposure.	DDI-effect
DDI-DrugBank.d48.s11.p15	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or @DRUG$ (eg, @DRUG$ and omeprazole) is likely to reduce dasatinib exposure.	DDI-false
DDI-DrugBank.d48.s11.p16	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or @DRUG$ (eg, famotidine and @DRUG$) is likely to reduce dasatinib exposure.	DDI-false
DDI-DrugBank.d48.s11.p17	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or @DRUG$ (eg, famotidine and omeprazole) is likely to reduce @DRUG$ exposure.	DDI-effect
DDI-DrugBank.d48.s11.p18	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, @DRUG$ and @DRUG$) is likely to reduce dasatinib exposure.	DDI-false
DDI-DrugBank.d48.s11.p19	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, @DRUG$ and omeprazole) is likely to reduce @DRUG$ exposure.	DDI-effect
DDI-DrugBank.d48.s11.p20	H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and @DRUG$) is likely to reduce @DRUG$ exposure.	DDI-effect
DDI-DrugBank.d48.s12.p0	The concomitant use of @DRUG$ or @DRUG$ with SPRYCEL is not recommended.	DDI-false
DDI-DrugBank.d48.s12.p1	The concomitant use of @DRUG$ or proton pump inhibitors with @DRUG$ is not recommended.	DDI-advise
DDI-DrugBank.d48.s12.p2	The concomitant use of H2 blockers or @DRUG$ with @DRUG$ is not recommended.	DDI-advise
DDI-DrugBank.d48.s14.p0	Drugs that may have their plasma concentration altered by @DRUG$ CYP3A4 Substrates: @DRUG$ is a time-dependent inhibitor of CYP3A4.	DDI-false
DDI-DrugBank.d48.s2.p0	In patients receiving treatment with @DRUG$, close monitoring for toxicity and a @DRUG$ dose reduction should be considered if systemic administration of a potent CYP3A4 inhibitor cannot be avoided.	DDI-false
DDI-DrugBank.d48.s8.p0	@DRUG$: Nonclinical data demonstrate that the solubility of @DRUG$ is pH dependent.	DDI-false
DDI-DrugBank.d480.s21.p0	@DRUG$ produced only minor changes in the levels of @DRUG$ and its metabolites.	DDI-mechanism
DDI-DrugBank.d480.s23.p0	Therefore, such combined treatment should be approached with caution and patients should be monitored closely when @DRUG$ is combined with these drugs, particularly with @DRUG$.	DDI-advise
DDI-DrugBank.d480.s26.p0	Such individuals are referred to as poor metabolizers of drugs such as @DRUG$, @DRUG$, the tricyclic antidepressants, and clozapine.	DDI-false
DDI-DrugBank.d480.s26.p1	Such individuals are referred to as poor metabolizers of drugs such as @DRUG$, dextromethorphan, the @DRUG$, and clozapine.	DDI-false
DDI-DrugBank.d480.s26.p2	Such individuals are referred to as poor metabolizers of drugs such as @DRUG$, dextromethorphan, the tricyclic antidepressants, and @DRUG$.	DDI-false
DDI-DrugBank.d480.s26.p3	Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, @DRUG$, the @DRUG$, and clozapine.	DDI-false
DDI-DrugBank.d480.s26.p4	Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, @DRUG$, the tricyclic antidepressants, and @DRUG$.	DDI-false
DDI-DrugBank.d480.s26.p5	Such individuals are referred to as poor metabolizers of drugs such as debrisoquin, dextromethorphan, the @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d480.s29.p0	Concomitant use of @DRUG$ with other drugs metabolized by cytochrome P450 2D6 may require lower doses than usually prescribed for either @DRUG$ or the other drug.	DDI-false
DDI-DrugBank.d480.s9.p0	@DRUG$ may potentiate the hypotensive effects of @DRUG$ and the anticholinergic effects of atropine-type drugs.	DDI-effect
DDI-DrugBank.d480.s9.p1	@DRUG$ may potentiate the hypotensive effects of antihypertensive drugs and the anticholinergic effects of @DRUG$-type drugs.	DDI-effect
DDI-DrugBank.d480.s9.p2	Clozapine may potentiate the hypotensive effects of @DRUG$ and the anticholinergic effects of @DRUG$-type drugs.	DDI-false
DDI-DrugBank.d482.s1.p0	Talk to your doctor if you are taking certain @DRUG$ such as @DRUG$, clarithromycin or azithromycin.	DDI-false
DDI-DrugBank.d482.s1.p1	Talk to your doctor if you are taking certain @DRUG$ such as erythromycin, @DRUG$ or azithromycin.	DDI-false
DDI-DrugBank.d482.s1.p2	Talk to your doctor if you are taking certain @DRUG$ such as erythromycin, clarithromycin or @DRUG$.	DDI-false
DDI-DrugBank.d482.s1.p3	Talk to your doctor if you are taking certain antibiotics such as @DRUG$, @DRUG$ or azithromycin.	DDI-false
DDI-DrugBank.d482.s1.p4	Talk to your doctor if you are taking certain antibiotics such as @DRUG$, clarithromycin or @DRUG$.	DDI-false
DDI-DrugBank.d482.s1.p5	Talk to your doctor if you are taking certain antibiotics such as erythromycin, @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d483.s4.p0	As with other @DRUG$, high concentrations of @DRUG$ may interfere with measurement of serum and urine creatinine levels by Jaffe  reaction and produce false increases in the levels of creatinine reported.	DDI-false
DDI-DrugBank.d485.s10.p0	@DRUG$: Combination @DRUG$ may increase or decrease the effects of coumarin derivatives.	DDI-false
DDI-DrugBank.d485.s10.p1	@DRUG$: Combination hormonal contraceptives may increase or decrease the effects of @DRUG$.	DDI-false
DDI-DrugBank.d485.s10.p2	Anticoagulants: Combination @DRUG$ may increase or decrease the effects of @DRUG$.	DDI-effect
DDI-DrugBank.d485.s12.p0	@DRUG$ (@DRUG$, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-false
DDI-DrugBank.d485.s12.p1	@DRUG$ (carbamazepine, @DRUG$, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-false
DDI-DrugBank.d485.s12.p2	@DRUG$ (carbamazepine, felbamate, @DRUG$, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-false
DDI-DrugBank.d485.s12.p3	@DRUG$ (carbamazepine, felbamate, phenobarbital, @DRUG$, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-false
DDI-DrugBank.d485.s12.p4	@DRUG$ (carbamazepine, felbamate, phenobarbital, phenytoin, @DRUG$): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-false
DDI-DrugBank.d485.s12.p5	@DRUG$ (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of @DRUG$ and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-mechanism
DDI-DrugBank.d485.s12.p6	@DRUG$ (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some @DRUG$, leading to possible decrease in contraceptive effectiveness.	DDI-mechanism
DDI-DrugBank.d485.s12.p7	Anticonvulsants (@DRUG$, @DRUG$, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-false
DDI-DrugBank.d485.s12.p8	Anticonvulsants (@DRUG$, felbamate, @DRUG$, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-false
DDI-DrugBank.d485.s12.p9	Anticonvulsants (@DRUG$, felbamate, phenobarbital, @DRUG$, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-false
DDI-DrugBank.d485.s12.p10	Anticonvulsants (@DRUG$, felbamate, phenobarbital, phenytoin, @DRUG$): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-false
DDI-DrugBank.d485.s12.p11	Anticonvulsants (@DRUG$, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of @DRUG$ and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-mechanism
DDI-DrugBank.d485.s12.p12	Anticonvulsants (@DRUG$, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some @DRUG$, leading to possible decrease in contraceptive effectiveness.	DDI-mechanism
DDI-DrugBank.d485.s12.p13	Anticonvulsants (carbamazepine, @DRUG$, @DRUG$, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-false
DDI-DrugBank.d485.s12.p14	Anticonvulsants (carbamazepine, @DRUG$, phenobarbital, @DRUG$, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-false
DDI-DrugBank.d485.s12.p15	Anticonvulsants (carbamazepine, @DRUG$, phenobarbital, phenytoin, @DRUG$): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-false
DDI-DrugBank.d485.s12.p16	Anticonvulsants (carbamazepine, @DRUG$, phenobarbital, phenytoin, topiramate): Increase the metabolism of @DRUG$ and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-mechanism
DDI-DrugBank.d485.s12.p17	Anticonvulsants (carbamazepine, @DRUG$, phenobarbital, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some @DRUG$, leading to possible decrease in contraceptive effectiveness.	DDI-mechanism
DDI-DrugBank.d485.s12.p18	Anticonvulsants (carbamazepine, felbamate, @DRUG$, @DRUG$, topiramate): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-false
DDI-DrugBank.d485.s12.p19	Anticonvulsants (carbamazepine, felbamate, @DRUG$, phenytoin, @DRUG$): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-false
DDI-DrugBank.d485.s12.p20	Anticonvulsants (carbamazepine, felbamate, @DRUG$, phenytoin, topiramate): Increase the metabolism of @DRUG$ and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-mechanism
DDI-DrugBank.d485.s12.p21	Anticonvulsants (carbamazepine, felbamate, @DRUG$, phenytoin, topiramate): Increase the metabolism of ethinyl estradiol and/or some @DRUG$, leading to possible decrease in contraceptive effectiveness.	DDI-mechanism
DDI-DrugBank.d485.s12.p22	Anticonvulsants (carbamazepine, felbamate, phenobarbital, @DRUG$, @DRUG$): Increase the metabolism of ethinyl estradiol and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-false
DDI-DrugBank.d485.s12.p23	Anticonvulsants (carbamazepine, felbamate, phenobarbital, @DRUG$, topiramate): Increase the metabolism of @DRUG$ and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-mechanism
DDI-DrugBank.d485.s12.p24	Anticonvulsants (carbamazepine, felbamate, phenobarbital, @DRUG$, topiramate): Increase the metabolism of ethinyl estradiol and/or some @DRUG$, leading to possible decrease in contraceptive effectiveness.	DDI-mechanism
DDI-DrugBank.d485.s12.p25	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, @DRUG$): Increase the metabolism of @DRUG$ and/or some progestins, leading to possible decrease in contraceptive effectiveness.	DDI-mechanism
DDI-DrugBank.d485.s12.p26	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, @DRUG$): Increase the metabolism of ethinyl estradiol and/or some @DRUG$, leading to possible decrease in contraceptive effectiveness.	DDI-mechanism
DDI-DrugBank.d485.s12.p27	Anticonvulsants (carbamazepine, felbamate, phenobarbital, phenytoin, topiramate): Increase the metabolism of @DRUG$ and/or some @DRUG$, leading to possible decrease in contraceptive effectiveness.	DDI-false
DDI-DrugBank.d485.s2.p0	@DRUG$: May increase plasma concentration of @DRUG$, possibly by inhibiting conjugation.	DDI-mechanism
DDI-DrugBank.d485.s23.p0	@DRUG$: @DRUG$ may induce the metabolism of combination hormonal contraceptives causing menstrual changes;	DDI-false
DDI-DrugBank.d485.s23.p1	@DRUG$: Griseofulvin may induce the metabolism of @DRUG$ causing menstrual changes;	DDI-false
DDI-DrugBank.d485.s23.p2	Griseofulvin: @DRUG$ may induce the metabolism of @DRUG$ causing menstrual changes;	DDI-mechanism
DDI-DrugBank.d485.s3.p0	Combination @DRUG$ may also decrease the plasma concentration of @DRUG$.	DDI-mechanism
DDI-DrugBank.d485.s31.p0	@DRUG$: @DRUG$ may inhibit the metabolism of prednisolone, leading to increased plasma concentrations.	DDI-false
DDI-DrugBank.d485.s31.p1	@DRUG$: Ethinyl estradiol may inhibit the metabolism of @DRUG$, leading to increased plasma concentrations.	DDI-false
DDI-DrugBank.d485.s31.p2	Prednisolone: @DRUG$ may inhibit the metabolism of @DRUG$, leading to increased plasma concentrations.	DDI-mechanism
DDI-DrugBank.d485.s36.p0	@DRUG$: @DRUG$ increases the metabolism of ethinyl estradiol and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.	DDI-false
DDI-DrugBank.d485.s36.p1	@DRUG$: Rifampin increases the metabolism of @DRUG$ and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.	DDI-false
DDI-DrugBank.d485.s36.p2	@DRUG$: Rifampin increases the metabolism of ethinyl estradiol and some @DRUG$ (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.	DDI-false
DDI-DrugBank.d485.s36.p3	@DRUG$: Rifampin increases the metabolism of ethinyl estradiol and some progestins (@DRUG$) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.	DDI-false
DDI-DrugBank.d485.s36.p4	Rifampin: @DRUG$ increases the metabolism of @DRUG$ and some progestins (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.	DDI-mechanism
DDI-DrugBank.d485.s36.p5	Rifampin: @DRUG$ increases the metabolism of ethinyl estradiol and some @DRUG$ (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.	DDI-mechanism
DDI-DrugBank.d485.s36.p6	Rifampin: @DRUG$ increases the metabolism of ethinyl estradiol and some progestins (@DRUG$) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.	DDI-mechanism
DDI-DrugBank.d485.s36.p7	Rifampin: Rifampin increases the metabolism of @DRUG$ and some @DRUG$ (norethindrone) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.	DDI-false
DDI-DrugBank.d485.s36.p8	Rifampin: Rifampin increases the metabolism of @DRUG$ and some progestins (@DRUG$) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.	DDI-false
DDI-DrugBank.d485.s36.p9	Rifampin: Rifampin increases the metabolism of ethinyl estradiol and some @DRUG$ (@DRUG$) resulting in decreased contraceptive effectiveness and increased menstrual irregularities.	DDI-false
DDI-DrugBank.d485.s39.p0	@DRUG$: @DRUG$ may increase the serum concentration of selegiline.	DDI-false
DDI-DrugBank.d485.s39.p1	@DRUG$: Combination hormonal contraceptives may increase the serum concentration of @DRUG$.	DDI-false
DDI-DrugBank.d485.s39.p2	Selegiline: @DRUG$ may increase the serum concentration of @DRUG$.	DDI-mechanism
DDI-DrugBank.d485.s6.p0	@DRUG$: May increase CYP metabolism of @DRUG$ leading to possible decrease in contraceptive effectiveness.	DDI-mechanism
DDI-DrugBank.d486.s0.p0	No drug interaction studies have been conducted for @DRUG$, however the use of orally administered @DRUG$ could, theoretically, interfere with the release of mesalamine in the colon.	DDI-false
DDI-DrugBank.d486.s0.p1	No drug interaction studies have been conducted for @DRUG$, however the use of orally administered antibiotics could, theoretically, interfere with the release of @DRUG$ in the colon.	DDI-false
DDI-DrugBank.d486.s0.p2	No drug interaction studies have been conducted for COLAZAL, however the use of orally administered @DRUG$ could, theoretically, interfere with the release of @DRUG$ in the colon.	DDI-false
DDI-DrugBank.d487.s1.p0	Drugs that induce hepatic enzymes such as @DRUG$, @DRUG$ and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	DDI-false
DDI-DrugBank.d487.s1.p1	Drugs that induce hepatic enzymes such as @DRUG$, phenytoin and @DRUG$ may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	DDI-false
DDI-DrugBank.d487.s1.p2	Drugs that induce hepatic enzymes such as @DRUG$, phenytoin and rifampin may increase the clearance of @DRUG$ and may require increases in corticosteroid dose to achieve the desired response.	DDI-mechanism
DDI-DrugBank.d487.s1.p3	Drugs that induce hepatic enzymes such as @DRUG$, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in @DRUG$ dose to achieve the desired response.	DDI-advise
DDI-DrugBank.d487.s1.p4	Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$ and @DRUG$ may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response.	DDI-false
DDI-DrugBank.d487.s1.p5	Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$ and rifampin may increase the clearance of @DRUG$ and may require increases in corticosteroid dose to achieve the desired response.	DDI-mechanism
DDI-DrugBank.d487.s1.p6	Drugs that induce hepatic enzymes such as phenobarbital, @DRUG$ and rifampin may increase the clearance of corticosteroids and may require increases in @DRUG$ dose to achieve the desired response.	DDI-advise
DDI-DrugBank.d487.s1.p7	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and @DRUG$ may increase the clearance of @DRUG$ and may require increases in corticosteroid dose to achieve the desired response.	DDI-mechanism
DDI-DrugBank.d487.s1.p8	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and @DRUG$ may increase the clearance of corticosteroids and may require increases in @DRUG$ dose to achieve the desired response.	DDI-advise
DDI-DrugBank.d487.s1.p9	Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of @DRUG$ and may require increases in @DRUG$ dose to achieve the desired response.	DDI-false
DDI-DrugBank.d487.s6.p0	@DRUG$ should be used cautiously in conjunction with @DRUG$ in patients suffering from hypopro-thrombinemia.	DDI-advise
DDI-DrugBank.d487.s8.p0	There are reports of enhanced as well as diminished effects of @DRUG$ when given concurrently with @DRUG$.	DDI-effect
DDI-DrugBank.d488.s4.p0	Thus in order to avoid bleeding, reduced dosage of @DRUG$ is recommended during treatment with @DRUG$ (human).	DDI-advise
DDI-DrugBank.d489.s1.p0	Concomitant administration of @DRUG$ with the oral @DRUG$ warfarin has been shown not to potentiate the anticoagulant effect of warfarin.	DDI-false
DDI-DrugBank.d489.s1.p1	Concomitant administration of @DRUG$ with the oral anticoagulant @DRUG$ has been shown not to potentiate the anticoagulant effect of warfarin.	DDI-false
DDI-DrugBank.d489.s1.p2	Concomitant administration of @DRUG$ with the oral anticoagulant warfarin has been shown not to potentiate the anticoagulant effect of @DRUG$.	DDI-false
DDI-DrugBank.d489.s1.p3	Concomitant administration of Kerlone with the oral @DRUG$ @DRUG$ has been shown not to potentiate the anticoagulant effect of warfarin.	DDI-false
DDI-DrugBank.d489.s1.p4	Concomitant administration of Kerlone with the oral @DRUG$ warfarin has been shown not to potentiate the anticoagulant effect of @DRUG$.	DDI-false
DDI-DrugBank.d489.s1.p5	Concomitant administration of Kerlone with the oral anticoagulant @DRUG$ has been shown not to potentiate the anticoagulant effect of @DRUG$.	DDI-false
DDI-DrugBank.d489.s2.p0	Catecholamine-depleting drugs (e.g., @DRUG$) may have an additive effect when given with @DRUG$ agents.	DDI-effect
DDI-DrugBank.d489.s4.p0	Should it be decided to discontinue therapy in patients receiving @DRUG$ and @DRUG$ concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of clonidine.	DDI-advise
DDI-DrugBank.d489.s4.p1	Should it be decided to discontinue therapy in patients receiving @DRUG$ and clonidine concurrently, the @DRUG$ should be discontinued slowly over several days before the gradual withdrawal of clonidine.	DDI-false
DDI-DrugBank.d489.s4.p2	Should it be decided to discontinue therapy in patients receiving @DRUG$ and clonidine concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of @DRUG$.	DDI-false
DDI-DrugBank.d489.s4.p3	Should it be decided to discontinue therapy in patients receiving beta-blockers and @DRUG$ concurrently, the @DRUG$ should be discontinued slowly over several days before the gradual withdrawal of clonidine.	DDI-false
DDI-DrugBank.d489.s4.p4	Should it be decided to discontinue therapy in patients receiving beta-blockers and @DRUG$ concurrently, the beta-blocker should be discontinued slowly over several days before the gradual withdrawal of @DRUG$.	DDI-false
DDI-DrugBank.d489.s4.p5	Should it be decided to discontinue therapy in patients receiving beta-blockers and clonidine concurrently, the @DRUG$ should be discontinued slowly over several days before the gradual withdrawal of @DRUG$.	DDI-advise
DDI-DrugBank.d489.s7.p0	Hypotension was more likely to occur if the @DRUG$ were a @DRUG$, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem.	DDI-false
DDI-DrugBank.d489.s7.p1	Hypotension was more likely to occur if the @DRUG$ were a dihydropyridine derivative, e.g., @DRUG$, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem.	DDI-false
DDI-DrugBank.d489.s7.p2	Hypotension was more likely to occur if the @DRUG$ were a dihydropyridine derivative, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either @DRUG$ or diltiazem.	DDI-false
DDI-DrugBank.d489.s7.p3	Hypotension was more likely to occur if the @DRUG$ were a dihydropyridine derivative, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or @DRUG$.	DDI-false
DDI-DrugBank.d489.s7.p4	Hypotension was more likely to occur if the calcium antagonist were a @DRUG$, e.g., @DRUG$, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or diltiazem.	DDI-false
DDI-DrugBank.d489.s7.p5	Hypotension was more likely to occur if the calcium antagonist were a @DRUG$, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either @DRUG$ or diltiazem.	DDI-false
DDI-DrugBank.d489.s7.p6	Hypotension was more likely to occur if the calcium antagonist were a @DRUG$, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or @DRUG$.	DDI-false
DDI-DrugBank.d489.s7.p7	Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., @DRUG$, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either @DRUG$ or diltiazem.	DDI-false
DDI-DrugBank.d489.s7.p8	Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., @DRUG$, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either verapamil or @DRUG$.	DDI-false
DDI-DrugBank.d489.s7.p9	Hypotension was more likely to occur if the calcium antagonist were a dihydropyridine derivative, e.g., nifedipine, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d489.s8.p0	Risk of Anaphylactic Reaction: Although it is known that patients on @DRUG$ may be refractory to @DRUG$ in the treatment of anaphylactic shock, beta-blockers can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.	DDI-effect
DDI-DrugBank.d489.s8.p1	Risk of Anaphylactic Reaction: Although it is known that patients on @DRUG$ may be refractory to epinephrine in the treatment of anaphylactic shock, @DRUG$ can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.	DDI-false
DDI-DrugBank.d489.s8.p2	Risk of Anaphylactic Reaction: Although it is known that patients on beta-blockers may be refractory to @DRUG$ in the treatment of anaphylactic shock, @DRUG$ can, in addition, interfere with the modulation of allergic reaction and lead to an increased severity and/or frequency of attacks.	DDI-false
DDI-DrugBank.d493.s4.p0	Therefore the, combination of @DRUG$ with other @DRUG$, including HUMIRA, may also result i n similar toxicities.	DDI-effect
DDI-DrugBank.d493.s4.p1	Therefore the, combination of @DRUG$ with other TNF-blocking agents, including @DRUG$, may also result i n similar toxicities.	DDI-effect
DDI-DrugBank.d493.s4.p2	Therefore the, combination of anakinra with other @DRUG$, including @DRUG$, may also result i n similar toxicities.	DDI-false
DDI-DrugBank.d495.s0.p0	Tablet If a patient receiving @DRUG$ is also taking @DRUG$, the effect of clonidine may be reduced, thus necessitating an increase in dosage.	DDI-effect
DDI-DrugBank.d495.s0.p1	Tablet If a patient receiving @DRUG$ is also taking tricyclic antidepressants, the effect of @DRUG$ may be reduced, thus necessitating an increase in dosage.	DDI-false
DDI-DrugBank.d495.s0.p2	Tablet If a patient receiving clonidine hydrochloride is also taking @DRUG$, the effect of @DRUG$ may be reduced, thus necessitating an increase in dosage.	DDI-false
DDI-DrugBank.d495.s5.p0	The effects of @DRUG$ on @DRUG$s analgesic actions are not known.	DDI-false
DDI-DrugBank.d497.s2.p0	However, in patients treated with oral @DRUG$, rare instances of drug interactions have occurred with high-dose @DRUG$ therapy.	DDI-int
DDI-DrugBank.d498.s2.p0	Local and some general @DRUG$, @DRUG$ and other drugs that interfere with neuromuscular transmission should be used cautiously, if at all, in patients with myasthenia gravis;	DDI-false
DDI-DrugBank.d499.s17.p0	Because prostaglandina play an important role in hemostasis and @DRUG$ has an effect on platelet function as well, concurent therapy with @DRUG$ and warfarin requires close monitoring of patients on both drugs.	DDI-false
DDI-DrugBank.d499.s17.p1	Because prostaglandina play an important role in hemostasis and @DRUG$ has an effect on platelet function as well, concurent therapy with ketoprofen and @DRUG$ requires close monitoring of patients on both drugs.	DDI-false
DDI-DrugBank.d499.s17.p2	Because prostaglandina play an important role in hemostasis and ketoprofen has an effect on platelet function as well, concurent therapy with @DRUG$ and @DRUG$ requires close monitoring of patients on both drugs.	DDI-advise
DDI-DrugBank.d499.s3.p0	@DRUG$: Concomitant administration of @DRUG$ and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.	DDI-false
DDI-DrugBank.d499.s3.p1	@DRUG$: Concomitant administration of magnesium hydroxide and @DRUG$ does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.	DDI-false
DDI-DrugBank.d499.s3.p2	@DRUG$: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of @DRUG$ administered as Orudis.	DDI-false
DDI-DrugBank.d499.s3.p3	@DRUG$: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as @DRUG$.	DDI-false
DDI-DrugBank.d499.s3.p4	Antacids: Concomitant administration of @DRUG$ and @DRUG$ does not interfere with the rate or extent of the absorption of ketoprofen administered as Orudis.	DDI-false
DDI-DrugBank.d499.s3.p5	Antacids: Concomitant administration of @DRUG$ and aluminum hydroxide does not interfere with the rate or extent of the absorption of @DRUG$ administered as Orudis.	DDI-false
DDI-DrugBank.d499.s3.p6	Antacids: Concomitant administration of @DRUG$ and aluminum hydroxide does not interfere with the rate or extent of the absorption of ketoprofen administered as @DRUG$.	DDI-false
DDI-DrugBank.d499.s3.p7	Antacids: Concomitant administration of magnesium hydroxide and @DRUG$ does not interfere with the rate or extent of the absorption of @DRUG$ administered as Orudis.	DDI-false
DDI-DrugBank.d499.s3.p8	Antacids: Concomitant administration of magnesium hydroxide and @DRUG$ does not interfere with the rate or extent of the absorption of ketoprofen administered as @DRUG$.	DDI-false
DDI-DrugBank.d499.s3.p9	Antacids: Concomitant administration of magnesium hydroxide and aluminum hydroxide does not interfere with the rate or extent of the absorption of @DRUG$ administered as @DRUG$.	DDI-false
DDI-DrugBank.d5.s12.p0	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most @DRUG$ (SSRIs, many @DRUG$), beta-blockers, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.	DDI-false
DDI-DrugBank.d5.s12.p1	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most @DRUG$ (SSRIs, many tricyclics), @DRUG$, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.	DDI-false
DDI-DrugBank.d5.s12.p2	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most @DRUG$ (SSRIs, many tricyclics), beta-blockers, @DRUG$, and antipsychotics are metabolized by the CYP2D6 isoenzyme.	DDI-false
DDI-DrugBank.d5.s12.p3	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most @DRUG$ (SSRIs, many tricyclics), beta-blockers, antiarrhythmics, and @DRUG$ are metabolized by the CYP2D6 isoenzyme.	DDI-false
DDI-DrugBank.d5.s12.p4	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many @DRUG$), @DRUG$, antiarrhythmics, and antipsychotics are metabolized by the CYP2D6 isoenzyme.	DDI-false
DDI-DrugBank.d5.s12.p5	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many @DRUG$), beta-blockers, @DRUG$, and antipsychotics are metabolized by the CYP2D6 isoenzyme.	DDI-false
DDI-DrugBank.d5.s12.p6	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many @DRUG$), beta-blockers, antiarrhythmics, and @DRUG$ are metabolized by the CYP2D6 isoenzyme.	DDI-false
DDI-DrugBank.d5.s12.p7	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), @DRUG$, @DRUG$, and antipsychotics are metabolized by the CYP2D6 isoenzyme.	DDI-false
DDI-DrugBank.d5.s12.p8	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), @DRUG$, antiarrhythmics, and @DRUG$ are metabolized by the CYP2D6 isoenzyme.	DDI-false
DDI-DrugBank.d5.s12.p9	Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most antidepressants (SSRIs, many tricyclics), beta-blockers, @DRUG$, and @DRUG$ are metabolized by the CYP2D6 isoenzyme.	DDI-false
DDI-DrugBank.d5.s19.p0	@DRUG$: Studies in animals demonstrate that the acute toxicity of @DRUG$ is enhanced by the MAO inhibitor phenelzine .	DDI-false
DDI-DrugBank.d5.s19.p1	@DRUG$: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the @DRUG$ phenelzine .	DDI-false
DDI-DrugBank.d5.s19.p2	@DRUG$: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor @DRUG$ .	DDI-false
DDI-DrugBank.d5.s19.p3	MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of @DRUG$ is enhanced by the @DRUG$ phenelzine .	DDI-false
DDI-DrugBank.d5.s19.p4	MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of @DRUG$ is enhanced by the MAO inhibitor @DRUG$ .	DDI-effect
DDI-DrugBank.d5.s19.p5	MAO Inhibitors: Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the @DRUG$ @DRUG$ .	DDI-false
DDI-DrugBank.d5.s3.p0	Therefore, the potential exists for a drug interaction between @DRUG$ and drugs that affect the CYP2B6 isoenzyme (e.g., @DRUG$ and cyclophosphamide).	DDI-int
DDI-DrugBank.d5.s3.p1	Therefore, the potential exists for a drug interaction between @DRUG$ and drugs that affect the CYP2B6 isoenzyme (e.g., orphenadrine and @DRUG$).	DDI-int
DDI-DrugBank.d5.s3.p2	Therefore, the potential exists for a drug interaction between WELLBUTRIN and drugs that affect the CYP2B6 isoenzyme (e.g., @DRUG$ and @DRUG$).	DDI-false
DDI-DrugBank.d5.s6.p0	Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of @DRUG$, the pharmacokinetics of @DRUG$ and hydroxybupropion were unaffected.	DDI-false
DDI-DrugBank.d5.s6.p1	Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of @DRUG$, the pharmacokinetics of bupropion and @DRUG$ were unaffected.	DDI-false
DDI-DrugBank.d5.s6.p2	Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of cimetidine, the pharmacokinetics of @DRUG$ and @DRUG$ were unaffected.	DDI-false
DDI-DrugBank.d5.s7.p0	However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d500.s1.p0	Since bacteriostatic drugs may interfere with the bactericidal action of @DRUG$, it is advisable to avoid giving @DRUG$ in conjunction with penicillin.	DDI-false
DDI-DrugBank.d500.s1.p1	Since bacteriostatic drugs may interfere with the bactericidal action of @DRUG$, it is advisable to avoid giving tetracyclines in conjunction with @DRUG$.	DDI-false
DDI-DrugBank.d500.s1.p2	Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving @DRUG$ in conjunction with @DRUG$.	DDI-advise
DDI-DrugBank.d500.s6.p0	Concurrent use of @DRUG$ may render oral @DRUG$ less effective.	DDI-effect
DDI-DrugBank.d501.s6.p0	However, appropriate monitoring of blood glucose should be performed when initiating @DRUG$ in diabetic patients and @DRUG$ dosage should be adjusted if needed.	DDI-advise
DDI-DrugBank.d503.s2.p0	If @DRUG$ is given concomitantly with @DRUG$, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.	DDI-advise
DDI-DrugBank.d503.s2.p1	If @DRUG$ is given concomitantly with opioids, the @DRUG$ dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.	DDI-false
DDI-DrugBank.d503.s2.p2	If @DRUG$ is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because @DRUG$ amplifies the therapeutic actions and side-effects of opioids massively.	DDI-false
DDI-DrugBank.d503.s2.p3	If @DRUG$ is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of @DRUG$ massively.	DDI-false
DDI-DrugBank.d503.s2.p4	If chlorprothixene is given concomitantly with @DRUG$, the @DRUG$ dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of opioids massively.	DDI-false
DDI-DrugBank.d503.s2.p5	If chlorprothixene is given concomitantly with @DRUG$, the opioid dose should be reduced (by approx. 50%), because @DRUG$ amplifies the therapeutic actions and side-effects of opioids massively.	DDI-false
DDI-DrugBank.d503.s2.p6	If chlorprothixene is given concomitantly with @DRUG$, the opioid dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of @DRUG$ massively.	DDI-false
DDI-DrugBank.d503.s2.p7	If chlorprothixene is given concomitantly with opioids, the @DRUG$ dose should be reduced (by approx. 50%), because @DRUG$ amplifies the therapeutic actions and side-effects of opioids massively.	DDI-false
DDI-DrugBank.d503.s2.p8	If chlorprothixene is given concomitantly with opioids, the @DRUG$ dose should be reduced (by approx. 50%), because chlorprothixene amplifies the therapeutic actions and side-effects of @DRUG$ massively.	DDI-false
DDI-DrugBank.d503.s2.p9	If chlorprothixene is given concomitantly with opioids, the opioid dose should be reduced (by approx. 50%), because @DRUG$ amplifies the therapeutic actions and side-effects of @DRUG$ massively.	DDI-effect
DDI-DrugBank.d505.s2.p0	@DRUG$: @DRUG$ has been reported to increase the plasma levels and cardiovascular effects of adenosine.	DDI-false
DDI-DrugBank.d505.s2.p1	@DRUG$: Dipyridamole has been reported to increase the plasma levels and cardiovascular effects of @DRUG$.	DDI-false
DDI-DrugBank.d505.s2.p2	Adenosine: @DRUG$ has been reported to increase the plasma levels and cardiovascular effects of @DRUG$.	DDI-mechanism
DDI-DrugBank.d506.s2.p0	Other @DRUG$ (eg, @DRUG$, procainamide, lidocaine, propranolol) have occasionally been used concurrently with Norpace.	DDI-false
DDI-DrugBank.d506.s2.p1	Other @DRUG$ (eg, quinidine, @DRUG$, lidocaine, propranolol) have occasionally been used concurrently with Norpace.	DDI-false
DDI-DrugBank.d506.s2.p2	Other @DRUG$ (eg, quinidine, procainamide, @DRUG$, propranolol) have occasionally been used concurrently with Norpace.	DDI-false
DDI-DrugBank.d506.s2.p3	Other @DRUG$ (eg, quinidine, procainamide, lidocaine, @DRUG$) have occasionally been used concurrently with Norpace.	DDI-false
DDI-DrugBank.d506.s2.p4	Other @DRUG$ (eg, quinidine, procainamide, lidocaine, propranolol) have occasionally been used concurrently with @DRUG$.	DDI-false
DDI-DrugBank.d506.s2.p5	Other antiarrhythmic drugs (eg, @DRUG$, @DRUG$, lidocaine, propranolol) have occasionally been used concurrently with Norpace.	DDI-false
DDI-DrugBank.d506.s2.p6	Other antiarrhythmic drugs (eg, @DRUG$, procainamide, @DRUG$, propranolol) have occasionally been used concurrently with Norpace.	DDI-false
DDI-DrugBank.d506.s2.p7	Other antiarrhythmic drugs (eg, @DRUG$, procainamide, lidocaine, @DRUG$) have occasionally been used concurrently with Norpace.	DDI-false
DDI-DrugBank.d506.s2.p8	Other antiarrhythmic drugs (eg, @DRUG$, procainamide, lidocaine, propranolol) have occasionally been used concurrently with @DRUG$.	DDI-false
DDI-DrugBank.d506.s2.p9	Other antiarrhythmic drugs (eg, quinidine, @DRUG$, @DRUG$, propranolol) have occasionally been used concurrently with Norpace.	DDI-false
DDI-DrugBank.d506.s2.p10	Other antiarrhythmic drugs (eg, quinidine, @DRUG$, lidocaine, @DRUG$) have occasionally been used concurrently with Norpace.	DDI-false
DDI-DrugBank.d506.s2.p11	Other antiarrhythmic drugs (eg, quinidine, @DRUG$, lidocaine, propranolol) have occasionally been used concurrently with @DRUG$.	DDI-false
DDI-DrugBank.d506.s2.p12	Other antiarrhythmic drugs (eg, quinidine, procainamide, @DRUG$, @DRUG$) have occasionally been used concurrently with Norpace.	DDI-false
DDI-DrugBank.d506.s2.p13	Other antiarrhythmic drugs (eg, quinidine, procainamide, @DRUG$, propranolol) have occasionally been used concurrently with @DRUG$.	DDI-false
DDI-DrugBank.d506.s2.p14	Other antiarrhythmic drugs (eg, quinidine, procainamide, lidocaine, @DRUG$) have occasionally been used concurrently with @DRUG$.	DDI-false
DDI-DrugBank.d506.s5.p0	Concomitant administration of @DRUG$ and @DRUG$ resulted in slight increases in plasma disopyramide levels and slight decreases in plasma quinidine levels.	DDI-mechanism
DDI-DrugBank.d506.s5.p1	Concomitant administration of @DRUG$ and quinidine resulted in slight increases in plasma @DRUG$ levels and slight decreases in plasma quinidine levels.	DDI-false
DDI-DrugBank.d506.s5.p2	Concomitant administration of @DRUG$ and quinidine resulted in slight increases in plasma disopyramide levels and slight decreases in plasma @DRUG$ levels.	DDI-false
DDI-DrugBank.d506.s5.p3	Concomitant administration of Norpace and @DRUG$ resulted in slight increases in plasma @DRUG$ levels and slight decreases in plasma quinidine levels.	DDI-false
DDI-DrugBank.d506.s5.p4	Concomitant administration of Norpace and @DRUG$ resulted in slight increases in plasma disopyramide levels and slight decreases in plasma @DRUG$ levels.	DDI-false
DDI-DrugBank.d506.s5.p5	Concomitant administration of Norpace and quinidine resulted in slight increases in plasma @DRUG$ levels and slight decreases in plasma @DRUG$ levels.	DDI-false
DDI-DrugBank.d506.s6.p0	@DRUG$ does not increase serum @DRUG$ levels.	DDI-false
DDI-DrugBank.d507.s5.p0	@DRUG$ (@DRUG$,porpranolol,timolol) may exacerbate rebound hypertension when guanfacine is withdrawn.	DDI-false
DDI-DrugBank.d507.s5.p1	@DRUG$ (nadolol,porpranolol,@DRUG$) may exacerbate rebound hypertension when guanfacine is withdrawn.	DDI-false
DDI-DrugBank.d507.s5.p2	@DRUG$ (nadolol,porpranolol,timolol) may exacerbate rebound hypertension when @DRUG$ is withdrawn.	DDI-effect
DDI-DrugBank.d507.s5.p3	Noncardioselective beta-blockers (@DRUG$,porpranolol,@DRUG$) may exacerbate rebound hypertension when guanfacine is withdrawn.	DDI-false
DDI-DrugBank.d507.s5.p4	Noncardioselective beta-blockers (@DRUG$,porpranolol,timolol) may exacerbate rebound hypertension when @DRUG$ is withdrawn.	DDI-effect
DDI-DrugBank.d507.s5.p5	Noncardioselective beta-blockers (nadolol,porpranolol,@DRUG$) may exacerbate rebound hypertension when @DRUG$ is withdrawn.	DDI-effect
DDI-DrugBank.d507.s7.p0	The gradual withdrawal of @DRUG$ or a @DRUG$ could be substituted.	DDI-false
DDI-DrugBank.d508.s3.p0	Because @DRUG$, @DRUG$, or Activase may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.	DDI-false
DDI-DrugBank.d508.s3.p1	Because @DRUG$, aspirin, or @DRUG$ may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.	DDI-false
DDI-DrugBank.d508.s3.p2	Because heparin, @DRUG$, or @DRUG$ may cause bleeding complications, careful monitoring for bleeding is advised, especially at arterial puncture sites.	DDI-false
DDI-DrugBank.d509.s19.p0	@DRUG$: Coadministration of @DRUG$ (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.	DDI-false
DDI-DrugBank.d509.s19.p1	@DRUG$: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with @DRUG$ (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.	DDI-false
DDI-DrugBank.d509.s19.p2	@DRUG$: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both @DRUG$ and its active metabolite, dehydro-aripiprazole.	DDI-false
DDI-DrugBank.d509.s19.p3	@DRUG$: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, @DRUG$.	DDI-false
DDI-DrugBank.d509.s19.p4	Carbamazepine: Coadministration of @DRUG$ (200 mg BID), a potent CYP3A4 inducer, with @DRUG$ (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole.	DDI-mechanism
DDI-DrugBank.d509.s19.p5	Carbamazepine: Coadministration of @DRUG$ (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both @DRUG$ and its active metabolite, dehydro-aripiprazole.	DDI-false
DDI-DrugBank.d509.s19.p6	Carbamazepine: Coadministration of @DRUG$ (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, @DRUG$.	DDI-false
DDI-DrugBank.d509.s19.p7	Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with @DRUG$ (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both @DRUG$ and its active metabolite, dehydro-aripiprazole.	DDI-false
DDI-DrugBank.d509.s19.p8	Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with @DRUG$ (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, @DRUG$.	DDI-false
DDI-DrugBank.d509.s19.p9	Carbamazepine: Coadministration of carbamazepine (200 mg BID), a potent CYP3A4 inducer, with aripiprazole (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both @DRUG$ and its active metabolite, @DRUG$.	DDI-false
DDI-DrugBank.d509.s8.p0	Inhibitors of CYP3A4 (eg, @DRUG$) or CYP2D6 (eg, @DRUG$, fluoxetine, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.	DDI-false
DDI-DrugBank.d509.s8.p1	Inhibitors of CYP3A4 (eg, @DRUG$) or CYP2D6 (eg, quinidine, @DRUG$, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.	DDI-false
DDI-DrugBank.d509.s8.p2	Inhibitors of CYP3A4 (eg, @DRUG$) or CYP2D6 (eg, quinidine, fluoxetine, or @DRUG$) can inhibit aripiprazole elimination and cause increased blood levels.	DDI-false
DDI-DrugBank.d509.s8.p3	Inhibitors of CYP3A4 (eg, @DRUG$) or CYP2D6 (eg, quinidine, fluoxetine, or paroxetine) can inhibit @DRUG$ elimination and cause increased blood levels.	DDI-mechanism
DDI-DrugBank.d509.s8.p4	Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, @DRUG$, @DRUG$, or paroxetine) can inhibit aripiprazole elimination and cause increased blood levels.	DDI-false
DDI-DrugBank.d509.s8.p5	Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, @DRUG$, fluoxetine, or @DRUG$) can inhibit aripiprazole elimination and cause increased blood levels.	DDI-false
DDI-DrugBank.d509.s8.p6	Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, @DRUG$, fluoxetine, or paroxetine) can inhibit @DRUG$ elimination and cause increased blood levels.	DDI-mechanism
DDI-DrugBank.d509.s8.p7	Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, @DRUG$, or @DRUG$) can inhibit aripiprazole elimination and cause increased blood levels.	DDI-false
DDI-DrugBank.d509.s8.p8	Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, @DRUG$, or paroxetine) can inhibit @DRUG$ elimination and cause increased blood levels.	DDI-mechanism
DDI-DrugBank.d509.s8.p9	Inhibitors of CYP3A4 (eg, ketoconazole) or CYP2D6 (eg, quinidine, fluoxetine, or @DRUG$) can inhibit @DRUG$ elimination and cause increased blood levels.	DDI-mechanism
DDI-DrugBank.d510.s0.p0	The concurrent use of @DRUG$ Injection with other @DRUG$ or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.	DDI-effect
DDI-DrugBank.d510.s0.p1	The concurrent use of @DRUG$ Injection with other anticholinergics or medications with anticholinergic activity, such as @DRUG$, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.	DDI-effect
DDI-DrugBank.d510.s0.p2	The concurrent use of @DRUG$ Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, @DRUG$, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.	DDI-effect
DDI-DrugBank.d510.s0.p3	The concurrent use of @DRUG$ Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or @DRUG$, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.	DDI-effect
DDI-DrugBank.d510.s0.p4	The concurrent use of Robinul Injection with other @DRUG$ or medications with anticholinergic activity, such as @DRUG$, antiparkinson drugs, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.	DDI-false
DDI-DrugBank.d510.s0.p5	The concurrent use of Robinul Injection with other @DRUG$ or medications with anticholinergic activity, such as phenothiazines, @DRUG$, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.	DDI-false
DDI-DrugBank.d510.s0.p6	The concurrent use of Robinul Injection with other @DRUG$ or medications with anticholinergic activity, such as phenothiazines, antiparkinson drugs, or @DRUG$, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.	DDI-false
DDI-DrugBank.d510.s0.p7	The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as @DRUG$, @DRUG$, or tricyclic antidepressants, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.	DDI-false
DDI-DrugBank.d510.s0.p8	The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as @DRUG$, antiparkinson drugs, or @DRUG$, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.	DDI-false
DDI-DrugBank.d510.s0.p9	The concurrent use of Robinul Injection with other anticholinergics or medications with anticholinergic activity, such as phenothiazines, @DRUG$, or @DRUG$, may intensify the antimuscarinic effects and may result in an increase in anticholinergic side effects.	DDI-false
DDI-DrugBank.d514.s3.p0	Ironically, @DRUG$ are often used in the treatment of @DRUG$ addiction while they cause much more severe withdrawal symptoms.	DDI-false
DDI-DrugBank.d516.s16.p0	Interaction between @DRUG$ and @DRUG$ has not been studied.	DDI-false
DDI-DrugBank.d516.s20.p0	@DRUG$ is unlikely to have a significant effect on @DRUG$ metabolism.	DDI-false
DDI-DrugBank.d516.s3.p0	@DRUG$ and @DRUG$: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p1	@DRUG$ and sucralfate: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p2	@DRUG$ and sucralfate: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p3	@DRUG$ and sucralfate: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p4	@DRUG$ and sucralfate: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p5	@DRUG$ and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p6	@DRUG$ and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p7	@DRUG$ and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p8	Antacids and @DRUG$: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p9	Antacids and @DRUG$: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p10	Antacids and @DRUG$: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p11	Antacids and @DRUG$: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p12	Antacids and @DRUG$: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p13	Antacids and @DRUG$: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p14	Antacids and @DRUG$: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p15	Antacids and sucralfate: @DRUG$ and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p16	Antacids and sucralfate: @DRUG$ and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p17	Antacids and sucralfate: @DRUG$ and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p18	Antacids and sucralfate: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p19	Antacids and sucralfate: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p20	Antacids and sucralfate: @DRUG$ and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	DDI-mechanism
DDI-DrugBank.d516.s3.p21	Antacids and sucralfate: Sucralfate and @DRUG$ containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p22	Antacids and sucralfate: Sucralfate and @DRUG$ containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p23	Antacids and sucralfate: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p24	Antacids and sucralfate: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p25	Antacids and sucralfate: Sucralfate and @DRUG$ containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p26	Antacids and sucralfate: Sucralfate and antacids containing @DRUG$ or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p27	Antacids and sucralfate: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p28	Antacids and sucralfate: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p29	Antacids and sucralfate: Sucralfate and antacids containing @DRUG$ or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	DDI-mechanism
DDI-DrugBank.d516.s3.p30	Antacids and sucralfate: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p31	Antacids and sucralfate: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p32	Antacids and sucralfate: Sucralfate and antacids containing magnesium or @DRUG$, as well as formulations containing divalent and trivalent cations such as Videx  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	DDI-mechanism
DDI-DrugBank.d516.s3.p33	Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with lomefloxacin and interfere with its bioavailability.	DDI-false
DDI-DrugBank.d516.s3.p34	Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as @DRUG$  (didanosine), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	DDI-mechanism
DDI-DrugBank.d516.s3.p35	Antacids and sucralfate: Sucralfate and antacids containing magnesium or aluminum, as well as formulations containing divalent and trivalent cations such as Videx  (@DRUG$), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with @DRUG$ and interfere with its bioavailability.	DDI-mechanism
DDI-DrugBank.d52.s1.p0	Concomitant treatment with @DRUG$ (@DRUG$) and drugs that affect platelet function may also increase the risk of bleeding.	DDI-false
DDI-DrugBank.d521.s5.p0	- a @DRUG$ such as @DRUG$ (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p1	- a @DRUG$ such as propranolol (@DRUG$), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p2	- a @DRUG$ such as propranolol (Inderal), @DRUG$ (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p3	- a @DRUG$ such as propranolol (Inderal), atenolol (@DRUG$), acebutolol (Sectral), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p4	- a @DRUG$ such as propranolol (Inderal), atenolol (Tenormin), @DRUG$ (Sectral), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p5	- a @DRUG$ such as propranolol (Inderal), atenolol (Tenormin), acebutolol (@DRUG$), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p6	- a @DRUG$ such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), @DRUG$ (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p7	- a @DRUG$ such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (@DRUG$), and others;	DDI-false
DDI-DrugBank.d521.s5.p8	- a beta-blocker such as @DRUG$ (@DRUG$), atenolol (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p9	- a beta-blocker such as @DRUG$ (Inderal), @DRUG$ (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p10	- a beta-blocker such as @DRUG$ (Inderal), atenolol (@DRUG$), acebutolol (Sectral), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p11	- a beta-blocker such as @DRUG$ (Inderal), atenolol (Tenormin), @DRUG$ (Sectral), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p12	- a beta-blocker such as @DRUG$ (Inderal), atenolol (Tenormin), acebutolol (@DRUG$), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p13	- a beta-blocker such as @DRUG$ (Inderal), atenolol (Tenormin), acebutolol (Sectral), @DRUG$ (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p14	- a beta-blocker such as @DRUG$ (Inderal), atenolol (Tenormin), acebutolol (Sectral), metoprolol (@DRUG$), and others;	DDI-false
DDI-DrugBank.d521.s5.p15	- a beta-blocker such as propranolol (@DRUG$), @DRUG$ (Tenormin), acebutolol (Sectral), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p16	- a beta-blocker such as propranolol (@DRUG$), atenolol (@DRUG$), acebutolol (Sectral), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p17	- a beta-blocker such as propranolol (@DRUG$), atenolol (Tenormin), @DRUG$ (Sectral), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p18	- a beta-blocker such as propranolol (@DRUG$), atenolol (Tenormin), acebutolol (@DRUG$), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p19	- a beta-blocker such as propranolol (@DRUG$), atenolol (Tenormin), acebutolol (Sectral), @DRUG$ (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p20	- a beta-blocker such as propranolol (@DRUG$), atenolol (Tenormin), acebutolol (Sectral), metoprolol (@DRUG$), and others;	DDI-false
DDI-DrugBank.d521.s5.p21	- a beta-blocker such as propranolol (Inderal), @DRUG$ (@DRUG$), acebutolol (Sectral), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p22	- a beta-blocker such as propranolol (Inderal), @DRUG$ (Tenormin), @DRUG$ (Sectral), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p23	- a beta-blocker such as propranolol (Inderal), @DRUG$ (Tenormin), acebutolol (@DRUG$), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p24	- a beta-blocker such as propranolol (Inderal), @DRUG$ (Tenormin), acebutolol (Sectral), @DRUG$ (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p25	- a beta-blocker such as propranolol (Inderal), @DRUG$ (Tenormin), acebutolol (Sectral), metoprolol (@DRUG$), and others;	DDI-false
DDI-DrugBank.d521.s5.p26	- a beta-blocker such as propranolol (Inderal), atenolol (@DRUG$), @DRUG$ (Sectral), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p27	- a beta-blocker such as propranolol (Inderal), atenolol (@DRUG$), acebutolol (@DRUG$), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p28	- a beta-blocker such as propranolol (Inderal), atenolol (@DRUG$), acebutolol (Sectral), @DRUG$ (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p29	- a beta-blocker such as propranolol (Inderal), atenolol (@DRUG$), acebutolol (Sectral), metoprolol (@DRUG$), and others;	DDI-false
DDI-DrugBank.d521.s5.p30	- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), @DRUG$ (@DRUG$), metoprolol (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p31	- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), @DRUG$ (Sectral), @DRUG$ (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p32	- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), @DRUG$ (Sectral), metoprolol (@DRUG$), and others;	DDI-false
DDI-DrugBank.d521.s5.p33	- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (@DRUG$), @DRUG$ (Lopressor), and others;	DDI-false
DDI-DrugBank.d521.s5.p34	- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (@DRUG$), metoprolol (@DRUG$), and others;	DDI-false
DDI-DrugBank.d521.s5.p35	- a beta-blocker such as propranolol (Inderal), atenolol (Tenormin), acebutolol (Sectral), @DRUG$ (@DRUG$), and others;	DDI-false
DDI-DrugBank.d522.s10.p0	Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving @DRUG$ concomitantly with other @DRUG$.	DDI-effect
DDI-DrugBank.d522.s11.p0	In addition, most @DRUG$ are contraindicated in patients receiving @DRUG$ therapy who have pre-existing cardiac abnormalities (arrhythmia, bradycardia, QT c interval prolongation, ischemic heart disease, congestive heart failure, etc.) or electrolyte disturbances.	DDI-advise
DDI-DrugBank.d522.s15.p0	@DRUG$ or @DRUG$: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.	DDI-false
DDI-DrugBank.d522.s15.p1	@DRUG$ or H 2 receptor antagonists: When @DRUG$ is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.	DDI-false
DDI-DrugBank.d522.s15.p2	@DRUG$ or H 2 receptor antagonists: When dirithromycin is administered immediately following @DRUG$ or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.	DDI-false
DDI-DrugBank.d522.s15.p3	@DRUG$ or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or @DRUG$, the absorption of dirithromycin is slightly enhanced.	DDI-false
DDI-DrugBank.d522.s15.p4	@DRUG$ or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of @DRUG$ is slightly enhanced.	DDI-false
DDI-DrugBank.d522.s15.p5	Antacids or @DRUG$: When @DRUG$ is administered immediately following antacids or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.	DDI-false
DDI-DrugBank.d522.s15.p6	Antacids or @DRUG$: When dirithromycin is administered immediately following @DRUG$ or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.	DDI-false
DDI-DrugBank.d522.s15.p7	Antacids or @DRUG$: When dirithromycin is administered immediately following antacids or @DRUG$, the absorption of dirithromycin is slightly enhanced.	DDI-false
DDI-DrugBank.d522.s15.p8	Antacids or @DRUG$: When dirithromycin is administered immediately following antacids or H 2 -receptor antagonists, the absorption of @DRUG$ is slightly enhanced.	DDI-false
DDI-DrugBank.d522.s15.p9	Antacids or H 2 receptor antagonists: When @DRUG$ is administered immediately following @DRUG$ or H 2 -receptor antagonists, the absorption of dirithromycin is slightly enhanced.	DDI-mechanism
DDI-DrugBank.d522.s15.p10	Antacids or H 2 receptor antagonists: When @DRUG$ is administered immediately following antacids or @DRUG$, the absorption of dirithromycin is slightly enhanced.	DDI-mechanism
DDI-DrugBank.d522.s15.p11	Antacids or H 2 receptor antagonists: When @DRUG$ is administered immediately following antacids or H 2 -receptor antagonists, the absorption of @DRUG$ is slightly enhanced.	DDI-false
DDI-DrugBank.d522.s15.p12	Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following @DRUG$ or @DRUG$, the absorption of dirithromycin is slightly enhanced.	DDI-false
DDI-DrugBank.d522.s15.p13	Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following @DRUG$ or H 2 -receptor antagonists, the absorption of @DRUG$ is slightly enhanced.	DDI-false
DDI-DrugBank.d522.s15.p14	Antacids or H 2 receptor antagonists: When dirithromycin is administered immediately following antacids or @DRUG$, the absorption of @DRUG$ is slightly enhanced.	DDI-false
DDI-DrugBank.d522.s23.p0	@DRUG$: Concurrent use of @DRUG$ and ergotamine or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.	DDI-false
DDI-DrugBank.d522.s23.p1	@DRUG$: Concurrent use of erythromycin and @DRUG$ or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.	DDI-false
DDI-DrugBank.d522.s23.p2	@DRUG$: Concurrent use of erythromycin and ergotamine or @DRUG$ has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.	DDI-false
DDI-DrugBank.d522.s23.p3	Ergotamine: Concurrent use of @DRUG$ and @DRUG$ or dihydroergotamine has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.	DDI-effect
DDI-DrugBank.d522.s23.p4	Ergotamine: Concurrent use of @DRUG$ and ergotamine or @DRUG$ has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.	DDI-effect
DDI-DrugBank.d522.s23.p5	Ergotamine: Concurrent use of erythromycin and @DRUG$ or @DRUG$ has been associated in some patients with acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.	DDI-false
DDI-DrugBank.d522.s5.p0	in one man, the C max of @DRUG$ was 8.1 ng/mL with @DRUG$ alone and 7.2 ng/mL with terfenadine plus dirithromycin.	DDI-false
DDI-DrugBank.d522.s5.p1	in one man, the C max of @DRUG$ was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with @DRUG$ plus dirithromycin.	DDI-false
DDI-DrugBank.d522.s5.p2	in one man, the C max of @DRUG$ was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with terfenadine plus @DRUG$.	DDI-false
DDI-DrugBank.d522.s5.p3	in one man, the C max of terfenadine was 8.1 ng/mL with @DRUG$ alone and 7.2 ng/mL with @DRUG$ plus dirithromycin.	DDI-false
DDI-DrugBank.d522.s5.p4	in one man, the C max of terfenadine was 8.1 ng/mL with @DRUG$ alone and 7.2 ng/mL with terfenadine plus @DRUG$.	DDI-false
DDI-DrugBank.d522.s5.p5	in one man, the C max of terfenadine was 8.1 ng/mL with terfenadine alone and 7.2 ng/mL with @DRUG$ plus @DRUG$.	DDI-mechanism
DDI-DrugBank.d523.s16.p0	The adverse experience profile seen with @DRUG$ was similar to that seen with @DRUG$ tablets.	DDI-false
DDI-DrugBank.d523.s2.p0	SIDE EFFECTS (@DRUG$) The most common adverse reaction during treatment with @DRUG$ is transient drowsiness (10-63%).	DDI-false
DDI-DrugBank.d525.s5.p0	@DRUG$ doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release @DRUG$ (sustained-release nifedipine) with no clinically significant adverse interactions.	DDI-false
DDI-DrugBank.d525.s5.p1	@DRUG$ doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release calcium channel blockers (sustained-release @DRUG$) with no clinically significant adverse interactions.	DDI-false
DDI-DrugBank.d525.s5.p2	Eprosartan doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release @DRUG$ (sustained-release @DRUG$) with no clinically significant adverse interactions.	DDI-false
DDI-DrugBank.d526.s18.p0	Observe the patient for possible diminished effect of @DRUG$ and increase the @DRUG$ dosage accordingly.	DDI-false
DDI-DrugBank.d526.s4.p0	@DRUG$ enhanced possibility of arrhythmias or @DRUG$ toxicity associated with hypokalemia.	DDI-false
DDI-DrugBank.d527.s3.p0	@DRUG$, @DRUG$, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
DDI-DrugBank.d527.s3.p1	@DRUG$, clonidine, @DRUG$ salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
DDI-DrugBank.d527.s3.p2	@DRUG$, clonidine, lithium salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
DDI-DrugBank.d527.s3.p3	@DRUG$, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.	DDI-effect
DDI-DrugBank.d527.s3.p4	Beta-blockers, @DRUG$, @DRUG$ salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
DDI-DrugBank.d527.s3.p5	Beta-blockers, @DRUG$, lithium salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
DDI-DrugBank.d527.s3.p6	Beta-blockers, @DRUG$, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.	DDI-effect
DDI-DrugBank.d527.s3.p7	Beta-blockers, clonidine, @DRUG$ salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
DDI-DrugBank.d527.s3.p8	Beta-blockers, clonidine, @DRUG$ salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.	DDI-effect
DDI-DrugBank.d527.s3.p9	Beta-blockers, clonidine, lithium salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.	DDI-effect
DDI-DrugBank.d527.s5.p0	In addition, under the influence of sympatholytic medicinal products such as @DRUG$, @DRUG$, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.	DDI-false
DDI-DrugBank.d527.s5.p1	In addition, under the influence of sympatholytic medicinal products such as @DRUG$, clonidine, @DRUG$, and reserpine, the signs of hypoglycemia may be reduced or absent.	DDI-false
DDI-DrugBank.d527.s5.p2	In addition, under the influence of sympatholytic medicinal products such as @DRUG$, clonidine, guanethidine, and @DRUG$, the signs of hypoglycemia may be reduced or absent.	DDI-false
DDI-DrugBank.d527.s5.p3	In addition, under the influence of sympatholytic medicinal products such as beta-blockers, @DRUG$, @DRUG$, and reserpine, the signs of hypoglycemia may be reduced or absent.	DDI-false
DDI-DrugBank.d527.s5.p4	In addition, under the influence of sympatholytic medicinal products such as beta-blockers, @DRUG$, guanethidine, and @DRUG$, the signs of hypoglycemia may be reduced or absent.	DDI-false
DDI-DrugBank.d527.s5.p5	In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, @DRUG$, and @DRUG$, the signs of hypoglycemia may be reduced or absent.	DDI-false
DDI-DrugBank.d529.s12.p0	@DRUG$, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p1	@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p2	@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p3	@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p4	@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p5	@DRUG$, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.	DDI-false
DDI-DrugBank.d529.s12.p6	Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p7	Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p8	Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p9	Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p10	Cimetidine, @DRUG$: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.	DDI-false
DDI-DrugBank.d529.s12.p11	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p12	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p13	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p14	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with @DRUG$ or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.	DDI-false
DDI-DrugBank.d529.s12.p15	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p16	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p17	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or @DRUG$ did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.	DDI-false
DDI-DrugBank.d529.s12.p18	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with cimetidine.	DDI-false
DDI-DrugBank.d529.s12.p19	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect @DRUG$ pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of flurbiprofen resulted with @DRUG$.	DDI-false
DDI-DrugBank.d529.s12.p20	Cimetidine, Ranitidine: In normal volunteers (n=9), pretreatment with cimetidine or ranitidine did not affect flurbiprofen pharmacokinetics except that a small (13 %) but statistically significant increase in the area under the serum concentration curve of @DRUG$ resulted with @DRUG$.	DDI-mechanism
DDI-DrugBank.d529.s19.p0	Although there was a slight reduction in blood sugar concentrations during concomitant administration of @DRUG$ and @DRUG$, there were no signs or symptoms of hypoglycemia.	DDI-effect
DDI-DrugBank.d529.s2.p0	@DRUG$: @DRUG$ like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.	DDI-false
DDI-DrugBank.d529.s2.p1	@DRUG$: Flurbiprofen like other @DRUG$, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.	DDI-false
DDI-DrugBank.d529.s2.p2	@DRUG$: Flurbiprofen like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving @DRUG$, and serious clinical bleeding has been reported.	DDI-false
DDI-DrugBank.d529.s2.p3	Anticoagulants: @DRUG$ like other @DRUG$, has been shown to affect bleeding parameters in patients receiving anti-coagulants, and serious clinical bleeding has been reported.	DDI-false
DDI-DrugBank.d529.s2.p4	Anticoagulants: @DRUG$ like other nonsteroidal anti-inflammatory drugs, has been shown to affect bleeding parameters in patients receiving @DRUG$, and serious clinical bleeding has been reported.	DDI-effect
DDI-DrugBank.d529.s2.p5	Anticoagulants: Flurbiprofen like other @DRUG$, has been shown to affect bleeding parameters in patients receiving @DRUG$, and serious clinical bleeding has been reported.	DDI-effect
DDI-DrugBank.d529.s6.p0	Concurrent use of @DRUG$ and @DRUG$ is therefore not recommended.	DDI-advise
DDI-DrugBank.d529.s7.p0	@DRUG$: The effect of @DRUG$ on blood pressure response to propranolol and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).	DDI-false
DDI-DrugBank.d529.s7.p1	@DRUG$: The effect of flurbiprofen on blood pressure response to @DRUG$ and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).	DDI-false
DDI-DrugBank.d529.s7.p2	@DRUG$: The effect of flurbiprofen on blood pressure response to propranolol and @DRUG$ was evaluated in men with mild uncomplicated hypertension (n = 10).	DDI-false
DDI-DrugBank.d529.s7.p3	Beta-adrenergic Blocking Agents: The effect of @DRUG$ on blood pressure response to @DRUG$ and atenolol was evaluated in men with mild uncomplicated hypertension (n = 10).	DDI-false
DDI-DrugBank.d529.s7.p4	Beta-adrenergic Blocking Agents: The effect of @DRUG$ on blood pressure response to propranolol and @DRUG$ was evaluated in men with mild uncomplicated hypertension (n = 10).	DDI-false
DDI-DrugBank.d529.s7.p5	Beta-adrenergic Blocking Agents: The effect of flurbiprofen on blood pressure response to @DRUG$ and @DRUG$ was evaluated in men with mild uncomplicated hypertension (n = 10).	DDI-false
DDI-DrugBank.d529.s8.p0	@DRUG$ pretreatment attenuated the hypotensive effect of a single dose of @DRUG$ but not atenolol.	DDI-effect
DDI-DrugBank.d529.s8.p1	@DRUG$ pretreatment attenuated the hypotensive effect of a single dose of propranolol but not @DRUG$.	DDI-false
DDI-DrugBank.d529.s8.p2	Flurbiprofen pretreatment attenuated the hypotensive effect of a single dose of @DRUG$ but not @DRUG$.	DDI-false
DDI-DrugBank.d53.s14.p0	@DRUG$ or @DRUG$ acute ergot toxicity characterized by severe peripheral vasospasm and dysesthesia.	DDI-false
DDI-DrugBank.d53.s8.p0	Co-administration with @DRUG$ or @DRUG$ had a modest effect on the pharmacokinetics of azithromycin.	DDI-false
DDI-DrugBank.d53.s8.p1	Co-administration with @DRUG$ or fluconazole had a modest effect on the pharmacokinetics of @DRUG$.	DDI-mechanism
DDI-DrugBank.d53.s8.p2	Co-administration with efavirenz or @DRUG$ had a modest effect on the pharmacokinetics of @DRUG$.	DDI-mechanism
DDI-DrugBank.d531.s1.p0	Other compounds that are substrates of CYP3A4 may have decreased plasma concentrations when coadministered with @DRUG$ (@DRUG$).	DDI-false
DDI-DrugBank.d531.s10.p0	@DRUG$: @DRUG$ GI Motility Agents Anti-Migraine Antifungal	DDI-false
DDI-DrugBank.d531.s10.p1	@DRUG$: Benzodiazepines GI Motility Agents @DRUG$ Antifungal	DDI-false
DDI-DrugBank.d531.s10.p2	@DRUG$: Benzodiazepines GI Motility Agents Anti-Migraine @DRUG$	DDI-false
DDI-DrugBank.d531.s10.p3	Antihistamines: @DRUG$ GI Motility Agents @DRUG$ Antifungal	DDI-false
DDI-DrugBank.d531.s10.p4	Antihistamines: @DRUG$ GI Motility Agents Anti-Migraine @DRUG$	DDI-false
DDI-DrugBank.d531.s10.p5	Antihistamines: Benzodiazepines GI Motility Agents @DRUG$ @DRUG$	DDI-false
DDI-DrugBank.d531.s11.p0	@DRUG$ @DRUG$, triazolam cisapride ergot derivatives voriconazole	DDI-false
DDI-DrugBank.d531.s11.p1	@DRUG$ midazolam, @DRUG$ cisapride ergot derivatives voriconazole	DDI-false
DDI-DrugBank.d531.s11.p2	@DRUG$ midazolam, triazolam @DRUG$ ergot derivatives voriconazole	DDI-false
DDI-DrugBank.d531.s11.p3	@DRUG$ midazolam, triazolam cisapride ergot derivatives @DRUG$	DDI-false
DDI-DrugBank.d531.s11.p4	astemizole @DRUG$, @DRUG$ cisapride ergot derivatives voriconazole	DDI-false
DDI-DrugBank.d531.s11.p5	astemizole @DRUG$, triazolam @DRUG$ ergot derivatives voriconazole	DDI-false
DDI-DrugBank.d531.s11.p6	astemizole @DRUG$, triazolam cisapride ergot derivatives @DRUG$	DDI-false
DDI-DrugBank.d531.s11.p7	astemizole midazolam, @DRUG$ @DRUG$ ergot derivatives voriconazole	DDI-false
DDI-DrugBank.d531.s11.p8	astemizole midazolam, @DRUG$ cisapride ergot derivatives @DRUG$	DDI-false
DDI-DrugBank.d531.s11.p9	astemizole midazolam, triazolam @DRUG$ ergot derivatives @DRUG$	DDI-false
DDI-DrugBank.d531.s19.p0	When coadministered with @DRUG$ in treatment-naive patients, the recommended dose of @DRUG$ is 300 mg with ritonavir 100 mg and SUSTIVA 600 mg (all once daily).	DDI-false
DDI-DrugBank.d531.s19.p1	When coadministered with @DRUG$ in treatment-naive patients, the recommended dose of atazanavir is 300 mg with @DRUG$ 100 mg and SUSTIVA 600 mg (all once daily).	DDI-false
DDI-DrugBank.d531.s19.p2	When coadministered with @DRUG$ in treatment-naive patients, the recommended dose of atazanavir is 300 mg with ritonavir 100 mg and @DRUG$ 600 mg (all once daily).	DDI-false
DDI-DrugBank.d531.s19.p3	When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of @DRUG$ is 300 mg with @DRUG$ 100 mg and SUSTIVA 600 mg (all once daily).	DDI-false
DDI-DrugBank.d531.s19.p4	When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of @DRUG$ is 300 mg with ritonavir 100 mg and @DRUG$ 600 mg (all once daily).	DDI-false
DDI-DrugBank.d531.s19.p5	When coadministered with SUSTIVA in treatment-naive patients, the recommended dose of atazanavir is 300 mg with @DRUG$ 100 mg and @DRUG$ 600 mg (all once daily).	DDI-false
DDI-DrugBank.d531.s31.p0	Alternatives to @DRUG$, such as @DRUG$, should be considered.	DDI-false
DDI-DrugBank.d531.s45.p0	Coadministration in HIV-infected individuals with a history of injection drug use resulted in decreased plasma levels of @DRUG$ and signs of @DRUG$ withdrawal.	DDI-false
DDI-DrugBank.d531.s5.p0	Drugs which induce CYP3A4 activity (eg, @DRUG$, @DRUG$, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.	DDI-false
DDI-DrugBank.d531.s5.p1	Drugs which induce CYP3A4 activity (eg, @DRUG$, rifampin, @DRUG$) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.	DDI-false
DDI-DrugBank.d531.s5.p2	Drugs which induce CYP3A4 activity (eg, @DRUG$, rifampin, rifabutin) would be expected to increase the clearance of @DRUG$ resulting in lowered plasma concentrations.	DDI-mechanism
DDI-DrugBank.d531.s5.p3	Drugs which induce CYP3A4 activity (eg, phenobarbital, @DRUG$, @DRUG$) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.	DDI-false
DDI-DrugBank.d531.s5.p4	Drugs which induce CYP3A4 activity (eg, phenobarbital, @DRUG$, rifabutin) would be expected to increase the clearance of @DRUG$ resulting in lowered plasma concentrations.	DDI-mechanism
DDI-DrugBank.d531.s5.p5	Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, @DRUG$) would be expected to increase the clearance of @DRUG$ resulting in lowered plasma concentrations.	DDI-mechanism
DDI-DrugBank.d531.s56.p0	Consider doubling the @DRUG$ dose in regimens where @DRUG$ is given 2 or 3 times a week.	DDI-false
DDI-DrugBank.d531.s74.p0	@DRUG$: @DRUG$ Phenobarbital Carbamazepine	DDI-false
DDI-DrugBank.d531.s74.p1	@DRUG$: Phenytoin @DRUG$ Carbamazepine	DDI-false
DDI-DrugBank.d531.s74.p2	@DRUG$: Phenytoin Phenobarbital @DRUG$	DDI-false
DDI-DrugBank.d531.s74.p3	Anticonvulsants: @DRUG$ @DRUG$ Carbamazepine	DDI-false
DDI-DrugBank.d531.s74.p4	Anticonvulsants: @DRUG$ Phenobarbital @DRUG$	DDI-false
DDI-DrugBank.d531.s74.p5	Anticonvulsants: Phenytoin @DRUG$ @DRUG$	DDI-false
DDI-DrugBank.d531.s78.p0	Drug interaction studies with @DRUG$ and these @DRUG$ have not been conducted.	DDI-false
DDI-DrugBank.d531.s78.p1	Drug interaction studies with @DRUG$ and these imidazole and @DRUG$ have not been conducted.	DDI-false
DDI-DrugBank.d531.s78.p2	Drug interaction studies with SUSTIVA and these @DRUG-DRUG$ have not been conducted.	DDI-false
DDI-DrugBank.d531.s90.p0	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p1	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p2	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p3	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p4	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, @DRUG$, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p5	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, @DRUG$, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p6	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, @DRUG$, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p7	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p8	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, @DRUG$, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p9	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, @DRUG$, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p10	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when @DRUG$ (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and @DRUG$.	DDI-false
DDI-DrugBank.d531.s90.p11	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p12	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p13	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p14	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, @DRUG$, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p15	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, @DRUG$, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p16	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, @DRUG$, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p17	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p18	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, @DRUG$, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p19	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, @DRUG$, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p20	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (@DRUG$) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and @DRUG$.	DDI-false
DDI-DrugBank.d531.s90.p21	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, @DRUG$, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p22	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p23	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, @DRUG$, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p24	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, @DRUG$, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p25	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, fluconazole, @DRUG$, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p26	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p27	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, @DRUG$, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p28	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, @DRUG$, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p29	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: @DRUG$, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and @DRUG$.	DDI-false
DDI-DrugBank.d531.s90.p30	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, @DRUG$, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p31	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, @DRUG$, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p32	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, @DRUG$, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p33	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, @DRUG$, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p34	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p35	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, @DRUG$, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p36	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, @DRUG$, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p37	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, @DRUG$, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and @DRUG$.	DDI-false
DDI-DrugBank.d531.s90.p38	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, @DRUG$, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p39	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, @DRUG$, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p40	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, @DRUG$, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p41	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p42	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, lorazepam, @DRUG$, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p43	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, @DRUG$, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p44	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, @DRUG$, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and @DRUG$.	DDI-false
DDI-DrugBank.d531.s90.p45	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, @DRUG$, @DRUG$, lamivudine, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p46	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, @DRUG$, fluconazole, @DRUG$, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p47	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, @DRUG$, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p48	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, @DRUG$, fluconazole, lamivudine, lorazepam, @DRUG$, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p49	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, @DRUG$, fluconazole, lamivudine, lorazepam, nelfinavir, @DRUG$, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p50	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, @DRUG$, fluconazole, lamivudine, lorazepam, nelfinavir, paroxetine, and @DRUG$.	DDI-false
DDI-DrugBank.d531.s90.p51	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, @DRUG$, @DRUG$, lorazepam, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p52	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, @DRUG$, lamivudine, @DRUG$, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p53	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, @DRUG$, lamivudine, lorazepam, @DRUG$, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p54	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, @DRUG$, lamivudine, lorazepam, nelfinavir, @DRUG$, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p55	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, @DRUG$, lamivudine, lorazepam, nelfinavir, paroxetine, and @DRUG$.	DDI-false
DDI-DrugBank.d531.s90.p56	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, @DRUG$, @DRUG$, nelfinavir, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p57	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, @DRUG$, lorazepam, @DRUG$, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p58	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, @DRUG$, lorazepam, nelfinavir, @DRUG$, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p59	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, @DRUG$, lorazepam, nelfinavir, paroxetine, and @DRUG$.	DDI-false
DDI-DrugBank.d531.s90.p60	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, @DRUG$, paroxetine, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p61	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, @DRUG$, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p62	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, @DRUG$, nelfinavir, paroxetine, and @DRUG$.	DDI-false
DDI-DrugBank.d531.s90.p63	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, @DRUG$, @DRUG$, and zidovudine.	DDI-false
DDI-DrugBank.d531.s90.p64	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, @DRUG$, paroxetine, and @DRUG$.	DDI-false
DDI-DrugBank.d531.s90.p65	Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when SUSTIVA (efavirenz) is given with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, lamivudine, lorazepam, nelfinavir, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d533.s0.p0	Effects of Other Drugs on @DRUG$ Based on in-vitro studies, @DRUG$ is metabolized by CYP 3A4.	DDI-false
DDI-DrugBank.d533.s3.p0	Co-administration of @DRUG$ resulted in about a 50% increase in @DRUG$ Cmax and AUC after multiple dosing.	DDI-mechanism
DDI-DrugBank.d533.s6.p0	Effects of @DRUG$ on Other Drugs @DRUG$ does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1, and CYP 3A) or induce CYP 3A4.	DDI-false
DDI-DrugBank.d536.s4.p0	@DRUG$ (e. g., @DRUG$) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.	DDI-false
DDI-DrugBank.d536.s4.p1	@DRUG$ (e. g., charcoal) and @DRUG$ containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.	DDI-false
DDI-DrugBank.d536.s4.p2	@DRUG$ (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., @DRUG$, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.	DDI-false
DDI-DrugBank.d536.s4.p3	@DRUG$ (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, @DRUG$) may reduce the effect of Acarbose and should not be taken concomitantly.	DDI-false
DDI-DrugBank.d536.s4.p4	@DRUG$ (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of @DRUG$ and should not be taken concomitantly.	DDI-mechanism
DDI-DrugBank.d536.s4.p5	Intestinal adsorbents (e. g., @DRUG$) and @DRUG$ containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.	DDI-false
DDI-DrugBank.d536.s4.p6	Intestinal adsorbents (e. g., @DRUG$) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., @DRUG$, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.	DDI-false
DDI-DrugBank.d536.s4.p7	Intestinal adsorbents (e. g., @DRUG$) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, @DRUG$) may reduce the effect of Acarbose and should not be taken concomitantly.	DDI-false
DDI-DrugBank.d536.s4.p8	Intestinal adsorbents (e. g., @DRUG$) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of @DRUG$ and should not be taken concomitantly.	DDI-mechanism
DDI-DrugBank.d536.s4.p9	Intestinal adsorbents (e. g., charcoal) and @DRUG$ containing carbohydrate-splitting enzymes (e. g., @DRUG$, pancreatin) may reduce the effect of Acarbose and should not be taken concomitantly.	DDI-false
DDI-DrugBank.d536.s4.p10	Intestinal adsorbents (e. g., charcoal) and @DRUG$ containing carbohydrate-splitting enzymes (e. g., amylase, @DRUG$) may reduce the effect of Acarbose and should not be taken concomitantly.	DDI-false
DDI-DrugBank.d536.s4.p11	Intestinal adsorbents (e. g., charcoal) and @DRUG$ containing carbohydrate-splitting enzymes (e. g., amylase, pancreatin) may reduce the effect of @DRUG$ and should not be taken concomitantly.	DDI-false
DDI-DrugBank.d536.s4.p12	Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., @DRUG$, @DRUG$) may reduce the effect of Acarbose and should not be taken concomitantly.	DDI-false
DDI-DrugBank.d536.s4.p13	Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., @DRUG$, pancreatin) may reduce the effect of @DRUG$ and should not be taken concomitantly.	DDI-mechanism
DDI-DrugBank.d536.s4.p14	Intestinal adsorbents (e. g., charcoal) and digestive enzyme preparations containing carbohydrate-splitting enzymes (e. g., amylase, @DRUG$) may reduce the effect of @DRUG$ and should not be taken concomitantly.	DDI-mechanism
DDI-DrugBank.d536.s6.p0	Studies in healthy volunteers have shown that @DRUG$ has no effect on either the pharmacokinetics or pharmacodynamics of @DRUG$, nifedipine, propranolol, or ranitidine.	DDI-false
DDI-DrugBank.d536.s6.p1	Studies in healthy volunteers have shown that @DRUG$ has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, @DRUG$, propranolol, or ranitidine.	DDI-false
DDI-DrugBank.d536.s6.p2	Studies in healthy volunteers have shown that @DRUG$ has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, @DRUG$, or ranitidine.	DDI-false
DDI-DrugBank.d536.s6.p3	Studies in healthy volunteers have shown that @DRUG$ has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, propranolol, or @DRUG$.	DDI-false
DDI-DrugBank.d536.s6.p4	Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of @DRUG$, @DRUG$, propranolol, or ranitidine.	DDI-false
DDI-DrugBank.d536.s6.p5	Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of @DRUG$, nifedipine, @DRUG$, or ranitidine.	DDI-false
DDI-DrugBank.d536.s6.p6	Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of @DRUG$, nifedipine, propranolol, or @DRUG$.	DDI-false
DDI-DrugBank.d536.s6.p7	Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, @DRUG$, @DRUG$, or ranitidine.	DDI-false
DDI-DrugBank.d536.s6.p8	Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, @DRUG$, propranolol, or @DRUG$.	DDI-false
DDI-DrugBank.d536.s6.p9	Studies in healthy volunteers have shown that Acarbose has no effect on either the pharmacokinetics or pharmacodynamics of digoxin, nifedipine, @DRUG$, or @DRUG$.	DDI-false
DDI-DrugBank.d536.s8.p0	@DRUG$ may affect @DRUG$ bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).	DDI-false
DDI-DrugBank.d536.s8.p1	@DRUG$ may affect digoxin bioavailabillty and may require dose adjustment of @DRUG$ by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).	DDI-false
DDI-DrugBank.d536.s8.p2	@DRUG$ may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max @DRUG$ by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).	DDI-false
DDI-DrugBank.d536.s8.p3	@DRUG$ may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of @DRUG$ by 9% (90% confidence limit: 19% decrease to 2% increase).	DDI-false
DDI-DrugBank.d536.s8.p4	Acarbose may affect @DRUG$ bioavailabillty and may require dose adjustment of @DRUG$ by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).	DDI-false
DDI-DrugBank.d536.s8.p5	Acarbose may affect @DRUG$ bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max @DRUG$ by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).	DDI-false
DDI-DrugBank.d536.s8.p6	Acarbose may affect @DRUG$ bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of @DRUG$ by 9% (90% confidence limit: 19% decrease to 2% increase).	DDI-false
DDI-DrugBank.d536.s8.p7	Acarbose may affect digoxin bioavailabillty and may require dose adjustment of @DRUG$ by 16% (90% confidence interval: 8-23%), decrease mean C max @DRUG$ by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of digoxin by 9% (90% confidence limit: 19% decrease to 2% increase).	DDI-false
DDI-DrugBank.d536.s8.p8	Acarbose may affect digoxin bioavailabillty and may require dose adjustment of @DRUG$ by 16% (90% confidence interval: 8-23%), decrease mean C max digoxin by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of @DRUG$ by 9% (90% confidence limit: 19% decrease to 2% increase).	DDI-false
DDI-DrugBank.d536.s8.p9	Acarbose may affect digoxin bioavailabillty and may require dose adjustment of digoxin by 16% (90% confidence interval: 8-23%), decrease mean C max @DRUG$ by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of @DRUG$ by 9% (90% confidence limit: 19% decrease to 2% increase).	DDI-false
DDI-DrugBank.d538.s0.p0	Known drug interactions include @DRUG$, @DRUG$, and alcohol.	DDI-false
DDI-DrugBank.d538.s0.p1	Known drug interactions include @DRUG$, tranquilizers, and @DRUG$.	DDI-false
DDI-DrugBank.d538.s0.p2	Known drug interactions include barbiturates, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d54.s10.p0	Therefore, 4 to 5 hours should elapse between administration of @DRUG$ and @DRUG$.	DDI-advise
DDI-DrugBank.d54.s11.p0	@DRUG$, Oral @DRUG$: Estrogens tend to increase serum thyroxine-binding globulin (TBg).	DDI-false
DDI-DrugBank.d54.s11.p1	@DRUG$, Oral Contraceptives: @DRUG$ tend to increase serum thyroxine-binding globulin (TBg).	DDI-false
DDI-DrugBank.d54.s11.p2	Estrogen, Oral @DRUG$: @DRUG$ tend to increase serum thyroxine-binding globulin (TBg).	DDI-false
DDI-DrugBank.d54.s12.p0	In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free @DRUG$ may be decreased when @DRUG$ are started thus increasing thyroid requirements.	DDI-mechanism
DDI-DrugBank.d54.s12.p1	In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free @DRUG$ may be decreased when estrogens are started thus increasing @DRUG$ requirements.	DDI-false
DDI-DrugBank.d54.s12.p2	In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free levothyroxine may be decreased when @DRUG$ are started thus increasing @DRUG$ requirements.	DDI-false
DDI-DrugBank.d54.s19.p0	@DRUG$: When administered to patients on a @DRUG$, this parenteral anesthetic may cause hypertension and tachycardia.	DDI-false
DDI-DrugBank.d54.s19.p1	@DRUG$: When administered to patients on a thyroid preparation, this parenteral @DRUG$ may cause hypertension and tachycardia.	DDI-false
DDI-DrugBank.d54.s19.p2	Ketamine: When administered to patients on a @DRUG$, this parenteral @DRUG$ may cause hypertension and tachycardia.	DDI-effect
DDI-DrugBank.d54.s27.p0	Pregnancy @DRUG$ and @DRUG$-containing oral contraceptives increase TBg concentrations.	DDI-false
DDI-DrugBank.d54.s27.p1	Pregnancy @DRUG$ and estrogen-containing oral @DRUG$ increase TBg concentrations.	DDI-false
DDI-DrugBank.d54.s27.p2	Pregnancy estrogens and @DRUG$-containing oral @DRUG$ increase TBg concentrations.	DDI-false
DDI-DrugBank.d543.s0.p0	The following agents may increase certain actions or side effects of @DRUG$. @DRUG$ antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p1	The following agents may increase certain actions or side effects of @DRUG$. amantadine @DRUG$ of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p2	The following agents may increase certain actions or side effects of @DRUG$. amantadine antiarrhythmic agents of class (e.g. @DRUG$), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p3	The following agents may increase certain actions or side effects of @DRUG$. amantadine antiarrhythmic agents of class (e.g. quinidine), @DRUG$ antipsychotic agents (e.g. phenothiazines), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p4	The following agents may increase certain actions or side effects of @DRUG$. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines @DRUG$ (e.g. phenothiazines), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p5	The following agents may increase certain actions or side effects of @DRUG$. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. @DRUG$), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p6	The following agents may increase certain actions or side effects of @DRUG$. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), @DRUG$.	DDI-false
DDI-DrugBank.d543.s0.p7	The following agents may increase certain actions or side effects of anticholinergic drugs. @DRUG$ @DRUG$ of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p8	The following agents may increase certain actions or side effects of anticholinergic drugs. @DRUG$ antiarrhythmic agents of class (e.g. @DRUG$), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p9	The following agents may increase certain actions or side effects of anticholinergic drugs. @DRUG$ antiarrhythmic agents of class (e.g. quinidine), @DRUG$ antipsychotic agents (e.g. phenothiazines), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p10	The following agents may increase certain actions or side effects of anticholinergic drugs. @DRUG$ antiarrhythmic agents of class (e.g. quinidine), antihistamines @DRUG$ (e.g. phenothiazines), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p11	The following agents may increase certain actions or side effects of anticholinergic drugs. @DRUG$ antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. @DRUG$), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p12	The following agents may increase certain actions or side effects of anticholinergic drugs. @DRUG$ antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), @DRUG$.	DDI-false
DDI-DrugBank.d543.s0.p13	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine @DRUG$ of class (e.g. @DRUG$), antihistamines antipsychotic agents (e.g. phenothiazines), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p14	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine @DRUG$ of class (e.g. quinidine), @DRUG$ antipsychotic agents (e.g. phenothiazines), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p15	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine @DRUG$ of class (e.g. quinidine), antihistamines @DRUG$ (e.g. phenothiazines), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p16	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine @DRUG$ of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. @DRUG$), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p17	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine @DRUG$ of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. phenothiazines), @DRUG$.	DDI-false
DDI-DrugBank.d543.s0.p18	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. @DRUG$), @DRUG$ antipsychotic agents (e.g. phenothiazines), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p19	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. @DRUG$), antihistamines @DRUG$ (e.g. phenothiazines), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p20	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. @DRUG$), antihistamines antipsychotic agents (e.g. @DRUG$), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p21	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. @DRUG$), antihistamines antipsychotic agents (e.g. phenothiazines), @DRUG$.	DDI-false
DDI-DrugBank.d543.s0.p22	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), @DRUG$ @DRUG$ (e.g. phenothiazines), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p23	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), @DRUG$ antipsychotic agents (e.g. @DRUG$), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p24	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), @DRUG$ antipsychotic agents (e.g. phenothiazines), @DRUG$.	DDI-false
DDI-DrugBank.d543.s0.p25	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines @DRUG$ (e.g. @DRUG$), benzodiazepines.	DDI-false
DDI-DrugBank.d543.s0.p26	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines @DRUG$ (e.g. phenothiazines), @DRUG$.	DDI-false
DDI-DrugBank.d543.s0.p27	The following agents may increase certain actions or side effects of anticholinergic drugs. amantadine antiarrhythmic agents of class (e.g. quinidine), antihistamines antipsychotic agents (e.g. @DRUG$), @DRUG$.	DDI-false
DDI-DrugBank.d544.s0.p0	No dose adjustment is necessary when @DRUG$ is added to triple-immunosuppression regimens including @DRUG$, corticosteroids, and either azathioprine or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d544.s0.p1	No dose adjustment is necessary when @DRUG$ is added to triple-immunosuppression regimens including cyclosporine, @DRUG$, and either azathioprine or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d544.s0.p2	No dose adjustment is necessary when @DRUG$ is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either @DRUG$ or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d544.s0.p3	No dose adjustment is necessary when @DRUG$ is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either azathioprine or @DRUG$.	DDI-false
DDI-DrugBank.d544.s0.p4	No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including @DRUG$, @DRUG$, and either azathioprine or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d544.s0.p5	No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including @DRUG$, corticosteroids, and either @DRUG$ or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d544.s0.p6	No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including @DRUG$, corticosteroids, and either azathioprine or @DRUG$.	DDI-false
DDI-DrugBank.d544.s0.p7	No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine, @DRUG$, and either @DRUG$ or mycophenolate mofetil.	DDI-false
DDI-DrugBank.d544.s0.p8	No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine, @DRUG$, and either azathioprine or @DRUG$.	DDI-false
DDI-DrugBank.d544.s0.p9	No dose adjustment is necessary when Simulect is added to triple-immunosuppression regimens including cyclosporine, corticosteroids, and either @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d546.s0.p0	Drug Interactions with @DRUG$: Concomitant use of @DRUG$ with beta-blockers should be avoided.	DDI-false
DDI-DrugBank.d546.s0.p1	Drug Interactions with @DRUG$: Concomitant use of fenoldopam with @DRUG$ should be avoided.	DDI-false
DDI-DrugBank.d546.s0.p2	Drug Interactions with Beta-Blockers: Concomitant use of @DRUG$ with @DRUG$ should be avoided.	DDI-advise
DDI-DrugBank.d546.s2.p0	Drug Interactions, General: Although there have been no formal interaction studies, intravenous @DRUG$ has been administered safely with drugs such as @DRUG$ and sublingual nitroglycerin.	DDI-false
DDI-DrugBank.d546.s2.p1	Drug Interactions, General: Although there have been no formal interaction studies, intravenous @DRUG$ has been administered safely with drugs such as digitalis and sublingual @DRUG$.	DDI-false
DDI-DrugBank.d546.s2.p2	Drug Interactions, General: Although there have been no formal interaction studies, intravenous fenoldopam has been administered safely with drugs such as @DRUG$ and sublingual @DRUG$.	DDI-false
DDI-DrugBank.d547.s2.p0	@DRUG$ Reversible increases in serum @DRUG$ concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some angiotensin II receptor antagonists.	DDI-false
DDI-DrugBank.d547.s2.p1	@DRUG$ Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of @DRUG$ with ACE inhibitors, and with some angiotensin II receptor antagonists.	DDI-false
DDI-DrugBank.d547.s2.p2	@DRUG$ Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with @DRUG$, and with some angiotensin II receptor antagonists.	DDI-false
DDI-DrugBank.d547.s2.p3	@DRUG$ Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some @DRUG$.	DDI-false
DDI-DrugBank.d547.s2.p4	Lithium Reversible increases in serum @DRUG$ concentrations and toxicity have been reported during concomitant administration of @DRUG$ with ACE inhibitors, and with some angiotensin II receptor antagonists.	DDI-false
DDI-DrugBank.d547.s2.p5	Lithium Reversible increases in serum @DRUG$ concentrations and toxicity have been reported during concomitant administration of lithium with @DRUG$, and with some angiotensin II receptor antagonists.	DDI-false
DDI-DrugBank.d547.s2.p6	Lithium Reversible increases in serum @DRUG$ concentrations and toxicity have been reported during concomitant administration of lithium with ACE inhibitors, and with some @DRUG$.	DDI-false
DDI-DrugBank.d547.s2.p7	Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of @DRUG$ with @DRUG$, and with some angiotensin II receptor antagonists.	DDI-mechanism
DDI-DrugBank.d547.s2.p8	Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of @DRUG$ with ACE inhibitors, and with some @DRUG$.	DDI-mechanism
DDI-DrugBank.d547.s2.p9	Lithium Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with @DRUG$, and with some @DRUG$.	DDI-false
DDI-DrugBank.d547.s3.p0	An increase in serum @DRUG$ concentration has been reported during concomitant administration of @DRUG$ with ATACAND, so careful monitoring of serum lithium levels is recommended during concomitant use.	DDI-false
DDI-DrugBank.d547.s3.p1	An increase in serum @DRUG$ concentration has been reported during concomitant administration of lithium with @DRUG$, so careful monitoring of serum lithium levels is recommended during concomitant use.	DDI-false
DDI-DrugBank.d547.s3.p2	An increase in serum @DRUG$ concentration has been reported during concomitant administration of lithium with ATACAND, so careful monitoring of serum @DRUG$ levels is recommended during concomitant use.	DDI-false
DDI-DrugBank.d547.s3.p3	An increase in serum lithium concentration has been reported during concomitant administration of @DRUG$ with @DRUG$, so careful monitoring of serum lithium levels is recommended during concomitant use.	DDI-mechanism
DDI-DrugBank.d547.s3.p4	An increase in serum lithium concentration has been reported during concomitant administration of @DRUG$ with ATACAND, so careful monitoring of serum @DRUG$ levels is recommended during concomitant use.	DDI-false
DDI-DrugBank.d547.s3.p5	An increase in serum lithium concentration has been reported during concomitant administration of lithium with @DRUG$, so careful monitoring of serum @DRUG$ levels is recommended during concomitant use.	DDI-false
DDI-DrugBank.d548.s0.p0	Potential for Other Drugs to Affect @DRUG$: Both CYP1A2 and CYP2D6 are responsible for @DRUG$ metabolism.	DDI-false
DDI-DrugBank.d548.s10.p0	Plasma @DRUG$ concentrations may need to be monitored and the dose of the @DRUG$ may need to be reduced if a TCA is co-administered with Duloxetine.	DDI-false
DDI-DrugBank.d548.s10.p1	Plasma @DRUG$ concentrations may need to be monitored and the dose of the TCA may need to be reduced if a @DRUG$ is co-administered with Duloxetine.	DDI-false
DDI-DrugBank.d548.s10.p2	Plasma @DRUG$ concentrations may need to be monitored and the dose of the TCA may need to be reduced if a TCA is co-administered with @DRUG$.	DDI-false
DDI-DrugBank.d548.s10.p3	Plasma TCA concentrations may need to be monitored and the dose of the @DRUG$ may need to be reduced if a @DRUG$ is co-administered with Duloxetine.	DDI-false
DDI-DrugBank.d548.s10.p4	Plasma TCA concentrations may need to be monitored and the dose of the @DRUG$ may need to be reduced if a TCA is co-administered with @DRUG$.	DDI-false
DDI-DrugBank.d548.s10.p5	Plasma TCA concentrations may need to be monitored and the dose of the TCA may need to be reduced if a @DRUG$ is co-administered with @DRUG$.	DDI-advise
DDI-DrugBank.d548.s11.p0	Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of @DRUG$, @DRUG$ and thioridazine should not be co-administered.	DDI-false
DDI-DrugBank.d548.s11.p1	Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of @DRUG$, Duloxetine and @DRUG$ should not be co-administered.	DDI-false
DDI-DrugBank.d548.s11.p2	Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, @DRUG$ and @DRUG$ should not be co-administered.	DDI-advise
DDI-DrugBank.d548.s22.p0	It is unknown whether the concomitant administration of @DRUG$ affects @DRUG$ absorption.	DDI-false
DDI-DrugBank.d548.s3.p0	Inhibitors of CYP2D6: Because CYP2D6 is involved in @DRUG$ metabolism, concomitant use of @DRUG$ with potent inhibitors of CYP2D6 may result in higher concentrations of duloxetine.	DDI-false
DDI-DrugBank.d548.s3.p1	Inhibitors of CYP2D6: Because CYP2D6 is involved in @DRUG$ metabolism, concomitant use of duloxetine with potent inhibitors of CYP2D6 may result in higher concentrations of @DRUG$.	DDI-false
DDI-DrugBank.d548.s3.p2	Inhibitors of CYP2D6: Because CYP2D6 is involved in duloxetine metabolism, concomitant use of @DRUG$ with potent inhibitors of CYP2D6 may result in higher concentrations of @DRUG$.	DDI-false
DDI-DrugBank.d548.s4.p0	@DRUG$ (20 mg QD) increased the concentration of @DRUG$ (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.	DDI-mechanism
DDI-DrugBank.d548.s4.p1	@DRUG$ (20 mg QD) increased the concentration of duloxetine (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of @DRUG$.	DDI-false
DDI-DrugBank.d548.s4.p2	Paroxetine (20 mg QD) increased the concentration of @DRUG$ (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of @DRUG$.	DDI-false
DDI-DrugBank.d549.s4.p0	Intravenous infusion of @DRUG$ had no effect on the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d550.s2.p0	@DRUG$: Co-administration of a single dose of intravenously administered @DRUG$ (20 mg) reduced the oral absorption of a single 400 mg dose of cefditoren pivoxil administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.	DDI-false
DDI-DrugBank.d550.s2.p1	@DRUG$: Co-administration of a single dose of intravenously administered famotidine (20 mg) reduced the oral absorption of a single 400 mg dose of @DRUG$ administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.	DDI-false
DDI-DrugBank.d550.s2.p2	H2-Receptor Antagonists: Co-administration of a single dose of intravenously administered @DRUG$ (20 mg) reduced the oral absorption of a single 400 mg dose of @DRUG$ administered following a meal, as evidenced by a 27% decrease in mean Cmax and a 22% decrease in mean AUC.	DDI-mechanism
DDI-DrugBank.d550.s3.p0	Although the clinical significance is not known, it is not recommended that @DRUG$ be taken concomitantly with @DRUG$.	DDI-false
DDI-DrugBank.d551.s2.p0	@DRUG$  decreased the Cmax and AUC of sustained-release @DRUG$ (Calan SR ) by approximately 31% and 11%, respectively.	DDI-mechanism
DDI-DrugBank.d551.s2.p1	@DRUG$  decreased the Cmax and AUC of sustained-release verapamil (@DRUG$ ) by approximately 31% and 11%, respectively.	DDI-mechanism
DDI-DrugBank.d551.s2.p2	WelChol  decreased the Cmax and AUC of sustained-release @DRUG$ (@DRUG$ ) by approximately 31% and 11%, respectively.	DDI-false
DDI-DrugBank.d551.s4.p0	In clinical studies, coadministration of @DRUG$  with @DRUG$, lovastatin, or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.	DDI-false
DDI-DrugBank.d551.s4.p1	In clinical studies, coadministration of @DRUG$  with atorvastatin, @DRUG$, or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.	DDI-false
DDI-DrugBank.d551.s4.p2	In clinical studies, coadministration of @DRUG$  with atorvastatin, lovastatin, or @DRUG$ did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.	DDI-false
DDI-DrugBank.d551.s4.p3	In clinical studies, coadministration of @DRUG$  with atorvastatin, lovastatin, or simvastatin did not interfere with the lipid-lowering activity of the @DRUG$.	DDI-false
DDI-DrugBank.d551.s4.p4	In clinical studies, coadministration of WelChol  with @DRUG$, @DRUG$, or simvastatin did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.	DDI-false
DDI-DrugBank.d551.s4.p5	In clinical studies, coadministration of WelChol  with @DRUG$, lovastatin, or @DRUG$ did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.	DDI-false
DDI-DrugBank.d551.s4.p6	In clinical studies, coadministration of WelChol  with @DRUG$, lovastatin, or simvastatin did not interfere with the lipid-lowering activity of the @DRUG$.	DDI-false
DDI-DrugBank.d551.s4.p7	In clinical studies, coadministration of WelChol  with atorvastatin, @DRUG$, or @DRUG$ did not interfere with the lipid-lowering activity of the HMG-CoA reductase inhibitor.	DDI-false
DDI-DrugBank.d551.s4.p8	In clinical studies, coadministration of WelChol  with atorvastatin, @DRUG$, or simvastatin did not interfere with the lipid-lowering activity of the @DRUG$.	DDI-false
DDI-DrugBank.d551.s4.p9	In clinical studies, coadministration of WelChol  with atorvastatin, lovastatin, or @DRUG$ did not interfere with the lipid-lowering activity of the @DRUG$.	DDI-false
DDI-DrugBank.d554.s0.p0	Certain @DRUG$, @DRUG$, cyclosporine, diuretic, foscarnet, and vaccines.	DDI-false
DDI-DrugBank.d554.s0.p1	Certain @DRUG$, cisplatin, @DRUG$, diuretic, foscarnet, and vaccines.	DDI-false
DDI-DrugBank.d554.s0.p2	Certain @DRUG$, cisplatin, cyclosporine, @DRUG$, foscarnet, and vaccines.	DDI-false
DDI-DrugBank.d554.s0.p3	Certain @DRUG$, cisplatin, cyclosporine, diuretic, @DRUG$, and vaccines.	DDI-false
DDI-DrugBank.d554.s0.p4	Certain @DRUG$, cisplatin, cyclosporine, diuretic, foscarnet, and @DRUG$.	DDI-false
DDI-DrugBank.d554.s0.p5	Certain antibiotic, @DRUG$, @DRUG$, diuretic, foscarnet, and vaccines.	DDI-false
DDI-DrugBank.d554.s0.p6	Certain antibiotic, @DRUG$, cyclosporine, @DRUG$, foscarnet, and vaccines.	DDI-false
DDI-DrugBank.d554.s0.p7	Certain antibiotic, @DRUG$, cyclosporine, diuretic, @DRUG$, and vaccines.	DDI-false
DDI-DrugBank.d554.s0.p8	Certain antibiotic, @DRUG$, cyclosporine, diuretic, foscarnet, and @DRUG$.	DDI-false
DDI-DrugBank.d554.s0.p9	Certain antibiotic, cisplatin, @DRUG$, @DRUG$, foscarnet, and vaccines.	DDI-false
DDI-DrugBank.d554.s0.p10	Certain antibiotic, cisplatin, @DRUG$, diuretic, @DRUG$, and vaccines.	DDI-false
DDI-DrugBank.d554.s0.p11	Certain antibiotic, cisplatin, @DRUG$, diuretic, foscarnet, and @DRUG$.	DDI-false
DDI-DrugBank.d554.s0.p12	Certain antibiotic, cisplatin, cyclosporine, @DRUG$, @DRUG$, and vaccines.	DDI-false
DDI-DrugBank.d554.s0.p13	Certain antibiotic, cisplatin, cyclosporine, @DRUG$, foscarnet, and @DRUG$.	DDI-false
DDI-DrugBank.d554.s0.p14	Certain antibiotic, cisplatin, cyclosporine, diuretic, @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d558.s10.p0	@DRUG$ at 400 mg daily (the maximum approved prescription dose) co-administered with @DRUG$ (500 mcg BID) for 7 days has been shown to increase dofetilide Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.	DDI-mechanism
DDI-DrugBank.d558.s10.p1	@DRUG$ at 400 mg daily (the maximum approved prescription dose) co-administered with TIKOSYN (500 mcg BID) for 7 days has been shown to increase @DRUG$ Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.	DDI-false
DDI-DrugBank.d558.s10.p2	Ketoconazole at 400 mg daily (the maximum approved prescription dose) co-administered with @DRUG$ (500 mcg BID) for 7 days has been shown to increase @DRUG$ Cmax by 53% in males and 97% in females, and AUC by 41% in males and 69% in females.	DDI-false
DDI-DrugBank.d558.s14.p0	In patients receiving @DRUG$ alone, @DRUG$ AUC increased by 27% and Cmax by 21%.	DDI-mechanism
DDI-DrugBank.d558.s25.p0	Inhibitors of this isoenzyme (e.g., @DRUG$, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p1	Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p2	Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p3	Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p4	Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p5	Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p6	Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p7	Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p8	Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p9	Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p10	Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.	DDI-advise
DDI-DrugBank.d558.s25.p11	Inhibitors of this isoenzyme (e.g., @DRUG$, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.	DDI-false
DDI-DrugBank.d558.s25.p12	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p13	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p14	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p15	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p16	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p17	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p18	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p19	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p20	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p21	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.	DDI-advise
DDI-DrugBank.d558.s25.p22	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, @DRUG$, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.	DDI-false
DDI-DrugBank.d558.s25.p23	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p24	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p25	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p26	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p27	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p28	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p29	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p30	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p31	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.	DDI-advise
DDI-DrugBank.d558.s25.p32	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, @DRUG$, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.	DDI-false
DDI-DrugBank.d558.s25.p33	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p34	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p35	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p36	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p37	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p38	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p39	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p40	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.	DDI-advise
DDI-DrugBank.d558.s25.p41	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, @DRUG$, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.	DDI-false
DDI-DrugBank.d558.s25.p42	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p43	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p44	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p45	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p46	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p47	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p48	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.	DDI-advise
DDI-DrugBank.d558.s25.p49	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, @DRUG$, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.	DDI-false
DDI-DrugBank.d558.s25.p50	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p51	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p52	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p53	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p54	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p55	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.	DDI-advise
DDI-DrugBank.d558.s25.p56	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, @DRUG$, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.	DDI-false
DDI-DrugBank.d558.s25.p57	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p58	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p59	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p60	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p61	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.	DDI-advise
DDI-DrugBank.d558.s25.p62	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, @DRUG$, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.	DDI-false
DDI-DrugBank.d558.s25.p63	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p64	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p65	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p66	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.	DDI-advise
DDI-DrugBank.d558.s25.p67	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, @DRUG$, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.	DDI-false
DDI-DrugBank.d558.s25.p68	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p69	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p70	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.	DDI-advise
DDI-DrugBank.d558.s25.p71	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, @DRUG$, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.	DDI-false
DDI-DrugBank.d558.s25.p72	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.	DDI-false
DDI-DrugBank.d558.s25.p73	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.	DDI-advise
DDI-DrugBank.d558.s25.p74	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, @DRUG$, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.	DDI-false
DDI-DrugBank.d558.s25.p75	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with @DRUG$ as they can potentially increase dofetilide levels.	DDI-advise
DDI-DrugBank.d558.s25.p76	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, @DRUG$) should be cautiously coadministered with TIKOSYN as they can potentially increase @DRUG$ levels.	DDI-false
DDI-DrugBank.d558.s25.p77	Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with @DRUG$ as they can potentially increase @DRUG$ levels.	DDI-false
DDI-DrugBank.d558.s33.p0	In addition, studies in healthy volunteers have shown that @DRUG$ does not affect the pharmacokinetics or pharmacodynamics of @DRUG$, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.	DDI-false
DDI-DrugBank.d558.s33.p1	In addition, studies in healthy volunteers have shown that @DRUG$ does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of @DRUG$ (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.	DDI-false
DDI-DrugBank.d558.s33.p2	In addition, studies in healthy volunteers have shown that @DRUG$ does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), @DRUG$, theophylline, or oral contraceptives.	DDI-false
DDI-DrugBank.d558.s33.p3	In addition, studies in healthy volunteers have shown that @DRUG$ does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, @DRUG$, or oral contraceptives.	DDI-false
DDI-DrugBank.d558.s33.p4	In addition, studies in healthy volunteers have shown that @DRUG$ does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral @DRUG$.	DDI-false
DDI-DrugBank.d558.s33.p5	In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of @DRUG$, or the pharmacokinetics of @DRUG$ (40 mg twice daily), phenytoin, theophylline, or oral contraceptives.	DDI-false
DDI-DrugBank.d558.s33.p6	In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of @DRUG$, or the pharmacokinetics of propranolol (40 mg twice daily), @DRUG$, theophylline, or oral contraceptives.	DDI-false
DDI-DrugBank.d558.s33.p7	In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of @DRUG$, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, @DRUG$, or oral contraceptives.	DDI-false
DDI-DrugBank.d558.s33.p8	In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of @DRUG$, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, theophylline, or oral @DRUG$.	DDI-false
DDI-DrugBank.d558.s33.p9	In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of @DRUG$ (40 mg twice daily), @DRUG$, theophylline, or oral contraceptives.	DDI-false
DDI-DrugBank.d558.s33.p10	In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of @DRUG$ (40 mg twice daily), phenytoin, @DRUG$, or oral contraceptives.	DDI-false
DDI-DrugBank.d558.s33.p11	In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of @DRUG$ (40 mg twice daily), phenytoin, theophylline, or oral @DRUG$.	DDI-false
DDI-DrugBank.d558.s33.p12	In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), @DRUG$, @DRUG$, or oral contraceptives.	DDI-false
DDI-DrugBank.d558.s33.p13	In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), @DRUG$, theophylline, or oral @DRUG$.	DDI-false
DDI-DrugBank.d558.s33.p14	In addition, studies in healthy volunteers have shown that TIKOSYN does not affect the pharmacokinetics or pharmacodynamics of warfarin, or the pharmacokinetics of propranolol (40 mg twice daily), phenytoin, @DRUG$, or oral @DRUG$.	DDI-false
DDI-DrugBank.d558.s37.p0	The mean clearances of @DRUG$ were 16% and 15% lower in patients on @DRUG$ and inhibitors of tubular organic cation transport, respectively.	DDI-mechanism
DDI-DrugBank.d558.s8.p0	In an analysis of the supraventricular arrhythmia and DIAMOND patient populations, the concomitant administration of @DRUG$ with @DRUG$ was associated with a higher occurrence of torsade de pointes.	DDI-effect
DDI-DrugBank.d559.s0.p0	The CNS effects of @DRUG$ may be enhanced by @DRUG$.	DDI-effect
DDI-DrugBank.d561.s3.p0	@DRUG$ Supplements and @DRUG$ Lotensin can attenuate potassium loss caused by thiazide diuretics.	DDI-false
DDI-DrugBank.d561.s3.p1	@DRUG$ Supplements and Potassium-Sparing Diuretics Lotensin can attenuate potassium loss caused by @DRUG$.	DDI-false
DDI-DrugBank.d561.s3.p2	Potassium Supplements and @DRUG$ Lotensin can attenuate potassium loss caused by @DRUG$.	DDI-effect
DDI-DrugBank.d561.s4.p0	@DRUG$ (@DRUG$, amiloride, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d561.s4.p1	@DRUG$ (spironolactone, @DRUG$, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d561.s4.p2	@DRUG$ (spironolactone, amiloride, @DRUG$, and others) or potassium supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d561.s4.p3	@DRUG$ (spironolactone, amiloride, triamterene, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d561.s4.p4	Potassium-sparing diuretics (@DRUG$, @DRUG$, triamterene, and others) or potassium supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d561.s4.p5	Potassium-sparing diuretics (@DRUG$, amiloride, @DRUG$, and others) or potassium supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d561.s4.p6	Potassium-sparing diuretics (@DRUG$, amiloride, triamterene, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d561.s4.p7	Potassium-sparing diuretics (spironolactone, @DRUG$, @DRUG$, and others) or potassium supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d561.s4.p8	Potassium-sparing diuretics (spironolactone, @DRUG$, triamterene, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d561.s4.p9	Potassium-sparing diuretics (spironolactone, amiloride, @DRUG$, and others) or @DRUG$ supplements can increase the risk of hyperkalemia.	DDI-false
DDI-DrugBank.d561.s6.p0	Oral @DRUG$ Interaction studies with @DRUG$ and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.	DDI-false
DDI-DrugBank.d561.s6.p1	Oral @DRUG$ Interaction studies with warfarin and @DRUG$ failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.	DDI-false
DDI-DrugBank.d561.s6.p2	Oral @DRUG$ Interaction studies with warfarin and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these @DRUG$.	DDI-false
DDI-DrugBank.d561.s6.p3	Oral Anticoagulants Interaction studies with @DRUG$ and @DRUG$ failed to identify any clinically important effects on the serum concentrations or clinical effects of these anticoagulants.	DDI-false
DDI-DrugBank.d561.s6.p4	Oral Anticoagulants Interaction studies with @DRUG$ and acenocoumarol failed to identify any clinically important effects on the serum concentrations or clinical effects of these @DRUG$.	DDI-false
DDI-DrugBank.d561.s6.p5	Oral Anticoagulants Interaction studies with warfarin and @DRUG$ failed to identify any clinically important effects on the serum concentrations or clinical effects of these @DRUG$.	DDI-false
DDI-DrugBank.d562.s10.p0	Seizures have been reported in patients taking another @DRUG$ and the @DRUG$ fenbufen concurrently.	DDI-effect
DDI-DrugBank.d562.s10.p1	Seizures have been reported in patients taking another @DRUG$ and the nonsteroidal anti-inflammatory drug @DRUG$ concurrently.	DDI-effect
DDI-DrugBank.d562.s10.p2	Seizures have been reported in patients taking another quinolone class antimicrobial and the @DRUG$ @DRUG$ concurrently.	DDI-false
DDI-DrugBank.d564.s0.p0	The administration of local @DRUG$ containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-false
DDI-DrugBank.d564.s0.p1	The administration of local @DRUG$ containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-false
DDI-DrugBank.d564.s0.p2	The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving @DRUG$ or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-false
DDI-DrugBank.d564.s0.p3	The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe, prolonged hypertension.	DDI-false
DDI-DrugBank.d564.s0.p4	The administration of local anesthetic solutions containing @DRUG$ or @DRUG$ to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-false
DDI-DrugBank.d564.s0.p5	The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving @DRUG$ or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-effect
DDI-DrugBank.d564.s0.p6	The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe, prolonged hypertension.	DDI-effect
DDI-DrugBank.d564.s0.p7	The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving @DRUG$ or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-effect
DDI-DrugBank.d564.s0.p8	The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe, prolonged hypertension.	DDI-effect
DDI-DrugBank.d564.s0.p9	The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$ or @DRUG$ may produce severe, prolonged hypertension.	DDI-false
DDI-DrugBank.d564.s1.p0	@DRUG$ and @DRUG$ may reduce or reverse the pressor effect of epinephrine.	DDI-false
DDI-DrugBank.d564.s1.p1	@DRUG$ and butyrophenones may reduce or reverse the pressor effect of @DRUG$.	DDI-effect
DDI-DrugBank.d564.s1.p2	Phenothiazines and @DRUG$ may reduce or reverse the pressor effect of @DRUG$.	DDI-effect
DDI-DrugBank.d565.s14.p0	The effect may be mediated by @DRUG$s known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of @DRUG$.	DDI-mechanism
DDI-DrugBank.d565.s15.p0	Patients currently receiving @DRUG$ therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with @DRUG$.	DDI-advise
DDI-DrugBank.d565.s20.p0	Since there have been conflicting results regarding the effect of @DRUG$ levels, it is recommended that @DRUG$ levels be monitored when initiating, adjusting, and discontinuing diltiazem hydrochloride therapy to avoid possible over- or under-digitalization.	DDI-false
DDI-DrugBank.d565.s20.p1	Since there have been conflicting results regarding the effect of @DRUG$ levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing @DRUG$ therapy to avoid possible over- or under-digitalization.	DDI-false
DDI-DrugBank.d565.s20.p2	Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that @DRUG$ levels be monitored when initiating, adjusting, and discontinuing @DRUG$ therapy to avoid possible over- or under-digitalization.	DDI-advise
DDI-DrugBank.d565.s33.p0	Studies showed that @DRUG$ increased the AUC of @DRUG$ and triazolam by 3-4 fold and the Cmax by 2-fold, compared to placebo.	DDI-mechanism
DDI-DrugBank.d565.s33.p1	Studies showed that @DRUG$ increased the AUC of midazolam and @DRUG$ by 3-4 fold and the Cmax by 2-fold, compared to placebo.	DDI-mechanism
DDI-DrugBank.d565.s33.p2	Studies showed that diltiazem increased the AUC of @DRUG$ and @DRUG$ by 3-4 fold and the Cmax by 2-fold, compared to placebo.	DDI-false
DDI-DrugBank.d565.s35.p0	These pharmacokinetic effects seen during @DRUG$ coadministration can result in increased clinical effects (e.g., prolonged sodation)of both @DRUG$ and triazolam.	DDI-effect
DDI-DrugBank.d565.s35.p1	These pharmacokinetic effects seen during @DRUG$ coadministration can result in increased clinical effects (e.g., prolonged sodation)of both midazolam and @DRUG$.	DDI-effect
DDI-DrugBank.d565.s35.p2	These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sodation)of both @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d565.s9.p0	In vitro, @DRUG$ appears to be displaced from its binding sites by @DRUG$.	DDI-mechanism
DDI-DrugBank.d566.s4.p0	When @DRUG$ @DRUG$ is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of fat-soluble vitamins should be considered.	DDI-false
DDI-DrugBank.d566.s4.p1	When @DRUG$ resin is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of @DRUG$ should be considered.	DDI-false
DDI-DrugBank.d566.s4.p2	When cholestyramine @DRUG$ is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of @DRUG$ should be considered.	DDI-false
DDI-DrugBank.d566.s5.p0	SINCE @DRUG$ @DRUG$ MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.	DDI-false
DDI-DrugBank.d566.s5.p1	SINCE @DRUG$ RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER @DRUG$ RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.	DDI-false
DDI-DrugBank.d566.s5.p2	SINCE @DRUG$ RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE @DRUG$ (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.	DDI-false
DDI-DrugBank.d566.s5.p3	SINCE CHOLESTYRAMINE @DRUG$ MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER @DRUG$ RESIN (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.	DDI-false
DDI-DrugBank.d566.s5.p4	SINCE CHOLESTYRAMINE @DRUG$ MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER CHOLESTYRAMINE @DRUG$ (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.	DDI-false
DDI-DrugBank.d566.s5.p5	SINCE CHOLESTYRAMINE RESIN MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER @DRUG$ @DRUG$ (OR AT AS GREAT AN INTERVAL AS POSSIBLE) TO AVOID IMPEDING THEIR ABSORPTION.	DDI-false
DDI-DrugBank.d567.s13.p0	@DRUG$s: In a small clinical trial in which @DRUG$ was administered to warfarin treated patients, no effect on prothrombin time was detected.	DDI-false
DDI-DrugBank.d567.s13.p1	@DRUG$s: In a small clinical trial in which lovastatin was administered to @DRUG$ treated patients, no effect on prothrombin time was detected.	DDI-false
DDI-DrugBank.d567.s13.p2	Coumarin Anticoagulants: In a small clinical trial in which @DRUG$ was administered to @DRUG$ treated patients, no effect on prothrombin time was detected.	DDI-false
DDI-DrugBank.d567.s15.p0	Also, bleeding and/or increased prothrombin time have been reported in a few patients taking @DRUG$s concomitantly with @DRUG$.	DDI-effect
DDI-DrugBank.d567.s16.p0	It is recommended that in patients taking @DRUG$, prothrombin time be determined before starting @DRUG$ and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.	DDI-advise
DDI-DrugBank.d567.s19.p0	@DRUG$ therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking @DRUG$.	DDI-false
DDI-DrugBank.d568.s11.p0	Nevertheless, plasma @DRUG$ levels should be monitored with appropriate adjustment to the @DRUG$ dose in accordance with standard clinical practice.	DDI-false
DDI-DrugBank.d568.s13.p0	@DRUG$ and @DRUG$ - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.	DDI-false
DDI-DrugBank.d568.s13.p1	@DRUG$ and Celexa - In a controlled study, a single dose of @DRUG$ 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.	DDI-false
DDI-DrugBank.d568.s13.p2	@DRUG$ and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic @DRUG$ 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.	DDI-false
DDI-DrugBank.d568.s13.p3	@DRUG$ and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to @DRUG$ given alone.	DDI-false
DDI-DrugBank.d568.s13.p4	Pimozide and @DRUG$ - In a controlled study, a single dose of @DRUG$ 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.	DDI-false
DDI-DrugBank.d568.s13.p5	Pimozide and @DRUG$ - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic @DRUG$ 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.	DDI-false
DDI-DrugBank.d568.s13.p6	Pimozide and @DRUG$ - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to @DRUG$ given alone.	DDI-false
DDI-DrugBank.d568.s13.p7	Pimozide and Celexa - In a controlled study, a single dose of @DRUG$ 2 mg co-administered with racemic @DRUG$ 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.	DDI-effect
DDI-DrugBank.d568.s13.p8	Pimozide and Celexa - In a controlled study, a single dose of @DRUG$ 2 mg co-administered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to @DRUG$ given alone.	DDI-false
DDI-DrugBank.d568.s13.p9	Pimozide and Celexa - In a controlled study, a single dose of pimozide 2 mg co-administered with racemic @DRUG$ 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to @DRUG$ given alone.	DDI-false
DDI-DrugBank.d568.s19.p0	The effect of @DRUG$ on the pharmacokinetics of @DRUG$ was not evaluated.	DDI-false
DDI-DrugBank.d568.s22.p0	@DRUG$ - Combined administration of racemic @DRUG$ (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.	DDI-false
DDI-DrugBank.d568.s22.p1	@DRUG$ - Combined administration of racemic citalopram (40 mg/day for 14 days) and @DRUG$ (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.	DDI-false
DDI-DrugBank.d568.s22.p2	@DRUG$ - Combined administration of racemic citalopram (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of @DRUG$, a CYP3A4 substrate.	DDI-false
DDI-DrugBank.d568.s22.p3	Carbamazepine - Combined administration of racemic @DRUG$ (40 mg/day for 14 days) and @DRUG$ (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.	DDI-false
DDI-DrugBank.d568.s22.p4	Carbamazepine - Combined administration of racemic @DRUG$ (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of @DRUG$, a CYP3A4 substrate.	DDI-false
DDI-DrugBank.d568.s22.p5	Carbamazepine - Combined administration of racemic citalopram (40 mg/day for 14 days) and @DRUG$ (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of @DRUG$, a CYP3A4 substrate.	DDI-false
DDI-DrugBank.d568.s28.p0	However, coadministration of @DRUG$ (20 mg) and @DRUG$ (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram.	DDI-false
DDI-DrugBank.d568.s28.p1	However, coadministration of @DRUG$ (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d568.s28.p2	However, coadministration of escitalopram (20 mg) and @DRUG$ (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d568.s29.p0	Because @DRUG$ is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease @DRUG$ clearance.	DDI-false
DDI-DrugBank.d568.s37.p0	Coadministration of @DRUG$ and @DRUG$ had no clinically significant effects on blood pressure or heart rate.	DDI-false
DDI-DrugBank.d568.s5.p0	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of @DRUG$ that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an @DRUG$ or aspirin potentiated the risk of bleeding.	DDI-effect
DDI-DrugBank.d568.s5.p1	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of @DRUG$ that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or @DRUG$ potentiated the risk of bleeding.	DDI-effect
DDI-DrugBank.d568.s5.p2	Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an @DRUG$ or @DRUG$ potentiated the risk of bleeding.	DDI-false
DDI-DrugBank.d568.s7.p0	@DRUG$ - In subjects who had received 21 days of 40 mg/day racemic @DRUG$, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.	DDI-false
DDI-DrugBank.d568.s7.p1	@DRUG$ - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day @DRUG$ for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.	DDI-false
DDI-DrugBank.d568.s7.p2	@DRUG$ - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in @DRUG$ AUC and Cmax of 43% and 39%, respectively.	DDI-false
DDI-DrugBank.d568.s7.p3	Cimetidine - In subjects who had received 21 days of 40 mg/day racemic @DRUG$, combined administration of 400 mg/day @DRUG$ for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.	DDI-mechanism
DDI-DrugBank.d568.s7.p4	Cimetidine - In subjects who had received 21 days of 40 mg/day racemic @DRUG$, combined administration of 400 mg/day cimetidine for 8 days resulted in an increase in @DRUG$ AUC and Cmax of 43% and 39%, respectively.	DDI-false
DDI-DrugBank.d568.s7.p5	Cimetidine - In subjects who had received 21 days of 40 mg/day racemic citalopram, combined administration of 400 mg/day @DRUG$ for 8 days resulted in an increase in @DRUG$ AUC and Cmax of 43% and 39%, respectively.	DDI-false
DDI-DrugBank.d57.s0.p0	In vitro mixing of an @DRUG$ with beta-lactamtype @DRUG$ (penicillins or cephalosporins) may result in a significant mutual inactivation.	DDI-effect
DDI-DrugBank.d57.s0.p1	In vitro mixing of an @DRUG$ with beta-lactamtype antibiotics (@DRUG$ or cephalosporins) may result in a significant mutual inactivation.	DDI-effect
DDI-DrugBank.d57.s0.p2	In vitro mixing of an @DRUG$ with beta-lactamtype antibiotics (penicillins or @DRUG$) may result in a significant mutual inactivation.	DDI-effect
DDI-DrugBank.d57.s0.p3	In vitro mixing of an aminoglycoside with beta-lactamtype @DRUG$ (@DRUG$ or cephalosporins) may result in a significant mutual inactivation.	DDI-false
DDI-DrugBank.d57.s0.p4	In vitro mixing of an aminoglycoside with beta-lactamtype @DRUG$ (penicillins or @DRUG$) may result in a significant mutual inactivation.	DDI-false
DDI-DrugBank.d57.s0.p5	In vitro mixing of an aminoglycoside with beta-lactamtype antibiotics (@DRUG$ or @DRUG$) may result in a significant mutual inactivation.	DDI-false
DDI-DrugBank.d571.s4.p0	Patients on oral @DRUG$ receiving @DRUG$ treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetic medication.	DDI-advise
DDI-DrugBank.d571.s4.p1	Patients on oral @DRUG$ receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their @DRUG$.	DDI-false
DDI-DrugBank.d571.s4.p2	Patients on oral antidiabetic agents receiving @DRUG$ treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their @DRUG$.	DDI-false
DDI-DrugBank.d6.s2.p0	If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of @DRUG$ than when @DRUG$ or nitrous oxide with a balanced technique are used.	DDI-false
DDI-DrugBank.d6.s2.p1	If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of @DRUG$ than when halothane or @DRUG$ with a balanced technique are used.	DDI-false
DDI-DrugBank.d6.s2.p2	If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of Enflurane than when @DRUG$ or @DRUG$ with a balanced technique are used.	DDI-false
DDI-DrugBank.d60.s0.p0	Administration of 0.1-mg/kg (2 x ED95) @DRUG$ at 10% or 95% recovery following an intubating dose of @DRUG$ (1 mg/kg) produced  95% neuromuscular block.	DDI-effect
DDI-DrugBank.d60.s1.p0	The time to onset of maximum block following @DRUG$ is approximately 2 minutes faster with prior administration of @DRUG$.	DDI-effect
DDI-DrugBank.d60.s14.p0	While the effects of chronic @DRUG$ or @DRUG$ therapy on the action of NIMBEX are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.	DDI-false
DDI-DrugBank.d60.s14.p1	While the effects of chronic @DRUG$ or carbamazepine therapy on the action of @DRUG$ are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.	DDI-effect
DDI-DrugBank.d60.s14.p2	While the effects of chronic phenytoin or @DRUG$ therapy on the action of @DRUG$ are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher.	DDI-effect
DDI-DrugBank.d60.s4.p0	The use of @DRUG$ before @DRUG$ to attenuate some of the side effects of succinylcholine has not been studied.	DDI-false
DDI-DrugBank.d60.s4.p1	The use of @DRUG$ before succinylcholine to attenuate some of the side effects of @DRUG$ has not been studied.	DDI-false
DDI-DrugBank.d60.s4.p2	The use of NIMBEX before @DRUG$ to attenuate some of the side effects of @DRUG$ has not been studied.	DDI-false
DDI-DrugBank.d63.s0.p0	@DRUG$ such as @DRUG$ (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p1	@DRUG$ such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p2	@DRUG$ such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p3	@DRUG$ such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p4	@DRUG$ such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p5	@DRUG$ such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p6	@DRUG$ such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p7	@DRUG$ such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p8	@DRUG$ such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p9	@DRUG$ such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p10	@DRUG$ such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p11	Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p12	Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p13	Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p14	Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p15	Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p16	Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p17	Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p18	Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p19	Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p20	Monoamine oxidase (MAO) inhibitors such as @DRUG$ (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p21	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p22	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p23	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p24	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p25	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p26	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p27	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p28	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p29	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., @DRUG$), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p30	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p31	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p32	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p33	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p34	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p35	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p36	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p37	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), @DRUG$ (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p38	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p39	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p40	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p41	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p42	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p43	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p44	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., @DRUG$), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p45	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p46	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p47	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p48	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p49	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p50	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), @DRUG$ (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p51	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p52	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p53	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p54	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p55	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., @DRUG$), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p56	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p57	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p58	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p59	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), @DRUG$ (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p60	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., @DRUG$), and @DRUG$ (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p61	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p62	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., @DRUG$), and tranylcypromine (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p63	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., @DRUG$): Using these medicines with L-tryptophan may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p64	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and @DRUG$ (e.g., Parnate): Using these medicines with @DRUG$ may increase the chance of side effects.	DDI-false
DDI-DrugBank.d63.s0.p65	Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., @DRUG$): Using these medicines with @DRUG$ may increase the chance of side effects.	DDI-false
DDI-DrugBank.d64.s3.p0	For example, since @DRUG$ may reduce the gastrointestinal absorption of both the oral @DRUG$ and vitamin K, the net effects are unpredictable.	DDI-mechanism
DDI-DrugBank.d64.s3.p1	For example, since @DRUG$ may reduce the gastrointestinal absorption of both the oral anticoagulants and @DRUG$, the net effects are unpredictable.	DDI-mechanism
DDI-DrugBank.d64.s3.p2	For example, since cholestyramine may reduce the gastrointestinal absorption of both the oral @DRUG$ and @DRUG$, the net effects are unpredictable.	DDI-false
DDI-DrugBank.d64.s88.p0	Oral @DRUG$ may potentiate the hypoglycemic action of @DRUG$, eg, tolbutamide and chlorpropamide, by inhibiting their metabolism in the liver.	DDI-mechanism
DDI-DrugBank.d64.s88.p1	Oral @DRUG$ may potentiate the hypoglycemic action of hypoglycemic agents, eg, @DRUG$ and chlorpropamide, by inhibiting their metabolism in the liver.	DDI-mechanism
DDI-DrugBank.d64.s88.p2	Oral @DRUG$ may potentiate the hypoglycemic action of hypoglycemic agents, eg, tolbutamide and @DRUG$, by inhibiting their metabolism in the liver.	DDI-mechanism
DDI-DrugBank.d64.s88.p3	Oral anticoagulants may potentiate the hypoglycemic action of @DRUG$, eg, @DRUG$ and chlorpropamide, by inhibiting their metabolism in the liver.	DDI-false
DDI-DrugBank.d64.s88.p4	Oral anticoagulants may potentiate the hypoglycemic action of @DRUG$, eg, tolbutamide and @DRUG$, by inhibiting their metabolism in the liver.	DDI-false
DDI-DrugBank.d64.s88.p5	Oral anticoagulants may potentiate the hypoglycemic action of hypoglycemic agents, eg, @DRUG$ and @DRUG$, by inhibiting their metabolism in the liver.	DDI-false
DDI-DrugBank.d64.s89.p0	Because oral @DRUG$ may interfere with the hepatic metabolism of @DRUG$, toxic levels of the anticonvulsant may occur when an oral anticoagulant and phenytoin are administered concurrently.	DDI-mechanism
DDI-DrugBank.d64.s89.p1	Because oral @DRUG$ may interfere with the hepatic metabolism of phenytoin, toxic levels of the @DRUG$ may occur when an oral anticoagulant and phenytoin are administered concurrently.	DDI-false
DDI-DrugBank.d64.s89.p2	Because oral @DRUG$ may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral @DRUG$ and phenytoin are administered concurrently.	DDI-false
DDI-DrugBank.d64.s89.p3	Because oral @DRUG$ may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral anticoagulant and @DRUG$ are administered concurrently.	DDI-false
DDI-DrugBank.d64.s89.p4	Because oral anticoagulants may interfere with the hepatic metabolism of @DRUG$, toxic levels of the @DRUG$ may occur when an oral anticoagulant and phenytoin are administered concurrently.	DDI-false
DDI-DrugBank.d64.s89.p5	Because oral anticoagulants may interfere with the hepatic metabolism of @DRUG$, toxic levels of the anticonvulsant may occur when an oral @DRUG$ and phenytoin are administered concurrently.	DDI-false
DDI-DrugBank.d64.s89.p6	Because oral anticoagulants may interfere with the hepatic metabolism of @DRUG$, toxic levels of the anticonvulsant may occur when an oral anticoagulant and @DRUG$ are administered concurrently.	DDI-false
DDI-DrugBank.d64.s89.p7	Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the @DRUG$ may occur when an oral @DRUG$ and phenytoin are administered concurrently.	DDI-false
DDI-DrugBank.d64.s89.p8	Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the @DRUG$ may occur when an oral anticoagulant and @DRUG$ are administered concurrently.	DDI-false
DDI-DrugBank.d64.s89.p9	Because oral anticoagulants may interfere with the hepatic metabolism of phenytoin, toxic levels of the anticonvulsant may occur when an oral @DRUG$ and @DRUG$ are administered concurrently.	DDI-mechanism
DDI-DrugBank.d64.s91.p0	The beneficial effects on arterial thrombus formation from combined therapy with @DRUG-DRUG$ must be weighed against an increased risk of inducing hemorrhage.	DDI-advise
DDI-DrugBank.d64.s93.p0	Drug/Laboratory Test Interferences: @DRUG$ and @DRUG$, including anisindione, or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.	DDI-false
DDI-DrugBank.d64.s93.p1	Drug/Laboratory Test Interferences: @DRUG$ and indanedione anticoagulants, including @DRUG$, or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.	DDI-false
DDI-DrugBank.d64.s93.p2	Drug/Laboratory Test Interferences: Dicumarol and @DRUG$, including @DRUG$, or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.	DDI-false
DDI-DrugBank.d65.s0.p0	@DRUG$ preparations are incompatible with @DRUG$ preparations.	DDI-int
DDI-DrugBank.d68.s3.p0	Coadministration of @DRUG$ did not have effects on either the safety or efficacy of @DRUG$ in the clinical trials.	DDI-false
DDI-DrugBank.d69.s0.p0	Use of @DRUG$ in a patient who has previously received @DRUG$ increases the risk of cardiotoxicity.	DDI-effect
DDI-DrugBank.d69.s1.p0	@DRUG$ should not be used in patients who have previously received the recommended maximum cumulative doses of @DRUG$ or Cerubidine.	DDI-advise
DDI-DrugBank.d69.s1.p1	@DRUG$ should not be used in patients who have previously received the recommended maximum cumulative doses of doxorubicin or @DRUG$.	DDI-false
DDI-DrugBank.d69.s1.p2	Cerubidine should not be used in patients who have previously received the recommended maximum cumulative doses of @DRUG$ or @DRUG$.	DDI-false
DDI-DrugBank.d69.s2.p0	@DRUG$ used concurrently with @DRUG$ may also result in increased cardiotoxicity.	DDI-effect
DDI-DrugBank.d7.s0.p0	The rate of metabolism and the leukopenic activity of @DRUG$ reportedly are increased by chronic administration of high doses of @DRUG$.	DDI-mechanism
DDI-DrugBank.d7.s2.p0	@DRUG$ treatment, which causes a marked and persistent inhibition of cholinesterase activity, potentiates the effect of @DRUG$.	DDI-effect
DDI-DrugBank.d70.s11.p0	The potential effects of @DRUG$ on the fertility of male animals were not studied but in a 6-month toxicology study, male rats treated with intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days, or 10 mg/rat/15 days @DRUG$ showed a loss of spermatozoa from the seminiferous tubules, seminiferous tubular atrophy, and degenerative changes in the epididymides.	DDI-false
DDI-DrugBank.d73.s0.p0	Catecholamine-depleting drugs (eg, @DRUG$) may have an additive effect when given with @DRUG$s.	DDI-effect
DDI-DrugBank.d73.s2.p0	@DRUG$ may also have an additive effect when given with @DRUG$ .	DDI-effect
DDI-DrugBank.d74.s3.p0	For this reason the dose of @DRUG$ should be restricted and an @DRUG$ administered as appropriate.	DDI-false
DDI-DrugBank.d75.s6.p0	No clinically relevant pharmacokinetic interactions between @DRUG$ and @DRUG$ were observed.	DDI-false
DDI-DrugBank.d76.s1.p0	In patients receiving another @DRUG$ in combination with @DRUG$ (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.	DDI-effect
DDI-DrugBank.d76.s1.p1	In patients receiving another @DRUG$ in combination with monoamine oxidase inhibitors (@DRUG$), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.	DDI-effect
DDI-DrugBank.d76.s1.p2	In patients receiving another serotonin reuptake inhibitor drug in combination with @DRUG$ (@DRUG$), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.	DDI-false
DDI-DrugBank.d76.s10.p0	Although it has not been definitively demonstrated that @DRUG$ is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of @DRUG$ with alprazolam.	DDI-false
DDI-DrugBank.d76.s10.p1	Although it has not been definitively demonstrated that @DRUG$ is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with @DRUG$.	DDI-false
DDI-DrugBank.d76.s10.p2	Although it has not been definitively demonstrated that fluvoxamine is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of @DRUG$ with @DRUG$.	DDI-int
DDI-DrugBank.d76.s14.p0	@DRUG$: When @DRUG$ (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;	DDI-false
DDI-DrugBank.d76.s14.p1	@DRUG$: When fluvoxamine maleate (100 mg qd) and @DRUG$ (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;	DDI-false
DDI-DrugBank.d76.s14.p2	@DRUG$: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of @DRUG$ were approximately twice those observed when alprazolam was administered alone;	DDI-false
DDI-DrugBank.d76.s14.p3	@DRUG$: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when @DRUG$ was administered alone;	DDI-false
DDI-DrugBank.d76.s14.p4	Alprazolam: When @DRUG$ (100 mg qd) and @DRUG$ (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when alprazolam was administered alone;	DDI-mechanism
DDI-DrugBank.d76.s14.p5	Alprazolam: When @DRUG$ (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of @DRUG$ were approximately twice those observed when alprazolam was administered alone;	DDI-false
DDI-DrugBank.d76.s14.p6	Alprazolam: When @DRUG$ (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when @DRUG$ was administered alone;	DDI-false
DDI-DrugBank.d76.s14.p7	Alprazolam: When fluvoxamine maleate (100 mg qd) and @DRUG$ (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of @DRUG$ were approximately twice those observed when alprazolam was administered alone;	DDI-false
DDI-DrugBank.d76.s14.p8	Alprazolam: When fluvoxamine maleate (100 mg qd) and @DRUG$ (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of alprazolam were approximately twice those observed when @DRUG$ was administered alone;	DDI-false
DDI-DrugBank.d76.s14.p9	Alprazolam: When fluvoxamine maleate (100 mg qd) and alprazolam (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of @DRUG$ were approximately twice those observed when @DRUG$ was administered alone;	DDI-false
DDI-DrugBank.d76.s20.p0	Because @DRUG$ reduces the clearance of both @DRUG$ and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.	DDI-mechanism
DDI-DrugBank.d76.s20.p1	Because @DRUG$ reduces the clearance of both diazepam and its active metabolite, @DRUG$, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.	DDI-mechanism
DDI-DrugBank.d76.s20.p2	Because fluvoxamine reduces the clearance of both @DRUG$ and its active metabolite, @DRUG$, there is a strong likelihood of substantial accumulation of both species during chronic co-administration.	DDI-false
DDI-DrugBank.d76.s28.p0	Therefore, if @DRUG$ is co-administered with @DRUG$, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of theophylline should to monitored.	DDI-advise
DDI-DrugBank.d76.s28.p1	Therefore, if @DRUG$ is co-administered with fluvoxamine maleate, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of @DRUG$ should to monitored.	DDI-false
DDI-DrugBank.d76.s28.p2	Therefore, if theophylline is co-administered with @DRUG$, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of @DRUG$ should to monitored.	DDI-false
DDI-DrugBank.d77.s16.p0	The extent to which @DRUG$-@DRUG$ interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the SSRI involved.	DDI-int
DDI-DrugBank.d77.s16.p1	The extent to which @DRUG$-TCA interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the @DRUG$ involved.	DDI-false
DDI-DrugBank.d77.s16.p2	The extent to which SSRI-@DRUG$ interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the @DRUG$ involved.	DDI-false
DDI-DrugBank.d78.s1.p0	Administration of @DRUG$ with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p1	Administration of @DRUG$ with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-mechanism
DDI-DrugBank.d78.s1.p2	Administration of @DRUG$ with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-mechanism
DDI-DrugBank.d78.s1.p3	Administration of @DRUG$ with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-mechanism
DDI-DrugBank.d78.s1.p4	Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-mechanism
DDI-DrugBank.d78.s1.p5	Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-mechanism
DDI-DrugBank.d78.s1.p6	Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-mechanism
DDI-DrugBank.d78.s1.p7	Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-mechanism
DDI-DrugBank.d78.s1.p8	Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-mechanism
DDI-DrugBank.d78.s1.p9	Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-mechanism
DDI-DrugBank.d78.s1.p10	Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-mechanism
DDI-DrugBank.d78.s1.p11	Administration of @DRUG$ with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p12	Administration of quinolones with @DRUG$ containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p13	Administration of quinolones with @DRUG$ containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p14	Administration of quinolones with @DRUG$ containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p15	Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p16	Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p17	Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p18	Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p19	Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p20	Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p21	Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p22	Administration of quinolones with @DRUG$ containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p23	Administration of quinolones with antacids containing @DRUG$, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p24	Administration of quinolones with antacids containing @DRUG$, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p25	Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p26	Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p27	Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p28	Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p29	Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p30	Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p31	Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p32	Administration of quinolones with antacids containing @DRUG$, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p33	Administration of quinolones with antacids containing aluminum, @DRUG$, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p34	Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p35	Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p36	Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p37	Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p38	Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p39	Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p40	Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p41	Administration of quinolones with antacids containing aluminum, @DRUG$, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p42	Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p43	Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p44	Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p45	Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p46	Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p47	Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p48	Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p49	Administration of quinolones with antacids containing aluminum, magnesium, or @DRUG$, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p50	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p51	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p52	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p53	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p54	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p55	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p56	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with @DRUG$, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p57	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p58	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p59	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p60	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p61	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p62	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as @DRUG$, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p63	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p64	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p65	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p66	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p67	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with @DRUG$ containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p68	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p69	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p70	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p71	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing @DRUG$ or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p72	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p73	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p74	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or @DRUG$, or with formulations containing divalent and trivalent cations such as VIDEX (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p75	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of quinolones, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p76	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s1.p77	Administration of quinolones with antacids containing aluminum, magnesium, or calcium, with sucralfate, with metal cations such as iron, or with multivitamins containing iron or zinc, or with formulations containing divalent and trivalent cations such as VIDEX (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of @DRUG$, resulting in systemic concentrations considerably lower than desired.	DDI-false
DDI-DrugBank.d78.s19.p0	@DRUG$ (@DRUG$): The concomitant administration of a nonsteroidal anti inflammatory drug with a quinolone may increase the risks of CNS stimulation and convulsions.	DDI-false
DDI-DrugBank.d78.s19.p1	@DRUG$ (NSAIDs): The concomitant administration of a @DRUG$ with a quinolone may increase the risks of CNS stimulation and convulsions.	DDI-false
DDI-DrugBank.d78.s19.p2	@DRUG$ (NSAIDs): The concomitant administration of a nonsteroidal anti inflammatory drug with a @DRUG$ may increase the risks of CNS stimulation and convulsions.	DDI-false
DDI-DrugBank.d78.s19.p3	Nonsteroidal Anti-inflammatory Drugs (@DRUG$): The concomitant administration of a @DRUG$ with a quinolone may increase the risks of CNS stimulation and convulsions.	DDI-false
DDI-DrugBank.d78.s19.p4	Nonsteroidal Anti-inflammatory Drugs (@DRUG$): The concomitant administration of a nonsteroidal anti inflammatory drug with a @DRUG$ may increase the risks of CNS stimulation and convulsions.	DDI-false
DDI-DrugBank.d78.s19.p5	Nonsteroidal Anti-inflammatory Drugs (NSAIDs): The concomitant administration of a @DRUG$ with a @DRUG$ may increase the risks of CNS stimulation and convulsions.	DDI-effect
DDI-DrugBank.d78.s6.p0	@DRUG$: @DRUG$ is a competitive inhibitor of the metabolism of theophylline.	DDI-false
DDI-DrugBank.d78.s6.p1	@DRUG$: Grepafloxacin is a competitive inhibitor of the metabolism of @DRUG$.	DDI-false
DDI-DrugBank.d78.s6.p2	Theophylline: @DRUG$ is a competitive inhibitor of the metabolism of @DRUG$.	DDI-mechanism
DDI-DrugBank.d78.s7.p0	Serum @DRUG$ concentrations increase when @DRUG$ is initiated in a patient maintained on theophylline.	DDI-false
DDI-DrugBank.d78.s7.p1	Serum @DRUG$ concentrations increase when grepafloxacin is initiated in a patient maintained on @DRUG$.	DDI-false
DDI-DrugBank.d78.s7.p2	Serum theophylline concentrations increase when @DRUG$ is initiated in a patient maintained on @DRUG$.	DDI-mechanism
DDI-DrugBank.d78.s8.p0	When initiating a multi-day course of @DRUG$ in a patient maintained on @DRUG$, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.	DDI-false
DDI-DrugBank.d78.s8.p1	When initiating a multi-day course of @DRUG$ in a patient maintained on theophylline, the @DRUG$ maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.	DDI-false
DDI-DrugBank.d78.s8.p2	When initiating a multi-day course of @DRUG$ in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of @DRUG$ and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.	DDI-false
DDI-DrugBank.d78.s8.p3	When initiating a multi-day course of @DRUG$ in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum @DRUG$ concentrations should be initiated as a guide to further dosage adjustments.	DDI-false
DDI-DrugBank.d78.s8.p4	When initiating a multi-day course of grepafloxacin in a patient maintained on @DRUG$, the @DRUG$ maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.	DDI-false
DDI-DrugBank.d78.s8.p5	When initiating a multi-day course of grepafloxacin in a patient maintained on @DRUG$, the theophylline maintenance dose should be halved for the period of concurrent use of @DRUG$ and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.	DDI-false
DDI-DrugBank.d78.s8.p6	When initiating a multi-day course of grepafloxacin in a patient maintained on @DRUG$, the theophylline maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum @DRUG$ concentrations should be initiated as a guide to further dosage adjustments.	DDI-false
DDI-DrugBank.d78.s8.p7	When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the @DRUG$ maintenance dose should be halved for the period of concurrent use of @DRUG$ and monitoring of serum theophylline concentrations should be initiated as a guide to further dosage adjustments.	DDI-advise
DDI-DrugBank.d78.s8.p8	When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the @DRUG$ maintenance dose should be halved for the period of concurrent use of grepafloxacin and monitoring of serum @DRUG$ concentrations should be initiated as a guide to further dosage adjustments.	DDI-false
DDI-DrugBank.d78.s8.p9	When initiating a multi-day course of grepafloxacin in a patient maintained on theophylline, the theophylline maintenance dose should be halved for the period of concurrent use of @DRUG$ and monitoring of serum @DRUG$ concentrations should be initiated as a guide to further dosage adjustments.	DDI-false
DDI-DrugBank.d79.s0.p0	The absorption of @DRUG$ may be affected by the simultaneous administration of indigestion remedies, @DRUG$ or zinc supplements.	DDI-mechanism
DDI-DrugBank.d79.s0.p1	The absorption of @DRUG$ may be affected by the simultaneous administration of indigestion remedies, iron or @DRUG$ supplements.	DDI-mechanism
DDI-DrugBank.d79.s0.p2	The absorption of lymecycline may be affected by the simultaneous administration of indigestion remedies, @DRUG$ or @DRUG$ supplements.	DDI-false
DDI-DrugBank.d8.s3.p0	Limited clinical experience indicates that requirements for @DRUG$ are reduced by 30 to 50% for the first sixty (60) minutes following @DRUG$ induction The concomitant use of erythromycin with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-mechanism
DDI-DrugBank.d8.s3.p1	Limited clinical experience indicates that requirements for @DRUG$ are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of @DRUG$ with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-false
DDI-DrugBank.d8.s3.p2	Limited clinical experience indicates that requirements for @DRUG$ are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with @DRUG$ can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-false
DDI-DrugBank.d8.s3.p3	Limited clinical experience indicates that requirements for @DRUG$ are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with ALFENTA can significantly inhibit @DRUG$ clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-false
DDI-DrugBank.d8.s3.p4	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following @DRUG$ induction The concomitant use of @DRUG$ with ALFENTA can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-false
DDI-DrugBank.d8.s3.p5	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following @DRUG$ induction The concomitant use of erythromycin with @DRUG$ can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-false
DDI-DrugBank.d8.s3.p6	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following @DRUG$ induction The concomitant use of erythromycin with ALFENTA can significantly inhibit @DRUG$ clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-false
DDI-DrugBank.d8.s3.p7	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of @DRUG$ with @DRUG$ can significantly inhibit ALFENTA clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-mechanism
DDI-DrugBank.d8.s3.p8	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of @DRUG$ with ALFENTA can significantly inhibit @DRUG$ clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-false
DDI-DrugBank.d8.s3.p9	Limited clinical experience indicates that requirements for volatile inhalation anesthetics are reduced by 30 to 50% for the first sixty (60) minutes following ALFENTA induction The concomitant use of erythromycin with @DRUG$ can significantly inhibit @DRUG$ clearance and may increase the risk of prolonged or delayed respiratory depression.	DDI-false
DDI-DrugBank.d81.s1.p0	@DRUG$: A study in normal healthy volunteers has shown that concomitant administration of @DRUG$  (isradipine) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.	DDI-false
DDI-DrugBank.d81.s1.p1	@DRUG$: A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  (@DRUG$) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.	DDI-false
DDI-DrugBank.d81.s1.p2	@DRUG$: A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  (isradipine) and @DRUG$ does not result in altered pharmacoktnetics of either drug.	DDI-false
DDI-DrugBank.d81.s1.p3	Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of @DRUG$  (@DRUG$) and hydrochlorothiazide does not result in altered pharmacoktnetics of either drug.	DDI-false
DDI-DrugBank.d81.s1.p4	Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of @DRUG$  (isradipine) and @DRUG$ does not result in altered pharmacoktnetics of either drug.	DDI-false
DDI-DrugBank.d81.s1.p5	Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of DynaCirc  (@DRUG$) and @DRUG$ does not result in altered pharmacoktnetics of either drug.	DDI-false
DDI-DrugBank.d81.s15.p0	Even though such interactions have not been seen in clinical studies with @DRUG$  (@DRUG$), an increased volume of circulating fluids might be required if such an interaction were to occur.	DDI-false
DDI-DrugBank.d81.s9.p0	@DRUG$: In a study in healthy volunteers, a six-day course of @DRUG$ at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in isradipine levels to below detectable limits.	DDI-false
DDI-DrugBank.d81.s9.p1	@DRUG$: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of @DRUG$ resulted in a reduction in isradipine levels to below detectable limits.	DDI-false
DDI-DrugBank.d81.s9.p2	@DRUG$: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in @DRUG$ levels to below detectable limits.	DDI-false
DDI-DrugBank.d81.s9.p3	Rifampicin: In a study in healthy volunteers, a six-day course of @DRUG$ at 600 mg/day followed by a single 5 mg dose of @DRUG$ resulted in a reduction in isradipine levels to below detectable limits.	DDI-mechanism
DDI-DrugBank.d81.s9.p4	Rifampicin: In a study in healthy volunteers, a six-day course of @DRUG$ at 600 mg/day followed by a single 5 mg dose of isradipine resulted in a reduction in @DRUG$ levels to below detectable limits.	DDI-false
DDI-DrugBank.d81.s9.p5	Rifampicin: In a study in healthy volunteers, a six-day course of rifampicin at 600 mg/day followed by a single 5 mg dose of @DRUG$ resulted in a reduction in @DRUG$ levels to below detectable limits.	DDI-false
DDI-DrugBank.d82.s0.p0	In normal volunteers receiving @DRUG$, the administration of @DRUG$ decreased the renal clearance and significantly increased the plasma levels of indomethacin.	DDI-false
DDI-DrugBank.d82.s0.p1	In normal volunteers receiving @DRUG$, the administration of diflunisal decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-false
DDI-DrugBank.d82.s0.p2	In normal volunteers receiving indomethacin, the administration of @DRUG$ decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-mechanism
DDI-DrugBank.d82.s1.p0	In some patients, combined use of @DRUG$ and @DRUG$ has been associated with fatal gastrointestinal hemorrhage.	DDI-effect
DDI-DrugBank.d82.s12.p0	Caution should be used if @DRUG$ is administered simultaneously with @DRUG$.	DDI-advise
DDI-DrugBank.d82.s16.p0	Capsules @DRUG$ 50 mg t.i.d. produced a clinically relevant elevation of plasma @DRUG$ and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.	DDI-mechanism
DDI-DrugBank.d82.s16.p1	Capsules @DRUG$ 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal @DRUG$ clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.	DDI-false
DDI-DrugBank.d82.s16.p2	Capsules @DRUG$ 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d82.s16.p3	Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma @DRUG$ and reduction in renal @DRUG$ clearance in psychiatric patients and normal subjects with steady state plasma lithium concentrations.	DDI-false
DDI-DrugBank.d82.s16.p4	Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma @DRUG$ and reduction in renal lithium clearance in psychiatric patients and normal subjects with steady state plasma @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d82.s16.p5	Capsules INDOCIN 50 mg t.i.d. produced a clinically relevant elevation of plasma lithium and reduction in renal @DRUG$ clearance in psychiatric patients and normal subjects with steady state plasma @DRUG$ concentrations.	DDI-false
DDI-DrugBank.d82.s24.p0	Therefore, when @DRUG$ and @DRUG$.	DDI-false
DDI-DrugBank.d82.s28.p0	It has been reported that the addition of @DRUG$ to a maintenance schedule of @DRUG$ resulted in reversible acute renal failure in two of four healthy volunteers.	DDI-effect
DDI-DrugBank.d82.s29.p0	@DRUG$ and @DRUG$ should not be administered together.	DDI-advise
DDI-DrugBank.d82.s30.p0	@DRUG$ and @DRUG$ each may be associated with increased serum potassium levels.	DDI-false
DDI-DrugBank.d82.s31.p0	The potential effects of @DRUG$ and @DRUG$ on potassium kinetics and renal function should be considered when these agents are administered concurrently.	DDI-effect
DDI-DrugBank.d82.s32.p0	Most of the above effects concerning @DRUG$ have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by @DRUG$.	DDI-effect
DDI-DrugBank.d82.s4.p0	The concomitant use of @DRUG$ with other @DRUG$ is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.	DDI-advise
DDI-DrugBank.d82.s8.p0	Caution should be exercised when @DRUG$ and @DRUG$ are administered concomitantly.	DDI-advise
DDI-DrugBank.d83.s0.p0	Patients on @DRUG$ therapy may require dosage adjustment of the anticoagulant during and after @DRUG$ therapy.	DDI-advise
DDI-DrugBank.d84.s2.p0	In healthy volunteers, @DRUG$ had no effect on the pharmacokinetics of @DRUG$.	DDI-false
DDI-DrugBank.d85.s8.p0	Inhibition of renal @DRUG$ clearance leading to increases in plasma @DRUG$ concentrations has also been reported.	DDI-false
DDI-DrugBank.d87.s16.p0	Drugs that inhibit cytochrome P450IID6, such as @DRUG$ , might increase the plasma concentrations of @DRUG$ in patients that are on chronic flecainide therapy;	DDI-mechanism
DDI-DrugBank.d87.s16.p1	Drugs that inhibit cytochrome P450IID6, such as @DRUG$ , might increase the plasma concentrations of flecainide in patients that are on chronic @DRUG$ therapy;	DDI-false
DDI-DrugBank.d87.s16.p2	Drugs that inhibit cytochrome P450IID6, such as quinidine , might increase the plasma concentrations of @DRUG$ in patients that are on chronic @DRUG$ therapy;	DDI-false
DDI-DrugBank.d87.s19.p0	Because both of these drugs have negative inotropic properties and the effects of coadministration with @DRUG$ are unknown, neither @DRUG$ nor verapamil should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.	DDI-false
DDI-DrugBank.d87.s19.p1	Because both of these drugs have negative inotropic properties and the effects of coadministration with @DRUG$ are unknown, neither disopyramide nor @DRUG$ should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.	DDI-false
DDI-DrugBank.d87.s19.p2	Because both of these drugs have negative inotropic properties and the effects of coadministration with @DRUG$ are unknown, neither disopyramide nor verapamil should be administered concurrently with @DRUG$ unless, in the judgment of the physician, the benefits of this combination outweigh the risks.	DDI-false
DDI-DrugBank.d87.s19.p3	Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither @DRUG$ nor @DRUG$ should be administered concurrently with TAMBOCOR unless, in the judgment of the physician, the benefits of this combination outweigh the risks.	DDI-false
DDI-DrugBank.d87.s19.p4	Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither @DRUG$ nor verapamil should be administered concurrently with @DRUG$ unless, in the judgment of the physician, the benefits of this combination outweigh the risks.	DDI-advise
DDI-DrugBank.d87.s19.p5	Because both of these drugs have negative inotropic properties and the effects of coadministration with TAMBOCOR are unknown, neither disopyramide nor @DRUG$ should be administered concurrently with @DRUG$ unless, in the judgment of the physician, the benefits of this combination outweigh the risks.	DDI-advise
DDI-DrugBank.d87.s20.p0	There has been too little experience with the coadministration of @DRUG$ with @DRUG$ or diltiazem to recommend concomitant use.	DDI-false
DDI-DrugBank.d87.s20.p1	There has been too little experience with the coadministration of @DRUG$ with nifedipine or @DRUG$ to recommend concomitant use.	DDI-false
DDI-DrugBank.d87.s20.p2	There has been too little experience with the coadministration of TAMBOCOR with @DRUG$ or @DRUG$ to recommend concomitant use.	DDI-false
DDI-DrugBank.d87.s4.p0	In this formal interaction study, @DRUG$ and @DRUG$ were each found to have negative inotropic effects;	DDI-false
DDI-DrugBank.d87.s7.p0	In @DRUG$ clinical trials, patients who were receiving @DRUG$ concurrently did not experience an increased incidence of side effects.	DDI-false
DDI-DrugBank.d87.s8.p0	Nevertheless, the possibility of additive negative inotropic effects of @DRUG$ and @DRUG$ should be recognized.	DDI-effect
DDI-DrugBank.d88.s2.p0	there was no effect on the 3 major metabolites (@DRUG$, @DRUG$ and FBAL).	DDI-false
DDI-DrugBank.d88.s2.p1	there was no effect on the 3 major metabolites (@DRUG$, 5-FU and @DRUG$).	DDI-false
DDI-DrugBank.d88.s2.p2	there was no effect on the 3 major metabolites (5-DFUR, @DRUG$ and @DRUG$).	DDI-false
DDI-DrugBank.d89.s4.p0	@DRUG$ administered concurrently with @DRUG$ reduced the urine volume in 4 healthy volunteers.	DDI-effect
DDI-DrugBank.d94.s11.p0	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p1	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p2	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p3	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p4	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p5	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p6	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p7	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p8	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p9	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p10	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p11	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p12	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p13	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p14	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p15	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p16	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p17	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p18	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p19	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p20	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p21	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p22	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p23	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p24	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p25	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p26	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p27	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p28	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p29	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p30	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p31	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p32	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p33	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p34	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p35	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p36	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p37	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p38	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p39	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p40	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p41	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p42	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p43	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-mechanism
DDI-DrugBank.d94.s11.p44	Agents that have been found, or are expected to have decreased plasma levels in the presence of @DRUG$ due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-mechanism
DDI-DrugBank.d94.s11.p45	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p46	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p47	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p48	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p49	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p50	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p51	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p52	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p53	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p54	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p55	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p56	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p57	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p58	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p59	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p60	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p61	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p62	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p63	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p64	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p65	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p66	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p67	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p68	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p69	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p70	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p71	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p72	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p73	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p74	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p75	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p76	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p77	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p78	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p79	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p80	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p81	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p82	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p83	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p84	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p85	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p86	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p87	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p88	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p89	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p90	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p91	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p92	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p93	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p94	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p95	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p96	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p97	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p98	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p99	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p100	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p101	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p102	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p103	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p104	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p105	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p106	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p107	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p108	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p109	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p110	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p111	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p112	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p113	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p114	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p115	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p116	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p117	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p118	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p119	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p120	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p121	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p122	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p123	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p124	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p125	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p126	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p127	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p128	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p129	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p130	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p131	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, @DRUG$, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p132	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p133	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p134	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p135	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p136	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p137	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p138	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p139	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p140	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p141	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p142	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p143	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p144	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p145	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p146	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p147	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p148	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p149	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p150	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p151	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p152	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p153	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p154	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p155	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p156	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p157	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p158	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p159	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p160	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p161	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p162	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p163	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p164	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p165	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p166	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p167	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p168	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p169	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p170	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p171	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p172	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p173	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p174	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p175	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p176	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p177	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p178	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p179	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p180	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p181	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p182	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p183	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p184	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p185	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p186	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p187	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p188	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p189	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p190	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p191	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p192	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p193	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p194	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p195	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p196	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p197	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p198	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p199	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p200	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p201	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p202	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p203	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p204	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p205	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p206	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p207	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p208	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p209	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p210	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p211	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p212	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p213	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p214	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, @DRUG$, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p215	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p216	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p217	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p218	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p219	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p220	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p221	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p222	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p223	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p224	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p225	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p226	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p227	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p228	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p229	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p230	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p231	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p232	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p233	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p234	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p235	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p236	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p237	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p238	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p239	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p240	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p241	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p242	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p243	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p244	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p245	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p246	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p247	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p248	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p249	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p250	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p251	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p252	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p253	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p254	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, @DRUG$, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p255	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p256	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p257	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p258	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p259	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p260	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p261	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p262	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p263	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p264	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p265	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p266	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p267	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p268	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p269	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p270	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p271	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p272	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p273	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p274	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p275	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p276	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p277	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p278	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p279	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p280	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p281	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p282	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p283	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p284	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p285	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p286	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p287	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p288	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p289	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p290	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p291	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p292	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p293	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, @DRUG$, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p294	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p295	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p296	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p297	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p298	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p299	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p300	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p301	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p302	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p303	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p304	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p305	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p306	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p307	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p308	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p309	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p310	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p311	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p312	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p313	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p314	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p315	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p316	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p317	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p318	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p319	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p320	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p321	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p322	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p323	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p324	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p325	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p326	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p327	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p328	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p329	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p330	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p331	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p332	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p333	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p334	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p335	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p336	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p337	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p338	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p339	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p340	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p341	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p342	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p343	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p344	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p345	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p346	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p347	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p348	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p349	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p350	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p351	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p352	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p353	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p354	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p355	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p356	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p357	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p358	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p359	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p360	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p361	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p362	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p363	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p364	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p365	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p366	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p367	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p368	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, @DRUG$, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p369	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p370	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p371	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p372	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p373	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p374	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p375	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p376	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p377	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p378	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p379	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p380	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p381	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p382	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p383	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p384	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p385	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p386	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p387	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p388	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p389	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p390	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p391	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p392	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p393	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p394	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p395	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p396	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p397	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p398	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p399	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p400	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p401	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p402	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p403	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p404	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, @DRUG$, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p405	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p406	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p407	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p408	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p409	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p410	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p411	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p412	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p413	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p414	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p415	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p416	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p417	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p418	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p419	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p420	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p421	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p422	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p423	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p424	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p425	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p426	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p427	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p428	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p429	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p430	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p431	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p432	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p433	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p434	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p435	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p436	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p437	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p438	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p439	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, @DRUG$, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p440	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p441	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p442	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p443	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p444	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p445	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p446	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p447	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p448	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p449	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p450	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p451	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p452	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p453	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p454	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p455	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p456	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p457	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p458	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p459	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p460	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p461	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p462	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p463	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p464	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p465	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p466	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p467	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p468	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p469	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p470	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p471	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p472	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p473	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p474	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p475	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p476	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p477	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p478	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p479	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p480	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p481	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p482	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p483	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p484	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p485	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p486	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p487	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p488	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p489	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p490	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p491	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p492	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p493	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p494	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p495	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p496	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p497	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p498	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p499	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p500	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p501	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p502	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p503	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p504	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p505	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p506	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, @DRUG$, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p507	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p508	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p509	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p510	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p511	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p512	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p513	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p514	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p515	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p516	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p517	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p518	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p519	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p520	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p521	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p522	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p523	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p524	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p525	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p526	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p527	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p528	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p529	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p530	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p531	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p532	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p533	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p534	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p535	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p536	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p537	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p538	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, @DRUG$, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p539	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p540	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p541	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p542	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p543	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p544	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p545	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p546	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p547	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p548	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p549	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p550	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p551	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p552	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p553	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p554	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p555	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p556	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p557	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p558	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p559	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p560	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p561	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p562	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p563	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p564	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p565	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p566	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p567	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p568	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p569	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, @DRUG$, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p570	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p571	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p572	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p573	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p574	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p575	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p576	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p577	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p578	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p579	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p580	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p581	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p582	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p583	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p584	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p585	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p586	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p587	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p588	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p589	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p590	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p591	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p592	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p593	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p594	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p595	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p596	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p597	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p598	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p599	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, @DRUG$, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p600	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p601	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p602	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p603	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p604	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p605	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p606	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p607	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p608	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p609	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p610	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p611	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p612	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p613	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p614	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p615	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p616	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p617	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p618	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p619	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p620	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p621	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p622	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p623	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p624	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p625	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p626	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p627	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p628	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, @DRUG$, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p629	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p630	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p631	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p632	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p633	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p634	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p635	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p636	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p637	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p638	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p639	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p640	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p641	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p642	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p643	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p644	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p645	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p646	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p647	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p648	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p649	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p650	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p651	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p652	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p653	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p654	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p655	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p656	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, @DRUG$, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p657	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p658	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p659	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p660	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p661	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p662	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p663	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p664	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p665	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p666	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p667	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p668	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p669	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p670	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p671	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p672	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p673	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p674	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p675	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p676	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p677	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p678	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p679	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p680	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p681	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p682	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p683	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, @DRUG$, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p684	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p685	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p686	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p687	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p688	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p689	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p690	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p691	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p692	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p693	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p694	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p695	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p696	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p697	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p698	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p699	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p700	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p701	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p702	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p703	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p704	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p705	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p706	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p707	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p708	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p709	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p710	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p711	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p712	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p713	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p714	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p715	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p716	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p717	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p718	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p719	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p720	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p721	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p722	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p723	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p724	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p725	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p726	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p727	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p728	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p729	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p730	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p731	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p732	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p733	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p734	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, @DRUG$, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p735	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p736	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p737	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p738	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p739	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p740	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p741	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p742	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p743	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p744	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p745	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p746	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p747	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p748	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p749	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p750	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p751	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p752	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p753	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p754	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p755	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p756	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p757	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p758	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p759	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p760	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p761	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p762	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p763	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p764	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p765	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p766	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p767	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p768	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p769	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p770	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p771	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p772	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p773	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p774	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p775	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p776	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p777	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p778	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p779	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p780	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p781	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, @DRUG$, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p782	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p783	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p784	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p785	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p786	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p787	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p788	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p789	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p790	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p791	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p792	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p793	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p794	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p795	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p796	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p797	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p798	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p799	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p800	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p801	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p802	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p803	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, @DRUG$, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p804	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p805	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p806	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p807	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p808	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p809	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p810	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p811	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p812	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p813	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p814	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p815	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p816	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p817	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p818	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p819	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p820	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p821	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p822	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p823	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p824	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, @DRUG$, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p825	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p826	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p827	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p828	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p829	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p830	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p831	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p832	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p833	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p834	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p835	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p836	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p837	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p838	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p839	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p840	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p841	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p842	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p843	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p844	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, @DRUG$, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p845	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p846	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p847	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p848	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p849	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p850	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p851	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p852	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p853	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p854	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p855	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p856	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p857	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p858	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p859	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p860	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p861	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p862	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p863	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p864	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p865	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p866	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p867	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p868	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p869	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p870	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p871	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p872	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p873	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p874	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p875	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p876	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p877	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p878	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p879	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p880	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p881	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, @DRUG$, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p882	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p883	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p884	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p885	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p886	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p887	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p888	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p889	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p890	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p891	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p892	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p893	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p894	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p895	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p896	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p897	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p898	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p899	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p900	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p901	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p902	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p903	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p904	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p905	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p906	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p907	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p908	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p909	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p910	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p911	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p912	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p913	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p914	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, @DRUG$, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p915	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p916	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p917	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p918	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p919	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p920	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p921	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p922	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p923	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p924	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p925	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p926	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p927	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p928	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p929	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral @DRUG$(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p930	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p931	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p932	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p933	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p934	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p935	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p936	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p937	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p938	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p939	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p940	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p941	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p942	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p943	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), @DRUG$, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p944	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p945	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p946	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p947	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p948	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p949	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p950	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p951	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p952	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p953	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p954	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p955	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p956	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, @DRUG$(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p957	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p958	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p959	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p960	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p961	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p962	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p963	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p964	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p965	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p966	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p967	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p968	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), @DRUG$, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p969	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p970	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p971	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p972	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p973	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p974	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p975	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p976	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p977	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p978	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p979	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, @DRUG$, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p980	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p981	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p982	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p983	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p984	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p985	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p986	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p987	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p988	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p989	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, @DRUG$, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p990	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p991	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p992	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p993	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p994	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p995	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p996	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p997	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p998	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, @DRUG$, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p999	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1000	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1001	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1002	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1003	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1004	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1005	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1006	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p1007	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1008	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1009	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1010	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1011	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1012	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1013	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, @DRUG$, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p1014	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1015	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1016	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1017	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1018	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1019	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, @DRUG$, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p1020	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1021	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1022	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1023	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1024	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, @DRUG$, triazolam, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p1025	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1026	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1027	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1028	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p1029	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, @DRUG$(5) , ziprasidone, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1030	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1031	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p1032	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , @DRUG$, and zonisamide.	DDI-false
DDI-DrugBank.d94.s11.p1033	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, @DRUG$(5) , ziprasidone, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s11.p1034	Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , @DRUG$, and @DRUG$.	DDI-false
DDI-DrugBank.d94.s14.p0	Pharmacological/Pharmacodynamic Interactions with @DRUG$ Concomitant administration of @DRUG$ and lithium may increase the risk of neurotoxic side effects.	DDI-false
DDI-DrugBank.d94.s14.p1	Pharmacological/Pharmacodynamic Interactions with @DRUG$ Concomitant administration of carbamazepine and @DRUG$ may increase the risk of neurotoxic side effects.	DDI-false
DDI-DrugBank.d94.s14.p2	Pharmacological/Pharmacodynamic Interactions with Carbamazepine Concomitant administration of @DRUG$ and @DRUG$ may increase the risk of neurotoxic side effects.	DDI-effect
DDI-DrugBank.d97.s20.p0	@DRUG$: @DRUG$	DDI-false
DDI-DrugBank.d97.s21.p0	May lead to loss of virologic response and possible resistance to @DRUG$ or to the class of @DRUG$ or other coadministered antiretroviral agents.	DDI-false
DDI-DrugBank.d97.s21.p1	May lead to loss of virologic response and possible resistance to @DRUG$ or to the class of protease inhibitors or other coadministered @DRUG$.	DDI-false
DDI-DrugBank.d97.s21.p2	May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of @DRUG$ or other coadministered @DRUG$.	DDI-false
DDI-DrugBank.d97.s26.p0	Combinations of these drugs have not been studied and coadministration of @DRUG$ and @DRUG$ is not recommended.	DDI-advise
DDI-DrugBank.d97.s41.p0	Increasing the @DRUG$ dose to 1000 mg every 8 hours does not compensate for the increased @DRUG$ metabolism due to efavirenz.	DDI-false
DDI-DrugBank.d97.s41.p1	Increasing the @DRUG$ dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to @DRUG$.	DDI-false
DDI-DrugBank.d97.s41.p2	Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased @DRUG$ metabolism due to @DRUG$.	DDI-mechanism
DDI-DrugBank.d97.s68.p0	@DRUG$ concentration   @DRUG$ concentration	DDI-false
DDI-DrugBank.d97.s70.p0	@DRUG$: @DRUG$	DDI-false
DDI-DrugBank.d97.s73.p0	@DRUG$: @DRUG$, tacrolimus, sirolimus	DDI-false
DDI-DrugBank.d97.s73.p1	@DRUG$: cyclosporine, @DRUG$, sirolimus	DDI-false
DDI-DrugBank.d97.s73.p2	@DRUG$: cyclosporine, tacrolimus, @DRUG$	DDI-false
DDI-DrugBank.d97.s73.p3	Immunosuppressants: @DRUG$, @DRUG$, sirolimus	DDI-false
DDI-DrugBank.d97.s73.p4	Immunosuppressants: @DRUG$, tacrolimus, @DRUG$	DDI-false
DDI-DrugBank.d97.s73.p5	Immunosuppressants: cyclosporine, @DRUG$, @DRUG$	DDI-false
DDI-DrugBank.d97.s78.p0	Dose reduction of @DRUG$ to 600 mg every 8 hours is recommended when administering @DRUG$ concurrently.	DDI-advise
DDI-DrugBank.d97.s8.p0	@DRUG$: @DRUG$	DDI-false
DDI-DrugBank.d97.s93.p0	@DRUG$ dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant @DRUG$ therapy.	DDI-advise
DDI-DrugBank.d99.s18.p0	and @DRUG$ When @DRUG$ is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.	DDI-false
DDI-DrugBank.d99.s18.p1	and @DRUG$ When amitriptyline HCl is given with @DRUG$ agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.	DDI-false
DDI-DrugBank.d99.s18.p2	and @DRUG$ When amitriptyline HCl is given with anticholinergic agents or @DRUG$ drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.	DDI-false
DDI-DrugBank.d99.s18.p3	and @DRUG$ When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including @DRUG$ combined with local anesthetics, close supervision and careful adjustment of dosages are required.	DDI-false
DDI-DrugBank.d99.s18.p4	and @DRUG$ When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local @DRUG$, close supervision and careful adjustment of dosages are required.	DDI-false
DDI-DrugBank.d99.s18.p5	and disulfiram When @DRUG$ is given with @DRUG$ agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.	DDI-false
DDI-DrugBank.d99.s18.p6	and disulfiram When @DRUG$ is given with anticholinergic agents or @DRUG$ drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.	DDI-false
DDI-DrugBank.d99.s18.p7	and disulfiram When @DRUG$ is given with anticholinergic agents or sympathomimetic drugs, including @DRUG$ combined with local anesthetics, close supervision and careful adjustment of dosages are required.	DDI-false
DDI-DrugBank.d99.s18.p8	and disulfiram When @DRUG$ is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local @DRUG$, close supervision and careful adjustment of dosages are required.	DDI-false
DDI-DrugBank.d99.s18.p9	and disulfiram When amitriptyline HCl is given with @DRUG$ agents or @DRUG$ drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.	DDI-false
DDI-DrugBank.d99.s18.p10	and disulfiram When amitriptyline HCl is given with @DRUG$ agents or sympathomimetic drugs, including @DRUG$ combined with local anesthetics, close supervision and careful adjustment of dosages are required.	DDI-false
DDI-DrugBank.d99.s18.p11	and disulfiram When amitriptyline HCl is given with @DRUG$ agents or sympathomimetic drugs, including epinephrine combined with local @DRUG$, close supervision and careful adjustment of dosages are required.	DDI-false
DDI-DrugBank.d99.s18.p12	and disulfiram When amitriptyline HCl is given with anticholinergic agents or @DRUG$ drugs, including @DRUG$ combined with local anesthetics, close supervision and careful adjustment of dosages are required.	DDI-false
DDI-DrugBank.d99.s18.p13	and disulfiram When amitriptyline HCl is given with anticholinergic agents or @DRUG$ drugs, including epinephrine combined with local @DRUG$, close supervision and careful adjustment of dosages are required.	DDI-false
DDI-DrugBank.d99.s18.p14	and disulfiram When amitriptyline HCl is given with anticholinergic agents or sympathomimetic drugs, including @DRUG$ combined with local @DRUG$, close supervision and careful adjustment of dosages are required.	DDI-false
DDI-DrugBank.d99.s2.p0	Poor metabolizers have higher than expected plasma concentrations of @DRUG$ (@DRUG$) when given usual doses.	DDI-false
DDI-DrugBank.d99.s7.p0	@DRUG$) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).	DDI-false
DDI-DrugBank.d99.s7.p1	@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and flecainide).	DDI-false
DDI-DrugBank.d99.s7.p2	@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ propafenone and flecainide).	DDI-false
DDI-DrugBank.d99.s7.p3	@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and flecainide).	DDI-false
DDI-DrugBank.d99.s7.p4	@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and @DRUG$).	DDI-false
DDI-DrugBank.d99.s7.p5	cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, @DRUG$, and the Type 1C antiarrhythmics propafenone and flecainide).	DDI-false
DDI-DrugBank.d99.s7.p6	cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the @DRUG$ propafenone and flecainide).	DDI-false
DDI-DrugBank.d99.s7.p7	cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and flecainide).	DDI-false
DDI-DrugBank.d99.s7.p8	cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics propafenone and @DRUG$).	DDI-false
DDI-DrugBank.d99.s7.p9	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the @DRUG$ propafenone and flecainide).	DDI-false
DDI-DrugBank.d99.s7.p10	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics @DRUG$ and flecainide).	DDI-false
DDI-DrugBank.d99.s7.p11	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and @DRUG$).	DDI-false
DDI-DrugBank.d99.s7.p12	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ @DRUG$ and flecainide).	DDI-false
DDI-DrugBank.d99.s7.p13	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ propafenone and @DRUG$).	DDI-false
DDI-DrugBank.d99.s7.p14	cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and @DRUG$).	DDI-false
DDI-DrugBank.d99.s8.p0	While all the selective @DRUG$ (@DRUG$), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
DDI-DrugBank.d99.s8.p1	While all the selective @DRUG$ (SSRIs), e.g., @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
DDI-DrugBank.d99.s8.p2	While all the selective @DRUG$ (SSRIs), e.g., fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
DDI-DrugBank.d99.s8.p3	While all the selective @DRUG$ (SSRIs), e.g., fluoxetine, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
DDI-DrugBank.d99.s8.p4	While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
DDI-DrugBank.d99.s8.p5	While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
DDI-DrugBank.d99.s8.p6	While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., fluoxetine, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
DDI-DrugBank.d99.s8.p7	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
DDI-DrugBank.d99.s8.p8	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
DDI-DrugBank.d99.s8.p9	While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, @DRUG$, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
DDI-MedLine.d102.s3.p0	injection of vehicle (corn oil, 0.1 mL/day), @DRUG$ (10 microg/kg/day or 4 mg/kg/day) and/or @DRUG$ (20 mg/kg/day), for eight days.	DDI-false
DDI-MedLine.d103.s1.p0	Two different types of therapy with @DRUG$ are used: physiological oral @DRUG$ supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.	DDI-false
DDI-MedLine.d103.s1.p1	Two different types of therapy with @DRUG$ are used: physiological oral magnesium supplementation which is totally atoxic since it palliates @DRUG$ deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.	DDI-false
DDI-MedLine.d103.s1.p2	Two different types of therapy with @DRUG$ are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the @DRUG$ intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.	DDI-false
DDI-MedLine.d103.s1.p3	Two different types of therapy with @DRUG$ are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological @DRUG$ therapy which may induce toxicity since it creates iatrogenic magnesium overload.	DDI-false
DDI-MedLine.d103.s1.p4	Two different types of therapy with @DRUG$ are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic @DRUG$ overload.	DDI-false
DDI-MedLine.d103.s1.p5	Two different types of therapy with magnesium are used: physiological oral @DRUG$ supplementation which is totally atoxic since it palliates @DRUG$ deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.	DDI-false
DDI-MedLine.d103.s1.p6	Two different types of therapy with magnesium are used: physiological oral @DRUG$ supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the @DRUG$ intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.	DDI-false
DDI-MedLine.d103.s1.p7	Two different types of therapy with magnesium are used: physiological oral @DRUG$ supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological @DRUG$ therapy which may induce toxicity since it creates iatrogenic magnesium overload.	DDI-false
DDI-MedLine.d103.s1.p8	Two different types of therapy with magnesium are used: physiological oral @DRUG$ supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic @DRUG$ overload.	DDI-false
DDI-MedLine.d103.s1.p9	Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates @DRUG$ deficiencies by simply normalizing the @DRUG$ intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload.	DDI-false
DDI-MedLine.d103.s1.p10	Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates @DRUG$ deficiencies by simply normalizing the magnesium intake and pharmacological @DRUG$ therapy which may induce toxicity since it creates iatrogenic magnesium overload.	DDI-false
DDI-MedLine.d103.s1.p11	Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates @DRUG$ deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic @DRUG$ overload.	DDI-false
DDI-MedLine.d103.s1.p12	Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the @DRUG$ intake and pharmacological @DRUG$ therapy which may induce toxicity since it creates iatrogenic magnesium overload.	DDI-false
DDI-MedLine.d103.s1.p13	Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the @DRUG$ intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic @DRUG$ overload.	DDI-false
DDI-MedLine.d103.s1.p14	Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological @DRUG$ therapy which may induce toxicity since it creates iatrogenic @DRUG$ overload.	DDI-false
DDI-MedLine.d103.s15.p0	Lastly local use of the mucocutaneous and cytoprotective properties of @DRUG$ is still valid, in @DRUG$ and for preservation of transplants particularly.	DDI-false
DDI-MedLine.d103.s6.p0	Specific and aspecific treatments of @DRUG$ depletion are tricky using for example @DRUG$, pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium.	DDI-false
DDI-MedLine.d103.s6.p1	Specific and aspecific treatments of @DRUG$ depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of @DRUG$, physiological doses of vitamin D and of selenium.	DDI-false
DDI-MedLine.d103.s6.p2	Specific and aspecific treatments of @DRUG$ depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of @DRUG$ and of selenium.	DDI-false
DDI-MedLine.d103.s6.p3	Specific and aspecific treatments of @DRUG$ depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of @DRUG$.	DDI-false
DDI-MedLine.d103.s6.p4	Specific and aspecific treatments of magnesium depletion are tricky using for example @DRUG$, pharmacological doses of @DRUG$, physiological doses of vitamin D and of selenium.	DDI-false
DDI-MedLine.d103.s6.p5	Specific and aspecific treatments of magnesium depletion are tricky using for example @DRUG$, pharmacological doses of vitamin B6, physiological doses of @DRUG$ and of selenium.	DDI-false
DDI-MedLine.d103.s6.p6	Specific and aspecific treatments of magnesium depletion are tricky using for example @DRUG$, pharmacological doses of vitamin B6, physiological doses of vitamin D and of @DRUG$.	DDI-false
DDI-MedLine.d103.s6.p7	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of @DRUG$, physiological doses of @DRUG$ and of selenium.	DDI-false
DDI-MedLine.d103.s6.p8	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of @DRUG$, physiological doses of vitamin D and of @DRUG$.	DDI-false
DDI-MedLine.d103.s6.p9	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of @DRUG$ and of @DRUG$.	DDI-false
DDI-MedLine.d104.s8.p0	In order to examine some molecular mechanisms of @DRUG$-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with @DRUG$, DCG-IV, and L-CCG-1 was carried out.	DDI-false
DDI-MedLine.d104.s8.p3	In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with @DRUG$, @DRUG$, and L-CCG-1 was carried out.	DDI-false
DDI-MedLine.d104.s8.p4	In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with @DRUG$, DCG-IV, and @DRUG$ was carried out.	DDI-false
DDI-MedLine.d104.s8.p5	In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, @DRUG$, and @DRUG$ was carried out.	DDI-false
DDI-MedLine.d105.s1.p0	Two studies were conducted in HIV-infected subjects to assess the potential for @DRUG$ to interact with @DRUG$ and dideoxyinosine.	DDI-false
DDI-MedLine.d105.s1.p1	Two studies were conducted in HIV-infected subjects to assess the potential for @DRUG$ to interact with zidovudine and @DRUG$.	DDI-false
DDI-MedLine.d105.s1.p2	Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with @DRUG$ and @DRUG$.	DDI-false
DDI-MedLine.d105.s4.p0	Subjects treated with 200 mg of @DRUG$ twice daily for 21 days received 1200 mg of @DRUG$ or an equivalent amount of placebo/day for Days 8 to 21.	DDI-false
DDI-MedLine.d109.s1.p0	The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, @DRUG$, at steady state on the pharmacokinetics of @DRUG$ following a single dose in healthy subjects.	DDI-false
DDI-MedLine.d11.s4.p0	This article looks at five commonly used @DRUG$ in turn (@DRUG$, cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.	DDI-false
DDI-MedLine.d11.s4.p1	This article looks at five commonly used @DRUG$ in turn (corticosteroids, @DRUG$, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.	DDI-false
DDI-MedLine.d11.s4.p2	This article looks at five commonly used @DRUG$ in turn (corticosteroids, cyclosporin, @DRUG$, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.	DDI-false
DDI-MedLine.d11.s4.p3	This article looks at five commonly used @DRUG$ in turn (corticosteroids, cyclosporin, azathioprine, @DRUG$, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.	DDI-false
DDI-MedLine.d11.s4.p4	This article looks at five commonly used @DRUG$ in turn (corticosteroids, cyclosporin, azathioprine, methotrexate, @DRUG$), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.	DDI-false
DDI-MedLine.d11.s4.p5	This article looks at five commonly used immunosuppressive drugs in turn (@DRUG$, @DRUG$, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.	DDI-false
DDI-MedLine.d11.s4.p6	This article looks at five commonly used immunosuppressive drugs in turn (@DRUG$, cyclosporin, @DRUG$, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.	DDI-false
DDI-MedLine.d11.s4.p7	This article looks at five commonly used immunosuppressive drugs in turn (@DRUG$, cyclosporin, azathioprine, @DRUG$, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.	DDI-false
DDI-MedLine.d11.s4.p8	This article looks at five commonly used immunosuppressive drugs in turn (@DRUG$, cyclosporin, azathioprine, methotrexate, @DRUG$), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.	DDI-false
DDI-MedLine.d11.s4.p9	This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, @DRUG$, @DRUG$, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.	DDI-false
DDI-MedLine.d11.s4.p10	This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, @DRUG$, azathioprine, @DRUG$, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.	DDI-false
DDI-MedLine.d11.s4.p11	This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, @DRUG$, azathioprine, methotrexate, @DRUG$), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.	DDI-false
DDI-MedLine.d11.s4.p12	This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, @DRUG$, @DRUG$, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.	DDI-false
DDI-MedLine.d11.s4.p13	This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, @DRUG$, methotrexate, @DRUG$), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.	DDI-false
DDI-MedLine.d11.s4.p14	This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin, azathioprine, @DRUG$, @DRUG$), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise.	DDI-false
DDI-MedLine.d110.s0.p0	@DRUG$ (@DRUG$) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.	DDI-false
DDI-MedLine.d110.s0.p1	@DRUG$ (18-MC) and @DRUG$: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.	DDI-false
DDI-MedLine.d110.s0.p2	18-Methoxycoronaridine (@DRUG$) and @DRUG$: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.	DDI-false
DDI-MedLine.d110.s10.p0	both compounds attenuate @DRUG$-induced locomotion in @DRUG$-experienced rats.	DDI-false
DDI-MedLine.d110.s15.p0	Both @DRUG$ and @DRUG$ are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite.	DDI-false
DDI-MedLine.d110.s15.p1	Both @DRUG$ and ibogaine are sequestered in fat and, like @DRUG$, 18-MC probably has an active metabolite.	DDI-false
DDI-MedLine.d110.s15.p2	Both @DRUG$ and ibogaine are sequestered in fat and, like ibogaine, @DRUG$ probably has an active metabolite.	DDI-false
DDI-MedLine.d110.s15.p3	Both 18-MC and @DRUG$ are sequestered in fat and, like @DRUG$, 18-MC probably has an active metabolite.	DDI-false
DDI-MedLine.d110.s15.p4	Both 18-MC and @DRUG$ are sequestered in fat and, like ibogaine, @DRUG$ probably has an active metabolite.	DDI-false
DDI-MedLine.d110.s15.p5	Both 18-MC and ibogaine are sequestered in fat and, like @DRUG$, @DRUG$ probably has an active metabolite.	DDI-false
DDI-MedLine.d110.s4.p0	Both @DRUG$ and @DRUG$ ameliorate opioid withdrawal signs.	DDI-false
DDI-MedLine.d110.s4.p1	Both @DRUG$ and 18-MC ameliorate @DRUG$ withdrawal signs.	DDI-false
DDI-MedLine.d110.s4.p2	Both ibogaine and @DRUG$ ameliorate @DRUG$ withdrawal signs.	DDI-false
DDI-MedLine.d110.s9.p0	@DRUG$ attenuates, but @DRUG$ potentiates, the acute locomotor effects of morphine;	DDI-false
DDI-MedLine.d110.s9.p1	@DRUG$ attenuates, but 18-MC potentiates, the acute locomotor effects of @DRUG$;	DDI-effect
DDI-MedLine.d110.s9.p2	Ibogaine attenuates, but @DRUG$ potentiates, the acute locomotor effects of @DRUG$;	DDI-effect
DDI-MedLine.d111.s10.p0	@DRUG$ decreased the binding of @DRUG$ by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L;	DDI-mechanism
DDI-MedLine.d112.s1.p0	The effect of @DRUG$ on the steady-state pharmacokinetics of @DRUG$ was evaluated in a randomized, double-blind study.	DDI-false
DDI-MedLine.d114.s6.p0	In contrast, in isolated single pancreatic acinar cells, @DRUG$ had no effect on @DRUG$-induced responses.	DDI-false
DDI-MedLine.d115.s14.p0	However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between @DRUG-DRUG$.	DDI-advise
DDI-MedLine.d115.s5.p0	@DRUG$ regimens consisted of two @DRUG$ and one protease inhibitor.	DDI-false
DDI-MedLine.d115.s5.p1	@DRUG$ regimens consisted of two reverse transcriptase inhibitors and one @DRUG$.	DDI-false
DDI-MedLine.d115.s5.p2	Antiretroviral regimens consisted of two @DRUG$ and one @DRUG$.	DDI-false
DDI-MedLine.d116.s1.p0	The drug interaction between @DRUG$ and @DRUG$ is not well known.	DDI-int
DDI-MedLine.d116.s3.p0	The concomitant administration of @DRUG$ and @DRUG$ resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect.	DDI-mechanism
DDI-MedLine.d116.s3.p1	The concomitant administration of @DRUG$ and warfarin resulted in the need for an unusually high maintenance dose of @DRUG$ (20 mg per day) in order to produce a therapeutic effect.	DDI-false
DDI-MedLine.d116.s3.p2	The concomitant administration of rifampin and @DRUG$ resulted in the need for an unusually high maintenance dose of @DRUG$ (20 mg per day) in order to produce a therapeutic effect.	DDI-false
DDI-MedLine.d118.s0.p0	@DRUG$: mammalian target of @DRUG$ inhibitor to prevent kidney rejection.	DDI-false
DDI-MedLine.d118.s2.p0	@DRUG$ works differently from the @DRUG$ currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus.	DDI-false
DDI-MedLine.d118.s2.p1	@DRUG$ works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of @DRUG$ does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus.	DDI-false
DDI-MedLine.d118.s2.p2	@DRUG$ works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with @DRUG$ or tacrolimus.	DDI-false
DDI-MedLine.d118.s2.p3	@DRUG$ works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or @DRUG$.	DDI-false
DDI-MedLine.d118.s2.p4	Sirolimus works differently from the @DRUG$ currently available, and except for increased lipid levels, the adverse reaction profile of @DRUG$ does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus.	DDI-false
DDI-MedLine.d118.s2.p5	Sirolimus works differently from the @DRUG$ currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with @DRUG$ or tacrolimus.	DDI-false
DDI-MedLine.d118.s2.p6	Sirolimus works differently from the @DRUG$ currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or @DRUG$.	DDI-false
DDI-MedLine.d118.s2.p7	Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of @DRUG$ does not appear to overlap to any great extent with that associated with @DRUG$ or tacrolimus.	DDI-false
DDI-MedLine.d118.s2.p8	Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of @DRUG$ does not appear to overlap to any great extent with that associated with cyclosporine or @DRUG$.	DDI-false
DDI-MedLine.d118.s2.p9	Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with @DRUG$ or @DRUG$.	DDI-false
DDI-MedLine.d118.s3.p0	While additional research is needed, the initial clinical data in kidney recipients suggest that @DRUG$, in combination with @DRUG$ or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	DDI-false
DDI-MedLine.d118.s3.p1	While additional research is needed, the initial clinical data in kidney recipients suggest that @DRUG$, in combination with cyclosporine or @DRUG$, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	DDI-false
DDI-MedLine.d118.s3.p2	While additional research is needed, the initial clinical data in kidney recipients suggest that @DRUG$, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in @DRUG$ or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	DDI-false
DDI-MedLine.d118.s3.p3	While additional research is needed, the initial clinical data in kidney recipients suggest that @DRUG$, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or @DRUG$ dosage, and permit steroid withdrawal (Kelly, 1999).	DDI-false
DDI-MedLine.d118.s3.p4	While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with @DRUG$ or @DRUG$, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	DDI-false
DDI-MedLine.d118.s3.p5	While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with @DRUG$ or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in @DRUG$ or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	DDI-false
DDI-MedLine.d118.s3.p6	While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with @DRUG$ or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or @DRUG$ dosage, and permit steroid withdrawal (Kelly, 1999).	DDI-false
DDI-MedLine.d118.s3.p7	While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or @DRUG$, might have the potential to reduce the frequency of rejection episodes, permit reductions in @DRUG$ or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).	DDI-false
DDI-MedLine.d118.s3.p8	While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or @DRUG$, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or @DRUG$ dosage, and permit steroid withdrawal (Kelly, 1999).	DDI-false
DDI-MedLine.d118.s3.p9	While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in @DRUG$ or @DRUG$ dosage, and permit steroid withdrawal (Kelly, 1999).	DDI-false
DDI-MedLine.d12.s3.p0	@DRUG$ at 10(-10) M or @DRUG$ at about 3 X 10(-9) M inhibits proliferation stimulated by EGF.	DDI-false
DDI-MedLine.d12.s3.p1	@DRUG$ at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by @DRUG$.	DDI-effect
DDI-MedLine.d12.s3.p2	Dexamethasone at 10(-10) M or @DRUG$ at about 3 X 10(-9) M inhibits proliferation stimulated by @DRUG$.	DDI-effect
DDI-MedLine.d120.s4.p0	@DRUG$ was more potent in lysing human red blood cells, whereas @DRUG$ was more potent in inhibiting yeast cell growth;	DDI-false
DDI-MedLine.d122.s1.p0	Many people use both @DRUG$ and @DRUG$ (i.e., cigarettes and other tobacco products).	DDI-false
DDI-MedLine.d124.s0.p0	Lack of interaction between @DRUG$ and @DRUG$: pharmacokinetics and drug disposition.	DDI-false
DDI-MedLine.d124.s2.p0	This decrease in absorption results in a 36% and 50% lower AUC for @DRUG$ and @DRUG$, respectively, which could cause clinical failures.	DDI-false
DDI-MedLine.d125.s1.p0	The biochemical toxicology of @DRUG$, a known metabolite of the major ingredient of the pesticide @DRUG$ (1,3-difluoro-2-propanol), was investigated in vivo and in vitro.	DDI-false
DDI-MedLine.d125.s1.p1	The biochemical toxicology of @DRUG$, a known metabolite of the major ingredient of the pesticide Gliftor (@DRUG$), was investigated in vivo and in vitro.	DDI-false
DDI-MedLine.d125.s1.p2	The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide @DRUG$ (@DRUG$), was investigated in vivo and in vitro.	DDI-false
DDI-MedLine.d125.s2.p0	Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted @DRUG$ to @DRUG$ in vitro.	DDI-false
DDI-MedLine.d125.s3.p0	Administration of @DRUG$ (100 mg kg(-1) body weight) to rats in vivo resulted in @DRUG$ synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation.	DDI-false
DDI-MedLine.d128.s10.p0	On the other hand, the enhanced secretion of colonic fluid by @DRUG$, given intraluminally, was only half of that in control rats, whereas the colonic transit-enhancing effect of @DRUG$ in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration.	DDI-false
DDI-MedLine.d13.s7.p0	On the basis of the estimated number of regular users of intravenous @DRUG$ in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and @DRUG$ addicts.	DDI-false
DDI-MedLine.d130.s4.p0	@DRUG$ was administered over the last two hours of the @DRUG$ infusion.	DDI-false
DDI-MedLine.d130.s6.p0	Comparison of @DRUG$ pharmacokinetics in patients treated with 202.5 mg/m2 plus @DRUG$ to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin.	DDI-false
DDI-MedLine.d130.s6.p1	Comparison of @DRUG$ pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without @DRUG$ indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin.	DDI-false
DDI-MedLine.d130.s6.p2	Comparison of @DRUG$ pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of @DRUG$.	DDI-false
DDI-MedLine.d130.s6.p3	Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus @DRUG$ to those in patients treated with 100 mg/m2 without @DRUG$ indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin.	DDI-false
DDI-MedLine.d130.s6.p4	Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus @DRUG$ to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of @DRUG$.	DDI-false
DDI-MedLine.d130.s6.p5	Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without @DRUG$ indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of @DRUG$.	DDI-false
DDI-MedLine.d131.s4.p0	On the contrary, @DRUG$ and @DRUG$ were agonists in induction of analgesia.	DDI-effect
DDI-MedLine.d131.s5.p0	It is concluded that @DRUG$ modulates in an opposite way the function of the enkephalinergic neurons and the central action of @DRUG$.	DDI-effect
DDI-MedLine.d132.s0.p0	The emerging roles of @DRUG$ in @DRUG$ therapy.	DDI-false
DDI-MedLine.d132.s10.p0	@DRUG$ has demonstrated superiority over @DRUG$ in nucleoside-experienced patients, although combining these 2 agents may represent the best approach in these circumstances.	DDI-false
DDI-MedLine.d132.s5.p0	A smaller 24-week study has suggested @DRUG$ may be superior to the @DRUG$ nelfinavir.	DDI-false
DDI-MedLine.d132.s5.p1	A smaller 24-week study has suggested @DRUG$ may be superior to the PI @DRUG$.	DDI-false
DDI-MedLine.d132.s5.p2	A smaller 24-week study has suggested nevirapine may be superior to the @DRUG$ @DRUG$.	DDI-false
DDI-MedLine.d134.s1.p0	An intravenous dose of 50 mg @DRUG$ was in respect of competitive suppression of organs actively concentrating @DRUG$ as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate.	DDI-false
DDI-MedLine.d134.s1.p1	An intravenous dose of 50 mg @DRUG$ was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of @DRUG$.	DDI-false
DDI-MedLine.d134.s1.p2	An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating @DRUG$ as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of @DRUG$.	DDI-false
DDI-MedLine.d134.s2.p0	An intravenous injection of @DRUG$ given later also produces a complete and immediately beginning depletion of @DRUG$ already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels.	DDI-mechanism
DDI-MedLine.d135.s5.p0	Acute dosing with @DRUG$ failed to alter the behavioral effects of @DRUG$ in either procedure even when tested up to doses that produced pharmacological effects alone.	DDI-false
DDI-MedLine.d137.s1.p0	AIMS/HYPOTHESIS: There is evidence that @DRUG$ and @DRUG$ cause renal and ocular vasodilation.	DDI-false
DDI-MedLine.d140.s13.p0	@DRUG$ doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered @DRUG$ dose level (P = .13, .82, and .76, respectively).	DDI-false
DDI-MedLine.d140.s15.p0	For a 4-fold range of @DRUG$ doses there were no differential effects on @DRUG$ dosing or pharmacokinetics.	DDI-false
DDI-MedLine.d15.s0.p0	[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p1	[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of @DRUG$]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p2	[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of @DRUG$ (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p3	[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and @DRUG$ (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p4	[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between @DRUG$ and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p5	[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for @DRUG$ in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p6	[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas @DRUG$ binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p7	[Stimulation by @DRUG$--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for @DRUG$ increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p8	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of @DRUG$]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p9	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of @DRUG$ (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p10	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and @DRUG$ (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p11	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between @DRUG$ and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p12	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for @DRUG$ in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p13	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas @DRUG$ binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p14	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for @DRUG$ increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p15	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of @DRUG$]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of @DRUG$ (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p16	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of @DRUG$]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and @DRUG$ (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p17	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of @DRUG$]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between @DRUG$ and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p18	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of @DRUG$]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for @DRUG$ in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p19	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of @DRUG$]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas @DRUG$ binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p20	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of @DRUG$]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for @DRUG$ increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p21	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of @DRUG$ (0.25 mg/kg) and @DRUG$ (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p22	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of @DRUG$ (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between @DRUG$ and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p23	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of @DRUG$ (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for @DRUG$ in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p24	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of @DRUG$ (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas @DRUG$ binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p25	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of @DRUG$ (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for @DRUG$ increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p26	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and @DRUG$ (0.25 mg/kg) resulted in the reduced interaction between @DRUG$ and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p27	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and @DRUG$ (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for @DRUG$ in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p28	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and @DRUG$ (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas @DRUG$ binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p29	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and @DRUG$ (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for @DRUG$ increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p30	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between @DRUG$ and low affinity binding sites for @DRUG$ in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p31	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between @DRUG$ and low affinity binding sites for apomorphine in subcortical structures, whereas @DRUG$ binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p32	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between @DRUG$ and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for @DRUG$ increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p33	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for @DRUG$ in subcortical structures, whereas @DRUG$ binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p34	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for @DRUG$ in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for @DRUG$ increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s0.p35	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics]  It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas @DRUG$ binding with high affinity binding sites for @DRUG$ increased both in the frontal cortex and subcortical structures of the forebrain.	DDI-false
DDI-MedLine.d15.s1.p0	After prolonged administration of @DRUG$ the displacing effect of @DRUG$, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding.	DDI-false
DDI-MedLine.d15.s1.p1	After prolonged administration of @DRUG$ the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on @DRUG$ binding.	DDI-false
DDI-MedLine.d15.s1.p2	After prolonged administration of neuroleptics the displacing effect of @DRUG$, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on @DRUG$ binding.	DDI-false
DDI-MedLine.d16.s0.p0	Interaction of @DRUG$ and @DRUG$ in rats.	DDI-int
DDI-MedLine.d17.s0.p0	In vitro interaction of @DRUG$ and @DRUG$ in placental vessels.	DDI-int
DDI-MedLine.d17.s1.p0	The interaction of @DRUG$ and synthetic @DRUG$ on placental vessels was studied in vitro.	DDI-false
DDI-MedLine.d17.s3.p0	In seven experiments reactions to @DRUG$ and @DRUG$ were PGF2alpha.	DDI-false
DDI-MedLine.d17.s3.p1	In seven experiments reactions to @DRUG$ and oxytocin were @DRUG$.	DDI-false
DDI-MedLine.d17.s3.p2	In seven experiments reactions to norepinephrine and @DRUG$ were @DRUG$.	DDI-false
DDI-MedLine.d17.s4.p0	@DRUG$ produced significantly increased vasoconstriction after a single administration of @DRUG$.	DDI-effect
DDI-MedLine.d18.s1.p0	The effect of a @DRUG$ extract from bovine lung, @DRUG$, on the dissolution rate of aerosol particles of budesonide was determined.	DDI-false
DDI-MedLine.d18.s1.p1	The effect of a @DRUG$ extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of @DRUG$ was determined.	DDI-false
DDI-MedLine.d18.s1.p2	The effect of a pulmonary surfactant extract from bovine lung, @DRUG$, on the dissolution rate of aerosol particles of @DRUG$ was determined.	DDI-false
DDI-MedLine.d18.s6.p0	@DRUG$ increased the extent of dissolution of @DRUG$ in proportion to the added concentration, which was also verified by equilibrium solubilization studies.	DDI-false
DDI-MedLine.d2.s0.p0	Failure of @DRUG$ to modify @DRUG$ induced hypertension in sheep.	DDI-false
DDI-MedLine.d2.s3.p0	@DRUG$ has no effect on the blood pressure or metabolic responses to @DRUG$ in sheep.	DDI-false
DDI-MedLine.d21.s11.p0	@DRUG$ neutralized the increase of glycemia induced by oral @DRUG$ overload.	DDI-false
DDI-MedLine.d21.s8.p0	An oral @DRUG$ overload of 1 ml of a 50% @DRUG$ solution was given to rats and blood glucose was determined after 30, 60 and 90 min.	DDI-false
DDI-MedLine.d21.s9.p0	@DRUG$ and @DRUG$ did not change fasting or overload glycemia.	DDI-false
DDI-MedLine.d23.s2.p0	Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of @DRUG$, ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.	DDI-effect
DDI-MedLine.d23.s2.p1	Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of Innovar, @DRUG$, or droperidol but not after administration of fentayl alone or after pentobarbital.	DDI-effect
DDI-MedLine.d23.s2.p2	Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of Innovar, ketamine, or @DRUG$ but not after administration of fentayl alone or after pentobarbital.	DDI-effect
DDI-MedLine.d23.s2.p3	Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of @DRUG$ alone or after pentobarbital.	DDI-false
DDI-MedLine.d23.s2.p4	Ventricular tachycardia induced by @DRUG$ was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after @DRUG$.	DDI-false
DDI-MedLine.d23.s2.p5	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of @DRUG$, @DRUG$, or droperidol but not after administration of fentayl alone or after pentobarbital.	DDI-false
DDI-MedLine.d23.s2.p6	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of @DRUG$, ketamine, or @DRUG$ but not after administration of fentayl alone or after pentobarbital.	DDI-false
DDI-MedLine.d23.s2.p7	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of @DRUG$, ketamine, or droperidol but not after administration of @DRUG$ alone or after pentobarbital.	DDI-false
DDI-MedLine.d23.s2.p8	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of @DRUG$, ketamine, or droperidol but not after administration of fentayl alone or after @DRUG$.	DDI-false
DDI-MedLine.d23.s2.p9	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, @DRUG$, or @DRUG$ but not after administration of fentayl alone or after pentobarbital.	DDI-false
DDI-MedLine.d23.s2.p10	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, @DRUG$, or droperidol but not after administration of @DRUG$ alone or after pentobarbital.	DDI-false
DDI-MedLine.d23.s2.p11	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, @DRUG$, or droperidol but not after administration of fentayl alone or after @DRUG$.	DDI-false
DDI-MedLine.d23.s2.p12	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or @DRUG$ but not after administration of @DRUG$ alone or after pentobarbital.	DDI-false
DDI-MedLine.d23.s2.p13	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or @DRUG$ but not after administration of fentayl alone or after @DRUG$.	DDI-false
DDI-MedLine.d23.s2.p14	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of @DRUG$ alone or after @DRUG$.	DDI-false
DDI-MedLine.d25.s0.p0	Rhabdomyolysis secondary to a drug interaction between @DRUG$ and @DRUG$.	DDI-effect
DDI-MedLine.d27.s0.p0	[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that @DRUG$ (1 mg/kg) removes the antiedematous action of @DRUG$, phenazepam, phenibut and amizyl and reduces the action of phentolamine.	DDI-effect
DDI-MedLine.d27.s0.p1	[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that @DRUG$ (1 mg/kg) removes the antiedematous action of diazepam, @DRUG$, phenibut and amizyl and reduces the action of phentolamine.	DDI-effect
DDI-MedLine.d27.s0.p2	[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that @DRUG$ (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, @DRUG$ and amizyl and reduces the action of phentolamine.	DDI-effect
DDI-MedLine.d27.s0.p3	[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that @DRUG$ (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and @DRUG$ and reduces the action of phentolamine.	DDI-effect
DDI-MedLine.d27.s0.p4	[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that @DRUG$ (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of @DRUG$.	DDI-effect
DDI-MedLine.d27.s0.p5	[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of @DRUG$, @DRUG$, phenibut and amizyl and reduces the action of phentolamine.	DDI-false
DDI-MedLine.d27.s0.p6	[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of @DRUG$, phenazepam, @DRUG$ and amizyl and reduces the action of phentolamine.	DDI-false
DDI-MedLine.d27.s0.p7	[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of @DRUG$, phenazepam, phenibut and @DRUG$ and reduces the action of phentolamine.	DDI-false
DDI-MedLine.d27.s0.p8	[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of @DRUG$, phenazepam, phenibut and amizyl and reduces the action of @DRUG$.	DDI-false
DDI-MedLine.d27.s0.p9	[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, @DRUG$, @DRUG$ and amizyl and reduces the action of phentolamine.	DDI-false
DDI-MedLine.d27.s0.p10	[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, @DRUG$, phenibut and @DRUG$ and reduces the action of phentolamine.	DDI-false
DDI-MedLine.d27.s0.p11	[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, @DRUG$, phenibut and amizyl and reduces the action of @DRUG$.	DDI-false
DDI-MedLine.d27.s0.p12	[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, @DRUG$ and @DRUG$ and reduces the action of phentolamine.	DDI-false
DDI-MedLine.d27.s0.p13	[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, @DRUG$ and amizyl and reduces the action of @DRUG$.	DDI-false
DDI-MedLine.d27.s0.p14	[The GABA-ergic system and brain edema]  It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and @DRUG$ and reduces the action of @DRUG$.	DDI-false
DDI-MedLine.d28.s7.p0	The @DRUG$ (@DRUG$ and pioglitazone), a new class of oral antidiabetic agents, are "insulin sensitizers"	DDI-false
DDI-MedLine.d28.s7.p1	The @DRUG$ (rosiglitazone and @DRUG$), a new class of oral antidiabetic agents, are "insulin sensitizers"	DDI-false
DDI-MedLine.d28.s7.p2	The @DRUG$ (rosiglitazone and pioglitazone), a new class of oral @DRUG$, are "insulin sensitizers"	DDI-false
DDI-MedLine.d28.s7.p3	The thiazolidinediones (@DRUG$ and @DRUG$), a new class of oral antidiabetic agents, are "insulin sensitizers"	DDI-false
DDI-MedLine.d28.s7.p4	The thiazolidinediones (@DRUG$ and pioglitazone), a new class of oral @DRUG$, are "insulin sensitizers"	DDI-false
DDI-MedLine.d28.s7.p5	The thiazolidinediones (rosiglitazone and @DRUG$), a new class of oral @DRUG$, are "insulin sensitizers"	DDI-false
DDI-MedLine.d3.s1.p0	The objective of this study was to determine if there is a pharmacokinetic interaction when @DRUG$ is given with @DRUG$ or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT).	DDI-false
DDI-MedLine.d3.s1.p1	The objective of this study was to determine if there is a pharmacokinetic interaction when @DRUG$ is given with rifabutin or @DRUG$ and to determine the effects of these drugs on the erythromycin breath test (ERMBT).	DDI-false
DDI-MedLine.d3.s1.p2	The objective of this study was to determine if there is a pharmacokinetic interaction when amprenavir is given with @DRUG$ or @DRUG$ and to determine the effects of these drugs on the erythromycin breath test (ERMBT).	DDI-false
DDI-MedLine.d3.s13.p0	@DRUG$ markedly increases the metabolic clearance of @DRUG$, and coadministration is contraindicated.	DDI-mechanism
DDI-MedLine.d3.s14.p0	@DRUG$ significantly decreases clearance of @DRUG$ and 25-O-desacetylrifabutin, and the combination is poorly tolerated.	DDI-mechanism
DDI-MedLine.d3.s14.p1	@DRUG$ significantly decreases clearance of rifabutin and @DRUG$, and the combination is poorly tolerated.	DDI-mechanism
DDI-MedLine.d3.s14.p2	Amprenavir significantly decreases clearance of @DRUG$ and @DRUG$, and the combination is poorly tolerated.	DDI-false
DDI-MedLine.d3.s6.p0	@DRUG$ did not significantly affect @DRUG$'s pharmacokinetics.	DDI-false
DDI-MedLine.d30.s1.p0	The behavioral effects of the stereoisomers of @DRUG$ (@DRUG$) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.	DDI-false
DDI-MedLine.d30.s1.p1	The behavioral effects of the stereoisomers of @DRUG$ (NANM) were compared with those of @DRUG$ (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.	DDI-false
DDI-MedLine.d30.s1.p2	The behavioral effects of the stereoisomers of @DRUG$ (NANM) were compared with those of phencyclidine (@DRUG$) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.	DDI-false
DDI-MedLine.d30.s1.p3	The behavioral effects of the stereoisomers of N-allylnormetazocine (@DRUG$) were compared with those of @DRUG$ (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.	DDI-false
DDI-MedLine.d30.s1.p4	The behavioral effects of the stereoisomers of N-allylnormetazocine (@DRUG$) were compared with those of phencyclidine (@DRUG$) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.	DDI-false
DDI-MedLine.d30.s1.p5	The behavioral effects of the stereoisomers of N-allylnormetazocine (NANM) were compared with those of @DRUG$ (@DRUG$) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation.	DDI-false
DDI-MedLine.d34.s11.p0	Because of the low dietary @DRUG$ concentration as compared to the @DRUG$ contents of the diets, no effect of cobalt on iron absorption and excretion occurred.	DDI-false
DDI-MedLine.d34.s11.p1	Because of the low dietary @DRUG$ concentration as compared to the iron contents of the diets, no effect of @DRUG$ on iron absorption and excretion occurred.	DDI-false
DDI-MedLine.d34.s11.p2	Because of the low dietary @DRUG$ concentration as compared to the iron contents of the diets, no effect of cobalt on @DRUG$ absorption and excretion occurred.	DDI-false
DDI-MedLine.d34.s11.p3	Because of the low dietary cobalt concentration as compared to the @DRUG$ contents of the diets, no effect of @DRUG$ on iron absorption and excretion occurred.	DDI-false
DDI-MedLine.d34.s11.p4	Because of the low dietary cobalt concentration as compared to the @DRUG$ contents of the diets, no effect of cobalt on @DRUG$ absorption and excretion occurred.	DDI-false
DDI-MedLine.d34.s11.p5	Because of the low dietary cobalt concentration as compared to the iron contents of the diets, no effect of @DRUG$ on @DRUG$ absorption and excretion occurred.	DDI-false
DDI-MedLine.d34.s9.p0	Consequently, the effect of @DRUG$ on the retention of @DRUG$ was lower than on absorption.	DDI-mechanism
DDI-MedLine.d38.s2.p0	However, the effects of stress and @DRUG$ on the subjective and behavioral effects of @DRUG$ have not been well studied in humans.	DDI-false
DDI-MedLine.d38.s8.p0	However, @DRUG$ pretreatment did not affect any of the physiological, behavioral, or subjective effects of @DRUG$.	DDI-false
DDI-MedLine.d39.s1.p0	We examined the effect of exogenous @DRUG$ on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli @DRUG$ in male rats and the deaths due to nonlethal and lethal doses of endotoxin.	DDI-false
DDI-MedLine.d39.s1.p1	We examined the effect of exogenous @DRUG$ on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of @DRUG$.	DDI-false
DDI-MedLine.d39.s1.p2	We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli @DRUG$ in male rats and the deaths due to nonlethal and lethal doses of @DRUG$.	DDI-false
DDI-MedLine.d42.s4.p0	METHODS: Clinical studies, case reports, and commentaries and editorials concerning @DRUG$ published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms @DRUG$, Viagra, and erectile dysfunction.	DDI-false
DDI-MedLine.d42.s4.p1	METHODS: Clinical studies, case reports, and commentaries and editorials concerning @DRUG$ published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms sildenafil, @DRUG$, and erectile dysfunction.	DDI-false
DDI-MedLine.d42.s4.p2	METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms @DRUG$, @DRUG$, and erectile dysfunction.	DDI-false
DDI-MedLine.d44.s2.p0	In this study, the effects of @DRUG$ upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day @DRUG$ or placebo for 1-month.	DDI-false
DDI-MedLine.d44.s6.p0	@DRUG$ elicited 62% enhancement of post-@DRUG$ lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment.	DDI-effect
DDI-MedLine.d45.s5.p0	Twelve strains of Staphylococcus aureus (a frequent cause of infection in @DRUG$, but not in @DRUG$ and tripelennamine, addicts) were completely inhibited by the drug combination.	DDI-false
DDI-MedLine.d45.s5.p1	Twelve strains of Staphylococcus aureus (a frequent cause of infection in @DRUG$, but not in pentazocine and @DRUG$, addicts) were completely inhibited by the drug combination.	DDI-false
DDI-MedLine.d45.s5.p2	Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in @DRUG$ and @DRUG$, addicts) were completely inhibited by the drug combination.	DDI-effect
DDI-MedLine.d46.s1.p0	STUDY OBJECTIVE: To evaluate the effect of @DRUG$ on the pharmacokinetics and cardiovascular safety of @DRUG$ at steady state in healthy men.	DDI-false
DDI-MedLine.d46.s9.p0	and phase 3 (days 45-52): @DRUG$ 10 mg 4 times/day (days 45-51) plus @DRUG$ 20 mg/day (days 45-52).	DDI-false
DDI-MedLine.d47.s3.p0	Moreover, its activity was enhanced when it was combined with either @DRUG$ or @DRUG$ with 90% parasite reduction at the highest concentration tested.	DDI-false
DDI-MedLine.d5.s0.p0	Repeated oral administration of @DRUG$ in sheep: interactions of @DRUG$ with bishydroxycoumarin, trichlorfon, and phenobarbital sodium.	DDI-false
DDI-MedLine.d5.s0.p1	Repeated oral administration of @DRUG$ in sheep: interactions of coumaphos with @DRUG$, trichlorfon, and phenobarbital sodium.	DDI-false
DDI-MedLine.d5.s0.p2	Repeated oral administration of @DRUG$ in sheep: interactions of coumaphos with bishydroxycoumarin, @DRUG$, and phenobarbital sodium.	DDI-false
DDI-MedLine.d5.s0.p3	Repeated oral administration of @DRUG$ in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and @DRUG$.	DDI-false
DDI-MedLine.d5.s0.p4	Repeated oral administration of coumaphos in sheep: interactions of @DRUG$ with @DRUG$, trichlorfon, and phenobarbital sodium.	DDI-false
DDI-MedLine.d5.s0.p5	Repeated oral administration of coumaphos in sheep: interactions of @DRUG$ with bishydroxycoumarin, @DRUG$, and phenobarbital sodium.	DDI-false
DDI-MedLine.d5.s0.p6	Repeated oral administration of coumaphos in sheep: interactions of @DRUG$ with bishydroxycoumarin, trichlorfon, and @DRUG$.	DDI-false
DDI-MedLine.d5.s0.p7	Repeated oral administration of coumaphos in sheep: interactions of coumaphos with @DRUG$, @DRUG$, and phenobarbital sodium.	DDI-false
DDI-MedLine.d5.s0.p8	Repeated oral administration of coumaphos in sheep: interactions of coumaphos with @DRUG$, trichlorfon, and @DRUG$.	DDI-false
DDI-MedLine.d5.s0.p9	Repeated oral administration of coumaphos in sheep: interactions of coumaphos with bishydroxycoumarin, @DRUG$, and @DRUG$.	DDI-false
DDI-MedLine.d5.s1.p0	Interactions between treatments with @DRUG$, @DRUG$ (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.	DDI-false
DDI-MedLine.d5.s1.p1	Interactions between treatments with @DRUG$, bishydroxycoumarin (an @DRUG$), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.	DDI-false
DDI-MedLine.d5.s1.p2	Interactions between treatments with @DRUG$, bishydroxycoumarin (an anticoagulant), @DRUG$ (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.	DDI-false
DDI-MedLine.d5.s1.p3	Interactions between treatments with @DRUG$, bishydroxycoumarin (an anticoagulant), trichlorfon (an @DRUG$), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.	DDI-false
DDI-MedLine.d5.s1.p4	Interactions between treatments with @DRUG$, bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and @DRUG$ (an inducer of microsomal enzymes) were investigated in sheep.	DDI-false
DDI-MedLine.d5.s1.p5	Interactions between treatments with coumaphos, @DRUG$ (an @DRUG$), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.	DDI-false
DDI-MedLine.d5.s1.p6	Interactions between treatments with coumaphos, @DRUG$ (an anticoagulant), @DRUG$ (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.	DDI-false
DDI-MedLine.d5.s1.p7	Interactions between treatments with coumaphos, @DRUG$ (an anticoagulant), trichlorfon (an @DRUG$), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.	DDI-false
DDI-MedLine.d5.s1.p8	Interactions between treatments with coumaphos, @DRUG$ (an anticoagulant), trichlorfon (an organophosphorous compound), and @DRUG$ (an inducer of microsomal enzymes) were investigated in sheep.	DDI-false
DDI-MedLine.d5.s1.p9	Interactions between treatments with coumaphos, bishydroxycoumarin (an @DRUG$), @DRUG$ (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.	DDI-false
DDI-MedLine.d5.s1.p10	Interactions between treatments with coumaphos, bishydroxycoumarin (an @DRUG$), trichlorfon (an @DRUG$), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.	DDI-false
DDI-MedLine.d5.s1.p11	Interactions between treatments with coumaphos, bishydroxycoumarin (an @DRUG$), trichlorfon (an organophosphorous compound), and @DRUG$ (an inducer of microsomal enzymes) were investigated in sheep.	DDI-false
DDI-MedLine.d5.s1.p12	Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), @DRUG$ (an @DRUG$), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep.	DDI-false
DDI-MedLine.d5.s1.p13	Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), @DRUG$ (an organophosphorous compound), and @DRUG$ (an inducer of microsomal enzymes) were investigated in sheep.	DDI-false
DDI-MedLine.d5.s1.p14	Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an @DRUG$), and @DRUG$ (an inducer of microsomal enzymes) were investigated in sheep.	DDI-false
DDI-MedLine.d51.s3.p0	The anxiogenic effects of @DRUG$ were reduced by pretreatment with @DRUG$, an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist.	DDI-effect
DDI-MedLine.d51.s3.p1	The anxiogenic effects of @DRUG$ were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by @DRUG$ (CPA), an A1-selective agonist.	DDI-false
DDI-MedLine.d51.s3.p2	The anxiogenic effects of @DRUG$ were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine (@DRUG$), an A1-selective agonist.	DDI-false
DDI-MedLine.d51.s3.p3	The anxiogenic effects of theophylline were reduced by pretreatment with @DRUG$, an A2-selective agonist, but not by @DRUG$ (CPA), an A1-selective agonist.	DDI-false
DDI-MedLine.d51.s3.p4	The anxiogenic effects of theophylline were reduced by pretreatment with @DRUG$, an A2-selective agonist, but not by N6-cyclopentyladenosine (@DRUG$), an A1-selective agonist.	DDI-false
DDI-MedLine.d51.s3.p5	The anxiogenic effects of theophylline were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by @DRUG$ (@DRUG$), an A1-selective agonist.	DDI-false
DDI-MedLine.d53.s3.p0	In the experiments reported here, we examined the interactions between @DRUG$ and the @DRUG$ 4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells.	DDI-false
DDI-MedLine.d53.s3.p1	In the experiments reported here, we examined the interactions between @DRUG$ and the antiestrogen @DRUG$ (TAM), which also induces apoptosis in MCF-7 cells.	DDI-false
DDI-MedLine.d53.s3.p2	In the experiments reported here, we examined the interactions between @DRUG$ and the antiestrogen 4-hydroxytamoxifen (@DRUG$), which also induces apoptosis in MCF-7 cells.	DDI-false
DDI-MedLine.d53.s3.p3	In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the @DRUG$ @DRUG$ (TAM), which also induces apoptosis in MCF-7 cells.	DDI-false
DDI-MedLine.d53.s3.p4	In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the @DRUG$ 4-hydroxytamoxifen (@DRUG$), which also induces apoptosis in MCF-7 cells.	DDI-false
DDI-MedLine.d53.s3.p5	In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the antiestrogen @DRUG$ (@DRUG$), which also induces apoptosis in MCF-7 cells.	DDI-false
DDI-MedLine.d53.s4.p0	Our data suggest that @DRUG$ significantly potentiates the reduction in cell number induced by @DRUG$ alone.	DDI-effect
DDI-MedLine.d54.s2.p0	Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation, study of the effects of @DRUG$ on these components may help to trace pathways which are affected by @DRUG$.	DDI-false
DDI-MedLine.d54.s3.p0	In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, @DRUG$ (2.0 g/kg), @DRUG$ (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days.	DDI-false
DDI-MedLine.d54.s3.p1	In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, @DRUG$ (2.0 g/kg), physostigmine (0.6 mg/kg) or @DRUG$ (15.0 mg/kg) on separate days.	DDI-false
DDI-MedLine.d54.s3.p2	In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg), @DRUG$ (0.6 mg/kg) or @DRUG$ (15.0 mg/kg) on separate days.	DDI-false
DDI-MedLine.d54.s8.p0	@DRUG$ pretreatment augmented the depressant effect of @DRUG$ on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3.	DDI-effect
DDI-MedLine.d54.s8.p1	@DRUG$ pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating @DRUG$'s influence on components P2 and P3.	DDI-effect
DDI-MedLine.d54.s8.p2	Physostigmine pretreatment augmented the depressant effect of @DRUG$ on the early components P1 and N1, while attenuating @DRUG$'s influence on components P2 and P3.	DDI-false
DDI-MedLine.d55.s4.p0	Careful observations on hepatotoxicity are suggested when @DRUG$ is prescribed with @DRUG$.	DDI-effect
DDI-MedLine.d57.s2.p0	Those for which effectiveness is reported includes @DRUG$, @DRUG$, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p1	Those for which effectiveness is reported includes @DRUG$, hydroxyzine, @DRUG$, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p2	Those for which effectiveness is reported includes @DRUG$, hydroxyzine, orphenadrine, @DRUG$, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p3	Those for which effectiveness is reported includes @DRUG$, hydroxyzine, orphenadrine, pyrilamine, @DRUG$, promethazine, methdilazine, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p4	Those for which effectiveness is reported includes @DRUG$, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, @DRUG$, methdilazine, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p5	Those for which effectiveness is reported includes @DRUG$, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, @DRUG$, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p6	Those for which effectiveness is reported includes @DRUG$, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and @DRUG$.	DDI-false
DDI-MedLine.d57.s2.p7	Those for which effectiveness is reported includes diphenhydramine, @DRUG$, @DRUG$, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p8	Those for which effectiveness is reported includes diphenhydramine, @DRUG$, orphenadrine, @DRUG$, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p9	Those for which effectiveness is reported includes diphenhydramine, @DRUG$, orphenadrine, pyrilamine, @DRUG$, promethazine, methdilazine, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p10	Those for which effectiveness is reported includes diphenhydramine, @DRUG$, orphenadrine, pyrilamine, phenyltoloxamine, @DRUG$, methdilazine, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p11	Those for which effectiveness is reported includes diphenhydramine, @DRUG$, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, @DRUG$, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p12	Those for which effectiveness is reported includes diphenhydramine, @DRUG$, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and @DRUG$.	DDI-false
DDI-MedLine.d57.s2.p13	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, @DRUG$, @DRUG$, phenyltoloxamine, promethazine, methdilazine, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p14	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, @DRUG$, pyrilamine, @DRUG$, promethazine, methdilazine, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p15	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, @DRUG$, pyrilamine, phenyltoloxamine, @DRUG$, methdilazine, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p16	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, @DRUG$, pyrilamine, phenyltoloxamine, promethazine, @DRUG$, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p17	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, @DRUG$, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and @DRUG$.	DDI-false
DDI-MedLine.d57.s2.p18	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, @DRUG$, @DRUG$, promethazine, methdilazine, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p19	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, @DRUG$, phenyltoloxamine, @DRUG$, methdilazine, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p20	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, @DRUG$, phenyltoloxamine, promethazine, @DRUG$, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p21	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, @DRUG$, phenyltoloxamine, promethazine, methdilazine, and @DRUG$.	DDI-false
DDI-MedLine.d57.s2.p22	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, @DRUG$, @DRUG$, methdilazine, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p23	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, @DRUG$, promethazine, @DRUG$, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p24	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, @DRUG$, promethazine, methdilazine, and @DRUG$.	DDI-false
DDI-MedLine.d57.s2.p25	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, @DRUG$, @DRUG$, and tripelennamine.	DDI-false
DDI-MedLine.d57.s2.p26	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, @DRUG$, methdilazine, and @DRUG$.	DDI-false
DDI-MedLine.d57.s2.p27	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, @DRUG$, and @DRUG$.	DDI-false
DDI-MedLine.d58.s3.p0	In this study we investigated the effect of @DRUG$ on high threshold voltage-dependent Ca(2+) channel subtypes using their @DRUG$ nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells.	DDI-false
DDI-MedLine.d58.s3.p1	In this study we investigated the effect of @DRUG$ on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers @DRUG$ (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells.	DDI-false
DDI-MedLine.d58.s3.p2	In this study we investigated the effect of @DRUG$ on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), @DRUG$ (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells.	DDI-false
DDI-MedLine.d58.s3.p3	In this study we investigated the effect of @DRUG$ on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or @DRUG$ (P-type) in bovine chromaffin cells.	DDI-false
DDI-MedLine.d58.s3.p4	In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their @DRUG$ @DRUG$ (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells.	DDI-false
DDI-MedLine.d58.s3.p5	In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their @DRUG$ nimodipine (L-type), @DRUG$ (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells.	DDI-false
DDI-MedLine.d58.s3.p6	In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their @DRUG$ nimodipine (L-type), omega-conotoxin GVIA (N-type), or @DRUG$ (P-type) in bovine chromaffin cells.	DDI-false
DDI-MedLine.d58.s3.p7	In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers @DRUG$ (L-type), @DRUG$ (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells.	DDI-false
DDI-MedLine.d58.s3.p8	In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers @DRUG$ (L-type), omega-conotoxin GVIA (N-type), or @DRUG$ (P-type) in bovine chromaffin cells.	DDI-false
DDI-MedLine.d58.s3.p9	In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), @DRUG$ (N-type), or @DRUG$ (P-type) in bovine chromaffin cells.	DDI-false
DDI-MedLine.d58.s7.p0	These data suggest that @DRUG$ are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an @DRUG$-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.	DDI-false
DDI-MedLine.d58.s7.p1	These data suggest that @DRUG$ are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an @DRUG$-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.	DDI-false
DDI-MedLine.d58.s7.p2	These data suggest that @DRUG$ are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and @DRUG$/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.	DDI-false
DDI-MedLine.d58.s7.p3	These data suggest that @DRUG$ are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/@DRUG$/omega-agatoxin VIA-resistant (presumptive Q-type) channel.	DDI-false
DDI-MedLine.d58.s7.p4	These data suggest that @DRUG$ are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/@DRUG$-resistant (presumptive Q-type) channel.	DDI-false
DDI-MedLine.d58.s7.p5	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an @DRUG$-sensitive (N-type) channel, an @DRUG$-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.	DDI-false
DDI-MedLine.d58.s7.p6	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an @DRUG$-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and @DRUG$/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.	DDI-false
DDI-MedLine.d58.s7.p7	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an @DRUG$-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/@DRUG$/omega-agatoxin VIA-resistant (presumptive Q-type) channel.	DDI-false
DDI-MedLine.d58.s7.p8	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an @DRUG$-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/@DRUG$-resistant (presumptive Q-type) channel.	DDI-false
DDI-MedLine.d58.s7.p9	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an @DRUG$-sensitive (P-type) channel and @DRUG$/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel.	DDI-false
DDI-MedLine.d58.s7.p10	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an @DRUG$-sensitive (P-type) channel and nimodipine/@DRUG$/omega-agatoxin VIA-resistant (presumptive Q-type) channel.	DDI-false
DDI-MedLine.d58.s7.p11	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an @DRUG$-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/@DRUG$-resistant (presumptive Q-type) channel.	DDI-false
DDI-MedLine.d58.s7.p12	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and @DRUG$/@DRUG$/omega-agatoxin VIA-resistant (presumptive Q-type) channel.	DDI-false
DDI-MedLine.d58.s7.p13	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and @DRUG$/omega-conotoxin GVIA/@DRUG$-resistant (presumptive Q-type) channel.	DDI-false
DDI-MedLine.d58.s7.p14	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/@DRUG$/@DRUG$-resistant (presumptive Q-type) channel.	DDI-false
DDI-MedLine.d60.s2.p0	The serum concentration of @DRUG$ increased dramatically from 16.6 to 49.1 microg/mL when @DRUG$ was coadministered, although the daily dosage of phenytoin and other drugs had not changed.	DDI-false
DDI-MedLine.d60.s2.p1	The serum concentration of @DRUG$ increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of @DRUG$ and other drugs had not changed.	DDI-false
DDI-MedLine.d60.s2.p2	The serum concentration of @DRUG$ increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other @DRUG$ had not changed.	DDI-false
DDI-MedLine.d60.s2.p3	The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when @DRUG$ was coadministered, although the daily dosage of @DRUG$ and other drugs had not changed.	DDI-false
DDI-MedLine.d60.s2.p4	The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when @DRUG$ was coadministered, although the daily dosage of phenytoin and other @DRUG$ had not changed.	DDI-false
DDI-MedLine.d60.s2.p5	The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of @DRUG$ and other @DRUG$ had not changed.	DDI-false
DDI-MedLine.d60.s3.p0	During @DRUG$ and fluvoxamine treatment, ataxia, a typical side effect of @DRUG$, was observed.	DDI-false
DDI-MedLine.d61.s3.p0	The pharmacokinetic variables for @DRUG$ were determined after a 1.0 mg intravenous dose of @DRUG$ in each subject, before and after oral amiodarone, 400 mg daily for 3 weeks.	DDI-false
DDI-MedLine.d61.s3.p1	The pharmacokinetic variables for @DRUG$ were determined after a 1.0 mg intravenous dose of digoxin in each subject, before and after oral @DRUG$, 400 mg daily for 3 weeks.	DDI-false
DDI-MedLine.d61.s3.p2	The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of @DRUG$ in each subject, before and after oral @DRUG$, 400 mg daily for 3 weeks.	DDI-false
DDI-MedLine.d62.s4.p0	Using in situ hybridization, we observed that @DRUG$ caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist @DRUG$ but not by an atypical neuroleptic clozapine.	DDI-effect
DDI-MedLine.d62.s4.p1	Using in situ hybridization, we observed that @DRUG$ caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an @DRUG$ clozapine.	DDI-false
DDI-MedLine.d62.s4.p2	Using in situ hybridization, we observed that @DRUG$ caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic @DRUG$.	DDI-false
DDI-MedLine.d62.s4.p3	Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist @DRUG$ but not by an @DRUG$ clozapine.	DDI-false
DDI-MedLine.d62.s4.p4	Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist @DRUG$ but not by an atypical neuroleptic @DRUG$.	DDI-false
DDI-MedLine.d62.s4.p5	Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an @DRUG$ @DRUG$.	DDI-false
DDI-MedLine.d63.s0.p0	Differential actions of intrathecal @DRUG$ on blocking the tail-flick inhibition induced by intraventricular @DRUG$ and morphine in rats.	DDI-false
DDI-MedLine.d63.s0.p1	Differential actions of intrathecal @DRUG$ on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and @DRUG$ in rats.	DDI-false
DDI-MedLine.d63.s0.p2	Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular @DRUG$ and @DRUG$ in rats.	DDI-false
DDI-MedLine.d63.s5.p0	On the other hand, intrathecal @DRUG$ (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular @DRUG$ (40 micrograms).	DDI-effect
DDI-MedLine.d66.s1.p0	The present work involved the administration of both @DRUG$ and @DRUG$ to groups of rats, followed by determination of the homocysteine excretion rate in urine.	DDI-false
DDI-MedLine.d68.s3.p0	Possible extrarenal mechanisms of action of @DRUG$ on @DRUG$ and iodamide transport were also examined.	DDI-false
DDI-MedLine.d68.s3.p1	Possible extrarenal mechanisms of action of @DRUG$ on verografine and @DRUG$ transport were also examined.	DDI-false
DDI-MedLine.d68.s3.p2	Possible extrarenal mechanisms of action of cimetidine on @DRUG$ and @DRUG$ transport were also examined.	DDI-false
DDI-MedLine.d7.s4.p0	With combined use, clinicians should be aware, when @DRUG$ is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum @DRUG$ concentrations.	DDI-effect
DDI-MedLine.d73.s4.p0	@DRUG$, like @DRUG$, produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment.	DDI-false
DDI-MedLine.d73.s4.p1	@DRUG$, like MPTP, produced depletions of striatal dopamine but these actions were potentiated by @DRUG$ pretreatment.	DDI-effect
DDI-MedLine.d73.s4.p2	Methamphetamine, like @DRUG$, produced depletions of striatal dopamine but these actions were potentiated by @DRUG$ pretreatment.	DDI-false
DDI-MedLine.d75.s3.p0	The percentage of neurons hyperpolarized by @DRUG-DRUG$ was significantly reduced when 1% but not <	DDI-false
DDI-MedLine.d75.s3.p1	The percentage of neurons hyperpolarized by @DRUG-DRUG$ was significantly reduced when 1% but not <	DDI-false
DDI-MedLine.d75.s3.p2	The percentage of neurons hyperpolarized by mu-, @DRUG-DRUG$ was significantly reduced when 1% but not <	DDI-false
DDI-MedLine.d76.s8.p0	@DRUG$ at 1% (m/v) in the presence of free @DRUG$ had no significant effect on the R-value of NaFlu compared to NaCMC alone.	DDI-false
DDI-MedLine.d76.s8.p1	@DRUG$ at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of @DRUG$ compared to NaCMC alone.	DDI-false
DDI-MedLine.d76.s8.p2	@DRUG$ at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of NaFlu compared to @DRUG$ alone.	DDI-false
DDI-MedLine.d76.s8.p3	NaCMC at 1% (m/v) in the presence of free @DRUG$ had no significant effect on the R-value of @DRUG$ compared to NaCMC alone.	DDI-false
DDI-MedLine.d76.s8.p4	NaCMC at 1% (m/v) in the presence of free @DRUG$ had no significant effect on the R-value of NaFlu compared to @DRUG$ alone.	DDI-false
DDI-MedLine.d76.s8.p5	NaCMC at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of @DRUG$ compared to @DRUG$ alone.	DDI-false
DDI-MedLine.d79.s1.p0	Concurrent administration of @DRUG$ and @DRUG$ significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely.	DDI-mechanism
DDI-MedLine.d79.s1.p1	Concurrent administration of @DRUG$ and didanosine significantly reduces the level of exposure to @DRUG$, but it is unclear how soon after didanosine administration indinavir may be given safely.	DDI-false
DDI-MedLine.d79.s1.p2	Concurrent administration of @DRUG$ and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after @DRUG$ administration indinavir may be given safely.	DDI-false
DDI-MedLine.d79.s1.p3	Concurrent administration of @DRUG$ and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration @DRUG$ may be given safely.	DDI-false
DDI-MedLine.d79.s1.p4	Concurrent administration of indinavir and @DRUG$ significantly reduces the level of exposure to @DRUG$, but it is unclear how soon after didanosine administration indinavir may be given safely.	DDI-false
DDI-MedLine.d79.s1.p5	Concurrent administration of indinavir and @DRUG$ significantly reduces the level of exposure to indinavir, but it is unclear how soon after @DRUG$ administration indinavir may be given safely.	DDI-false
DDI-MedLine.d79.s1.p6	Concurrent administration of indinavir and @DRUG$ significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration @DRUG$ may be given safely.	DDI-false
DDI-MedLine.d79.s1.p7	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to @DRUG$, but it is unclear how soon after @DRUG$ administration indinavir may be given safely.	DDI-false
DDI-MedLine.d79.s1.p8	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to @DRUG$, but it is unclear how soon after didanosine administration @DRUG$ may be given safely.	DDI-false
DDI-MedLine.d79.s1.p9	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after @DRUG$ administration @DRUG$ may be given safely.	DDI-false
DDI-MedLine.d79.s3.p0	Median gastric pH was significantly higher when @DRUG$ was taken after @DRUG$ administration;	DDI-mechanism
DDI-MedLine.d82.s1.p0	The intestinal absorption of @DRUG$(@DRUG$) has been investigated in the chick by means of the in situ ligated duodenal loop technique.	DDI-false
DDI-MedLine.d83.s15.p0	Pharmacoeconomic analyses indicate that @DRUG$ does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with @DRUG$.	DDI-false
DDI-MedLine.d83.s6.p0	In contrast, preliminary results from an 8-week controlled study suggested @DRUG$ 2 to 6 mg/day was superior to @DRUG$ 5 to 20 mg/day against positive and anxiety/depressive symptoms (p < 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology.	DDI-false
DDI-MedLine.d84.s4.p0	The antimicrobial combinations of @DRUG$ with four @DRUG$ resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances.	DDI-effect
DDI-MedLine.d86.s0.p0	Pharmacokinetic interaction between single oral doses of @DRUG$ and @DRUG$ in healthy volunteers.	DDI-mechanism
DDI-MedLine.d86.s2.p0	Several clinically important interactions have previously been reported for other @DRUG$ that are metabolized by the same enzyme and for @DRUG$.	DDI-false
DDI-MedLine.d86.s5.p0	RESULTS: The geometric mean (90% confidence interval) whole blood @DRUG$ area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with @DRUG$ coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours.	DDI-mechanism
DDI-MedLine.d86.s5.p1	RESULTS: The geometric mean (90% confidence interval) whole blood @DRUG$ area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of @DRUG$ decreased slightly, from 79 to 67 hours.	DDI-false
DDI-MedLine.d86.s5.p2	RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with @DRUG$ coadministration, whereas the mean elimination half-life of @DRUG$ decreased slightly, from 79 to 67 hours.	DDI-false
DDI-MedLine.d89.s0.p0	Therapeutic drug monitoring can avoid iatrogenic alterations caused by @DRUG$ (MDP)-@DRUG$ interaction.	DDI-effect
DDI-MedLine.d89.s8.p0	The data presented here demonstrate that with serial pharmacokinetic dosing of @DRUG$, the iatrogenic alteration caused by @DRUG$ therapy can be avoided.	DDI-false
DDI-MedLine.d90.s1.p0	Evoked hind limb digital extensor tension (hoof twitch) was maintained at 40% of baseline for 1 h by @DRUG$ infusion in 7 horses anaesthetised with @DRUG$.	DDI-false
DDI-MedLine.d90.s11.p0	It was concluded that, although @DRUG$ did augment the neuromuscular blockade of @DRUG$, the effect was minimal.	DDI-effect
DDI-MedLine.d93.s6.p0	The 20% v/v solution of @DRUG$ was prepared in water from a stock solution of 95% @DRUG$.	DDI-false
DDI-MedLine.d94.s12.p0	The uptake inhibitors @DRUG$ and @DRUG$ (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.	DDI-false
DDI-MedLine.d94.s12.p1	The uptake inhibitors @DRUG$ and desipramine (3 mumol/liter) potentiated the positive inotropic effects of @DRUG$ in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.	DDI-effect
DDI-MedLine.d94.s12.p2	The uptake inhibitors cocaine and @DRUG$ (3 mumol/liter) potentiated the positive inotropic effects of @DRUG$ in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium.	DDI-effect
DDI-MedLine.d94.s13.p0	Radioligand binding experiments using the uptake inhibitor hydrogen-3 @DRUG$ revealed a significant decrease by approximately 30% in @DRUG$ uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < 0.05).	DDI-false
DDI-MedLine.d95.s4.p0	@DRUG$ (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with @DRUG$ (8 micromol/l) or KCl (125 mmol/l) from both lean and dietary-obese rats.	DDI-false
DDI-MedLine.d95.s4.p1	@DRUG$ (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or @DRUG$ (125 mmol/l) from both lean and dietary-obese rats.	DDI-false
DDI-MedLine.d95.s4.p2	Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with @DRUG$ (8 micromol/l) or @DRUG$ (125 mmol/l) from both lean and dietary-obese rats.	DDI-false
DDI-MedLine.d95.s9.p0	This study indicates that: (a) the maximal effects of @DRUG$ on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of @DRUG$ in lean animals (where endothelial function is not impaired), but not in dietary-obese rats, are mediated via NO.	DDI-false
DDI-MedLine.d98.s0.p0	Behavioral responses to repeated @DRUG$ exposure in mice selectively bred for differential sensitivity to @DRUG$.	DDI-false
DDI-MedLine.d99.s8.p0	Plasma was analyzed for @DRUG$, and urine was analyzed for @DRUG$ and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC.	DDI-false
DDI-MedLine.d99.s8.p1	Plasma was analyzed for @DRUG$, and urine was analyzed for tolbutamide and its two metabolites, @DRUG$ and carboxytolbutamide by means of HPLC.	DDI-false
DDI-MedLine.d99.s8.p2	Plasma was analyzed for @DRUG$, and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and @DRUG$ by means of HPLC.	DDI-false
DDI-MedLine.d99.s8.p3	Plasma was analyzed for tolbutamide, and urine was analyzed for @DRUG$ and its two metabolites, @DRUG$ and carboxytolbutamide by means of HPLC.	DDI-false
DDI-MedLine.d99.s8.p4	Plasma was analyzed for tolbutamide, and urine was analyzed for @DRUG$ and its two metabolites, 4-hydroxytolbutamide and @DRUG$ by means of HPLC.	DDI-false
DDI-MedLine.d99.s8.p5	Plasma was analyzed for tolbutamide, and urine was analyzed for tolbutamide and its two metabolites, @DRUG$ and @DRUG$ by means of HPLC.	DDI-false
